
<html lang="en"     class="pb-page"  data-request-id="a84de2bb-a1c4-4fb6-b212-75e87475a67c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c01917;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-4;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial" /></meta><meta name="dc.Creator" content="Yuji  Koriyama" /></meta><meta name="dc.Creator" content="Akihiro  Hori" /></meta><meta name="dc.Creator" content="Hisanori  Ito" /></meta><meta name="dc.Creator" content="Shuji  Yonezawa" /></meta><meta name="dc.Creator" content="Yoshiyasu  Baba" /></meta><meta name="dc.Creator" content="Norihiko  Tanimoto" /></meta><meta name="dc.Creator" content="Tatsuhiko  Ueno" /></meta><meta name="dc.Creator" content="Shiho  Yamamoto" /></meta><meta name="dc.Creator" content="Takahiko  Yamamoto" /></meta><meta name="dc.Creator" content="Naoya  Asada" /></meta><meta name="dc.Creator" content="Kenji  Morimoto" /></meta><meta name="dc.Creator" content="Shunsuke  Einaru" /></meta><meta name="dc.Creator" content="Katsunori  Sakai" /></meta><meta name="dc.Creator" content="Takushi  Kanazu" /></meta><meta name="dc.Creator" content="Akihiro  Matsuda" /></meta><meta name="dc.Creator" content="Yoshitaka  Yamaguchi" /></meta><meta name="dc.Creator" content="Takuya  Oguma" /></meta><meta name="dc.Creator" content="Maarten  Timmers" /></meta><meta name="dc.Creator" content="Luc  Tritsmans" /></meta><meta name="dc.Creator" content="Ken-ichi  Kusakabe" /></meta><meta name="dc.Creator" content="Akira  Kato" /></meta><meta name="dc.Creator" content="Gaku  Sakaguchi" /></meta><meta name="dc.Description" content="Accumulation of amyloid β peptides (Aβ) is thought to be one of the causal factors of Alzheimer’s disease (AD). The aspartyl protease β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is t..." /></meta><meta name="Description" content="Accumulation of amyloid β peptides (Aβ) is thought to be one of the causal factors of Alzheimer’s disease (AD). The aspartyl protease β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is t..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 15, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01917" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01917" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01917" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01917" /></link>
        
    
    

<title>Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01917" /></meta><meta property="og:title" content="Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0014.jpeg" /></meta><meta property="og:description" content="Accumulation of amyloid β peptides (Aβ) is thought to be one of the causal factors of Alzheimer’s disease (AD). The aspartyl protease β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the rate-limiting protease for Aβ production, and therefore, BACE1 inhibition is a promising therapeutic approach for the treatment of AD. Starting with a dihydro-1,3-thiazine-based lead, Compound J, we discovered atabecestat 1 (JNJ-54861911) as a centrally efficacious BACE1 inhibitor that was advanced into the EARLY Phase 2b/3 clinical trial for the treatment of preclinical AD patients. Compound 1 demonstrated robust and dose-dependent Aβ reduction and showed sufficient safety margins in preclinical models. The potential of reactive metabolite formation was evaluated in a covalent binding study to assess its irreversible binding to human hepatocytes. Unfortunately, the EARLY trial was discontinued due to significant elevation of liver enzymes, and subsequent analysis of the clinical outcomes showed dose-related cognitive worsening." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01917"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01917">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01917&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01917&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01917&amp;href=/doi/10.1021/acs.jmedchem.0c01917" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1873-1888</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01886" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c01955" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yuji Koriyama</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuji Koriyama</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +81-6-6209-6976; Email: <a href="/cdn-cgi/l/email-protection#4c3539392625622723233e25352d212d0c3f24252322232b25622f2362263c"><span class="__cf_email__" data-cfemail="5d2428283734733632322f34243c303c1d2e35343233323a34733e3273372d">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuji++Koriyama">Yuji Koriyama</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Akihiro Hori</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Akihiro Hori</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Akihiro++Hori">Akihiro Hori</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hisanori Ito</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hisanori Ito</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hisanori++Ito">Hisanori Ito</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuji Yonezawa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuji Yonezawa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuji++Yonezawa">Shuji Yonezawa</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yoshiyasu Baba</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yoshiyasu Baba</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yoshiyasu++Baba">Yoshiyasu Baba</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Norihiko Tanimoto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Norihiko Tanimoto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Norihiko++Tanimoto">Norihiko Tanimoto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tatsuhiko Ueno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tatsuhiko Ueno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tatsuhiko++Ueno">Tatsuhiko Ueno</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shiho Yamamoto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shiho Yamamoto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shiho++Yamamoto">Shiho Yamamoto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Takahiko Yamamoto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Takahiko Yamamoto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Takahiko++Yamamoto">Takahiko Yamamoto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Naoya Asada</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Naoya Asada</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Laboratory for Development, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Naoya++Asada">Naoya Asada</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kenji Morimoto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kenji Morimoto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Laboratory for Development, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kenji++Morimoto">Kenji Morimoto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shunsuke Einaru</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shunsuke Einaru</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Laboratory for Development, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shunsuke++Einaru">Shunsuke Einaru</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katsunori Sakai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katsunori Sakai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Laboratory for Development, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katsunori++Sakai">Katsunori Sakai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Takushi Kanazu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Takushi Kanazu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Laboratory for Development, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Takushi++Kanazu">Takushi Kanazu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Akihiro Matsuda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Akihiro Matsuda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Laboratory for Development, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Akihiro++Matsuda">Akihiro Matsuda</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yoshitaka Yamaguchi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yoshitaka Yamaguchi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Laboratory for Development, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yoshitaka++Yamaguchi">Yoshitaka Yamaguchi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Takuya Oguma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Takuya Oguma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Takuya++Oguma">Takuya Oguma</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6305-2305" title="Orcid link">http://orcid.org/0000-0002-6305-2305</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maarten Timmers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maarten Timmers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, a division of Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maarten++Timmers">Maarten Timmers</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luc Tritsmans</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luc Tritsmans</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Janssen Research & Development, a division of Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luc++Tritsmans">Luc Tritsmans</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ken-ichi Kusakabe</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ken-ichi Kusakabe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +81-6-6331-6190; Fax: +81-6-6332-6385; Email: <a href="/cdn-cgi/l/email-protection#caa1afa4e7a3a9a2a3e4a1bfb9aba1aba8af8ab9a2a3a5a4a5ada3e4a9a5e4a0ba"><span class="__cf_email__" data-cfemail="452e202b682c262d2c6b2e3036242e24272005362d2c2a2b2a222c6b262a6b2f35">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ken-ichi++Kusakabe">Ken-ichi Kusakabe</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9055-8267" title="Orcid link">http://orcid.org/0000-0001-9055-8267</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Akira Kato</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Akira Kato</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Akira++Kato">Akira Kato</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Gaku Sakaguchi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gaku Sakaguchi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gaku++Sakaguchi">Gaku Sakaguchi</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01917&amp;href=/doi/10.1021%2Facs.jmedchem.0c01917" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1873–1888</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 15, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 November 2020</li><li><span class="item_label"><b>Published</b> online</span>15 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 February 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01917" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01917</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1873%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYuji%2BKoriyama%252C%2BAkihiro%2BHori%252C%2BHisanori%2BIto%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D4%26contentID%3Dacs.jmedchem.0c01917%26title%3DDiscovery%2Bof%2BAtabecestat%2B%2528JNJ-54861911%2529%253A%2BA%2BThiazine-Based%2B%25CE%25B2-Amyloid%2BPrecursor%2BProtein%2BCleaving%2BEnzyme%2B1%2BInhibitor%2BAdvanced%2Bto%2Bthe%2BPhase%2B2b%252F3%2BEARLY%2BClinical%2BTrial%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1888%26publicationDate%3DFebruary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01917"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1729</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01917" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yuji&quot;,&quot;last_name&quot;:&quot;Koriyama&quot;},{&quot;first_name&quot;:&quot;Akihiro&quot;,&quot;last_name&quot;:&quot;Hori&quot;},{&quot;first_name&quot;:&quot;Hisanori&quot;,&quot;last_name&quot;:&quot;Ito&quot;},{&quot;first_name&quot;:&quot;Shuji&quot;,&quot;last_name&quot;:&quot;Yonezawa&quot;},{&quot;first_name&quot;:&quot;Yoshiyasu&quot;,&quot;last_name&quot;:&quot;Baba&quot;},{&quot;first_name&quot;:&quot;Norihiko&quot;,&quot;last_name&quot;:&quot;Tanimoto&quot;},{&quot;first_name&quot;:&quot;Tatsuhiko&quot;,&quot;last_name&quot;:&quot;Ueno&quot;},{&quot;first_name&quot;:&quot;Shiho&quot;,&quot;last_name&quot;:&quot;Yamamoto&quot;},{&quot;first_name&quot;:&quot;Takahiko&quot;,&quot;last_name&quot;:&quot;Yamamoto&quot;},{&quot;first_name&quot;:&quot;Naoya&quot;,&quot;last_name&quot;:&quot;Asada&quot;},{&quot;first_name&quot;:&quot;Kenji&quot;,&quot;last_name&quot;:&quot;Morimoto&quot;},{&quot;first_name&quot;:&quot;Shunsuke&quot;,&quot;last_name&quot;:&quot;Einaru&quot;},{&quot;first_name&quot;:&quot;Katsunori&quot;,&quot;last_name&quot;:&quot;Sakai&quot;},{&quot;first_name&quot;:&quot;Takushi&quot;,&quot;last_name&quot;:&quot;Kanazu&quot;},{&quot;first_name&quot;:&quot;Akihiro&quot;,&quot;last_name&quot;:&quot;Matsuda&quot;},{&quot;first_name&quot;:&quot;Yoshitaka&quot;,&quot;last_name&quot;:&quot;Yamaguchi&quot;},{&quot;first_name&quot;:&quot;Takuya&quot;,&quot;last_name&quot;:&quot;Oguma&quot;},{&quot;first_name&quot;:&quot;Maarten&quot;,&quot;last_name&quot;:&quot;Timmers&quot;},{&quot;first_name&quot;:&quot;Luc&quot;,&quot;last_name&quot;:&quot;Tritsmans&quot;},{&quot;first_name&quot;:&quot;Ken-ichi&quot;,&quot;last_name&quot;:&quot;Kusakabe&quot;},{&quot;first_name&quot;:&quot;Akira&quot;,&quot;last_name&quot;:&quot;Kato&quot;},{&quot;first_name&quot;:&quot;Gaku&quot;,&quot;last_name&quot;:&quot;Sakaguchi&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;1873-1888&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01917&quot;},&quot;abstract&quot;:&quot;Accumulation of amyloid β peptides (Aβ) is thought to be one of the causal factors of Alzheimer’s disease (AD). The aspartyl protease β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the rate-limiting protease for Aβ production, and therefore, BACE1 inhibition is a promising therapeutic approach for the treatment of AD. Starting with a dihydro-1,3-thiazine-based lead, Compound J, we discovered atabecestat 1 (JNJ-54861911) as a centrally efficacious BACE1 inhibitor that was advanced into the EARLY Phase 2b/3 clinical trial for the treatment of preclinical AD patients. Compound 1 demonstrated robust and dose-dependent Aβ reduction and showed sufficient safety margins in preclinical models. The potential of reactive metabolite formation was evaluated in a covalent binding study to assess its irreversible binding to human hepatocytes. Unfortunately, the EARLY trial was discontinued due to significant elevation of liver enzymes, and subsequent analysis of the clinical outcomes showed dose-related cogn&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01917&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01917" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01917&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01917" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01917&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01917" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01917&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01917&amp;href=/doi/10.1021/acs.jmedchem.0c01917" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01917" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01917" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01917%26sid%3Dliteratum%253Aachs%26pmid%3D33588527%26genre%3Darticle%26aulast%3DKoriyama%26date%3D2021%26atitle%3DDiscovery%2Bof%2BAtabecestat%2B%2528JNJ-54861911%2529%253A%2BA%2BThiazine-Based%2B%25CE%25B2-Amyloid%2BPrecursor%2BProtein%2BCleaving%2BEnzyme%2B1%2BInhibitor%2BAdvanced%2Bto%2Bthe%2BPhase%2B2b%252F3%2BEARLY%2BClinical%2BTrial%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D4%26spage%3D1873%26epage%3D1888%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/jmcmar.2021.64.issue-4/20210225/jmcmar.2021.64.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Accumulation of amyloid β peptides (Aβ) is thought to be one of the causal factors of Alzheimer’s disease (AD). The aspartyl protease β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the rate-limiting protease for Aβ production, and therefore, BACE1 inhibition is a promising therapeutic approach for the treatment of AD. Starting with a dihydro-1,3-thiazine-based lead, Compound J, we discovered atabecestat <b>1</b> (JNJ-54861911) as a centrally efficacious BACE1 inhibitor that was advanced into the EARLY Phase 2b/3 clinical trial for the treatment of preclinical AD patients. Compound <b>1</b> demonstrated robust and dose-dependent Aβ reduction and showed sufficient safety margins in preclinical models. The potential of reactive metabolite formation was evaluated in a covalent binding study to assess its irreversible binding to human hepatocytes. Unfortunately, the EARLY trial was discontinued due to significant elevation of liver enzymes, and subsequent analysis of the clinical outcomes showed dose-related cognitive worsening.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88663" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88663" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Globally, there were over 50 million people living with dementia in 2019, and the number is expected to increase to 152 million by 2050.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Alzheimer’s disease (AD) is the most common cause of dementia, which accounts for approximately 60–80% of its cases. The cost of medical care and long-term care for individuals with dementias, including AD, presents a substantial impact on public and personal finance. Indeed, in the United States, the total cost of caring for patients with dementia is estimated to increase from $305 billion in 2020 to more than $1.1 trillion in 2050.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Unfortunately, no therapeutic is yet available to prevent, reverse, or even slow the disease, although some symptomatic agents, such as donepezil or memantine, are being prescribed. Interestingly, one estimation suggests that delaying the onset by just 5 years may suppress the number of cases by up to 50% over 50 years, pointing to the need to develop effective disease-modifying treatments.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Evidence obtained in the Dominantly Inherited Alzheimer Network (DIAN) study enrolling individuals who carry mutations in genes such as APP, PSEN1, or PSEN2 that cause familial AD has indicated that amyloid β peptide 42 (Aβ<sub>42</sub>) levels in the cerebrospinal fluid (CSF) begin to decline 25 years before cognitive impairment becomes evident, and Aβ deposition in the brain is detected 15 years before the onset of symptoms, which points to accumulation of Aβ as a causative of AD.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Amyloid precursor protein (APP) is first cleaved by β-site amyloid precursor protein cleaving enzyme 1 (BACE1, also known as β-secretase) followed by γ-secretase to generate Aβ peptides. As BACE1 is a rate-limiting enzyme of Aβ production, it is one of the prime targets for AD therapeutics, and its inhibition offers the potential to delay or even prevent the disease progression, given its critical role in Aβ accumulation in the pathogenesis of AD.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The Icelandic mutation of A673T in APP reduces affinity for BACE1, resulting in approximately 40% inhibition of Aβ production and is protective against AD and cognitive impairment in elderly individuals, providing further support for BACE1 being a promising target for AD therapeutics.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">Since the identification of BACE1 in 1999, a number of academic and industrial institutes have pursued potent and centrally active BACE1 inhibitors.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Initial explorations focused on transition state and substrate-based drug design, leading to identification of high affinity peptide and peptidomimetic inhibitors with high topological polar surface area (TPSA) and molecular weight. Such physical properties, however, prevented cellular and brain penetration, thereby resulting in suboptimal Aβ reduction in the brain following oral administration. The discovery of amidine-based inhibitors overcame the obstacles observed with the peptidomimetic inhibitors, as they have more optimal TPSA and molecular weight for central nervous system (CNS) drugs.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Elaboration of amidine-based inhibitors along with structure-based drug design and fine-tuning of its basicity culminated in clinical compounds such as atabecestat (JNJ-54861911, <b>1</b>),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> LY-2811376 (<b>2</b>),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> LY-2886721 (<b>3</b>),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> LY-3202626 (<b>4</b>),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> verubecestat (MK-8931, <b>5</b>),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> lanabecestat (AZD-3293, <b>6</b>),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> elenbecestat (E-2609, <b>7</b>),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and umibecestat (CNP-520, <b>8</b>)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>).</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0013.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Representative BACE1 Inhibitors That Advanced into Clinical Trials</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Unfortunately, clinical trials of all of these BACE1 inhibitors were discontinued due to findings of lack of efficacy, retinal/liver toxicity, or even cognitive impairment.<a onclick="showRef(event, 'cit7f ref16'); return false;" href="javascript:void(0);" class="ref cit7f ref16">(7f,16)</a> The clinical trials for compounds <b>1</b>, <b>2</b>, and <b>3</b> were terminated because compounds <b>1</b><a onclick="showRef(event, 'cit8d'); return false;" href="javascript:void(0);" class="ref cit8d">(8d)</a> and <b>3</b><a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> exhibited liver toxicity likely due to the potential of reactive metabolite formation caused by thiazine structures, while retinal toxicity derived from cathepsin D (CatD) inhibition was evident with <b>2</b>.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> This raised the importance of structural alerts resulting in reactive metabolite formation and minimizing inhibition of cathepsin D. Compounds <b>5</b>,<a onclick="showRef(event, 'cit12d cit12e'); return false;" href="javascript:void(0);" class="ref cit12d cit12e">(12d,e)</a><b>6</b>,<a onclick="showRef(event, 'cit13b'); return false;" href="javascript:void(0);" class="ref cit13b">(13b)</a> and <b>7</b><a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a> did not meet their clinical end point or showed no clinical benefit in the interim analysis in patients with mild cognitive impairment (MCI) or mild to moderate AD. Considering that Aβ accumulation begins 15 years before cognitive symptom onset,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> their administration was too late to start therapeutic intervention even for patients with MCI. Two Phase 2/3 clinical trials of compounds <b>1</b> and <b>8</b> evaluated the ability to prevent AD in cognitively unimpaired people who were at high risk for dementia due to AD (i.e., preclinical AD). Disappointingly, both <b>1</b><a onclick="showRef(event, 'cit8c'); return false;" href="javascript:void(0);" class="ref cit8c">(8c)</a> and <b>8</b><a onclick="showRef(event, 'cit15b'); return false;" href="javascript:void(0);" class="ref cit15b">(15b)</a> led to cognitive worsening, and other BACE1 inhibitors <b>4</b> and <b>5</b> also displayed cognitive liability.<a onclick="showRef(event, 'cit12e'); return false;" href="javascript:void(0);" class="ref cit12e">(12e)</a> The clinical evidence points to the importance of further elucidating the biological function of BACE1 and its homologue BACE2, for which the clinical BACE1 inhibitors have suboptimal selectivity. Note that BACE2 was found to be expressed in the brain and to have several neural substrates.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Further considerations are presented in <a class="ref internalNav" href="#sec6" aria-label="Future Directions">Future Directions</a>. Herein, we disclose the design, synthesis, and characterization of thiazine-based BACE1 inhibitors and the rational design based on a p<i>K</i><sub>a</sub> lowering approach which culminated in the discovery of atabecestat <b>1</b> that was advanced into the Phase 2b/3 clinical trial EARLY for the prevention of AD.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Background of Lead Identification</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78878" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78878" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Shortly after BACE1 was discovered in 1999, our research program started with high throughput screening (HTS) using a biochemical HTRF BACE1 assay.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> However, this campaign drew blanks similarly to those of other pharmaceutical companies. Most companies subsequently turned to fragment- or substrate-based drug design utilizing the crystal structure of OM99-2 bound to BACE1.<a onclick="showRef(event, 'cit7a cit7b'); return false;" href="javascript:void(0);" class="ref cit7a cit7b">(7a,b)</a> Regardless of this trend, we devoted our efforts to a phenotypic HTS based on a cellular assay, where cells expressing human wild-type human APP, and inhibition of Aβ<sub>40</sub> levels were measured. In 2003, the HTS campaign successfully afforded a hit compound <b>9</b> with a 1,3-thiazine scaffold having an IC<sub>50</sub> value of 2.6 μM without significant cellular toxicity (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In parallel with our efforts, the research group at Roche also identified <b>9</b> in their HTS campaign.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In 2005, our hit-to-lead efforts utilizing BACE1 structures led to the identification of <b>11</b>, known as Compound J,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> via an interim lead <b>10</b>, which gave the first thiazine-based BACE1 inhibitors disclosed in patent literature. More importantly, the amide linker contained in <b>11</b> is a commonly used pharmacophore in clinical BACE1 inhibitors and contributes to excellent selectivity over the antitarget CatD.<a onclick="showRef(event, 'cit7a'); return false;" href="javascript:void(0);" class="ref cit7a">(7a)</a> Further efforts using parallel synthesis of the amide group resulted in <b>12</b> possessing a cyanopyridine, which mitigated CYP2D6 inhibition (<b>11</b>: IC<sub>50</sub> = <1 μM, <b>12</b>: IC<sub>50</sub> = 3.6 μM). At the time that <b>11</b> and <b>12</b> were identified, avoiding QT interval prolongation caused by inhibition of the hERG channel became a requirement for drug discovery programs;<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> in addition, P-gp mediated transport was found to be the main gatekeeper for the blood–brain barrier (BBB).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Unfortunately, the lead <b>12</b> showed high hERG inhibitory activity (91% inhibition at 5 μM) and high P-gp efflux (efflux ratio = 52 in MDCK cells), which required further optimization to mitigate these issues (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Medicinal chemistry progression from hit to clinical candidate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Inhibitor Design and Optimization</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">At the onset of our lead optimization effort, several reports demonstrated that controlling basicity and lipophilicity could be a successful approach to reducing hERG inhibition.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Analysis of physicochemical features related to P-gp efflux had indicated that a compound with a p<i>K</i><sub>a</sub> < 8 would be less likely to be a P-gp substrate.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The p<i>K</i><sub>a</sub> and LogD at pH 7.4 for <b>12</b> were determined to be 9.0 and 1.2, respectively. Thus, the highly basic and moderately lipophilic profile of <b>12</b> prompted us to adopt the p<i>K</i><sub>a</sub>-lowering approach to reduce both hERG inhibition and P-gp efflux.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> To test this hypothesis, we pursued a series of analogues containing a double bond or a fluorine atom on the thiazine headgroup (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The two analogues with a double bond (<b>1</b> and <b>13</b>) successfully reduced p<i>K</i><sub>a</sub>, leading to a significantly reduced P-gp efflux, whereas the thiazine <b>13</b> with an exocyclic double bond was accompanied by reduced metabolic stability in human and rat microsomes. It was unclear why the P-gp efflux ratio in <b>14</b> with a 4-fluoromethyl group remained moderate-to-high despite a basicity similar to <b>13</b>. Perhaps, the higher intrinsic permeability observed for <b>13</b> relative to that of <b>14</b> could be attributed to the reduced P-gp efflux. Compound <b>1</b> achieved a balanced profile in terms of potency, P-gp efflux, and metabolic stability, whereas the hERG inhibitory activity could be improved.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Head Group Exploration to Reduce Basicity</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0010.gif" alt="" id="GRAPHIC-d7e688-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">BACE1 IC<sub>50</sub> values were determined using biochemical homogeneous time-resolved fluorescence (HTRF)-based assay and are the averages of at least two determinations. For <b>1</b>, mean ± SD was calculated from triplicate data. β-Secretase Inhibitor IV (CAS#: 797035-11-1) showed an IC<sub>50</sub> value of 13 nM.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Cellular IC<sub>50</sub> values were determined by measuring the levels of secreted Aβ<sub>40</sub> in human APP-transfected human neuroblastoma (SH-SY5Y) cells via an HTRF-based assay and are the average of at least two determinations. For <b>1</b>, mean ± SD was calculated from triplicate data. β-Secretase Inhibitor IV showed an IC<sub>50</sub> value of 25 nM.</p></div><div class="footnote" id="t1fn3"><sup><sup>z</sup></sup><p class="last">Metabolic stability represents percent remaining after 30 min incubation in human liver (HLM) and rat (RLM) microsomes.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">hERG inhibition was measured at 5 μM in CHO cells transfected with hERG channels using an automated patch clamp system.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">P-gp efflux ratio was determined with MDCK cells transfected with human MDR1 at Absorption Systems.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Permeability was measured using wild-type MDCK cells.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">p<i>K</i><sub>a</sub> was determined by capillary electrophoresis (CE).</p></div></div><div></div></div><div class="NLM_p">The amide substituents (the tail group) of compound <b>1</b> were explored to lower hERG inhibitory activity (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). As a result, incorporation of substituents at the ortho-position on the carbonyl in <b>1</b>, such as <b>15</b>, lowered hERG activity relative to <b>1</b>, but this improvement came at the cost of increased P-gp efflux. A change to a fluorine instead of the cyano group in <b>1</b> was accompanied by loss of BACE1 and cellular potency. Similarly to compound <b>11</b>, the chloropyridine analogue <b>17</b> had high hERG potency and CYP2D6 inhibition. A significant reduction in hERG potency was realized when a methoxypyrazine was incorporated. Unfortunately, this change was also associated with a CYP2D6 IC<sub>50</sub> value below 1 μM and low metabolic stability in human microsomes. Although a backup program<a onclick="showRef(event, 'ref18 ref25'); return false;" href="javascript:void(0);" class="ref ref18 ref25">(18,25)</a> for atabecestat later showed us how to balance profiles among hERG, CYP2D6 inhibition, and metabolic stability by keeping the methoxypyrazine tail group, this issue was not addressed during this optimization effort. Therefore, compound <b>1</b> (JNJ-54861911, atabecestat) with the most promising profile was advanced to <i><i>in vivo</i></i> cardiovascular safety studies following pharmacokinetic (PK) and pharmacodynamic (PD) characterization to correctly estimate the cardiovascular risk associated with its hERG potential.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Tail Group Exploration to Reduce hERG Potency</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0011.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0012.gif" alt="" id="GRAPHIC-d7e802-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">BACE1 IC<sub>50</sub> values were determined using biochemical homogeneous time-resolved fluorescence (HTRF)-based assay and are the average of at least two determinations.. For <b>1</b>, mean ± SD was calculated from triplicate data. β-Secretase Inhibitor IV (CAS#: 797035-11-1) showed an IC<sub>50</sub> value of 13 nM.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Cellular IC<sub>50</sub> values were determined by measuring the levels of secreted Aβ<sub>40</sub> in human APP-transfected human neuroblastoma (SH-SY5Y) cells via an HTRF-based assay and are the average of at least two determinations. For <b>1</b>, mean ± SD was calculated from triplicate data. β-Secretase Inhibitor IV showed an IC<sub>50</sub> value of 25 nM.</p></div><div class="footnote" id="t2fn3"><sup><sup>z</sup></sup><p class="last">Metabolic stability represents percent remaining after 30 min incubation in human (HLM) and rat liver (RLM) microsomes.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">hERG inhibition was measured at 5 μM in CHO cells transfected with hERG channels using an automated patch clamp system.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">P-gp efflux ratio was determined in MDCK cells transfected with human MDR1 at Absorption Systems.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">CYP2D6 inhibition was measured with 5 μM dextromethorphan using human microsomes.</p></div></div><div></div></div><div class="NLM_p">The cocrystal structure of <b>1</b> bound to human BACE1 was solved (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The amidine on the thiazine headgroup forms hydrogen bond interactions with the catalytic residues Asp32 and Asp228. The amide hydrogen also engaged in the hydrogen bond interaction, confirming the molecular basis of the amide pharmacophore. The cyano group in <b>1</b> projects deeply toward the S3 pocket and forms a van der Waals contact with Ala335, explaining why the fluoro <b>16</b> impaired potency relative to <b>1</b>. The fluorine atom on the phenyl ring also has a van der Waals contact with the side chain of Tyr71. The corresponding nonfluoro analogue showed reduced BACE1 potency (IC<sub>50</sub> = 34 nM vs 9.8 nM; data not shown), confirming the importance of the interaction.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structure of <b>1</b> bound to human BACE1 determined at 2.3 Å resolution (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7DCZ">7DCZ</a>). Key residues of Asp228, Asp32, Tyr71, Gly230, and Ala335 are shown in stick style. Compound <b>1</b> is shown by sticks with green carbons. Oxygen, nitrogen, fluorine, and sulfur atoms are colored red, blue, sky blue, and yellow, respectively. Hydrogen bonds are shown as dashed lines. The pocket surface colored gray is shown in B.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Preclinical Characterization</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55314" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55314" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> <i>In Vitro</i> Profiles</h3><div class="NLM_p">Prior to <i><i>in vivo</i></i> preclinical studies, <i>in vitro</i> pharmacological, physicochemical, and ADME profiles were characterized. Compound <b>1</b> showed comparable potency for mouse and dog BACE1 with IC<sub>50</sub> values of 9.7 and 12 nM, respectively. Compound <b>1</b> was a crystalline material that showed good aqueous solubility of >1000 and 5.6 μg/mL at pH 1.2 and 6.8, respectively. Its LogD at pH 7.4 was 2.4. Regarding the safety pharmacology, its hERG IC<sub>50</sub> value was determined to be 0.50 μM using a manual patch cramp assay; <b>1</b> inhibited BACE2 (IC<sub>50</sub> = 5.6 nM) with comparable potency as for BACE1, whereas it was extremely selective over CatD and CatE (IC<sub>50</sub> = >100 μM). Compound <b>1</b> was not mutagenic in the Ames test.</div><div class="NLM_p last">Metabolic stability in human, rat, mouse, and dog hepatocytes was also moderate-to-good (77, 53, 37, and 81% remaining after 120 min incubation), whereas <b>1</b> was significantly metabolized in monkey hepatocytes (4% remaining). The unbound fraction in serum of <b>1</b> was measured to be 0.060, 0.11, 0.083, 0.077, 0.056, and 0.144 in human, rat, mouse, dog, monkey, and guinea pig. The ability of <b>1</b> to inhibit human CYP isoforms 1A2, 2C9, 2C19, 2D6, and 3A4 was found to be moderate-to-low; compound <b>1</b> showed IC<sub>50</sub> values of 10, 21, >100, 15, and 33 μM, respectively. However, a shift in IC<sub>50</sub> following 30 min preincubation of <b>1</b> was observed (IC<sub>50</sub> = <10 μM), indicating that <b>1</b> may cause time-dependent inhibition (TDI) of CYP3A4, raising concern about clinical drug–drug interactions (DDIs). In addition, the TDI potential observed in <b>1</b> might result in electrophilic reactive metabolite (RM) formation,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> which can deplete the endogenous antioxidant glutathione (GSH) and/or bind covalently to liver proteins, leading to drug-induced liver injury (DILI). The covalent binding of the liver proteins can also trigger an immune response via hapten formation, which is a causal factor of idiosyncratic adverse drug reactions (IADRs).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Therefore, to quantitatively estimate the potential of RM formation, we assessed the covalent binding capability of <b>1</b> following PK/PD characterization and cardiovascular safety study.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> PK/PD Study</h3><div class="NLM_p">Single oral administration of <b>1</b> to rat caused dose-dependent plasma, cortical, and CSF Aβ<sub>40</sub> reductions at doses of 0.1, 0.3, 1, 3, and 10 mg/kg. At 1 mg/kg, reduction in Aβ<sub>40</sub> levels reached approximately 60% in CSF, and significant Aβ reduction was maintained for 10 h (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), where a CSF-to-unbound plasma ratio (<i>K</i><sub>p,uu,CSF</sub>) reached 0.88. The PK/PD profile of <b>1</b> was also evaluated in dog. Repeated oral administration of <b>1</b> for 14 days dose-dependently reduced CSF Aβ<sub>40</sub> and Aβ<sub>42</sub> and maintained 50% Aβ reduction for 24 h at doses above 0.3 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Plasma levels to lower CSF Aβ<sub>40</sub> or Aβ<sub>42</sub> by 50% (EC<sub>50</sub>) were 22 and 24 ng/mL, respectively (unbound EC<sub>50</sub> = 1.9 and 2.0 ng/mL, respectively). No significant difference in CSF Aβ reductions and compound levels (plasma and CSF) between day 1 and day 14 was observed (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01917/suppl_file/jm0c01917_si_001.pdf" class="ext-link">Supporting Information</a>, Table S1). Reflecting the good brain distribution observed in rat, compound <b>1</b> showed high CNS penetration in dog (<i>K</i><sub>p,uu,CSF</sub> = 0.98).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of compound <b>1</b> on CSF Aβ<sub>40</sub> levels after single oral administration in male Sprague–Dawley (Crl:CD(SD)) rats (<i>n</i> = 64, vehicle: 0.5% methyl cellulose (MC); <i>n</i> = 63, untreated control for Aβ measurement; <i>n</i> = 32, each dose). Compound <b>1</b> was administered orally, and Aβ<sub>40</sub> amounts in the CSF were measured using an ELISA system at the points of 0.5, 1, 2, 4, 6, 8, 10, and 24 h after administration. Aβ levels are represented as the percentage of untreated rats at each sampling point. Data shown were mean ± SEM for 7 to 8 rats in each time point of each group. *<i>p</i> < 0.05, **<i>p</i> < 0.01 versus vehicle group (Dunnett’s test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of compound <b>1</b> on CSF Aβ<sub>40</sub> levels after repeated oral administration in TOYO Beagle dogs (<i>n</i> = 3, vehicle; <i>n</i> = 3, each dose). Compound <b>1</b> was administered orally, and Aβ<sub>40</sub> amounts in the CSF were measured using an enzyme-linked immunosorbent assay (ELISA) system at the points of 12 and 24 h after administration at Day 1 (A) and Day 14 (B). Data shown are mean ± standard error of mean (SEM) levels expressed in percent from the predose level for 3 dogs in each group. **<i>p</i> < 0.01 versus vehicle group (Dunnett’s test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Amyloid Plaque Formation</h3><div class="NLM_p">Having established the PK/PD relationship for compound <b>1</b>, the inhibitory effect of <b>1</b> on plaque formation using PS/APP mouse was investigated. Male PS/APP mice (24 to 30 weeks old at the initiation of dosing) were given 15 mg/kg bid or 30 mg/kg qd for 168 days, where <b>1</b> caused significant inhibition of the number of Aβ plaques and Aβ plaque load in the cortex and hippocampus after repeated dosing compared with vehicle treatment (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Taken together, these data demonstrated robust Aβ reduction at low plasma concentrations in rodent and nonrodent species, leading to inhibition of Aβ plaque formation with chromic administration of <b>1</b>.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Aβ plaque quantification in the brain after repeated administration for 168 days in PS/APP mice (B6;SJL-TgN(APPSWE) × PS1<sup>I213T</sup> KI; <i>n</i> = 35, vehicle (0.5% MC); <i>n</i> = 15, untreated control for Aβ measurement; <i>n</i> = 35, each dose). Compound <b>1</b> was administered orally for 168 days, and the number of plaques and the plaque area in the cortex (A and B) and hippocampus (C and D) were measured by immunostaining using antiAβ antibody 24 to 32 h after the last administration. Untreated: control mice before administration (24 to 30 weeks old of PS/APP mice). Data shown are mean ± standard error (SE) for mice in each group. **<i>p</i> < 0.01 versus 0 mg/kg, once daily (vehicle) group (Dunnett’s test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> PK Study in Multiple Species and Human Dose Projection</h3><div class="NLM_p">Pharmacokinetic parameters of <b>1</b> were determined in rat, dog, and monkey (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Reflecting the metabolic stability in hepatocytes, compound <b>1</b> showed good to excellent oral bioavailability and low to moderate total clearance in rat and dog, whereas in monkey, moderate-to-high clearance and moderate oral availability were observed. The volume of distributions at steady state (Vd<sub>ss</sub>) were relatively unchanged across the species and showed high values of ∼3.2, indicating that <b>1</b> can be highly permeable to tissues. Using the PK parameters, allometric scaling along with dog PK/PD data was used for human dose and PK/PD projections. Assuming an oral bioavailability of 50% and absorption rate constant (<i>k</i><sub>a</sub>) of 0.5, the target trough level in plasma was set to the dog EC<sub>50</sub> value, which led to a once daily projected dose of 30 mg with estimated <i>C</i><sub>max</sub> and AUC of 61.8 ng/mL and 672 ng·h/mL, respectively.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. PK Profiles of 1 in Rats, Dogs, and Monkeys</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">iv<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">po<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Vd<sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat/Sprague–Dawley<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">22.8</td><td class="colsep0 rowsep0" align="char" char=".">4.46</td><td class="colsep0 rowsep0" align="char" char=".">5.52</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">386</td><td class="colsep0 rowsep0" align="char" char=".">73.9</td><td class="colsep0 rowsep0" align="char" char=".">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog/beagle<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">6.02</td><td class="colsep0 rowsep0" align="char" char=".">3.13</td><td class="colsep0 rowsep0" align="char" char=".">8.48</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">2610</td><td class="colsep0 rowsep0" align="char" char=".">223</td><td class="colsep0 rowsep0" align="char" char=".">87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey/cynomolgus<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">16.3</td><td class="colsep0 rowsep0" align="char" char=".">2.87</td><td class="colsep0 rowsep0" align="char" char=".">2.72</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">337</td><td class="colsep0 rowsep0" align="char" char=".">30.7</td><td class="colsep0 rowsep0" align="char" char=".">32</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Dosed as a solution of DMA/20% HP-β-CD in 100 mmol/L citrate buffer solution (1:9, v/v).</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Dosed as a suspension of 0.5% (w/v) MC aqueous solution.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last"><i>n</i> = 4.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last"><i>n</i> = 3.</p></div></div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Covalent Binding</h3><div class="NLM_p">To estimate the potential for bioactivation of <b>1</b>, metabolism-dependent covalent binding (CVB) was determined (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The CVB study was carried out with human liver microsomes at concentrations of 10 and 50 μM of <b>1</b>. Radiolabeled compound <b>1</b> with a <sup>14</sup>C atom on the amidine carbon was synthesized to measure the CVB levels of <b>1</b> based on the total amount of radio activity (synthesis of [<sup>14</sup>C]-<b>1</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01917/suppl_file/jm0c01917_si_001.pdf" class="ext-link">Supporting Information</a>). The use of CVB evaluation has been well-discussed in several articles.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> For comparison, pioglitazone was included as a control with a low concern of DILI risks. Although pioglitazone was used as a negative control given its rare frequency of DILI, it was indeed associated with elevations of liver enzymes in the clinic.<a onclick="showRef(event, 'cit26d'); return false;" href="javascript:void(0);" class="ref cit26d">(26d)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, compound <b>1</b> was found to form RM(s) and showed metabolite NADPH-dependent CVB values of 419 and 3780 pmol/mg protein at 10 and 50 μM, respectively. Importantly, no significant difference in CVB burden between <b>1</b> and pioglitazone was observed, indicating that the likelihood of DILI risks might be of the same level as pioglitazone. However, primary pathways of metabolism observed in human hepatocytes and <i>in vivo</i> were found to be hydrolysis of the amide bond to form the aniline and GSH addition. Based on the current understanding of the metabolic pathways, microsomal incubations may not be relevant to estimate the human situations; GSH addition and amide hydrolysis could be underestimated in microsomes, which is a limitation of this study.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Covalent Bond Binding Values of [<sup>14</sup>C]-<b>1</b> and [<sup>3</sup>H]-Pioglitazone in Human Liver Microsomes</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">concentration (μmol/L)</th><th class="colsep0 rowsep0" align="center" char=".">total covalent bond binding (pmol/mg protein)</th><th class="colsep0 rowsep0" align="center" char=".">NADPH independent covalent bond binding (pmol/mg protein)</th><th class="colsep0 rowsep0" align="center" char=".">NADPH dependent covalent bond binding (pmol/mg protein)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">[<sup>14</sup>C]-<b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">425</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">419</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">3804</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">3780</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">[<sup>3</sup>H]-pioglitazone</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">599</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">594</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">3458</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">3446</td></tr></tbody></table></div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Cardiovascular Safety Study</h3><div class="NLM_p last">As discussed above, compound <b>1</b> inhibited the hERG channel with an IC<sub>50</sub> value of 0.50 μM in a manual patch clamp assay. Therefore, the potential of cardiovascular safety associated with hERG inhibition was evaluated in guinea pig and dog. In urethane-anesthetized guinea pigs (<i>n</i> = 4), compound <b>1</b> was administered intravenously at doses of 1, 3, and 10 mg/kg over a period of 10 at 30 min intervals, with no notable effect on QTc prolongation (less than 10%) being observed at doses of up to 10 mg/kg. Mean <i>C</i><sub>max</sub> values at 1, 3, and 10 mg/kg were measured to be 264, 1180, and 4680 ng/mL, respectively. Based on the no-observed-adverse-effect level (NOAEL) of the <i>C</i><sub>max</sub> at 10 mg/kg (1783 nM free) and the human projected <i>C</i><sub>max</sub> (168 nM, 9.42 nM free), the safety margin in this study was calculated to be 189-fold. In conscious dogs (<i>n</i> = 3), <b>1</b> was administered orally at doses of 3, 10, and 100 mg/kg. Although no significant QTc prolongation was seen at 3 and 10 mg/kg, compound <b>1</b> prolonged QTc up to 15.1% relative to vehicle at 100 mg/kg, with the <i>C</i><sub>max</sub> values being 438, 1287, and 3467 ng/mL at 3, 10, and 100 mg/kg, respectively. The safely margin over the NOAEL (595 nM free) at 10 mg/kg was determined to be 63-fold. With the favorable cardiovascular safety profile observed in these studies, compound <b>1</b> progressed to tolerability studies.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Repeated Dose Toxicology Study in Rat and Dog</h3><div class="NLM_p last">Prior to the repeated dose studies, oral single dose studies were performed in rats and dogs. In rats, no adverse effects were observed at 0, 20, 60, and 200 mg/kg, whereas significant findings, such as salivation and hypothermia, were observed at 2000 mg/kg. In single dose studies in dogs, compound <b>1</b> was given at 0, 30, 100, and 300 mg/kg, with tonic conversion being observed at 300 mg/kg. Based on the adverse effects observed in the single dose studies, doses for repeated dose studies in rats and dogs for a period of 1-month were set to 0. 20, 60, and 200 mg/kg/day in rats (<i>n</i> = 10 animals/sex/group) and 0, 3, 10, 100 mg/kg/day in dogs (<i>n</i> = 4 animals/sex/group). In the 1-month study in rats, an NOAEL of 20 mg/kg/day was established, with AUCs in males and females being 10.6 and 20.6 μg.h/mL, respectively. At 200 mg/kg, there were several clinical pathology changes including decrease in red blood cell parameters and increase in cholesterol and liver enzymes of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The mean safety margin of males and females over the human projected AUC (0.672 μg·h/mL) was considered to be 23-fold. In the 1-month dog study, short-lasting clonic convulsions and QTc prolongation were pronounced at 100 mg/kg. In addition, slight decreases in red blood cell and serum parameters, such as ALT, alkaline phosphatase (ALP), and cholesterol, were seen without any histological correlates. The NOAEL was determined to be 10 mg/kg/day, with the AUC being 18.4 and 11.5 μg·h/mL in males and females, respectively, and the mean safety margin of both sexes being 22.3-fold. On the basis of the safety profiles observed in the tolerability study as well as other nonclinical results, we selected <b>1</b> (JNJ-54861911, atabecestat) as our candidate for clinical development.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Summary of Clinical Studies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36024" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36024" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A series of Phase 1 clinical studies to assess PK, safety, and PD effects on Aβ production was conducted with healthy participants. In single (SAD) and multiple ascending dose (MAD) studies, <b>1</b> was well-tolerated at doses of up to 150 mg/day; <b>1</b> was given once per day for 14 days in the MAD study. Dose-dependent reductions of CSF Aβ<sub>40</sub> were observed, reaching approximately 50, 80–85, 90, and 90–95% reductions at 5, 30, 50, and 90 mg/day, respectively, on day 14. The mean <i>C</i><sub>max</sub> values for 5, 30, and 50 mg/day on day 14 were 38.7, 202, and 364 ng/mL, respectively. Also, the mean AUC values were 548, 2897, and 5509 ng·h/mL, respectively.<a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">(8a)</a> Consistent with the animal data, compound <b>1</b> showed high CNS penetration (<i>K</i><sub>p,uu,CSF</sub> = 0.69, measured at 30 mg/day on day 14 based on the AUC values).</div><div class="NLM_p">A clinical DDI study was performed to evaluate the interaction potential of <b>1</b> as a perpetrator when coadministered with a drug cocktail of CYP3A4, CYP2C9, and CYP1A2 substrates, i.e. midazolam, caffeine, and tolbutamide. No significant changes in PK parameters for the drug cocktail with and without <b>1</b> were observed following single-dose administration, indicating no clinically significant effects on the activity of the CYP enzymes. The DDI effects observed in the nonclinical study were not reflected in the clinic.<a onclick="showRef(event, 'cit8c'); return false;" href="javascript:void(0);" class="ref cit8c">(8c)</a></div><div class="NLM_p">A thorough QT study was performed with healthy participants given a therapeutic dose of 50 mg/day and a supratherapeutic dose of 150 mg/day. Compound <b>1</b> showed clinically relevant QTc prolongation at 150 mg/kg on Day 7, whereas the dose of 50 mg/day did not carry regulatory concerns for QTc prolongation according to the guidelines. The mean <i>C</i><sub>max</sub> values for 50 and 150 mg/day following 7-day administrations were 513 and 1380 ng/mL, respectively. The unbound <i>C</i><sub>max</sub> at 150 mg/day was calculated to be 0.21 μM, which was at a similar level to the hERG IC<sub>50</sub> value of 0.50 μM.<a onclick="showRef(event, 'cit8c'); return false;" href="javascript:void(0);" class="ref cit8c">(8c)</a></div><div class="NLM_p last">Prior to large phase 2b/3 global clinical development, a Phase 2a clinical study was started to evaluate PD activity of <b>1</b> in the intended target population of patients diagnosed with early AD, i.e., preclinical AD (Clinical Dementia Rating (CDR) = 0) or mild cognitive impairment due to AD (CDR = 0.5) with a positive CSF biomarker signature (reduced CSF amyloid levels). The patients given a once-daily dose of 10 mg or 50 mg for 4 weeks achieved 60–70% and 90% CSF Aβ<sub>40</sub> reductions compared with the placebo, respectively.<a onclick="showRef(event, 'cit8b'); return false;" href="javascript:void(0);" class="ref cit8b">(8b)</a> The Phase 2b/3 EARLY clinical trial enrolled 557 patients with preclinical AD randomized to 5 mg or 25 mg <b>1</b> or placebo. Significant increase in ALS and AST (>3 times the upper limit of the normal level (ULN)) was observed in 11% of patients treated with <b>1</b>, compared to 0.5% of patients receiving the placebo; one patient receiving 25 mg of <b>1</b> met the criteria of Hy’s Law (ALT more than 3 times ULN and total bilirubin more than 2 times ULN), which led to discontinuation of further development of <b>1</b>.<a onclick="showRef(event, 'cit8d'); return false;" href="javascript:void(0);" class="ref cit8d">(8d)</a> The EARLY trial evaluated the efficacy of <b>1</b> using the Preclinical Alzheimer’s Cognitive Composite (PACC) score as the primary end point and the Repeatable Battery for the Assessment of Neuropsychological Battery (RBANS) score as a secondary end point. At 6 and 12 months, worsening of cognitive performance was evident at doses of 5 and 25 mg compared to the placebo. Decline in the RBANS total score at 3 months was also observed for the treatment group over the placebo. In addition to the cognitive worsening, neuropsychiatric adverse events, such as depression, sleep/dreaming, and anxiety, were confirmed in the treatment group over the placebo group levels.<a onclick="showRef(event, 'cit8c'); return false;" href="javascript:void(0);" class="ref cit8c">(8c)</a></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Future Directions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33337" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33337" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To date, all BACE1 inhibitor clinical trials have been discontinued.<a onclick="showRef(event, 'cit7f ref16'); return false;" href="javascript:void(0);" class="ref cit7f ref16">(7f,16)</a> Initial clinical-stage BACE1 inhibitors such as <b>2</b> and AMG-8718 could not achieve selectivity over CatD, resulting in retinal toxicity.<a onclick="showRef(event, 'cit7b ref9 ref27'); return false;" href="javascript:void(0);" class="ref cit7b ref9 ref27">(7b,9,27)</a> Extending substituents into the S3 pocket using amide groups addressed the issue of selectivity over CatD, leading to thiazine-based inhibitors <b>1</b>, <b>3</b>, and <b>7</b>.<a onclick="showRef(event, 'cit7a cit7b'); return false;" href="javascript:void(0);" class="ref cit7a cit7b">(7a,b)</a> Although the thiazines were found to be potent in humans, the substructure has the potential to form reactive metabolites, which may have led to the significant elevation of liver enzymes observed with compounds <b>1</b> and <b>3</b>, consequently resulting in their termination.<a onclick="showRef(event, 'cit8d ref10'); return false;" href="javascript:void(0);" class="ref cit8d ref10">(8d,10)</a> In addition to the structural issue, initial BACE1 inhibitors containing an amidine moiety have high basicity along with a certain level of lipophilicity, which is likely to be associated with liabilities on P-gp recognition, CYP2D6 inhibition, and phospholipidosis. Significant medicinal chemistry efforts were able to balance basicity and lipophilicity to mitigate the issues and culminate in compounds <b>5</b> and <b>8</b>, except for suboptimal selectivity over BACE2.<a onclick="showRef(event, 'cit7a cit7b'); return false;" href="javascript:void(0);" class="ref cit7a cit7b">(7a,b)</a></div><div class="NLM_p">Disappointingly, both compounds <b>5</b> and <b>8</b> as well as <b>1</b> progressed into Phase 3 clinical trials but led to a cognitive deficit in prodromal and preclinical AD patients,<a onclick="showRef(event, 'cit8c cit12e cit15b'); return false;" href="javascript:void(0);" class="ref cit8c cit12e cit15b">(8c,12e,15b)</a> although compound <b>6</b> did not lead to cognitive decline in MCI and mild AD patients.<a onclick="showRef(event, 'cit13b'); return false;" href="javascript:void(0);" class="ref cit13b">(13b)</a> Neuropsychiatric adverse events were evident in the treatment groups compared with the placebo among the BACE1 inhibitors.<a onclick="showRef(event, 'cit8c cit12e'); return false;" href="javascript:void(0);" class="ref cit8c cit12e">(8c,12e)</a> Such evidence hints at the involvement of on-target mechanisms. Although initial investigations of BACE1 KO mice did not disclose major phenotypes, several mild neuronal phenotypes, such as reduced myelination, synaptic deficits, impaired memory, and axonal targeting errors, were revealed in more in-depth studies. BACE1 is found to have numerous substrates and thereby plays an important role in a number of functions in the brain.<a onclick="showRef(event, 'ref16 ref28'); return false;" href="javascript:void(0);" class="ref ref16 ref28">(16,28)</a> Indeed, the undesirable phenotypes observed in BACE1 KO mice, such as hypomyelination, deficient synaptic plasticity, or axon guidance abnormalities, can be explained by loss of the function of BACE1 substrates such as neuregulin 1 (NRG1), seizure protein 6 (SEZ6), or a close homologue of the neural cell adhesion molecule L1 (CHL1), respectively.<a onclick="showRef(event, 'ref16 ref28'); return false;" href="javascript:void(0);" class="ref ref16 ref28">(16,28)</a> Therefore, the key to restart development of a BACE1 inhibitor is to identify the level of BACE1 inhibition that can discriminate achieving efficacy from causing cognitive worsening. We believe that progress in biomarkers to measure levels of Aβ and p-tau181/p-tau217 in the plasma could pave the way to correctly estimate the timing of the intervention through the development of Aβ antibodies such as aducanumab or BAN2410. However, considering the cognitive worsening observed with the BACE1 inhibitors, biomarkers capable of early detection of cognitive symptoms or any other neuronal functional changes are required to ensure further development from the ethical standpoint. An alternative approach would be the development of a BACE1 inhibitor with substrate selectivity for APP versus the nondesired BACE1 substrate that causes the cognitive worsening.</div><div class="NLM_p last">The BACE1 inhibitors exhibiting cognitive decline lack selectivity over BACE2.<a onclick="showRef(event, 'cit7f ref16'); return false;" href="javascript:void(0);" class="ref cit7f ref16">(7f,16)</a> Although compound <b>8</b> did not show hypopigmentation in preclinical models or significant hair color changes in humans, it has only 3-fold selectivity over BACE2.<a onclick="showRef(event, 'cit15b'); return false;" href="javascript:void(0);" class="ref cit15b">(15b)</a> Regarding the selectivity of <b>1</b> and <b>5</b>, they were slightly BACE2 selective given their IC<sub>50</sub> ratios.<a onclick="showRef(event, 'cit12a cit12b'); return false;" href="javascript:void(0);" class="ref cit12a cit12b">(12a,b)</a> The physiological functions of BACE2 are much less known than those of BACE1. Unlike BACE1, BACE2 is highly expressed in peripheral tissues, such as the pancreas, skin, or eye, but is also present at low levels in the brain.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Early investigations identified peripheral BACE2 substrates, such as the pigment cell-specific melanocyte protein (PMEL),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> the pro-proliferative type I transmembrane protein 27 (TMEM27),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and islet amyloid peptide (IAPP).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> BACE2 processes PMEL, which is expressed in the pigment cells of the eye and skin to generate functional amyloids and consequently cause melanogenesis. Indeed, BACE2 KO mice exhibited fur depigmentation, implying its important role during melanogenesis.<a onclick="showRef(event, 'ref5 ref16'); return false;" href="javascript:void(0);" class="ref ref5 ref16">(5,16)</a> As for TMEM27 and IAPP, they are responsible for glucose homeostasis. Inhibition of processing of TMEM27 in pancreatic β-cells using BACE2 KO mice led to increased β-cell production. Both IAPP and insulin are secreted into the blood, where IAPP has a protective role against glucose metabolism.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Recent reports highlighted certain roles of BACE2 in the brain.<a onclick="showRef(event, 'ref17 ref32'); return false;" href="javascript:void(0);" class="ref ref17 ref32">(17,32)</a> The authors pinpointed the expression of BACE2 in neurons and glia and identified several BACE2 substrates in the brain. Of these, the vascular cell adhesion molecule 1 (VCAM1) was found to play a role in neuroinflammation, which is one of the hallmarks of AD, as inflammation stimuli were found to increase VCAM expression.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Another report points to BACE2 as a protective enzyme against amyloidosis.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> People with Down’s syndrome have triplication of chromosome 21, and 70% develop AD during their lifetime, whereas 100% of non- Down’s syndrome people inheriting triplication of APP display AD-like symptoms. The BACE2 gene also sits on chromosome 21 and is known to have θ-secretase activity, preventing formation of Aβ and serving as an Aβ-degrading protease. The authors indicated that BACE2 could contribute to the delayed onset in 30% of individuals with Down’s syndrome and serve as an AD suppressor gene.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The accumulated evidence for BACE2 indicates that chronic inhibition of BACE2 could cause unwanted side effects and thereby warrant pursuing BACE1 selective inhibitors. However, although the above findings suggest the potential involvement of cognitive function derived from BACE2, there is no direct evidence linking BACE2 inhibition to the cognitive worsening that has backed BACE1 inhibitors into a corner. Taken together, elucidating the biological functions of BACE1, along with development of biomarkers to measure the unwanted side effects derived from BACE1 inhibition, are required to identify the levels at which a given BACE1 inhibitor can achieve efficacy but avoid cognitive worsening. It also remains a critical challenge to elucidate BACE2 biology in the brain as well as its involvement in cognitive function. We believe that accumulation of such evidence can lead to restarting the development of next-generation BACE1 inhibitors with high selectivity over BACE2.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14243" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14243" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The medicinal chemistry routes of synthesizing <b>1</b> and its analogues possessing different tail groups are outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Well-established diastereoselective alkylation to an Ellman’s imine of <b>21</b><a onclick="showRef(event, 'cit18a'); return false;" href="javascript:void(0);" class="ref cit18a">(18a)</a> enabled construction of the <i>tert</i>-amine <b>22</b> having the desired chiral stereocenter. The amine <b>22</b> was treated with HCl to remove both <i>t-</i>butyl sulfinyl and <i>t</i>-butyl groups, followed by borane reduction to afford the amino alcohol <b>23</b>. After 9-fluorenylmethoxycarbonyl (Fmoc) protection of the amino group, the primary alcohol was oxidized with 2-iodoxybenzoic acid (IBX), and the resulting aldehyde was converted to dimethylacetal, which was subsequently treated with piperidine to remove the Fmoc group to afford <b>24</b>. The obtained amine was reacted with benzoyl isothiocyanate to form <i>N</i>-hydroxypropyl thiourea followed by cyclization under acidic conditions to give <b>25</b>. After reduction of the nitro group using iron, the aniline <b>26</b> was successfully condensed with the corresponding carboxylic acids using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> or 1-(3-dimehylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC·HCl) with 1 equiv of HCl to furnish the targeting thiazine <b>1</b> and its analogues <b>15</b>–<b>18</b>.</div><figure id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>1</b> and Its Analogues <b>15</b>–<b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (<i>i</i>-Pr)<sub>2</sub>NH, <i>n</i>-BuLi, <i>t</i>-BuOAc, Ti(O<i>i</i>-Pr)<sub>3</sub>Cl, THF, −78 °C, 77%; (b) HCl, MeOH, dioxane, rt: (c) BH<sub>3</sub>, 0 °C to rt, then HCl, EtOAc, <i>i</i>-Pr<sub>2</sub>O, rt; (d) NaHCO<sub>3</sub>, Fmoc <i>N</i>-hydroxysuccinimide ester, THF/H<sub>2</sub>O; (e) IBX, DMSO, rt; (f) CH(OMe)<sub>3</sub>, Amberlite, MeOH, reflux, then piperidine, DMF, rt, 54% in 3 steps; (g) BzNCS, acetone 0 °C then H<sub>2</sub>SO<sub>4</sub>, 40 °C, 78%; (h) Fe, AcOH/H<sub>2</sub>O, 50 °C, 92%; (i) RCO<sub>2</sub>H, DMT-MM, MeOH, rt; or RCO<sub>2</sub>H, HCl, EDC·HCl, MeOH, 0 °C, 16–88%.</p></p></figure><div class="NLM_p">The thiazine <b>13</b>, which has an exocyclic alkene moiety, was synthesized by a procedure outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The thiourea <b>28</b> was prepared from <b>27</b><a onclick="showRef(event, 'cit18a'); return false;" href="javascript:void(0);" class="ref cit18a">(18a)</a> by removal of the sulfinyl group, followed by thiourea formation. The thiazine ring possessing exo-olefin <b>29</b> was constructed by iodine-mediated cyclization and the telescoped elimination reaction. After global deacylation by hydrazine, the resulting aniline <b>30</b> was condensed with 5-cyanopicolinic acid to afford <b>13</b>.</div><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Thiazine <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HCl, H<sub>2</sub>O, rt; (b) BzNCS, DCM, 0 °C to rt, 95% in 2 steps; (c) I<sub>2</sub>, DCM, rt; (d) pyrrolidine, THF, 60 °C, 80% in 2 steps; (e) hydrazine hydrate, EtOH, rt, 74%; (f) 5-cyanopicolinic acid, DMT-MM, MeOH, rt, 46%.</p></p></figure><div class="NLM_p">Synthesis of 4-fluoromethyl dihydrothiazine <b>14</b> commenced with the addition of <i>tert</i>-butyl acetate to the known Ellman’s imine <b>31</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The resulting <i>tert</i>-butyl ester was converted to a carboxylic acid and reduced to the primary alcohol <b>32</b> by borane. The thiazine cyclization was accomplished by Ghosez’s reagent<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> after benzoylthiourea formation to give <b>33</b>. Debenzoylation, regioselective nitration, and reduction followed by condensation with 5-cyanopicolinic acid afforded the desired thiazine <b>14</b> possessing a fluoromethyl group.</div><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Dihydrothiazine <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LDA, <i>t</i>-BuOAc, Ti(O<i>i-</i>Pr)<sub>3</sub>Cl, THF, −78 °C; (b) HCl, dioxane, 60 °C; (c) BH<sub>3</sub>, THF, 45 °C, 75% in 3 steps; (d) BzNCS, DCM, 0 °C to rt; (e) Ghosez’s reagent, DCM, 0 °C to rt, 81% in 2 steps; (f) aq. H<sub>2</sub>SO<sub>4</sub>, 50 °C, 71%; (g) H<sub>2</sub>SO<sub>4</sub>, HNO<sub>3</sub>, 98%; (h) Fe, HCl, MeOH, 50 °C; (i) 5-cyanopicolinic acid, HCl, WSCD·HCl, MeOH, rt, 53% in 2 steps.</p></p></figure></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58003" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58003" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Starting with the lead compound <b>12</b>, we designed and synthesized thiazine head groups that undergo key interactions with the catalytic aspartic acid residues through leveraging the p<i>K</i><sub>a</sub> lowering approach, and the subsequent medicinal chemistry efforts culminated in the discovery of compound <b>1</b>, which mitigated high P-gp efflux and consequently demonstrated robust central Aβ reduction in preclinical models. Compound <b>1</b> was a potent inhibitor of BACE2 but completely avoided inhibition of CatD. Although <b>1</b> inhibited hERG at submicromolar concentrations, its promising potency ensured a safety margin in nonrodent cardiovascular models. Time-dependent inhibition (TDI) of CYP3A4 and covalent binding to human hepatocytes using radiolabeled <b>1</b> were confirmed, implying that <b>1</b> has the potential to form reactive metabolites. Human dose projection along with the CVB study in human microsomes indicated that the likelihood of DILI risks might be at the same level as pioglitazone. Compound <b>1</b> demonstrated robust and dose-dependent inhibition of Aβ production in humans and advanced to the EARLY Phase 2b/3 clinical trial. Unfortunately, significant elevation of liver enzymes halted further development of compound <b>1</b>, and subsequent analysis of clinical efficacy confirmed dose-dependent cognitive worsening.</div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20268" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20268" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Chemistry</h3><div class="NLM_p last">All commercial solvents and reagents were used without further purification. Column chromatography was done on a purification system using prepacked silica gel columns (Fuji Silysia, Biotage, or Yamazen). <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance system operating at 400 and 100 MHz, respectively. Chemical shifts are reported as ppm, and tetramethylsilane was used as an internal reference. For peak multiplicities, the following abbreviations are used: singlet (s), doublet (d), double doublets (dd), double double doublet (ddd), double triplet (dt), triplet (t), quartet (q), multiplet (m), and broad peak (br). The purity of the compounds used in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> was greater than 95% using the following analysis method: analytical LC/MS was done on a Shimadzu Shim-pack XR-ODS (C<sub>18</sub>, 2.2 μm, 3.0 × 50 mm; a linear gradient from 10% to 100% B over 3 min and then 100% B for 1 min (A = 0.1% formic acid in water, B = 0.1% formic acid in MeCN); flow rate = 1.6 mL/min) using a Shimadzu UFLC system equipped with a LCMS-2020 mass spectrometer, SPD-M20A photodiode array detector (detection at 254 nm), LC-20AD binary gradient module, and SIL-20AC sample manager. High resolution mass spectra (HRMS) were determined with a Thermo Fisher Scientific LTQ Orbitrap.</div></div><div id="sec9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>tert</i>-Butyl (<i>S</i>)-3-(((<i>R</i>)-<i>tert</i>-Butylsulfinyl)amino)-3-(2-fluoro-5-nitrophenyl)butanoate (<b>22</b>)</h3><div class="NLM_p last">To a stirred solution of diisopropylamine (13.1 mL, 21.0 mmol) in THF (8.0 mL) was added <i>n</i>-butyllithium (1.6 M in <i>n</i>-hexane, 3.26 mL, 27.9 mmol) at −78 °C. After stirring for 30 min at 0 °C, <i>tert</i>-butyl acetate (3.26 mL, 24.5 mmol) in THF (8.0 mL) was added at −78 °C. After stirring for 30 min at the same temperature, Ti(O<i>i</i>-Pr)<sub>3</sub>Cl (7.03 mL, 27.9 mmol) in THF (8.0 mL) was added and stirred for 30 min at the same temperature. To the solution, <b>21</b><a onclick="showRef(event, 'cit18a'); return false;" href="javascript:void(0);" class="ref cit18a">(18a)</a> (2.00 g, 6.99 mmol) in THF (8.0 mL) was added at −78 °C. After stirring for 2 h, the reaction mixture was poured into aq. NH<sub>4</sub>Cl, and volatile solvents were evaporated. Water was added to the residue, and the aqueous layer was extracted with EtOAc. The organic layer was washed with water and brine, then dried over Na<sub>2</sub>SO<sub>4</sub>. The crude product was purified by silica gel column chromatography (<i>n</i>-hexane/EtOAc) to afford <b>22</b> (2.16 g, 5.37 mmol, 77%) as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.30 (9H, s), 1.86 (3H, s), 3.11 (1H, dd, <i>J</i> = 16.2, 2.1 Hz), 3.26 (1H, dd, <i>J</i> = 16.2, 2.1 Hz), 5.55 (1H, s), 7.18 (1H, dd, <i>J</i> = 11.1, 8.9 Hz), 8.18 (1H, ddd, <i>J</i> = 8.9, 4.0, 2.8 Hz), 8.53 (1H, dd, <i>J</i> = 7.0, 2.8 Hz). MS-ESI (<i>m</i>/<i>z</i>): 403 [M + H]<sup>+</sup>.</div></div><div id="sec9_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>S</i>)-3-Amino-3-(2-fluoro-5-nitrophenyl)butan-1-ol hydrochloride (<b>23</b>)</h3><div class="NLM_p last">To <b>22</b> (14.1 g, 34.9 mmol) were added HCl (4 M in dioxane, 52 mL) and MeOH (1.7 mL, 41.9 mmol), and the solution was stirred overnight. To the reaction mixture was added ether (150 mL), and the resulting precipitate was filtered, washed with ether, and then dried. To a stirred solution of BH<sub>3</sub> (1.0 M in THF 92 mL, 92 mmol), the residue was added portionwise at 0 °C. After stirring at rt overnight, the reaction mixture was poured into ice water, and aq 1 M NaOH was added to basify the reaction medium. The aqueous layer was extracted with EtOAc, and the organic layer was washed with brine, dried over MgSO<sub>4</sub>, and then dried under reduced pressure. To the resulting brown oil were added diisopropyl ether and HCl (4 M in EtOAc, 8 mL) to give a precipitate, which was filtered and dried to afford <b>23</b> (6.12 g, 23.1 mmol, 75%) as a brown solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.78 (3H, s), 2.21–2.34 (2H, m), 3.27–3.50 (3H, m), 7.64 (1H, dd, <i>J</i> = 11.6, 9.1 Hz), 8.36–8.48 (2H, m), 9.06 (3H, br s). MS-ESI (<i>m</i>/<i>z</i>): 229 [M + H]<sup>+</sup>.</div></div><div id="sec9_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>S</i>)-2-(2-Fluoro-5-nitrophenyl)-4,4-dimethoxybutan-2-amine (<b>24</b>)</h3><div class="NLM_p last">To a stirred solution of <b>23</b> (6.12 g, 23.1 mmol) in THF/water (60 mL/30 mL) were added NaHCO<sub>3</sub> (3.88 g, 46.2 mmol) and Fmoc <i>N</i>-hydroxysuccinimide ester (7.80 g, 23.1 mmol) at room temperature. After stirring for 2 h at the same temperature, the aqueous layer was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. To the residue in DMSO (30 mL) was added 2-iodobenzoic acid (6.47 g, 23.1 mmol) at room temperature. After stirring overnight, water and EtOAc were added, and then the insoluble materials were filtered off. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. To the residue in MeOH (100 mL) were added methyl orthoformate (0.128 mL, 1.16 mmol) and Amberlite (2.0 g), and the solution was heated to reflux for 2.5 h. Insoluble materials were filtered off, and the volatile compounds were removed under reduced pressure. To the residue were added DMF (20 mL) and piperidine (2.75 mL, 27.7 mmol). After stirring for 40 min, piperidine (0.69 mL, 6.95 mmol) was added, and the solution was stirred for an additional 30 min. To the reaction mixture were added AcOH and water. The aqueous layer was extracted with EtOAc, and the organic layer was washed with water and brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (<i>n</i>-hexane/EtOAc, 50–80% EtOAc) to afford <b>24</b> (3.37 g, 12.4 mmol, 54%) as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.57 (3H, s), 2.09 (1H, dd, <i>J</i> = 14.4, 6.8 Hz), 2.35–2.42 (1H, m), 3.19 (6H, s), 4.13 (1H, dd, <i>J</i> = 6.8, 4.3 Hz), 7.16 (1H, dd, <i>J</i> = 10.8, 9.0 Hz), 8.13–8.18 (1H, m), 8.62 (1H, dd, <i>J</i> = 6.8, 2.8 Hz). MS-ESI (<i>m</i>/<i>z</i>): 273 [M + H]<sup>+</sup>.</div></div><div id="sec9_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>S</i>)-4-(2-Fluoro-5-nitrophenyl)-4-methyl-4<i>H</i>-1,3-thiazin-2-amine (<b>25</b>)</h3><div class="NLM_p last">To a stirred solution of <b>24</b> (3.37 g, 12.4 mmol) in acetone (12 mL) was added benzoyl isothiocyanate (1.70 mL, 12.6 mmol) at 0 °C. After stirring for 30 min, conc. H<sub>2</sub>SO<sub>4</sub> (13 mL) was added, and the solution was heated to 40 °C overnight. To the reaction mixture were added ice (40 g), THF (10 mL), and conc. aqueous ammonia (20 mL). The aqueous layer was extracted with EtOAc, and the organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (<i>n</i>-hexane/EtOAc, 20–50% EtOAc) to afford <b>25</b> (2.59 g, 9.69 mmol, 78%) as a yellow foam. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.70 (3H, s), 6.24 (1H, dd, <i>J</i> = 9.5, 4.6 Hz), 6.34 (1H, d, <i>J</i> = 9.5 Hz), 7.16 (1H, dd, <i>J</i> = 10.5, 8.8 Hz), 8.13 (1H, ddd, <i>J</i> = 8.8, 4.1, 3.0 Hz), 8.43 (1H, dd, <i>J</i> = 6.8, 3.0 Hz). MS-ESI (<i>m</i>/<i>z</i>): 268 [M + H]<sup>+</sup>.</div></div><div id="sec9_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>S</i>)-4-(5-Amino-2-fluorophenyl)-4-methyl-5,6-dihydro-4<i>H</i>-1,3-thiazin-2-amine (<b>26</b>)</h3><div class="NLM_p last">To a stirred solution of <b>26</b> (2.59 g, 9.69 mmol) in AcOH/water (13 mL/1.3 mL) was added iron (2.16 g, 38.8 mmol). After stirring for 1 h at 50 °C, to the reaction mixture were added conc. aq. NH<sub>3</sub> and EtOAc, and the insoluble materials were filtered off. The aqueous layer was extracted with EtOAc, and the organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure to afford <b>26</b> (2.12 g, 8.93 mmol, 92%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.67 (3H, s), 3.53 (2H, br s), 6.21–6.30 (2H, m), 6.50 (1H, dd, <i>J</i> = 7.5, 4.3 Hz), 6.74–6.85 (2H, m). MS-ESI (<i>m</i>/<i>z</i>): 238 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>11</sub>H<sub>12</sub>FN<sub>3</sub>S; C, 55.68; H, 5.10; F, 8.01; N, 17.71; S, 13.51. Found: C, 55.36; H, 5.03; N, 17.89; F, 8.00; S,13.40.</div></div><div id="sec9_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>S</i>)-<i>N</i>-(3-(2-Amino-4-methyl-4<i>H</i>-1,3-thiazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide (<b>1</b>)</h3><div class="NLM_p last">To a stirred solution of <b>26</b> (147 mg, 0.619 mmol) and 5-cyanopicolinic acid (94.0 mg, 0.623 mmol) in MeOH (5.0 mL) was added 2 M HCl (0.310 mmol, 0.619 mmol) and cooled to 0 °C. To the solution, EDC·HCl (125 mg, 0.650 mmol) was added. After stirring for 1 h at the same temperature, 2 M aq. NaOH (0.31 mL) and 5% aq. K<sub>2</sub>CO<sub>3</sub> were added, and the resulting solid was filtered and dried to afford <b>1</b> (200 mg, 0.544 mmol, 88%) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.56 (3H, s), 6.16 (1H, dd, <i>J</i> = 9.5, 4.3 Hz), 6.32 (2H, s), 6.48 (1H, d, <i>J</i> = 9.5 Hz), 7.14 (1H, t, <i>J</i> = 10.2 Hz), 7.74–7.78 (1H, m), 7.95–7.92 (1H, m), 8.28 (1H, d, <i>J</i> = 8.3 Hz), 8.58 (1H, d, <i>J</i> = 8.3 Hz), 9.19 (1H, s), 10.77 (1H, s). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 28.8 (d, <i>J</i> = 2.9 Hz), 58.9 (d, <i>J</i> = 3.7 Hz), 111.5, 116.1 (d, <i>J</i> = 24.9 Hz), 116.6, 116.7, 120.8 (d, <i>J</i> = 8.8 Hz), 121.0 (d, <i>J</i> = 5.1 Hz), 122. 3, 127.5 (d, <i>J</i> = 2.9 Hz), 133.4 (d, <i>J</i> = 2.9 Hz), 134.8 (d, <i>J</i> = 12.5 Hz), 142.1, 148.1, 151.4, 152.5, 156.8 (d, <i>J</i> = 243.5 Hz), 161.1. MS-ESI (<i>m</i>/<i>z</i>): 368 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>15</sub>FN<sub>5</sub>OS<sup>+</sup>, 368.0976; found, 368.0971. Anal. Calcd for C<sub>18</sub>H<sub>14</sub>FN<sub>5</sub>OS; C, 58.85; H, 3.84; N, 19.06; F, 5.17; S, 8.73. Found: C, 58.66; H, 3.99; N, 18.84; F, 5.20; S, 8.67.</div></div><div id="sec9_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>S</i>)-<i>N</i>-(3-(2-Amino-4-methyl-4<i>H</i>-1,3-thiazin-4-yl)-4-fluorophenyl)-3-chloro-5-cyanopicolinamide (<b>15</b>)</h3><div class="NLM_p last">Compound <b>15</b> was prepared in a manner similar to that for <b>1</b> from <b>26</b> (165 mg, 0.696 mmol) using 2-chloro-5-cyanopicolinic acid (152 mg, 0.835 mmol) in 85% yield (240 mg, 0.594 mmol). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.54 (3H, s), 6.15 (1H, dd, <i>J</i> = 9.5, 4.7 Hz), 6.31 (2H, br s), 6.45 (1H, d, <i>J</i> = 9.5 Hz), 7.14 (1H, dd, <i>J</i> = 11.4, 8.7 Hz), 7.62–7.70 (2H, m), 8.76 (1H, d, <i>J</i> = 1.7 Hz), 9.06 (1H, d, <i>J</i> = 1.7 Hz), 10.84 (1H, br s). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 28.6 (d, <i>J</i> = 3.6 Hz), 59.0 (d, <i>J</i> = 4.4 Hz), 112.7, 114.3, 115. Seven (d, <i>J</i> = 1.4 Hz), 116.9 (d, <i>J</i> = 25.6 Hz), 119.7 (d, <i>J</i> = 3.7 Hz), 119.9 (d, <i>J</i> = 8.8 Hz), 128.7 (d, <i>J</i> = 3 7 Hz), 132.7 (d, <i>J</i> = 2.2 Hz), 132.8, 134.8 (d, <i>J</i> = 13.2 Hz), 143.8, 147.8, 148.5, 150.3, 156.9 (d, <i>J</i> = 245.8), 159.1. MS-ESI (<i>m</i>/<i>z</i>): 402 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>14</sub>ClFN<sub>5</sub>OS<sup>+</sup>, 402.0586; found, 402.0586.</div></div><div id="sec9_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>S</i>)-<i>N</i>-(3-(2-Amino-4-methyl-4<i>H</i>-1,3-thiazin-4-yl)-4-fluorophenyl)-5-fluoropicolinamide (<b>16</b>)</h3><div class="NLM_p last">To a stirred solution of <b>26</b> (50.0 mg, 0.211 mmol) in MeOH (1.0 mL) were added 5-fluoropicolinic acid (35.7 mg, 0.253 mmol) and DMT-MM (72.9 mg, 0.232 mmol). After stirring for 6 h at room temperature, additional DMT-MM (6.6 mg, 0.02 mmol) was added, and the solution was stirred for 3 h. To the reaction mixture was added aq. Na<sub>2</sub>CO<sub>3</sub>, and the aqueous layer was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. To the crude product were added EtOAc and ether, and the resulting solid was filtered and dried to afford <b>16</b> (31.9 mg, 89.0 μmol, 42%) as a pale yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.56 (3H, s), 6.16 (1H, dd, <i>J</i> = 9.6, 4.2 Hz), 6.30 (2H, s), 6.47 (1H, d, <i>J</i> = 9.6 Hz), 7.13 (1H, dd, <i>J</i> = 11.2, 9.2 Hz), 7.74 (1H, m), 7.90 (1H, m), 7.98 (1H, m), 8.22 (1H, m), 8.65 (1H, s), 10.54 (1H, s). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 28.8, 57.9, 116.0 (d, <i>J</i> = 24 Hz), 116.7, 120.5 (d, <i>J</i> = 8.1 Hz), 120.7 (d, <i>J</i> = 5.1 Hz), 124.6 (d, <i>J</i> = 5.9 Hz), 124.8 (d, <i>J</i> = 18.3), 127.5 (d, <i>J</i> = 2.9 Hz), 133.7 (d, <i>J</i> = 2.9 Hz), 135.8 (d, <i>J</i> = 12.8 Hz), 136.8 (d, <i>J</i> = 24.9 Hz), 146.6 (d, <i>J</i> = 3.7 Hz), 148.0, 156.1 (d, <i>J</i> = 242.8 Hz), 160.8 (d, <i>J</i> = 258.8 Hz), 161.4. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>15</sub>F<sub>2</sub>N<sub>4</sub>OS<sup>+</sup>, 361.0929; found, 361.0924.</div></div><div id="sec9_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>S</i>)-<i>N</i>-(3-(2-Amino-4-methyl-4<i>H</i>-1,3-thiazin-4-yl)-4-fluorophenyl)-5-chloropicolinamide (<b>17</b>)</h3><div class="NLM_p last">Compound <b>17</b> was prepared in a manner similar to that for <b>16</b> from <b>26</b> (94.8 mg, 0.400 mmol) using 5-chloropicolinic acid (50.4 mg, 0.320 mmol) in 16% yield (24.1 mg, 0.0640 mmol) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.56 (3H, s), 6.16 (1H, dd, <i>J</i> = 9.5, 4.5 Hz), 6.31 (2H, s), 6.47 (1H, d, <i>J</i> = 9.7 Hz), 7.13 (1H, dd, <i>J</i> = 11.4, 8.9 Hz), 7.73–7.76 (1H, m), 7.91 (1H, dd, <i>J</i> = 7.2, 2.4 Hz), 8.21–8.13 (2H, m), 8.78 (1H, d, <i>J</i> = 1.8 Hz), 10.60 (1H, s). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 28.7 (d, <i>J</i> = 2.2 Hz), 59.0 (d, <i>J</i> = 4.4 Hz), 115.7, 116.7 (d, <i>J</i> = 24.2 Hz), 119.5 (d, <i>J</i> = 4.4 Hz), 119.6 (d, <i>J</i> = 8.8 Hz), 123.4, 128.8 (d, <i>J</i> = 3.7 Hz), 133.1 (d, <i>J</i> = 3.7 Hz), 134.5 (d, <i>J</i> = 12.5 Hz), 135.2, 137.4, 147.0, 147.9, 150.2, 156.6 (d, <i>J</i> = 245.7 Hz), 161.0. MS-ESI (<i>m</i>/<i>z</i>): 377 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>15</sub>ClFN<sub>4</sub>OS<sup>+</sup>, 377.0634; found, 377.0631.</div></div><div id="sec9_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (<i>S</i>)-<i>N</i>-(3-(2-Amino-4-methyl-4<i>H</i>-1,3-thiazin-4-yl)-4-fluorophenyl)-5-methoxypyrazine-2-carboxamide (<b>18</b>)</h3><div class="NLM_p last">Compound <b>18</b> was prepared in a manner similar to that for <b>16</b> from <b>26</b> (47.4 mg, 0.200 mmol) using 5-methoxypyrazine-2-carboxylic acid (30.8 mg, 0.200 mmol) in 65% yield (48.4 mg, 0.130 mmol) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.71 (3H, s), 4.06 (3H, s), 6.28 (2H, d, <i>J</i> = 2.1 Hz), 7.04 (1H, dd, <i>J</i> = 11.2, 8.8 Hz), 7.60 (2H, dd, <i>J</i> = 6.8, 2.8 Hz), 7.83 (1H, ddd, <i>J</i> = 8.8, 4.1, 2.8 Hz), 8.14 (1H, d, <i>J</i> = 1.2 Hz), 9.0 (1H, d, <i>J</i> = 1.2 Hz), 9.45 (1H, s). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 28.5 (d, <i>J</i> = 3.7 Hz), 54.4, 59.1 (d, <i>J</i> = 3.7 Hz), 115.6, 116.8 (d, <i>J</i> = 24.9 Hz), 119.4 (d, <i>J</i> = 4.4 Hz), 119.7 (d, <i>J</i> = 8.8 Hz), 128.8 (d, <i>J</i> = 3.7 Hz), 133.2 (d, <i>J</i> = 2.2 Hz), 133.3, 134.4, 137.3, 141.9, 149.8, 156.7 (d, <i>J</i> = 243.6 Hz), 161.0, 162.3. MS-ESI (<i>m</i>/<i>z</i>): 374 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>17</sub>FN<sub>5</sub>O<sub>2</sub>S<sup>+</sup>, 374.1082; found, 374.1077.</div></div><div id="sec9_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>S</i>)-<i>N</i>-((2-(2-Fluoro-5-(2,2,2-trifluoroacetamido)phenyl)pent-4-en-2-yl)carbamothioyl)benzamide (<b>28</b>)</h3><div class="NLM_p last">Compound <b>27</b><a onclick="showRef(event, 'cit18a'); return false;" href="javascript:void(0);" class="ref cit18a">(18a)</a> (3.99 g, 10.1 mmol) in 2 M aq. HCl (20 mL, 40 mmol) was stirred at room temperature for 1 h. After concentration under reduced pressure, the solution was diluted with EtOAc, and the organic layer was extracted with water and 2 M aq. HCl. The combined aqueous layers were basified with K<sub>2</sub>CO<sub>3</sub> and extracted with EtOAc. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. To the residue in DCM (20 mL) was added at 0 °C benzoyl isothiocyanate (1.43 mL, 10.6 mmol). After stirring for 5 min, the reaction mixture was warmed to room temperature and stirred for 45 min. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (<i>n</i>-hexane/EtOAc, 10–50% EtOAc) to afford <b>28</b> (4.34 g, 9.57 mmol, 95% in 2 steps) as a white amorphous substance. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.00 (3H, s), 2.73, (1H, dd, <i>J</i> = 13.1, 6.6), 3.18 (1H, dd, <i>J</i> = 13.1, 7.6), 5.24 (1H, d, <i>J</i> = 10.6), 5.29 (1H, <i>J</i> = 17.2 Hz), 5.67–5.79 (1H, m), 6.99–7.07 (1H, dd, <i>J</i> = 10.4, 10.4 Hz), 7.45–7.53 (3H, m), 7.57–7.65 (2H, m), 7.83 (2H, d, <i>J</i> = 7.07), 8.39 (1H, s), 8.86 (1H, s), 11.36 (1H, s).</div></div><div id="sec9_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>S</i>)-<i>N</i>-(4-(2-Fluoro-5-(2,2,2-trifluoroacetamido)phenyl)-4-methyl-6-methylene-5,6-dihydro-4<i>H</i>-1,3-thiazin-2-yl)benzamide (<b>29</b>)</h3><div class="NLM_p last">To a stirred solution of <b>28</b> (4.34 g, 9.57 mmol) in DCM (220 mL) was added at 0 °C iodine (3.64 g, 14.4 mmol). After stirring at room temperature for 2 h, the reaction mixture was quenched with aq. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>. The aqueous media was basified (pH > 11) with K<sub>2</sub>CO<sub>3</sub> and extracted with CHCl<sub>3</sub>. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. To the resulting brown amorphous substance in THF (130 mL) was added pyrrolidine (3.96 mL, 47.9 mmol). After stirring at 60 °C for 2 h, The volatile materials were evaporated, and water was added. The aqueous layer was extracted with EtOAc. The organic layer was washed with water and brine and dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The crude product was purified by silica gel column chromatography (<i>n</i>-hexane/EtOAc, 10–50% EtOAc) to afford <b>29</b> (3.44 g, 7.62 mmol, 80% in 2 steps) as a yellow amorphous substance. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.71 (3H, s), 2.71, (1H, d, <i>J</i> = 14.1 Hz), 3.39 (1H, d, <i>J</i> = 14.1 Hz), 5.01 (1H, s), 5.09 (1H, s), 7.10 (1H, dd, <i>J</i> = 10.6, 10.1 Hz), 7.31–7.40 (4H, m), 7.47 (1H, dd, <i>J</i> = 7.0, 7.0 Hz), 8.05 (2H, d, <i>J</i> = 7.6 Hz), 8.08–8.13 (1H, m). MS-ESI (<i>m</i>/<i>z</i>): 452 [M + H]<sup>+</sup>.</div></div><div id="sec9_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>S</i>)-4-(5-Amino-2-fluorophenyl)-4-methyl-6-methylene-5,6-dihydro-4<i>H</i>-1,3-thiazin-2-amine (<b>30</b>)</h3><div class="NLM_p last">To a stirred solution of <b>29</b> (100 mg, 0.222 mmol) in EtOH (1 mL) was added hydrazine hydrate (54.0 μL, 1.11 mmol). After stirring overnight at room temperature, the reaction mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (<i>n</i>-hexane/EtOAc, 50–100% EtOAc) to afford <b>30</b> (40.3 mg, 0.160 mmol, 74%) as a yellow amorphous substance. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.54 (3H, s), 2.53, (1H, d, <i>J</i> = 13.6), 2.89 (1H, d, <i>J</i> = 13.6), 4.97 (1H, s), 5.09 (1H, s), 6.45–6.51 (1H, m) 6.73–6.84 (2H, m).</div></div><div id="sec9_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>S</i>)-<i>N</i>-(3-(2-Amino-4-methyl-6-methylene-5,6-dihydro-4<i>H</i>-1,3-thiazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide (<b>13</b>)</h3><div class="NLM_p last">Compound <b>13</b> was prepared in a manner similar to that for <b>16</b> from <b>30</b> (96.3 mg, 0.391 mmol) using 5-cyanopicolinic acid (75.0 mg, 0.508 mmol) in 46% yield (69.0 mg, 0.181 mmol) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 2.48–2.53 (3H, m), 2.73 (1H, d, <i>J</i> = 15.2 Hz), 4.95 (1H, s), 5.08 (1H, s), 6.23 (2H, br s), 7.14 (1H, dd, <i>J</i> = 9.9, 9.9 Hz), 7.75 (1H, br s), 7.91 (1H, d, <i>J</i> = 5.1 Hz), 8.27 (1H, d, <i>J</i> = 8.1 Hz), 8.57 (1H, d, <i>J</i> = 8.1 Hz), 9.19 (1H, s), 10.73 (1H, s). MS-ESI (<i>m</i>/<i>z</i>): 382 [M + H]<sup>+</sup>. <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 28.3, 57.7, 57.8, 109.8, 111.5, 116.1 (d, <i>J</i> = 25.6 Hz), 116.6, 121.0 (d, <i>J</i> = 8.8 Hz), 122.0 (d, <i>J</i> = 5.1 Hz), 122.3, 133.7 (d, <i>J</i> = 2.9 Hz), 134.3 (d, <i>J</i> = 13.2 Hz), 136.9, 142.1, 147.5, 151.4, 152.6, 156.7 (d, <i>J</i> = 242 Hz), 161.0. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>17</sub>FN<sub>5</sub>OS<sup>+</sup>, 382.1132; found, 382.1128.</div></div><div id="sec9_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>S</i>)-3-Amino-4-fluoro-3-(2-fluorophenyl)butan-1-ol (<b>32</b>)</h3><div class="NLM_p last">To a stirred solution of lithium diisopropylamide (2 M in THF/heptane/ethylbenzene, 6.65 mL, 13.3 mmol) was added at −78 °C <i>tert</i>-butyl acetate (1.80 mL, 13.3 mmol) in THF (1 mL) over 5 min under N<sub>2</sub>. After stirring for 30 min at the same temperature, Ti(O<i>i-</i>Pr)<sub>3</sub>Cl in THF (8.0 mL) was added over 15 min. After stirring for 35 min, <b>31</b> (1.15 g, 4.43 mmol) in THF (6.0 mL) was added over 15 min. After stirring for 15 min at the same temperature, the reaction was quenched with saturated aq. NH<sub>4</sub>Cl (4.0 mL) and diluted with EtOAc. The insoluble materials were filtered off, and the resulting organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The residue in 1,4-dioxane (2.0 mL) and HCl (4 M in 1,4-dioxane, 6.65 mL, 26.6 mmol) was warmed to 60 °C. After stirring for 20 min, 1,4-dioxane (3.0 mL) was added, and the mixture was stirred for 30 min. The reaction was cooled to 0 °C; ether (10 mL) was added, and the resulting solid was filtered and dried to give an amino acid hydrochloride (902 mg) as a white solid. To the solid was added BH<sub>3</sub> (1.0 M in THF, 10.8 mL, 10.8 mmol) at room temperature. After stirring at 45 °C for 1 h, the reaction was quenched with MeOH and water. The aqueous layer was basified with NaHCO<sub>3</sub> and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure to give <b>32</b> (659 mg, 3.28 mmol, 92%) as a pale yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.02–2.19 (2H, m), 3.41–3.49 (1H, m), 3.62–3.68 (1H, m), 4.49 (1H, dd, <i>J</i> = 47.4, 9.0 Hz), 4.71 (2H, ddd, <i>J</i> = 47.8, 9.0, 1.9 Hz), 7.05 (1H, ddd, <i>J</i> = 12.8, 8.2, 1.6 Hz), 7.20 (1H, ddd, <i>J</i> = 8.0, 8.0, 1.2 Hz), 7.28–7.36 (1H, m), 7.57 (1H, ddd, <i>J</i> = 8.0, 8.0, 1.0 Hz). MS-ESI (<i>m</i>/<i>z</i>): 374 [M + H]<sup>+</sup>.</div></div><div id="sec9_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>S</i>)-<i>N</i>-(4-(Fluoromethyl)-4-(2-fluorophenyl)-5,6-dihydro-4<i>H</i>-1,3-thiazin-2-yl)benzamide (<b>33</b>)</h3><div class="NLM_p last">To a stirred solution of <b>32</b> (659 mg, 3.28 mmol) in DCM (6.0 mL) was added at 0 °C benzoyl isothiocyanate (464 μL, 3.44 mmol). After stirring overnight at room temperature, Ghosez’s reagent (1-chloro-<i>N</i>,<i>N</i>-2-trimethylpropenylamine) (677 μL, 4.91 mmol) was added. After stirring for 40 min, Ghosez’s reagent (135 μL, 0.984 mmol) was added. After stirring for 1 h, Ghosez’s reagent (90.0 μL, 0.656 mmol) was added and stirred for 25 min. The reaction mixture was concentrated and treated with <i>i</i>-Pr<sub>2</sub>O. The resulting solid was filtered and then suspended in ether, filtered, and dried <i>in vacuo</i> to afford <b>33</b> (918 mg, 2.65 mmol, 81% in 2 steps) as a pale yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.48–2.59 (1H, m), 2.70–2.86 (2H, m), 3.04 (2H, ddd, <i>J</i> = 17.8, 7.3, 4.7 Hz), 4.90 (1H, dd, <i>J</i> = 46.2, 10.0 Hz), 4.97 (1H, dd, <i>J</i> = 46.7, 10.1 Hz), 7.16 (1H, dd, <i>J</i> = 12.5, 8.2 Hz), 7.27–7.33 (1H, m), 7.40–7.69 (5H, m), 8.38–8.41 (2H, m), 13.78 (1H, br s). MS-ESI (<i>m</i>/<i>z</i>): 374 [M + H]<sup>+</sup>.</div></div><div id="sec9_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>S</i>)-4-(Fluoromethyl)-4-(2-fluorophenyl)-5,6-dihydro-4<i>H</i>-1,3-thiazin-2-amine (<b>34</b>)</h3><div class="NLM_p last">A mixture of <b>33</b> (898 mg, 2.59 mmol) and aq. H<sub>2</sub>SO<sub>4</sub> (18 M, 2.0 mL) was heated to 50 °C. After stirring for 1 h, the reaction mixture was cooled to 0 °C, and ice and 28% aq. NH<sub>3</sub> were added. The aqueous layer was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The residue was triturated with <i>i</i>Pr<sub>2</sub>O, and the resulting solid was filtered and dried to afford <b>35</b> (447 mg, 1.85 mmol, 71%) as a beige solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.97 (1H, ddd, <i>J</i> = 13.1, 13.1, 4.0 Hz), 2.57–2.74 (2H, m), 2.93 (1H, ddd, <i>J</i> = 12.2, 4.1, 4.1 Hz), 4.47–4.83 (2H, m), 7.03 (1H, ddd, <i>J</i> = 12.5, 7.8, 1.3 Hz), 7.14 (1H, ddd, <i>J</i> = 7.8, 7.8, 1.2 Hz), 7.28–7.40 (2H, m). MS-ESI (<i>m</i>/<i>z</i>): 243 [M + H]<sup>+</sup>.</div></div><div id="sec9_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>S</i>)-4-(2-Fluoro-5-nitrophenyl)-4-(fluoromethyl)-5,6-dihydro-4<i>H</i>-1,3-thiazin-2-amine (<b>35</b>)</h3><div class="NLM_p last">To a stirred solution of <b>34</b> (407 mg, 1.68 mmol) in aq. H<sub>2</sub>SO<sub>4</sub> (18 M, 1.6 mL), conc. HNO<sub>3</sub> (150 μL, 3.36 mmol) in conc. H<sub>2</sub>SO<sub>4</sub> (0.4 mL) was added at −15 °C over 20 min. After stirring for 40 min at 0 °C, to the reaction mixture were added ice and aq. NH<sub>3</sub> (28%, 6 mL) dropwise. The aqueous layer was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure to give <b>35</b> (474 mg, 1.65 mmol, 98%) as a yellow foam. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.03–2.13 (1H, m), 2.51 (1H, ddd, <i>J</i> = 13.8, 6.1, 4.8 Hz), 2.71 (1H, td, <i>J</i> = 11.9, 3.6 Hz), 3.02 (1H, dt, <i>J</i> = 13.2, 4.8 Hz), 4.50–4.73 (4H, m), 7.20 (2H, dd, <i>J</i> = 10.9, 8.9 Hz), 8.22–8.17 (1H, m), 8.40 (1H, dd, <i>J</i> = 6.7, 2.9 Hz). MS-ESI (<i>m</i>/<i>z</i>): 288 [M + H]<sup>+</sup>.</div></div><div id="sec9_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>S</i>)-<i>N</i>-(3-(2-Amino-4-(fluoromethyl)-5,6-dihydro-4<i>H</i>-1,3-thiazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide (<b>14</b>)</h3><div class="NLM_p last">To a stirred solution of <b>35</b> (58.5 mg, 0.204 mmol) in MeOH (1.5 mL) were added conc. HCl (12 M, 50 μL) and iron (56.9 mg, 1.02 mmol). After stirring at 50 °C for 2 h, insoluble materials were filtered off and washed with MeOH. The filtrate was concentrated, and the resulting residue was diluted with EtOAc and 2 M aq. NaOH (0.5 mL), which was then filtered through Celite. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. To a stirred solution of the residue in MeOH (1 mL) were added 5-cyanopicolinic acid hydrate (32.2 mg, 0.194 mmol), 2 M aq. HCl (97 μL, 0.19 mmol), and EDC·HCl. After stirring for 1 h, 2 M aq. NaOH (0.12 mL) was added at 0 °C. The resulting solid was filtered, washed with MeOH, water, and ether, and dried <i>in vacuo</i> to give <b>14</b> (40.0 mg, 0.103 mmol, 53%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.97–2.07 (1H, m), 2.60 (1H, ddd, <i>J</i> = 13.7, 4.5, 4.5 Hz), 2.77 (1H, ddd, <i>J</i> = 12.2, 12.2, 3.5 Hz), 2.98 (1H, ddd, <i>J</i> = 12.2, 4.5, 4.5 Hz), 4.49–4.81 (2H, m), 7.10 (1H, dd, <i>J</i> = 11.6, 8.9 Hz), 7.45 (1H, dd, <i>J</i> = 7.0, 2.8 Hz), 8.04 (1H, ddd, <i>J</i> = 8.9, 4.1, 2.9 Hz), 8.20 (1H, dd, <i>J</i> = 8.1, 2.0 Hz), 8.42 (1H, d, <i>J</i> = 8.2 Hz), 8.89–8.90 (1H, m), 9.84 (1H, br s). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 21.9, 25.1, 59.8 (dd, <i>J</i> = 17.6, 5.1 Hz), 88.5 (dd, <i>J</i> = 178, 2.9 Hz), 111.5, 116.2 (d, <i>J</i> = 24.9 Hz), 116.6, 121.8 (d, <i>J</i> = 8.8 Hz), 122.3, 123.9, 129.1 (dd, <i>J</i> = 13.2, 5.1 Hz) 134.0, 142.1, 151.4, 151.5, 152.4, 155.9 (d, <i>J</i> = 244.3 Hz), 161.2. MS-ESI (<i>m</i>/<i>z</i>): 388 [M + H]<sup>+</sup>. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>F<sub>2</sub>N<sub>5</sub>OS<sup>+</sup>, 388.1038; found, 388.1032.</div></div><div id="sec9_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Biochemical BACE1 Assay</h3><div class="NLM_p last">The biochemical BACE1 IC<sub>50</sub> values were determined by HTRF assay using an APP derived peptide as described previously.<a onclick="showRef(event, 'cit18a'); return false;" href="javascript:void(0);" class="ref cit18a">(18a)</a></div></div><div id="sec9_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Cellular Aβ Assay</h3><div class="NLM_p last">The cellular Aβ IC<sub>50</sub> values were determined by measuring Aβ<sub>40</sub> using HTRF assay in SH-SY5Y cells expressing human APP as described previously.<a onclick="showRef(event, 'cit18a'); return false;" href="javascript:void(0);" class="ref cit18a">(18a)</a></div></div><div id="sec9_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>In Vitro</i> ADMET Assays</h3><div class="NLM_p last">Metabolic stability in microsomes, P-gp efflux ratio, protein binding, CYP IC<sub>50</sub>, and hERG inhibitory activity were determined according to procedures described previously.<a onclick="showRef(event, 'ref18 ref27'); return false;" href="javascript:void(0);" class="ref ref18 ref27">(18,27)</a></div></div><div id="sec9_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>In Vivo</i> Experiments</h3><div class="NLM_p last">All the procedures were in accordance with regulations and established guidelines and were approved by the Shionogi Animal Care and Use Committee. In vivo experimental procedures are given in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01917/suppl_file/jm0c01917_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec9_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Clinical Studies</h3><div class="NLM_p last">All clinical study protocols and their amendments were approved by the appropriate Independent Ethics Committees/Institutional Review Boards. Written informed consent was obtained from all participants before their participation in any clinical study. All study procedures were in accordance with current ICH guidelines on Good Clinical Practice (GCP), applicable regulatory and country-specific requirements, and the principles of the Declaration of Helsinki.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01917" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05613" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05613" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01917?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01917</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental procedures for PK/PD study; measurement of Aβ plaque formation in PS/APP mice; determination of CVB values in human liver microsomes; synthesis of [<sup>14</sup>C]-<b>15</b>, <sup>1</sup>H, and <sup>13</sup>C NMR spectra for compound <b>1</b>; HPLC traces for compounds <b>1</b>, <b>13</b>, <b>14</b>, <b>15</b>, <b>16</b>, <b>17</b>, and <b>18</b>; and crystallographic data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01917/suppl_file/jm0c01917_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES strings, BACE1 IC<sub>50</sub>, and cellular Aβ<sub>40</sub> IC<sub>50</sub> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01917/suppl_file/jm0c01917_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01917/suppl_file/jm0c01917_si_001.pdf">jm0c01917_si_001.pdf (528.22 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01917/suppl_file/jm0c01917_si_002.csv">jm0c01917_si_002.csv (0.91 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB accession code for the X-ray structure of <b>1</b> bound to human BACE1 is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7DCZ">7DCZ</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c01917" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27242" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27242" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuji Koriyama</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bbc2ceced1d295d0d4d4c9d2c2dad6dafbc8d3d2d4d5d4dcd295d8d495d1cb"><span class="__cf_email__" data-cfemail="314844445b581f5a5e5e435848505c50714259585e5f5e56581f525e1f5b41">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ken-ichi Kusakabe</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9055-8267" title="Orcid link">http://orcid.org/0000-0001-9055-8267</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#375c52591a5e545f5e195c4244565c56555277445f5e585958505e195458195d47"><span class="__cf_email__" data-cfemail="94fff1fab9fdf7fcfdbaffe1e7f5fff5f6f1d4e7fcfdfbfafbf3fdbaf7fbbafee4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akihiro Hori</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hisanori Ito</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuji Yonezawa</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yoshiyasu Baba</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Norihiko Tanimoto</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tatsuhiko Ueno</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shiho Yamamoto</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takahiko Yamamoto</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span>; 
    <span>Present Address:
                        T.Y.: API Process Development Department (Biotechnology), Pharmaceutical Technology Division, Chugai Pharmaceutical Co., Ltd., 5-1, Ukima 5-chome, Kita-ku, Tokyo, 115-8543, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naoya Asada</span> - <span class="hlFld-Affiliation affiliation">Research Laboratory for Development, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenji Morimoto</span> - <span class="hlFld-Affiliation affiliation">Research Laboratory for Development, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shunsuke Einaru</span> - <span class="hlFld-Affiliation affiliation">Research Laboratory for Development, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katsunori Sakai</span> - <span class="hlFld-Affiliation affiliation">Research Laboratory for Development, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takushi Kanazu</span> - <span class="hlFld-Affiliation affiliation">Research Laboratory for Development, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akihiro Matsuda</span> - <span class="hlFld-Affiliation affiliation">Research Laboratory for Development, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yoshitaka Yamaguchi</span> - <span class="hlFld-Affiliation affiliation">Research Laboratory for Development, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takuya Oguma</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6305-2305" title="Orcid link">http://orcid.org/0000-0002-6305-2305</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maarten Timmers</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research & Development, a division of Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luc Tritsmans</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research & Development, a division of Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akira Kato</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gaku Sakaguchi</span> - <span class="hlFld-Affiliation affiliation">Medicinal Research Laboratories, , Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3925-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62780" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62780" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Hidekuni Yamakawa, Chie Unemura, and Motoko Hosono for the biological assays; Yumiko Takagi for the elemental analysis; Atsushi Morimoto for the HRMS analysis; and Yukiko Kan for the NMR analysis. We also thank Dieder Moechars and Harrie Gijsen for critically reading the manuscript and helpful comments. We gratefully thank the members of the Janssen-Shionogi research collaboration for the support of this program.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">ALP</td><td class="NLM_def"><p class="first last">alkaline phosphatase</p></td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine aminotransferase</p></td></tr><tr><td class="NLM_term">APP</td><td class="NLM_def"><p class="first last">amyloid precursor protein</p></td></tr><tr><td class="NLM_term">AST</td><td class="NLM_def"><p class="first last">aspartate aminotransferase</p></td></tr><tr><td class="NLM_term">BACE1</td><td class="NLM_def"><p class="first last">β-site amyloid precursor protein cleaving enzyme 1</p></td></tr><tr><td class="NLM_term">CatD</td><td class="NLM_def"><p class="first last">cathepsin D</p></td></tr><tr><td class="NLM_term">CDR</td><td class="NLM_def"><p class="first last">Clinical Dementia Rating</p></td></tr><tr><td class="NLM_term">CHL1</td><td class="NLM_def"><p class="first last">close homologue of neural cell adhesion molecule L1</p></td></tr><tr><td class="NLM_term">CSF</td><td class="NLM_def"><p class="first last">cerebrospinal fluid</p></td></tr><tr><td class="NLM_term">DDI</td><td class="NLM_def"><p class="first last">drug–drug interaction</p></td></tr><tr><td class="NLM_term">DIAN</td><td class="NLM_def"><p class="first last">Dominantly Inherited Alzheimer Network</p></td></tr><tr><td class="NLM_term">DILI</td><td class="NLM_def"><p class="first last">drug-induced liver injury</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high throughput screening</p></td></tr><tr><td class="NLM_term">EDC·HCl</td><td class="NLM_def"><p class="first last">1-(3-dimehylaminopropyl)-3-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">Fmoc</td><td class="NLM_def"><p class="first last">9-fluorenylmethoxycarbonyl</p></td></tr><tr><td class="NLM_term">IADR</td><td class="NLM_def"><p class="first last">idiosyncratic adverse drug reaction</p></td></tr><tr><td class="NLM_term">IAPP</td><td class="NLM_def"><p class="first last">islet amyloid peptide</p></td></tr><tr><td class="NLM_term">IBX</td><td class="NLM_def"><p class="first last">2-iodoxybenzoic acid</p></td></tr><tr><td class="NLM_term">MAD</td><td class="NLM_def"><p class="first last">multiple ascending dose</p></td></tr><tr><td class="NLM_term">MC</td><td class="NLM_def"><p class="first last">methyl cellulose</p></td></tr><tr><td class="NLM_term">MCI</td><td class="NLM_def"><p class="first last">mild cognitive impairment</p></td></tr><tr><td class="NLM_term">NOAEL</td><td class="NLM_def"><p class="first last">no observed adverse effect level</p></td></tr><tr><td class="NLM_term">NRG1</td><td class="NLM_def"><p class="first last">neuregulin 1</p></td></tr><tr><td class="NLM_term">PACC</td><td class="NLM_def"><p class="first last">Preclinical Alzheimer’s Cognitive Composite</p></td></tr><tr><td class="NLM_term">PMEL</td><td class="NLM_def"><p class="first last">pigment cell-specific melanocyte protein</p></td></tr><tr><td class="NLM_term">TMEM27</td><td class="NLM_def"><p class="first last">pro-proliferative type I transmembrane protein 27</p></td></tr><tr><td class="NLM_term">RBANS</td><td class="NLM_def"><p class="first last">Repeatable Battery for the Assessment of Neuropsychological Battery</p></td></tr><tr><td class="NLM_term">SAD</td><td class="NLM_def"><p class="first last">single ascending dose</p></td></tr><tr><td class="NLM_term">SEZ6</td><td class="NLM_def"><p class="first last">seizure protein 6</p></td></tr><tr><td class="NLM_term">TDI</td><td class="NLM_def"><p class="first last">time-dependent inhibition</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">ULN</td><td class="NLM_def"><p class="first last">upper limit of the normal level</p></td></tr><tr><td class="NLM_term">VCAM1</td><td class="NLM_def"><p class="first last">vascular cell adhesion molecule 1</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30745" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30745" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span>Alzheimer’s
Disease International.
World Alzheimer Report 2019. <a href="https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf" class="extLink">https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf</a> (accessed April 30, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Alzheimer%E2%80%99s%0ADisease+International.%0AWorld+Alzheimer+Report+2019.+https%3A%2F%2Fwww.alz.co.uk%2Fresearch%2FWorldAlzheimerReport2019.pdf+%28accessed+April+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span>Alzheimer’s Association.
2020 Alzheimer’s Disease Facts and Figures. <a href="https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf" class="extLink">https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf</a> (accessed April 30, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Alzheimer%E2%80%99s+Association.%0A2020+Alzheimer%E2%80%99s+Disease+Facts+and+Figures.+https%3A%2F%2Fwww.alz.org%2Fmedia%2FDocuments%2Falzheimers-facts-and-figures.pdf+%28accessed+April+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winblad, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amouyel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brayne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodaty, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cedazo-Minguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edvardsson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fratiglioni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisoni, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georges, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jönsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivipelto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangialasche, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rikkert, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakmar, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheltens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjernberg, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldemar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wimo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterberg, H.</span></span> <span> </span><span class="NLM_article-title">Defeating Alzheimer’s disease and other dementias: a priority for European science and society</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(16)00062-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2FS1474-4422%2816%2900062-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=26987701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A280%3ADC%252BC28fhsF2gsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=455-532&author=B.+Winbladauthor=P.+Amouyelauthor=S.+Andrieuauthor=C.+Ballardauthor=C.+Brayneauthor=H.+Brodatyauthor=A.+Cedazo-Minguezauthor=B.+Duboisauthor=D.+Edvardssonauthor=H.+Feldmanauthor=L.+Fratiglioniauthor=G.+B.+Frisoniauthor=S.+Gauthierauthor=J.+Georgesauthor=C.+Graffauthor=K.+Iqbalauthor=F.+Jessenauthor=G.+Johanssonauthor=L.+J%C3%B6nssonauthor=M.+Kivipeltoauthor=M.+Knappauthor=F.+Mangialascheauthor=R.+Melisauthor=A.+Nordbergauthor=M.+O.+Rikkertauthor=C.+Qiuauthor=T.+P.+Sakmarauthor=P.+Scheltensauthor=L.+S.+Schneiderauthor=R.+Sperlingauthor=L.+O.+Tjernbergauthor=G.+Waldemarauthor=A.+Wimoauthor=H.+Zetterberg&title=Defeating+Alzheimer%E2%80%99s+disease+and+other+dementias%3A+a+priority+for+European+science+and+society&doi=10.1016%2FS1474-4422%2816%2900062-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Defeating Alzheimer's disease and other dementias: a priority for European science and society</span></div><div class="casAuthors">Winblad Bengt; Amouyel Philippe; Andrieu Sandrine; Ballard Clive; Brayne Carol; Brodaty Henry; Cedazo-Minguez Angel; Johansson Gunilla; Jonsson Linus; Tjernberg Lars O; Wimo Anders; Dubois Bruno; Edvardsson David; Feldman Howard; Fratiglioni Laura; Mangialasche Francesca; Qiu Chengxuan; Frisoni Giovanni B; Gauthier Serge; Georges Jean; Graff Caroline; Iqbal Khalid; Jessen Frank; Kivipelto Miia; Knapp Martin; Melis Rene; Rikkert Marcel Olde; Nordberg Agneta; Sakmar Thomas P; Scheltens Philip; Schneider Lon S; Sperling Reisa; Waldemar Gunhild; Zetterberg Henrik</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-532</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQx4RT_lerTHq91pGlMMoT5fW6udTcc2eYvq3avcaoSU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fhsF2gsQ%253D%253D&md5=c27e2804d324e1b44d4b5d8eb2a01dd8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2816%2900062-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252816%252900062-4%26sid%3Dliteratum%253Aachs%26aulast%3DWinblad%26aufirst%3DB.%26aulast%3DAmouyel%26aufirst%3DP.%26aulast%3DAndrieu%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DC.%26aulast%3DBrayne%26aufirst%3DC.%26aulast%3DBrodaty%26aufirst%3DH.%26aulast%3DCedazo-Minguez%26aufirst%3DA.%26aulast%3DDubois%26aufirst%3DB.%26aulast%3DEdvardsson%26aufirst%3DD.%26aulast%3DFeldman%26aufirst%3DH.%26aulast%3DFratiglioni%26aufirst%3DL.%26aulast%3DFrisoni%26aufirst%3DG.%2BB.%26aulast%3DGauthier%26aufirst%3DS.%26aulast%3DGeorges%26aufirst%3DJ.%26aulast%3DGraff%26aufirst%3DC.%26aulast%3DIqbal%26aufirst%3DK.%26aulast%3DJessen%26aufirst%3DF.%26aulast%3DJohansson%26aufirst%3DG.%26aulast%3DJ%25C3%25B6nsson%26aufirst%3DL.%26aulast%3DKivipelto%26aufirst%3DM.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DMangialasche%26aufirst%3DF.%26aulast%3DMelis%26aufirst%3DR.%26aulast%3DNordberg%26aufirst%3DA.%26aulast%3DRikkert%26aufirst%3DM.%2BO.%26aulast%3DQiu%26aufirst%3DC.%26aulast%3DSakmar%26aufirst%3DT.%2BP.%26aulast%3DScheltens%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DL.%2BS.%26aulast%3DSperling%26aufirst%3DR.%26aulast%3DTjernberg%26aufirst%3DL.%2BO.%26aulast%3DWaldemar%26aufirst%3DG.%26aulast%3DWimo%26aufirst%3DA.%26aulast%3DZetterberg%26aufirst%3DH.%26atitle%3DDefeating%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520other%2520dementias%253A%2520a%2520priority%2520for%2520European%2520science%2520and%2520society%26jtitle%3DLancet%2520Neurol.%26date%3D2016%26volume%3D15%26spage%3D455%26epage%3D532%26doi%3D10.1016%2FS1474-4422%2816%2900062-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benzinger, T. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazey, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santacruz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghetti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klunk, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDade, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossor, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span> <span> </span><span class="NLM_article-title">Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1202753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1056%2FNEJMoa1202753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=22784036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=795-804&author=R.+J.+Batemanauthor=C.+Xiongauthor=T.+L.+S.+Benzingerauthor=A.+M.+Faganauthor=A.+Goateauthor=N.+C.+Foxauthor=D.+S.+Marcusauthor=N.+J.+Cairnsauthor=X.+Xieauthor=T.+M.+Blazeyauthor=D.+M.+Holtzmanauthor=A.+Santacruzauthor=V.+Bucklesauthor=A.+Oliverauthor=K.+Moulderauthor=P.+S.+Aisenauthor=B.+Ghettiauthor=W.+E.+Klunkauthor=E.+McDadeauthor=R.+N.+Martinsauthor=C.+L.+Mastersauthor=R.+Mayeuxauthor=J.+M.+Ringmanauthor=M.+N.+Rossorauthor=P.+R.+Schofieldauthor=R.+A.+Sperlingauthor=S.+Sallowayauthor=J.+C.+Morris&title=Dominantly+Inherited+Alzheimer+Network.+Clinical+and+biomarker+changes+in+dominantly+inherited+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMoa1202753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and biomarker changes in dominantly inherited Alzheimer's disease</span></div><div class="casAuthors">Bateman, Randall J.; Xiong, Chengjie; Benzinger, Tammie L. S.; Fagan, Anne M.; Goate, Alison; Fox, Nick C.; Marcus, Daniel S.; Cairns, Nigel J.; Xie, Xianyun; Blazey, Tyler M.; Holtzman, David M.; Santacruz, Anna; Buckles, Virginia; Oliver, Angela; Moulder, Krista; Aisen, Paul S.; Ghetti, Bernardino; Klunk, William E.; McDade, Eric; Martins, Ralph N.; Masters, Colin L.; Mayeux, Richard; Ringman, John M.; Rossor, Martin N.; Schofield, Peter R.; Sperling, Reisa A.; Salloway, Stephen; Morris, John C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">795-804</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The order and magnitude of pathol. processes in Alzheimer's disease are not well understood, partly because the disease develops over many years.  Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to det. the sequence and magnitude of pathol. changes that culminate in symptomatic disease.  METHODS: In this prospective, longitudinal study, we analyzed data from 128 participants who underwent baseline clin. and cognitive assessments, brain imaging, and cerebrospinal fluid (CSF) and blood tests.  We used the participant's age at baseline assessment and the parent's age at the onset of symptoms of Alzheimer's disease to calc. the estd. years from expected symptom onset (age of the participant minus parent's age at symptom onset).  We conducted cross-sectional analyses of baseline data in relation to estd. years from expected symptom onset in order to det. the relative order and magnitude of pathophysiol. changes.  RESULTS: Concns. of amyloid-beta (Aβ)42 in the CSF appeared to decline 25 years before expected symptom onset.  Aβ deposition, as measured by positron-emission tomog. with the use of Pittsburgh compd. B, was detected 15 years before expected symptom onset.  Increased concns. of tau protein in the CSF and an increase in brain atrophy were detected 15 years before expected symptom onset.  Cerebral hypometabolism and impaired episodic memory were obsd. 10 years before expected symptom onset.  Global cognitive impairment, as measured by the Mini-Mental State Examn. and the Clin. Dementia Rating scale, was detected 5 years before expected symptom onset, and patients met diagnostic criteria for dementia at an av. of 3 years after expected symptom onset.  CONCLUSIONS: We found that autosomal dominant Alzheimer's disease was assocd. with a series of pathophysiol. changes over decades in CSF biochem. markers of Alzheimer's disease, brain amyloid deposition, and brain metab. as well as progressive cognitive impairment.  Our results require confirmation with the use of longitudinal data and may not apply to patients with sporadic Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptJNV9eDXBCLVg90H21EOLACvtfcHk0lg1Wqs3hagEtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktL7J&md5=c4f999ea3401af9651a2770724757bed</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1202753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1202753%26sid%3Dliteratum%253Aachs%26aulast%3DBateman%26aufirst%3DR.%2BJ.%26aulast%3DXiong%26aufirst%3DC.%26aulast%3DBenzinger%26aufirst%3DT.%2BL.%2BS.%26aulast%3DFagan%26aufirst%3DA.%2BM.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DFox%26aufirst%3DN.%2BC.%26aulast%3DMarcus%26aufirst%3DD.%2BS.%26aulast%3DCairns%26aufirst%3DN.%2BJ.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DBlazey%26aufirst%3DT.%2BM.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26aulast%3DSantacruz%26aufirst%3DA.%26aulast%3DBuckles%26aufirst%3DV.%26aulast%3DOliver%26aufirst%3DA.%26aulast%3DMoulder%26aufirst%3DK.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DGhetti%26aufirst%3DB.%26aulast%3DKlunk%26aufirst%3DW.%2BE.%26aulast%3DMcDade%26aufirst%3DE.%26aulast%3DMartins%26aufirst%3DR.%2BN.%26aulast%3DMasters%26aufirst%3DC.%2BL.%26aulast%3DMayeux%26aufirst%3DR.%26aulast%3DRingman%26aufirst%3DJ.%2BM.%26aulast%3DRossor%26aufirst%3DM.%2BN.%26aulast%3DSchofield%26aufirst%3DP.%2BR.%26aulast%3DSperling%26aufirst%3DR.%2BA.%26aulast%3DSalloway%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26atitle%3DDominantly%2520Inherited%2520Alzheimer%2520Network.%2520Clinical%2520and%2520biomarker%2520changes%2520in%2520dominantly%2520inherited%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D795%26epage%3D804%26doi%3D10.1056%2FNEJMoa1202753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span> <span> </span><span class="NLM_article-title">Targeting the β secretase BACE1 for Alzheimer’s disease therapy</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(13)70276-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2FS1474-4422%2813%2970276-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=24556009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1Cntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=319-329&author=R.+Yanauthor=R.+Vassar&title=Targeting+the+%CE%B2+secretase+BACE1+for+Alzheimer%E2%80%99s+disease+therapy&doi=10.1016%2FS1474-4422%2813%2970276-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the β secretase BACE1 for Alzheimer's disease therapy</span></div><div class="casAuthors">Yan, Riqiang; Vassar, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-329</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The β secretase, widely known as β-site amyloid precursor protein cleaving enzyme 1 (BACE1), initiates the prodn. of the toxic amyloid β (Aβ) that plays a crucial early part in Alzheimer's disease pathogenesis.  BACE1 is a prime therapeutic target for lowering cerebral Aβ concns. in Alzheimer's disease, and clin. development of BACE1 inhibitors is being intensely pursued.  Although BACE1 inhibitor drug development has proven challenging, several promising BACE1 inhibitors have recently entered human clin. trials.  The safety and efficacy of these drugs are being tested at present in healthy individuals and patients with Alzheimer's disease, and will soon be tested in individuals with presymptomatic Alzheimer's disease.  Although hopes are high that BACE1 inhibitors might be efficacious for the prevention or treatment of Alzheimer's disease, concerns have been raised about potential mechanism-based side-effects of these drugs.  The potential of therapeutic BACE1 inhibition might prove to be a watershed in the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8SsSfCAC6nbVg90H21EOLACvtfcHk0ljmtVcNtCEURw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1Cntbo%253D&md5=11aeb06fee19cafc0b361e2c43900806</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2813%2970276-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252813%252970276-X%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26aulast%3DVassar%26aufirst%3DR.%26atitle%3DTargeting%2520the%2520%25CE%25B2%2520secretase%2520BACE1%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520therapy%26jtitle%3DLancet%2520Neurol.%26date%3D2014%26volume%3D13%26spage%3D319%26epage%3D329%26doi%3D10.1016%2FS1474-4422%2813%2970276-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snaedal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulem, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudbjartsson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhangale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttenlocher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsdottir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreassen, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jönsson, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palotie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, K.</span></span> <span> </span><span class="NLM_article-title">A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>488</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1038/nature11283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1038%2Fnature11283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=22801501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2012&pages=96-99&author=T.+Jonssonauthor=J.+K.+Atwalauthor=S.+Steinbergauthor=J.+Snaedalauthor=P.+V.+Jonssonauthor=S.+Bjornssonauthor=H.+Stefanssonauthor=P.+Sulemauthor=D.+Gudbjartssonauthor=J.+Maloneyauthor=K.+Hoyteauthor=A.+Gustafsonauthor=Y.+Liuauthor=Y.+Luauthor=T.+Bhangaleauthor=R.+R.+Grahamauthor=J.+Huttenlocherauthor=G.+Bjornsdottirauthor=O.+A.+Andreassenauthor=E.+G.+J%C3%B6nssonauthor=A.+Palotieauthor=T.+W.+Behrensauthor=O.+T.+Magnussonauthor=A.+Kongauthor=U.+Thorsteinsdottirauthor=R.+J.+Wattsauthor=K.+Stefansson&title=A+mutation+in+APP+protects+against+Alzheimer%E2%80%99s+disease+and+age-related+cognitive+decline&doi=10.1038%2Fnature11283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A mutation in APP protects against Alzheimer's disease and age-related cognitive decline</span></div><div class="casAuthors">Jonsson, Thorlakur; Atwal, Jasvinder K.; Steinberg, Stacy; Snaedal, Jon; Jonsson, Palmi V.; Bjornsson, Sigurbjorn; Stefansson, Hreinn; Sulem, Patrick; Gudbjartsson, Daniel; Maloney, Janice; Hoyte, Kwame; Gustafson, Amy; Liu, Yichin; Lu, Yanmei; Bhangale, Tushar; Graham, Robert R.; Huttenlocher, Johanna; Bjornsdottir, Gyda; Andreassen, Ole A.; Joensson, Erik G.; Palotie, Aarno; Behrens, Timothy W.; Magnusson, Olafur T.; Kong, Augustine; Thorsteinsdottir, Unnur; Watts, Ryan J.; Stefansson, Kari</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">488</span>
        (<span class="NLM_cas:issue">7409</span>),
    <span class="NLM_cas:pages">96-99</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The prevalence of dementia in the Western world in people over the age of 60 has been estd. to be greater than 5%, about two-thirds of which are due to Alzheimer's disease.  The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3).  Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1795 Icelanders.  We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease.  This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approx. 40% redn. in the formation of amyloidogenic peptides in vitro.  The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease.  Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4AFwQCLRQOLVg90H21EOLACvtfcHk0ljmtVcNtCEURw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73M&md5=4db9cb2e3842d5a9d4af4ce102249b70</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature11283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11283%26sid%3Dliteratum%253Aachs%26aulast%3DJonsson%26aufirst%3DT.%26aulast%3DAtwal%26aufirst%3DJ.%2BK.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DSnaedal%26aufirst%3DJ.%26aulast%3DJonsson%26aufirst%3DP.%2BV.%26aulast%3DBjornsson%26aufirst%3DS.%26aulast%3DStefansson%26aufirst%3DH.%26aulast%3DSulem%26aufirst%3DP.%26aulast%3DGudbjartsson%26aufirst%3DD.%26aulast%3DMaloney%26aufirst%3DJ.%26aulast%3DHoyte%26aufirst%3DK.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DBhangale%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DR.%2BR.%26aulast%3DHuttenlocher%26aufirst%3DJ.%26aulast%3DBjornsdottir%26aufirst%3DG.%26aulast%3DAndreassen%26aufirst%3DO.%2BA.%26aulast%3DJ%25C3%25B6nsson%26aufirst%3DE.%2BG.%26aulast%3DPalotie%26aufirst%3DA.%26aulast%3DBehrens%26aufirst%3DT.%2BW.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DKong%26aufirst%3DA.%26aulast%3DThorsteinsdottir%26aufirst%3DU.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26aulast%3DStefansson%26aufirst%3DK.%26atitle%3DA%2520mutation%2520in%2520APP%2520protects%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520age-related%2520cognitive%2520decline%26jtitle%3DNature%26date%3D2012%26volume%3D488%26spage%3D96%26epage%3D99%26doi%3D10.1038%2Fnature11283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Oehlrich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokopcova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span> <span> </span><span class="NLM_article-title">The evolution of amidine-based brain penetrant BACE1 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2033</span>– <span class="NLM_lpage">2045</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2Fj.bmcl.2014.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=24704031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvVSqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2033-2045&author=D.+Oehlrichauthor=H.+Prokopcovaauthor=H.+J.+M.+Gijsen&title=The+evolution+of+amidine-based+brain+penetrant+BACE1+inhibitors&doi=10.1016%2Fj.bmcl.2014.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of amidine-based brain penetrant BACE1 inhibitors</span></div><div class="casAuthors">Oehlrich, Daniel; Prokopcova, Hana; Gijsen, Harrie J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2033-2045</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Beta site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors hold great potential as disease modifying anti-Alzheimer's drugs.  This digest provides an overview of the amidine contg. class of BACE1 inhibitors, of which multiple examples are now progressing through clin. trials.  The various structural modifications highlight the struggle to combine potency with the optimal properties for a brain penetrant BACE1 inhibitor, and illustrate the crowded competitive landscape.  This overview concludes with a summary of potential issues including substrate and target selectivity and a synopsis of the status of the current and past clin. assets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-4h1WxzUvbbVg90H21EOLACvtfcHk0ljmtVcNtCEURw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvVSqsrY%253D&md5=a929f7f1be0c7d2ff1a10fc5853de06b</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DOehlrich%26aufirst%3DD.%26aulast%3DProkopcova%26aufirst%3DH.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26atitle%3DThe%2520evolution%2520of%2520amidine-based%2520brain%2520penetrant%2520BACE1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2033%26epage%3D2045%26doi%3D10.1016%2Fj.bmcl.2014.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span>; <span class="NLM_string-name">Gijsen, H. J. M.</span></span> <span> </span><span class="NLM_article-title">Targeting β-secretase (BACE) for the Treatment of Alzheimer’s Disease</span>. In  <i>Comprehensive Medicinal Chemistry III</i>, <span class="NLM_edition">3</span>rd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Chackalamannil, S.</span>, <span class="NLM_string-name">Rotella, D. P.</span>, <span class="NLM_string-name">Ward, S. E.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Oxford</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">7</span>, pp  <span class="NLM_fpage">326</span>– <span class="NLM_lpage">383</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2FB978-0-12-409547-2.13809-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=326-383&author=A.+Hall&author=H.+J.+M.+Gijsenauthor=S.+Chackalamannil&author=D.+P.+Rotella&author=S.+E.+Ward&title=Comprehensive+Medicinal+Chemistry+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-409547-2.13809-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-409547-2.13809-0%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DA.%26atitle%3DTargeting%2520%25CE%25B2-secretase%2520%2528BACE%2529%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26btitle%3DComprehensive%2520Medicinal%2520Chemistry%2520III%26aulast%3DChackalamannil%26aufirst%3DS.%26pub%3DElsevier%26date%3D2017%26volume%3D7%26spage%3D326%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rombouts, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span> <span> </span><span class="NLM_article-title">New evolutions in the BACE1 inhibitor field from 2014 to 2018</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">777</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2Fj.bmcl.2018.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=30709653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=761-777&author=C.-C.+Hsiaoauthor=F.+Romboutsauthor=H.+J.+M.+Gijsen&title=New+evolutions+in+the+BACE1+inhibitor+field+from+2014+to+2018&doi=10.1016%2Fj.bmcl.2018.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">New evolutions in the BACE1 inhibitor field from 2014 to 2018</span></div><div class="casAuthors">Hsiao, Chien-Chi; Rombouts, Frederik; Gijsen, Harrie J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">761-777</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors offer the potential of disease-modifying treatment for Alzheimer's disease (AD).  Since 2014, major breakthroughs have appeared in the field of BACE1 inhibitors.  This review provides an overview of amidine-based BACE1 inhibitors between 2014 and 2018.  Herein are summarized (i) the structure-activity relationship, (ii) the physiol. results and (iii) the potential risks from a lack of selectivity.  This review also summarizes clin. scope, results and outlook of the compds. that have been or are currently under development in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3OfI_B-BJ-LVg90H21EOLACvtfcHk0ljQ9PlZR0INNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCmu7s%253D&md5=049eda6ce97b31a04b5b579afd3e11e5</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DHsiao%26aufirst%3DC.-C.%26aulast%3DRombouts%26aufirst%3DF.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26atitle%3DNew%2520evolutions%2520in%2520the%2520BACE1%2520inhibitor%2520field%2520from%25202014%2520to%25202018%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D761%26epage%3D777%26doi%3D10.1016%2Fj.bmcl.2018.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osswald, H. L.</span></span> <span> </span><span class="NLM_article-title">BACE1 (β-secretase) inhibitors for the treatment of Alzheimer’s disease</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">6765</span>– <span class="NLM_lpage">6813</span>, <span class="refDoi"> DOI: 10.1039/C3CS60460H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1039%2FC3CS60460H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=24691405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2mt7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=6765-6813&author=A.+K.+Ghoshauthor=H.+L.+Osswald&title=BACE1+%28%CE%B2-secretase%29+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1039%2FC3CS60460H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7dR"><div class="casContent"><span class="casTitleNuber">7d</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Ghosh, Arun K.; Osswald, Heather L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6765-6813</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">BACE1 (β-secretase, memapsin 2, Asp2) has emerged as a promising target for the treatment of Alzheimer's disease.  BACE1 is an aspartic protease which functions in the first step of the pathway leading to the prodn. and deposition of amyloid-β peptide (Aβ).  Its gene deletion showed only mild phenotypes.  BACE1 inhibition has direct implications in the Alzheimer's disease pathol. without largely affecting viability.  However, inhibiting BACE1 selectively in vivo has presented many challenges to medicinal chemists.  Since its identification in 2000, inhibitors covering many different structural classes have been designed and developed.  These inhibitors can be largely classified as either peptidomimetic or non-peptidic inhibitors.  Progress in these fields resulted in inhibitors that contain many targeted drug-like characteristics.  In this review, we describe structure-based design strategies and evolution of a wide range of BACE1 inhibitors including compds. that have been shown to reduce brain Aβ, rescue the cognitive decline in transgenic AD mice and inhibitor drug candidates that are currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri59_pgGAbxLVg90H21EOLACvtfcHk0ljQ9PlZR0INNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2mt7nJ&md5=dab445bf7efb6fdc0c80e032d3bb0071</span></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1039%2FC3CS60460H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC3CS60460H%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DOsswald%26aufirst%3DH.%2BL.%26atitle%3DBACE1%2520%2528%25CE%25B2-secretase%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2014%26volume%3D43%26spage%3D6765%26epage%3D6813%26doi%3D10.1039%2FC3CS60460H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeever, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillard, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. B.</span></span> <span> </span><span class="NLM_article-title">Structure based design of β-site APP cleaving enzyme 1 (BACE) inhibitors for the treatment of Alzheimer’s disease. disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4156</span>– <span class="NLM_lpage">4180</span>, <span class="refDoi"> DOI: 10.1021/jm301659n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301659n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKgtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4156-4180&author=J.+Yuanauthor=S.+Venkatramanauthor=Y.+Zhengauthor=B.+M.+McKeeverauthor=L.+W.+Dillardauthor=S.+B.+Singh&title=Structure+based+design+of+%CE%B2-site+APP+cleaving+enzyme+1+%28BACE%29+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease.+disease&doi=10.1021%2Fjm301659n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7eR"><div class="casContent"><span class="casTitleNuber">7e</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of β-Site APP Cleaving Enzyme 1 (BACE1) Inhibitors for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Yuan, Jing; Venkatraman, Shankar; Zheng, Yajun; McKeever, Brian M.; Dillard, Lawrence W.; Singh, Suresh B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4156-4180</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The amyloid hypothesis asserts that excess prodn. or reduced clearance of the amyloid-β (Aβ) peptides in the brain initiates a sequence of events that ultimately lead to Alzheimer's disease dementia.  The Aβ hypothesis has identified BACE1 as a therapeutic target to treat Alzheimer's and led to medicinal chem. efforts to design its inhibitors both in the pharmaceutical industry and in academia.  This review summarizes two distinct categories of inhibitors designed based on conformational states of "closed" and "open" forms of the enzyme.  In each category the inhibitors are classified based on the core catalytic interaction group or the aspartyl binding motif (ABM).  This review covers the description of inhibitors in each ABM class with X-ray crystal structures of key compds., their binding modes, related structure-activity data highlighting potency advances, and addnl. properties such as selectivity profile, P-gp efflux, pharmacokinetic, and pharmacodynamic data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRLs7KN_eIzbVg90H21EOLACvtfcHk0ljkxECW0aeVUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKgtr0%253D&md5=b703f57572b737b47658d86f5b730087</span></div><a href="/servlet/linkout?suffix=cit7e&amp;dbid=16384&amp;doi=10.1021%2Fjm301659n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301659n%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DMcKeever%26aufirst%3DB.%2BM.%26aulast%3DDillard%26aufirst%3DL.%2BW.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DStructure%2520based%2520design%2520of%2520%25CE%25B2-site%2520APP%2520cleaving%2520enzyme%25201%2520%2528BACE%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease.%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4156%26epage%3D4180%26doi%3D10.1021%2Fjm301659n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rombouts, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span> <span> </span><span class="NLM_article-title">Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1080/13543776.2021.1832463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1080%2F13543776.2021.1832463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=33006491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FmsVyltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2021&pages=25-52&author=F.+Romboutsauthor=K.-I.+Kusakabeauthor=C.-C.+Hsiaoauthor=H.+J.+M.+Gijsen&title=Small-molecule+BACE1+inhibitors%3A+a+patent+literature+review+%282011+to+2020%29&doi=10.1080%2F13543776.2021.1832463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7fR"><div class="casContent"><span class="casTitleNuber">7f</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)</span></div><div class="casAuthors">Rombouts Frederik; Hsiao Chien-Chi; Gijsen Harrie J M; Kusakabe Ken-Ichi</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on therapeutic patents</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Inhibition of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) has been extensively pursued as potential disease-modifying treatment for Alzheimer's disease (AD).  Clinical failures with BACE inhibitors have progressively raised the bar forever cleaner candidates with reduced cardiovascular liability, toxicity risk, and increased selectivity over cathepsin D (CatD) and BACE2.  AREAS COVERED:  This review provides an overview of patented BACE1 inhibitors between 2011 and 2020 per pharmaceutical company or research group and highlights the progress that was made in dialing out toxicity liabilities.  EXPERT OPINION:  Despite an increasingly crowded IP situation, significant progress was made using highly complex chemistry in avoiding toxicity liabilities, with BACE1/BACE2 selectivity being the most remarkable achievement.  However, clinical trial data suggest on-target toxicity is likely a contributing factor, which implies the only potential future of BACE1 inhibitors lies in careful titration of highly selective compounds in early populations where the amyloid burden is still minimal as prophylactic therapy, or as an affordable oral maintenance therapy following amyloid-clearing therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRr9NKN_f1WVVm8bhe6roZYfW6udTcc2eabnku_waltGbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FmsVyltg%253D%253D&md5=e7bc2b32c79cebbb2ab82259fa139b73</span></div><a href="/servlet/linkout?suffix=cit7f&amp;dbid=16384&amp;doi=10.1080%2F13543776.2021.1832463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2021.1832463%26sid%3Dliteratum%253Aachs%26aulast%3DRombouts%26aufirst%3DF.%26aulast%3DKusakabe%26aufirst%3DK.-I.%26aulast%3DHsiao%26aufirst%3DC.-C.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26atitle%3DSmall-molecule%2520BACE1%2520inhibitors%253A%2520a%2520patent%2520literature%2520review%2520%25282011%2520to%25202020%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2021%26volume%3D31%26spage%3D25%26epage%3D52%26doi%3D10.1080%2F13543776.2021.1832463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Timmers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Broeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramael, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slemmon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Waepenaert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieltjes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelborghs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercken, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Nueten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tritsmans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streffer, J. R.</span></span> <span> </span><span class="NLM_article-title">Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor</span>. <i>Alzheimers Dement (N Y)</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">212</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=201-212&author=M.+Timmersauthor=B.+Van+Broeckauthor=S.+Ramaelauthor=J.+Slemmonauthor=K.+De+Waepenaertauthor=A.+Russuauthor=J.+Bogertauthor=H.+Stieltjesauthor=L.+M.+Shawauthor=S.+Engelborghsauthor=D.+Moecharsauthor=M.+Merckenauthor=E.+Liuauthor=V.+Sinhaauthor=J.+Kempauthor=L.+Van+Nuetenauthor=L.+Tritsmansauthor=J.+R.+Streffer&title=Profiling+the+dynamics+of+CSF+and+plasma+A%CE%B2+reduction+after+treatment+with+JNJ-54861911%2C+a+potent+oral+BACE+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTimmers%26aufirst%3DM.%26aulast%3DVan%2BBroeck%26aufirst%3DB.%26aulast%3DRamael%26aufirst%3DS.%26aulast%3DSlemmon%26aufirst%3DJ.%26aulast%3DDe%2BWaepenaert%26aufirst%3DK.%26aulast%3DRussu%26aufirst%3DA.%26aulast%3DBogert%26aufirst%3DJ.%26aulast%3DStieltjes%26aufirst%3DH.%26aulast%3DShaw%26aufirst%3DL.%2BM.%26aulast%3DEngelborghs%26aufirst%3DS.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DMercken%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DSinha%26aufirst%3DV.%26aulast%3DKemp%26aufirst%3DJ.%26aulast%3DVan%2BNueten%26aufirst%3DL.%26aulast%3DTritsmans%26aufirst%3DL.%26aulast%3DStreffer%26aufirst%3DJ.%2BR.%26atitle%3DProfiling%2520the%2520dynamics%2520of%2520CSF%2520and%2520plasma%2520A%25CE%25B2%2520reduction%2520after%2520treatment%2520with%2520JNJ-54861911%252C%2520a%2520potent%2520oral%2520BACE%2520inhibitor%26jtitle%3DAlzheimers%2520Dement%2520%2528N%2520Y%2529%26date%3D2016%26volume%3D2%26spage%3D201%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Timmers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streffer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominaga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiraishi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatikola, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smekens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borjesson-Hanson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreasen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matias-Guiu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baquero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesseur, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tritsmans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Nueten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelborghs, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study</span>. <i>Alzheimer’s Res. Ther</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">85/1</span>– <span class="NLM_lpage">85/18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1186%2Fs13195-018-0415-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=85%2F1-85%2F18&author=M.+Timmersauthor=J.+R.+Strefferauthor=A.+Russuauthor=Y.+Tominagaauthor=H.+Shimizuauthor=A.+Shiraishiauthor=K.+Tatikolaauthor=P.+Smekensauthor=A.+Borjesson-Hansonauthor=N.+Andreasenauthor=J.+Matias-Guiuauthor=M.+Baqueroauthor=M.+Boadaauthor=I.+Tesseurauthor=L.+Tritsmansauthor=L.+Van+Nuetenauthor=S.+Engelborghs&title=Pharmacodynamics+of+atabecestat+%28JNJ-54861911%29%2C+an+oral+BACE1+inhibitor+in+patients+with+early+Alzheimer%E2%80%99s+disease%3A+randomized%2C+double-blind%2C+placebo-controlled+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1186%2Fs13195-018-0415-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13195-018-0415-6%26sid%3Dliteratum%253Aachs%26aulast%3DTimmers%26aufirst%3DM.%26aulast%3DStreffer%26aufirst%3DJ.%2BR.%26aulast%3DRussu%26aufirst%3DA.%26aulast%3DTominaga%26aufirst%3DY.%26aulast%3DShimizu%26aufirst%3DH.%26aulast%3DShiraishi%26aufirst%3DA.%26aulast%3DTatikola%26aufirst%3DK.%26aulast%3DSmekens%26aufirst%3DP.%26aulast%3DBorjesson-Hanson%26aufirst%3DA.%26aulast%3DAndreasen%26aufirst%3DN.%26aulast%3DMatias-Guiu%26aufirst%3DJ.%26aulast%3DBaquero%26aufirst%3DM.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DTesseur%26aufirst%3DI.%26aulast%3DTritsmans%26aufirst%3DL.%26aulast%3DVan%2BNueten%26aufirst%3DL.%26aulast%3DEngelborghs%26aufirst%3DS.%26atitle%3DPharmacodynamics%2520of%2520atabecestat%2520%2528JNJ-54861911%2529%252C%2520an%2520oral%2520BACE1%2520inhibitor%2520in%2520patients%2520with%2520early%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther%26date%3D2018%26volume%3D10%26spage%3D85%252F1%26epage%3D85%252F18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, G.</span></span> <span> </span><span class="NLM_article-title">Preliminary results of a trial of atabecestat in preclinical Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1485</span>, <span class="refDoi"> DOI: 10.1056/NEJMc1813435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1056%2FNEJMc1813435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=30970197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FjvFGqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=1483-1485&author=D.+Henleyauthor=N.+Raghavanauthor=R.+Sperlingauthor=P.+Aisenauthor=R.+Ramanauthor=G.+Romano&title=Preliminary+results+of+a+trial+of+atabecestat+in+preclinical+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMc1813435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease</span></div><div class="casAuthors">Henley David; Raghavan Nandini; Sperling Reisa; Aisen Paul; Raman Rema; Romano Gary</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1483-1485</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfD9bI0ZsheHELvajU9pjPfW6udTcc2ebgx--YEg8-ELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FjvFGqtg%253D%253D&md5=42b37561fb1b3bd8102b7ba3ba64d588</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1813435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1813435%26sid%3Dliteratum%253Aachs%26aulast%3DHenley%26aufirst%3DD.%26aulast%3DRaghavan%26aufirst%3DN.%26aulast%3DSperling%26aufirst%3DR.%26aulast%3DAisen%26aufirst%3DP.%26aulast%3DRaman%26aufirst%3DR.%26aulast%3DRomano%26aufirst%3DG.%26atitle%3DPreliminary%2520results%2520of%2520a%2520trial%2520of%2520atabecestat%2520in%2520preclinical%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D1483%26epage%3D1485%26doi%3D10.1056%2FNEJMc1813435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streffer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brashear, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesseur, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tritsmans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Nueten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelborghs, S.</span></span> <span> </span><span class="NLM_article-title">Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study</span>. <i>Alzheimer's Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">58</span>, <span class="refDoi"> DOI: 10.1186/s13195-020-00614-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1186%2Fs13195-020-00614-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptlKgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=58&author=G.+Novakauthor=J.+R.+Strefferauthor=M.+Timmersauthor=D.+Henleyauthor=H.+R.+Brashearauthor=J.+Bogertauthor=A.+Russuauthor=L.+Janssensauthor=I.+Tesseurauthor=L.+Tritsmansauthor=L.+Van+Nuetenauthor=S.+Engelborghs&title=Long-term+safety+and+tolerability+of+atabecestat+%28JNJ-54861911%29%2C+an+oral+BACE1+inhibitor%2C+in+early+Alzheimer%E2%80%99s+disease+spectrum+patients%3A+a+randomized%2C+double-blind%2C+placebo-controlled+study+and+a+two-period+extension+study&doi=10.1186%2Fs13195-020-00614-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8dR"><div class="casContent"><span class="casTitleNuber">8d</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study</span></div><div class="casAuthors">Novak, Gerald; Streffer, Johannes Rolf; Timmers, Maarten; Henley, David; Brashear, H. Robert; Bogert, Jennifer; Russu, Alberto; Janssens, Luc; Tesseur, Ina; Tritsmans, Luc; Van Nueten, Luc; Engelborghs, Sebastiaan</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's Research & Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58</span>CODEN:
                <span class="NLM_cas:coden">ARTLCD</span>;
        ISSN:<span class="NLM_cas:issn">1758-9193</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Long-term safety and effect of atabecestat on cognitive performance in participants with pre-dementia AD in two phase 2 studies were assessed.  In placebo-controlled double-blind parent ALZ2002 study, participants aged 50 to 85 years were randomized to placebo or atabecestat 10 or 50 mg once daily for 6 mo.  Participants entered ALZ2004, 12-mo treatment extension with placebo or atabecestat 10 or 25 mg, followed by open-label phase.  Safety, changes in CSF biomarker levels, brain vol., and effects on cognitive performance were assessed.  Results: Of 114 participants randomized in ALZ2002, 99 completed, 90 entered ALZ2004 double-blind phase and 77 progressed to open-label phase.  CSF Aβ fragments and sAPPβ were reduced dose-proportionately.  Decreases in whole brain and hippocampal vols. were greater in participants with mild cognitive impairment due to AD than in preclin. AD, but were not affected by treatment.  In ALZ2004, change from baseline in RBANS trended toward worse scores for atabecestat vs. placebo.  Elevated liver enzyme adverse events reported in 12 participants on atabecestat resulted in dosage modification and increased frequency of safety monitoring.  Treatment discontinuation normalized ALT or AST in all except one with pretreatment elevation, which remained mildly elevated.  No case met ALT/AST > 3x ULN and total bilirubin > 2x ULN.  Conclusion: Atabecestat was assocd. with trend toward declines in cognition, and elevation of liver enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2u7CJgya_lLVg90H21EOLACvtfcHk0ljv6YtHmr7HYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptlKgsr8%253D&md5=5e091a6f701db4bf4464d0e2b8eebba3</span></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=10.1186%2Fs13195-020-00614-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13195-020-00614-5%26sid%3Dliteratum%253Aachs%26aulast%3DNovak%26aufirst%3DG.%26aulast%3DStreffer%26aufirst%3DJ.%2BR.%26aulast%3DTimmers%26aufirst%3DM.%26aulast%3DHenley%26aufirst%3DD.%26aulast%3DBrashear%26aufirst%3DH.%2BR.%26aulast%3DBogert%26aufirst%3DJ.%26aulast%3DRussu%26aufirst%3DA.%26aulast%3DJanssens%26aufirst%3DL.%26aulast%3DTesseur%26aufirst%3DI.%26aulast%3DTritsmans%26aufirst%3DL.%26aulast%3DVan%2BNueten%26aufirst%3DL.%26aulast%3DEngelborghs%26aufirst%3DS.%26atitle%3DLong-term%2520safety%2520and%2520tolerability%2520of%2520atabecestat%2520%2528JNJ-54861911%2529%252C%2520an%2520oral%2520BACE1%2520inhibitor%252C%2520in%2520early%2520Alzheimer%25E2%2580%2599s%2520disease%2520spectrum%2520patients%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%2520and%2520a%2520two-period%2520extension%2520study%26jtitle%3DAlzheimer%2527s%2520Res.%2520Ther.%26date%3D2020%26volume%3D12%26spage%3D58%26doi%3D10.1186%2Fs13195-020-00614-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martenyi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBell, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calligaro, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span> <span> </span><span class="NLM_article-title">Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">16507</span>– <span class="NLM_lpage">16516</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.3647-11.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1523%2FJNEUROSCI.3647-11.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=22090477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFaksL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=16507-16516&author=P.+C.+Mayauthor=R.+A.+Deanauthor=S.+L.+Loweauthor=F.+Martenyiauthor=S.+M.+Sheehanauthor=L.+N.+Boggsauthor=S.+A.+Monkauthor=B.+M.+Mathesauthor=D.+J.+Mergottauthor=B.+M.+Watsonauthor=S.+L.+Stoutauthor=D.+E.+Timmauthor=E.+S.+LaBellauthor=C.+R.+Gonzalesauthor=M.+Nakanoauthor=S.+S.+Jheeauthor=M.+Yenauthor=L.+Ereshefskyauthor=T.+D.+Lindstromauthor=D.+O.+Calligaroauthor=P.+J.+Cockeauthor=D.+G.+Hallauthor=S.+Friedrichauthor=M.+Citronauthor=J.+E.+Audia&title=Robust+central+reduction+of+amyloid-%CE%B2+in+humans+with+an+orally+available%2C+non-peptidic+%CE%B2-secretase+inhibitor&doi=10.1523%2FJNEUROSCI.3647-11.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor</span></div><div class="casAuthors">May, Patrick C.; Dean, Robert A.; Lowe, Stephen L.; Martenyi, Ferenc; Sheehan, Scott M.; Boggs, Leonard N.; Monk, Scott A.; Mathes, Brian M.; Mergott, Dustin J.; Watson, Brian M.; Stout, Stephanie L.; Timm, David E.; LaBell, Elizabeth Smith; Gonzales, Celedon R.; Nakano, Masako; Jhee, Stanford S.; Yen, Mark; Ereshefsky, Larry; Lindstrom, Terry D.; Calligaro, David O.; Cocke, Patrick J.; Hall, D. Greg; Friedrich, Stuart; Citron, Martin; Audia, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">16507-16516</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">According to the amyloid cascade hypothesis, cerebral deposition of amyloid-β peptide (Aβ) is crit. for Alzheimer's disease (AD) pathogenesis.  Aβ generation is initiated when β-secretase (BACE1) cleaves the amyloid precursor protein.  For more than a decade, BACE1 has been a prime target for designing drugs to prevent or treat AD.  However, development of such agents has turned out to be extremely challenging, with major hurdles in cell penetration, oral bioavailability/metabolic clearance, and brain access.  Using a fragment-based chem. strategy, we have generated LY2811376 [(S)-4-(2,4-difluoro-5-pyrimidin-5-yl-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]thiazin-2-ylamine], the first orally available non-peptidic BACE1 inhibitor that produces profound Aβ-lowering effects in animals.  The biomarker changes obtained in preclin. animal models translate into man at doses of LY2811376 that were safe and well tolerated in healthy volunteers.  Prominent and long-lasting Aβ redns. in lumbar CSF were measured after oral dosing of 30 or 90 mg of LY2811376.  This represents the first translation of BACE1-driven biomarker changes in CNS from preclin. animal models to man.  Because of toxicol. findings identified in longer-term preclin. studies, this compd. is no longer progressing in clin. development.  However, BACE1 remains a viable target because the adverse effects reported here were recapitulated in LY2811376-treated BACE1 KO mice and thus are unrelated to BACE1 inhibition.  The magnitude and duration of central Aβ redn. obtainable with BACE1 inhibition positions this protease as a tractable small-mol. target through which to test the amyloid hypothesis in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqns_TvT2bZrVg90H21EOLACvtfcHk0ljv6YtHmr7HYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFaksL7F&md5=8f21f91ebd77e5fcf8b58b51c73a1a6b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3647-11.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3647-11.2011%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DP.%2BC.%26aulast%3DDean%26aufirst%3DR.%2BA.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DMartenyi%26aufirst%3DF.%26aulast%3DSheehan%26aufirst%3DS.%2BM.%26aulast%3DBoggs%26aufirst%3DL.%2BN.%26aulast%3DMonk%26aufirst%3DS.%2BA.%26aulast%3DMathes%26aufirst%3DB.%2BM.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26aulast%3DWatson%26aufirst%3DB.%2BM.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DTimm%26aufirst%3DD.%2BE.%26aulast%3DLaBell%26aufirst%3DE.%2BS.%26aulast%3DGonzales%26aufirst%3DC.%2BR.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DJhee%26aufirst%3DS.%2BS.%26aulast%3DYen%26aufirst%3DM.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DLindstrom%26aufirst%3DT.%2BD.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DCocke%26aufirst%3DP.%2BJ.%26aulast%3DHall%26aufirst%3DD.%2BG.%26aulast%3DFriedrich%26aufirst%3DS.%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26atitle%3DRobust%2520central%2520reduction%2520of%2520amyloid-%25CE%25B2%2520in%2520humans%2520with%2520an%2520orally%2520available%252C%2520non-peptidic%2520%25CE%25B2-secretase%2520inhibitor%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26spage%3D16507%26epage%3D16516%26doi%3D10.1523%2FJNEUROSCI.3647-11.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borders, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brier, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calligaro, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevorkyan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komjathy, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martenyi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaught, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winneroski, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span> <span> </span><span class="NLM_article-title">The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1210</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4129-14.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1523%2FJNEUROSCI.4129-14.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=25609634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Oit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1199-1210&author=P.+C.+Mayauthor=B.+A.+Willisauthor=S.+L.+Loweauthor=R.+A.+Deanauthor=S.+A.+Monkauthor=P.+J.+Cockeauthor=J.+E.+Audiaauthor=L.+N.+Boggsauthor=A.+R.+Bordersauthor=R.+A.+Brierauthor=D.+O.+Calligaroauthor=T.+A.+Dayauthor=L.+Ereshefskyauthor=J.+A.+Ericksonauthor=H.+Gevorkyanauthor=C.+R.+Gonzalesauthor=D.+E.+Jamesauthor=S.+S.+Jheeauthor=S.+F.+Komjathyauthor=L.+Liauthor=T.+D.+Lindstromauthor=B.+M.+Mathesauthor=F.+Martenyiauthor=S.+M.+Sheehanauthor=S.+L.+Stoutauthor=D.+E.+Timmauthor=G.+M.+Vaughtauthor=B.+M.+Watsonauthor=L.+L.+Winneroskiauthor=Z.+Yangauthor=D.+J.+Mergott&title=The+potent+BACE1+inhibitor+LY2886721+elicits+robust+central+A%CE%B2+pharmacodynamic+responses+in+mice%2C+dogs%2C+and+humans&doi=10.1523%2FJNEUROSCI.4129-14.2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans</span></div><div class="casAuthors">May, Patrick C.; Willis, Brian A.; Lowe, Stephen L.; Dean, Robert A.; Monk, Scott A.; Cocke, Patrick J.; Audia, James E.; Boggs, Leonard N.; Borders, Anthony R.; Brier, Richard A.; Calligaro, David O.; Day, Theresa A.; Ereshefsky, Larry; Erickso, Jon A.; Gevorkyan, Hykop; Gonzales, Celedon R.; James, Douglas E.; Jhee, Stanford S.; Komjathy, Steven F.; Li, Linglin; Lindstrom, Terry D.; Mathe, Brian M.; Martenyi, Ferenc; Sheehan, Scott M.; Stout, Stephanie L.; Timm, David E.; Vaught, Grant M.; Watson, Brian M.; Winneroski, Leonard L.; Yang, Zhixiang; Mergott, Dustin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1199-1210, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD).  Therefore, the development of potent and selective inhibitors of BACE1 has been a focus of many drug discovery efforts in academia and industry.  Herein, we report the nonclin. and early clin. development of LY2886721, a BACE1 active site inhibitor that reached phase 2 clin. trials in AD.  LY2886721 has high selectivity against key off-target proteases, which efficiently translates in vitro activity into robust in vivo amyloid β lowering in nonclin. animal models.  Similar potent and persistent amyloid β lowering was obsd. in plasma and lumbar CSF when single and multiple doses of LY2886721 were administered to healthy human subjects.  Collectively, these data add support for BACE1 inhibition as an effective means of amyloid lowering and as an attractive target for potential disease modification therapy in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDDFLhcsiUDLVg90H21EOLACvtfcHk0liZnJldy_O1IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Oit78%253D&md5=7e16cc00767a8af4da7dd17b6e40e8f5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4129-14.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4129-14.2015%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DP.%2BC.%26aulast%3DWillis%26aufirst%3DB.%2BA.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DDean%26aufirst%3DR.%2BA.%26aulast%3DMonk%26aufirst%3DS.%2BA.%26aulast%3DCocke%26aufirst%3DP.%2BJ.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DBoggs%26aufirst%3DL.%2BN.%26aulast%3DBorders%26aufirst%3DA.%2BR.%26aulast%3DBrier%26aufirst%3DR.%2BA.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DDay%26aufirst%3DT.%2BA.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DErickson%26aufirst%3DJ.%2BA.%26aulast%3DGevorkyan%26aufirst%3DH.%26aulast%3DGonzales%26aufirst%3DC.%2BR.%26aulast%3DJames%26aufirst%3DD.%2BE.%26aulast%3DJhee%26aufirst%3DS.%2BS.%26aulast%3DKomjathy%26aufirst%3DS.%2BF.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLindstrom%26aufirst%3DT.%2BD.%26aulast%3DMathes%26aufirst%3DB.%2BM.%26aulast%3DMartenyi%26aufirst%3DF.%26aulast%3DSheehan%26aufirst%3DS.%2BM.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DTimm%26aufirst%3DD.%2BE.%26aulast%3DVaught%26aufirst%3DG.%2BM.%26aulast%3DWatson%26aufirst%3DB.%2BM.%26aulast%3DWinneroski%26aufirst%3DL.%2BL.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520potent%2520BACE1%2520inhibitor%2520LY2886721%2520elicits%2520robust%2520central%2520A%25CE%25B2%2520pharmacodynamic%2520responses%2520in%2520mice%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DJ.%2520Neurosci.%26date%3D2015%26volume%3D35%26spage%3D1199%26epage%3D1210%26doi%3D10.1523%2FJNEUROSCI.4129-14.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D.</span>; <span class="NLM_string-name">Audia, J.</span>; <span class="NLM_string-name">Barberis, M.</span>; <span class="NLM_string-name">Beck, J.</span>; <span class="NLM_string-name">Boggs, L.</span>; <span class="NLM_string-name">Boyer, R.</span>; <span class="NLM_string-name">Brier, R.</span>; <span class="NLM_string-name">Borders, A.</span>; <span class="NLM_string-name">Daugherty, L.</span>; <span class="NLM_string-name">Dean, R.</span>; <span class="NLM_string-name">Ereshefsky, L.</span>; <span class="NLM_string-name">Erickson, J.</span>; <span class="NLM_string-name">Garcia-Losada, P.</span>; <span class="NLM_string-name">Gevorkyan, H.</span>; <span class="NLM_string-name">Green, S.</span>; <span class="NLM_string-name">Hembre, E.</span>; <span class="NLM_string-name">Irizarry, M.</span>; <span class="NLM_string-name">James, D.</span>; <span class="NLM_string-name">Jhee, S.</span>; <span class="NLM_string-name">Lin, Q.</span>; <span class="NLM_string-name">Lopez, J.</span>; <span class="NLM_string-name">Lo, A.</span>; <span class="NLM_string-name">Lowe, S.</span>; <span class="NLM_string-name">Mathes, B.</span>; <span class="NLM_string-name">May, P.</span>; <span class="NLM_string-name">McKinzie, D.</span>; <span class="NLM_string-name">Monk, S.</span>; <span class="NLM_string-name">Nakano, M.</span>; <span class="NLM_string-name">Porter, W.</span>; <span class="NLM_string-name">Shi, Y.</span>; <span class="NLM_string-name">Stout, S.</span>; <span class="NLM_string-name">Timm, D.</span>; <span class="NLM_string-name">Watson, B.</span>; <span class="NLM_string-name">Willis, B.</span>; <span class="NLM_string-name">Winneroski, L.</span>; <span class="NLM_string-name">Yang, Z.</span>; <span class="NLM_string-name">Zimmer, J.</span></span> <span> </span><span class="NLM_article-title">Discovery, Structure Disclosure, and Early Clinical Development of LY3202626, a Low-Dose, CNS-penetrant BACE Inhibitor</span>.  <i>Abstracts of Papers</i>; <span class="NLM_publisher-name">256th ACS National Meeting & Exposition</span>, <span class="NLM_publisher-loc">Boston, MA, United States</span>, August 19–23, <span class="NLM_year">2018</span>.  <span class="NLM_fpage">MEDI-330</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=MEDI-330&author=D.+Mergott&author=J.+Audia&author=M.+Barberis&author=J.+Beck&author=L.+Boggs&author=R.+Boyer&author=R.+Brier&author=A.+Borders&author=L.+Daugherty&author=R.+Dean&author=L.+Ereshefsky&author=J.+Erickson&author=P.+Garcia-Losada&author=H.+Gevorkyan&author=S.+Green&author=E.+Hembre&author=M.+Irizarry&author=D.+James&author=S.+Jhee&author=Q.+Lin&author=J.+Lopez&author=A.+Lo&author=S.+Lowe&author=B.+Mathes&author=P.+May&author=D.+McKinzie&author=S.+Monk&author=M.+Nakano&author=W.+Porter&author=Y.+Shi&author=S.+Stout&author=D.+Timm&author=B.+Watson&author=B.+Willis&author=L.+Winneroski&author=Z.+Yang&author=J.+Zimmer&title=Discovery%2C+Structure+Disclosure%2C+and+Early+Clinical+Development+of+LY3202626%2C+a+Low-Dose%2C+CNS-penetrant+BACE+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMergott%26aufirst%3DD.%26atitle%3DDiscovery%252C%2520Structure%2520Disclosure%252C%2520and%2520Early%2520Clinical%2520Development%2520of%2520LY3202626%252C%2520a%2520Low-Dose%252C%2520CNS-penetrant%2520BACE%2520Inhibitor%26jtitle%3DAbstracts%2520of%2520Papers%26pub%3D256th%2520ACS%2520National%2520Meeting%2520%2526%2520Exposition%26date%3D2018%26spage%3DMEDI-330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunskill, A. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iserloh, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazakevich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meredith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misiaszek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossiter, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-8931)–A β-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10435</span>– <span class="NLM_lpage">10450</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00307</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00307" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKnsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10435-10450&author=J.+D.+Scottauthor=S.+W.+Liauthor=A.+P.+J.+Brunskillauthor=X.+Chenauthor=K.+Coxauthor=J.+N.+Cummingauthor=M.+Formanauthor=E.+J.+Gilbertauthor=R.+A.+Hodgsonauthor=L.+A.+Hydeauthor=Q.+Jiangauthor=U.+Iserlohauthor=I.+Kazakevichauthor=R.+Kuvelkarauthor=H.+Meiauthor=J.+Meredithauthor=J.+Misiaszekauthor=P.+Orthauthor=L.+M.+Rossiterauthor=M.+Slaterauthor=J.+Stoneauthor=C.+O.+Stricklandauthor=J.+H.+Voigtauthor=G.+Wangauthor=H.+Wangauthor=Y.+Wuauthor=W.+J.+Greenleeauthor=E.+M.+Parkerauthor=M.+E.+Kennedyauthor=A.+W.+Stamford&title=Discovery+of+the+3-imino-1%2C2%2C4-thiadiazinane+1%2C1-dioxide+derivative+verubecestat+%28MK-8931%29%E2%80%93A+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+1+inhibitor+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.6b00307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Scott, Jack D.; Li, Sarah W.; Brunskill, Andrew P. J.; Chen, Xia; Cox, Kathleen; Cumming, Jared N.; Forman, Mark; Gilbert, Eric J.; Hodgson, Robert A.; Hyde, Lynn A.; Jiang, Qin; Iserloh, Ulrich; Kazakevich, Irina; Kuvelkar, Reshma; Mei, Hong; Meredith, John; Misiaszek, Jeffrey; Orth, Peter; Rossiter, Lana M.; Slater, Meagan; Stone, Julie; Strickland, Corey O.; Voigt, Johannes H.; Wang, Ganfeng; Wang, Hongwu; Wu, Yusheng; Greenlee, William J.; Parker, Eric M.; Kennedy, Matthew E.; Stamford, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10435-10450</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Verubecestat (MK-8931), a diaryl amide substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide deriv., is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clin. evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease.  Although not selective over the closely related aspartyl protease BACE2, verubecesat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain Aβ levels in rats and nonhuman primates, and CSF Aβ levels in humans.  In this annotation, the authors describe the discovery of verubecesat, including design, validation, and selected SAR around the novel iminothiadiazinane dioxide core, as well as aspects of its preclin. and Phase 1 clin. characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpN5wdoirs8rVg90H21EOLACvtfcHk0ljjoX_JqZYHsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKnsLnI&md5=517155e2d4f186261b1451ff4556a621</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00307%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DBrunskill%26aufirst%3DA.%2BP.%2BJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DForman%26aufirst%3DM.%26aulast%3DGilbert%26aufirst%3DE.%2BJ.%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DIserloh%26aufirst%3DU.%26aulast%3DKazakevich%26aufirst%3DI.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DMeredith%26aufirst%3DJ.%26aulast%3DMisiaszek%26aufirst%3DJ.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DRossiter%26aufirst%3DL.%2BM.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DStone%26aufirst%3DJ.%26aulast%3DStrickland%26aufirst%3DC.%2BO.%26aulast%3DVoigt%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26atitle%3DDiscovery%2520of%2520the%25203-imino-1%252C2%252C4-thiadiazinane%25201%252C1-dioxide%2520derivative%2520verubecestat%2520%2528MK-8931%2529%25E2%2580%2593A%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10435%26epage%3D10450%26doi%3D10.1021%2Facs.jmedchem.6b00307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dockendorf, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleijn, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palcza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troyer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, M. S.</span></span> <span> </span><span class="NLM_article-title">The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra150</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aad9704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1126%2Fscitranslmed.aad9704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=27807285" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra150&author=M.+E.+Kennedyauthor=X.+Chenauthor=R.+A.+Hodgsonauthor=L.+A.+Hydeauthor=R.+Kuvelkarauthor=E.+M.+Parkerauthor=A.+W.+Stamfordauthor=J.+N.+Cummingauthor=W.+Liauthor=J.+D.+Scottauthor=K.+Coxauthor=M.+F.+Dockendorfauthor=H.+J.+Kleijnauthor=H.+Meiauthor=J.+A.+Stoneauthor=M.+Eganauthor=L.+Ereshefskyauthor=S.+Jheeauthor=B.+A.+Mattsonauthor=J.+Palczaauthor=M.+Tanenauthor=M.+D.+Troyerauthor=J.+L.+Tsengauthor=M.+S.+Forman&title=The+BACE1+inhibitor+verubecestat+%28MK-8931%29+reduces+CNS+%CE%B2-amyloid+in+animal+models+and+in+Alzheimer%E2%80%99s+disease+patients&doi=10.1126%2Fscitranslmed.aad9704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aad9704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aad9704%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DDockendorf%26aufirst%3DM.%2BF.%26aulast%3DKleijn%26aufirst%3DH.%2BJ.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DStone%26aufirst%3DJ.%2BA.%26aulast%3DEgan%26aufirst%3DM.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DJhee%26aufirst%3DS.%26aulast%3DMattson%26aufirst%3DB.%2BA.%26aulast%3DPalcza%26aufirst%3DJ.%26aulast%3DTanen%26aufirst%3DM.%26aulast%3DTroyer%26aufirst%3DM.%2BD.%26aulast%3DTseng%26aufirst%3DJ.%2BL.%26aulast%3DForman%26aufirst%3DM.%2BS.%26atitle%3DThe%2520BACE1%2520inhibitor%2520verubecestat%2520%2528MK-8931%2529%2520reduces%2520CNS%2520%25CE%25B2-amyloid%2520in%2520animal%2520models%2520and%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520patients%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra150%26doi%3D10.1126%2Fscitranslmed.aad9704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span>; <span class="NLM_string-name">Scott, J. D.</span>; <span class="NLM_string-name">Strickland, C. O.</span></span> <span> </span><span class="NLM_article-title">Verubecestat</span>. In  <i>Comprehensive Medicinal Chemistry III</i>, <span class="NLM_edition">3</span>rd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Chackalamannil, S.</span>, <span class="NLM_string-name">Rotella, D. P.</span>, <span class="NLM_string-name">Ward, S. E.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Oxford</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">8</span>, pp  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">251</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=204-251&author=J.+N.+Cumming&author=J.+D.+Scott&author=C.+O.+Stricklandauthor=S.+Chackalamannil&author=D.+P.+Rotella&author=S.+E.+Ward&title=Comprehensive+Medicinal+Chemistry+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26atitle%3DVerubecestat%26btitle%3DComprehensive%2520Medicinal%2520Chemistry%2520III%26aulast%3DChackalamannil%26aufirst%3DS.%26pub%3DElsevier%26date%3D2017%26volume%3D8%26spage%3D204%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kost, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozley, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, D.</span></span> <span> </span><span class="NLM_article-title">Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">1691</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1706441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1056%2FNEJMoa1706441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=29719179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFyqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1691-1703&author=M.+F.+Eganauthor=J.+Kostauthor=P.+N.+Tariotauthor=P.+S.+Aisenauthor=J.+L.+Cummingsauthor=B.+Vellasauthor=C.+Surauthor=Y.+Mukaiauthor=T.+Vossauthor=C.+Furtekauthor=E.+Mahoneyauthor=L.+H.+Mozleyauthor=R.+Vandenbergheauthor=Y.+Moauthor=D.+Michelson&title=Randomized+trial+of+verubecestat+for+mild-to-moderate+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMoa1706441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease</span></div><div class="casAuthors">Egan, Michael F.; Kost, James; Tariot, Pierre N.; Aisen, Paul S.; Cummings, Jeffrey L.; Vellas, Bruno; Sur, Cyrille; Mukai, Yuki; Voss, Tiffini; Furtek, Christine; Mahoney, Erin; Mozley, Lyn Harper; Vandenberghe, Rik; Mo, Yi; Michelson, David</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1691-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Alzheimer's disease is characterized by the deposition of amyloid-beta (Aβ) plaques in the brain.  Aβ is produced from the sequential cleavage of amyloid precursor protein by β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) followed by γ-secretase.  Verubecestat is an oral BACE-1 inhibitor that reduces the Aβ level in the cerebrospinal fluid of patients with Alzheimer's disease.  Methods: We conducted a randomized, double-blind, placebo-controlled, 78-wk trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had a clin. diagnosis of mild-to-moderate Alzheimer's disease.  The coprimary outcomes were the change from baseline to week 78 in the score on the cognitive subscale of the Alzheimer's disease Assessment Scale (ADAS-cog; scores range from 0 to 70, with higher scores indicating worse dementia) and in the score on the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory scale (ADCS-ADL; scores range from 0 to 78, with lower scores indicating worse function).  Results: A total of 1958 patients underwent randomization; 653 were randomly assigned to receive verubecestat at a dose of 12 mg per day (the 12-mg group), 652 to receive verubecestat at a dose of 40 mg per day (the 40-mg group), and 653 to receive matching placebo.  The trial was terminated early for futility 50 mo after onset, which was within 5 mo before its scheduled completion, and after enrollment of the planned 1958 patients was complete.  The estd. mean change from baseline to week 78 in the ADAS-cog score was 7.9 in the 12-mg group, 8.0 in the 40-mg group, and 7.7 in the placebo group (P = 0.63 for the comparison between the 12-mg group and the placebo group and P = 0.46 for the comparison between the 40-mg group and the placebo group).  The estd. mean change from baseline to week 78 in the ADCS-ADL score was -8.4 in the 12-mg group, -8.2 in the 40-mg group, and -8.9 in the placebo group (P = 0.49 for the comparison between the 12-mg group and the placebo group and P = 0.32 for the comparison between the 40-mg group and the placebo group).  Adverse events, including rash, falls and injuries, sleep disturbance, suicidal ideation, wt. loss, and hair-color change, were more common in the verubecestat groups than in the placebo group. conclusions Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was assocd. with treatment-related adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroW5Tf-VIj2LVg90H21EOLACvtfcHk0ljjoX_JqZYHsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFyqsbs%253D&md5=e6ecfbd2981616b343468ae8bed1db2d</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706441%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DKost%26aufirst%3DJ.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DCummings%26aufirst%3DJ.%2BL.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DMukai%26aufirst%3DY.%26aulast%3DVoss%26aufirst%3DT.%26aulast%3DFurtek%26aufirst%3DC.%26aulast%3DMahoney%26aufirst%3DE.%26aulast%3DMozley%26aufirst%3DL.%2BH.%26aulast%3DVandenberghe%26aufirst%3DR.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DMichelson%26aufirst%3DD.%26atitle%3DRandomized%2520trial%2520of%2520verubecestat%2520for%2520mild-to-moderate%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D1691%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1706441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kost, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dyck, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozley, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, D.</span></span> <span> </span><span class="NLM_article-title">Randomized trial of verubecestat for prodromal Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">1408</span>– <span class="NLM_lpage">1420</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1812840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1056%2FNEJMoa1812840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=30970186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFehtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=1408-1420&author=M.+F.+Eganauthor=J.+Kostauthor=T.+Vossauthor=Y.+Mukaiauthor=P.+S.+Aisenauthor=J.+L.+Cummingsauthor=P.+N.+Tariotauthor=B.+Vellasauthor=C.+H.+van+Dyckauthor=M.+Boadaauthor=Y.+Zhangauthor=W.+Liauthor=C.+Furtekauthor=E.+Mahoneyauthor=L.+H.+Mozleyauthor=Y.+Moauthor=C.+Surauthor=D.+Michelson&title=Randomized+trial+of+verubecestat+for+prodromal+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMoa1812840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12eR"><div class="casContent"><span class="casTitleNuber">12e</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of verubecestat for prodromal Alzheimer's disease</span></div><div class="casAuthors">Egan, Michael F.; Kost, James; Voss, Tiffini; Mukai, Yuki; Aisen, Paul S.; Cummings, Jeffrey L.; Tariot, Pierre N.; Vellas, Bruno; van Dyck, Christopher H.; Boada, Merce; Zhang, Ying; Li, Wen; Furtek, Christine; Mahoney, Erin; Mozley, Lyn Harper; Mo, Yi; Sur, Cyrille; Michelson, David</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1408-1420</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia.  Verubecestat is an orally administered β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor that blocks prodn. of amyloid-beta (Aβ).  The drug did not prevent clin. progression in a trial involving patients with mild-to-moderate dementia due to Alzheimer's disease. methods We conducted a randomized, double-blind, placebo-controlled, 104-wk trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had memory impairment and elevated brain amyloid levels but whose condition did not meet the case definition of dementia.  The primary outcome was the change from baseline to week 104 in the score on the Clin. Dementia Rating Scale-Sum of Boxes (CDR-SB; scores range from 0 to 18, with higher scores indicating worse cognition and daily function).  Secondary outcomes included other assessments of cognition and daily function. results The trial was terminated for futility after 1454 patients had been enrolled; 485 had been assigned to receive verubecestat at a dose of 12 mg per day (the 12-mg group), 484 to receive verubecestat at a dose of 40 mg per day (the 40-mg group), and 485 to receive placebo.  A total of 234 patients, 231 patients, and 239 patients per group, resp., completed 104 wk of the trial regimen.  The estd. mean change from baseline to week 104 in the CDR-SB score was 1.65 in the 12-mg group, 2.02 in the 40-mg group, and 1.58 in the placebo group (P = 0.67 for the comparison between the 12-mg group and the placebo group and P = 0.01 for the comparison between the 40-mg group and the placebo group), suggesting a worse outcome in the higher-dose group than in the placebo group.  The estd. rate of progression to dementia due to Alzheimer's disease was 24.5, 25.5, and 19.3 events per 100 patient-years in the 12-mg group, the 40-mg group, and the placebo group, resp. (hazard ratio for 40 mg vs. placebo, 1.38; 97.51% confidence interval, 1.07 to 1.79, not adjusted for multiple comparisons), favoring placebo.  Adverse events were more common in the verubecestat groups than in the placebo group. conclusions Verubecestat did not improve clin. ratings of dementia among patients with prodromal Alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who received placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2_0d9EBVvSrVg90H21EOLACvtfcHk0li4QRGAVpPbXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFehtrY%253D&md5=4f46fb485bfbd366eca939d40a7ee873</span></div><a href="/servlet/linkout?suffix=cit12e&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1812840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1812840%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DKost%26aufirst%3DJ.%26aulast%3DVoss%26aufirst%3DT.%26aulast%3DMukai%26aufirst%3DY.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DCummings%26aufirst%3DJ.%2BL.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3Dvan%2BDyck%26aufirst%3DC.%2BH.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DFurtek%26aufirst%3DC.%26aulast%3DMahoney%26aufirst%3DE.%26aulast%3DMozley%26aufirst%3DL.%2BH.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DMichelson%26aufirst%3DD.%26atitle%3DRandomized%2520trial%2520of%2520verubecestat%2520for%2520prodromal%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D1408%26epage%3D1420%26doi%3D10.1056%2FNEJMoa1812840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Eketjall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspersson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogstedt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeppsson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falting, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeberlein, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugler, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebers, G.</span></span> <span> </span><span class="NLM_article-title">AZD3293: A novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.3233/JAD-150834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.3233%2FJAD-150834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=26890753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A280%3ADC%252BC28jhvFWqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2016&pages=1109-1123&author=S.+Eketjallauthor=J.+Jansonauthor=K.+Kasperssonauthor=A.+Bogstedtauthor=F.+Jeppssonauthor=J.+Faltingauthor=S.+B.+Haeberleinauthor=A.+R.+Kuglerauthor=R.+C.+Alexanderauthor=G.+Cebers&title=AZD3293%3A+A+novel%2C+orally+active+BACE1+inhibitor+with+high+potency+and+permeability+and+markedly+slow+off-rate+kinetics&doi=10.3233%2FJAD-150834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics</span></div><div class="casAuthors">Eketjall Susanna; Janson Juliette; Bogstedt Anna; Eketjall Susanna; Janson Juliette; Bogstedt Anna; Kaspersson Karin; Jeppsson Fredrik; Falting Johanna; Jeppsson Fredrik; Haeberlein Samantha Budd; Kugler Alan R; Alexander Robert C; Cebers Gvido</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease : JAD</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1109-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A growing body of pathological, biomarker, genetic, and mechanistic data suggests that amyloid accumulation, as a result of changes in production, processing, and/or clearance of brain amyloid-β peptide (Aβ) concentrations, plays a key role in the pathogenesis of Alzheimer's disease (AD).  Beta-secretase 1 (BACE1) mediates the first step in the processing of amyloid-β protein precursor (AβPP) to Aβ peptides, with the soluble N terminal fragment of AβPP (sAβPPβ) as a direct product, and BACE1 inhibition is an attractive target for therapeutic intervention to reduce the production of Aβ.  Here, we report the in vitro and in vivo pharmacological profile of AZD3293, a potent, highly permeable, orally active, blood-brain barrier (BBB) penetrating, BACE1 inhibitor with unique slow off-rate kinetics.  The in vitro potency of AZD3293 was demonstrated in several cellular models, including primary cortical neurons.  In vivo in mice, guinea pigs, and dogs, AZD3293 displayed significant dose- and time-dependent reductions in plasma, cerebrospinal fluid, and brain concentrations of Aβ40, Aβ42, and sAβPPβ.  The in vitro potency of AZD3293 in mouse and guinea pig primary cortical neuronal cells was correlated to the in vivo potency expressed as free AZD3293 concentrations in mouse and guinea pig brains.  In mice and dogs, the slow off-rate from BACE1 may have translated into a prolongation of the observed effect beyond the turnover rate of Aβ.  The preclinical data strongly support the clinical development of AZD3293, and patients with AD are currently being recruited into a combined Phase 2/3 study to test the disease-modifying properties of AZD3293.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8YDBirvcLa6qcneEtCi92fW6udTcc2eah3eJ4HNMVz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jhvFWqtA%253D%253D&md5=afb144f0247c7dd1ecf2ccd8bebcafa4</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.3233%2FJAD-150834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-150834%26sid%3Dliteratum%253Aachs%26aulast%3DEketjall%26aufirst%3DS.%26aulast%3DJanson%26aufirst%3DJ.%26aulast%3DKaspersson%26aufirst%3DK.%26aulast%3DBogstedt%26aufirst%3DA.%26aulast%3DJeppsson%26aufirst%3DF.%26aulast%3DFalting%26aufirst%3DJ.%26aulast%3DHaeberlein%26aufirst%3DS.%2BB.%26aulast%3DKugler%26aufirst%3DA.%2BR.%26aulast%3DAlexander%26aufirst%3DR.%2BC.%26aulast%3DCebers%26aufirst%3DG.%26atitle%3DAZD3293%253A%2520A%2520novel%252C%2520orally%2520active%2520BACE1%2520inhibitor%2520with%2520high%2520potency%2520and%2520permeability%2520and%2520markedly%2520slow%2520off-rate%2520kinetics%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2016%26volume%3D50%26spage%3D1109%26epage%3D1123%26doi%3D10.3233%2FJAD-150834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selzler, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bragg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krull, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shcherbinin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shering, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacSweeney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, J. R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials</span>. <i>JAMA Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1001/jamaneurol.2019.3988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1001%2Fjamaneurol.2019.3988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=31764959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A280%3ADC%252BB3MfivFehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2020&pages=199-209&author=A.+M.+Wesselsauthor=P.+N.+Tariotauthor=J.+A.+Zimmerauthor=K.+J.+Selzlerauthor=S.+M.+Braggauthor=S.+W.+Andersenauthor=J.+Landryauthor=J.+H.+Krullauthor=A.+M.+Downingauthor=B.+A.+Willisauthor=S.+Shcherbininauthor=J.+Mullenauthor=P.+Barkerauthor=J.+Schumiauthor=C.+Sheringauthor=B.+R.+Matthewsauthor=R.+A.+Sternauthor=B.+Vellasauthor=S.+Cohenauthor=E.+MacSweeneyauthor=M.+Boadaauthor=J.+R.+Sims&title=Efficacy+and+safety+of+lanabecestat+for+treatment+of+early+and+mild+Alzheimer+disease%3A+The+AMARANTH+and+DAYBREAK-ALZ+randomized+clinical+trials&doi=10.1001%2Fjamaneurol.2019.3988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials</span></div><div class="casAuthors">Wessels Alette M; Zimmer Jennifer A; Selzler Katherine J; Bragg Sonja M; Andersen Scott W; Landry John; Krull James H; Downing AnnCatherine M; Willis Brian A; Shcherbinin Sergey; Matthews Brandy R; Sims John R; Tariot Pierre N; Mullen Jamie; Barker Peter; Schumi Jennifer; Shering Craig; Mullen Jamie; Stern Robert A; Vellas Bruno; Cohen Sharon; MacSweeney Emer; Boada Merce; Boada Merce</div><div class="citationInfo"><span class="NLM_cas:title">JAMA neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-209</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Alzheimer disease (AD) is a neurodegenerative disorder characterized by cognitive deterioration and impaired activities of daily living.  Current treatments provide only minor symptomatic improvements with limited benefit duration.  Lanabecestat, a brain-permeable inhibitor of human beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1/β-secretase), was developed to modify the clinical course of AD by slowing disease progression.  Objective:  To assess whether lanabecestat slows the progression of AD compared with placebo in patients with early AD (mild cognitive impairment) and mild AD dementia.  Design, Setting, and Participants:  AMARANTH (first patient visit on September 30, 2014; last patient visit on October 4, 2018) and DAYBREAK-ALZ (first patient visit on July 1, 2016; last patient visit on September 28, 2018) were randomized, placebo-controlled, phase 2/3 and phase 3 clinical trials lasting 104 weeks and 78 weeks, respectively.  AMARANTH and DAYBREAK-ALZ were multicenter, global, double-blind studies conducted at 257 and 251 centers, respectively, located in 15 and 18 countries or territories, respectively.  A population-based sample of men and women aged 55 to 85 years who met National Institute on Aging-Alzheimer's Association criteria for early AD or mild AD dementia was screened using cognitive assessments, and the presence of amyloid was confirmed.  Patients were excluded for unstable medical conditions or medication use, significant cerebrovascular pathologic findings, or a history of vitiligo and/or current evidence of postinflammatory hypopigmentation.  AMARANTH screened 6871 patients; 2218 (32.3%) were randomized, and 539 patients completed the study.  DAYBREAK-ALZ screened 5706 patients; 1722 (30.2%) were randomized, and 76 patients completed the study.  Interventions:  Patients were randomized (1:1:1) to once-daily oral doses of lanabecestat (20 mg), lanabecestat (50 mg), or placebo.  Main Outcomes and Measures:  The primary outcome measure was change from baseline on the 13-item Alzheimer Disease Assessment Scale-cognitive subscale.  Secondary outcomes included Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory, Clinical Dementia Rating, Functional Activities Questionnaire, Mini-Mental State Examination, and Neuropsychiatric Inventory.  Efficacy analyses were conducted on the intent-to-treat population.  Results:  Among 2218 AMARANTH patients, the mean (SD) age was 71.3 (7.1) years, and 1177 of 2218 (53.1%) were women.  Among 1722 DAYBREAK-ALZ patients, the mean (SD) age was 72.3 (7.0) years, and 1023 of 1722 (59.4%) were women.  Both studies were terminated early after futility analysis.  There were no consistent, reproducible dose-related findings on primary or secondary efficacy measures.  Psychiatric adverse events, weight loss, and hair color changes were reported in a higher percentage of patients receiving lanabecestat than placebo.  Conclusions and Relevance:  Treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline.  Trial Registration:  ClinicalTrials.gov identifiers: NCT02245737 and NCT02783573.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWiVGh1IBjdC86Js-BCLiifW6udTcc2eaDFChoQl6e37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfivFehug%253D%253D&md5=af37918a3575efef243bd58895bcdb78</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1001%2Fjamaneurol.2019.3988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaneurol.2019.3988%26sid%3Dliteratum%253Aachs%26aulast%3DWessels%26aufirst%3DA.%2BM.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DZimmer%26aufirst%3DJ.%2BA.%26aulast%3DSelzler%26aufirst%3DK.%2BJ.%26aulast%3DBragg%26aufirst%3DS.%2BM.%26aulast%3DAndersen%26aufirst%3DS.%2BW.%26aulast%3DLandry%26aufirst%3DJ.%26aulast%3DKrull%26aufirst%3DJ.%2BH.%26aulast%3DDowning%26aufirst%3DA.%2BM.%26aulast%3DWillis%26aufirst%3DB.%2BA.%26aulast%3DShcherbinin%26aufirst%3DS.%26aulast%3DMullen%26aufirst%3DJ.%26aulast%3DBarker%26aufirst%3DP.%26aulast%3DSchumi%26aufirst%3DJ.%26aulast%3DShering%26aufirst%3DC.%26aulast%3DMatthews%26aufirst%3DB.%2BR.%26aulast%3DStern%26aufirst%3DR.%2BA.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DMacSweeney%26aufirst%3DE.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DSims%26aufirst%3DJ.%2BR.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520lanabecestat%2520for%2520treatment%2520of%2520early%2520and%2520mild%2520Alzheimer%2520disease%253A%2520The%2520AMARANTH%2520and%2520DAYBREAK-ALZ%2520randomized%2520clinical%2520trials%26jtitle%3DJAMA%2520Neurol.%26date%3D2020%26volume%3D77%26spage%3D199%26epage%3D209%26doi%3D10.1001%2Fjamaneurol.2019.3988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> Alzforum. <a href="https://www.alzforum.org/therapeutics/elenbecestat" class="extLink">https://www.alzforum.org/therapeutics/elenbecestat</a> (accessed August 10, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Alzforum.+https%3A%2F%2Fwww.alzforum.org%2Ftherapeutics%2Felenbecestat+%28accessed+August+10%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span>; <span class="NLM_string-name">Motoki, T.</span>; <span class="NLM_string-name">Kaneko, T.</span>; <span class="NLM_string-name">Takaishi, M.</span>; <span class="NLM_string-name">Ishida, T.</span>; <span class="NLM_string-name">Takeda, K.</span>; <span class="NLM_string-name">Kita, Y.</span>; <span class="NLM_string-name">Yamamoto, N.</span>; <span class="NLM_string-name">Khan, A.</span>; <span class="NLM_string-name">Dimopoulos, P.</span></span> Preparation of Condensed Aminodihydrothiazine Derivatives as Inhibitors of β-Site APP-cleaving Enzyme 1 (BACE1). <span class="NLM_patent">WO 2009091016 A1</span>, July 23, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Suzuki%2C+Y.%3B+Motoki%2C+T.%3B+Kaneko%2C+T.%3B+Takaishi%2C+M.%3B+Ishida%2C+T.%3B+Takeda%2C+K.%3B+Kita%2C+Y.%3B+Yamamoto%2C+N.%3B+Khan%2C+A.%3B+Dimopoulos%2C+P.+Preparation+of+Condensed+Aminodihydrothiazine+Derivatives+as+Inhibitors+of+%CE%B2-Site+APP-cleaving+Enzyme+1+%28BACE1%29.+WO+2009091016+A1%2C+July+23%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DY.%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ufer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouzade-Dominguez, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huledal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lueoend, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueeger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tintelnot-Blomley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staufenbiel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimshek, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieauff, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubost, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avrameas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezous, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vormfelde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, A.</span></span> <span> </span><span class="NLM_article-title">Lopez Lopez, C. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer’s disease</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e9316</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.15252%2Femmm.201809316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=30224383" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=e9316&author=U.+Neumannauthor=M.+Uferauthor=L.+H.+Jacobsonauthor=M.-L.+Rouzade-Dominguezauthor=G.+Huledalauthor=C.+Kollyauthor=R.+M.+Lueoendauthor=R.+Machauerauthor=S.+J.+Veenstraauthor=K.+Hurthauthor=H.+Rueegerauthor=M.+Tintelnot-Blomleyauthor=M.+Staufenbielauthor=D.+R.+Shimshekauthor=L.+Perrotauthor=W.+Frieauffauthor=V.+Dubostauthor=H.+Schillerauthor=B.+Voggauthor=K.+Beltzauthor=A.+Avrameasauthor=S.+Kretzauthor=N.+Pezousauthor=J.+Rondeauauthor=N.+Beckmannauthor=A.+Hartmannauthor=S.+Vormfeldeauthor=O.+J.+Davidauthor=B.+Galliauthor=R.+Ramosauthor=A.+Graf&title=Lopez+Lopez%2C+C.+The+BACE-1+inhibitor+CNP520+for+prevention+trials+in+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.15252%2Femmm.201809316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201809316%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DU.%26aulast%3DUfer%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DL.%2BH.%26aulast%3DRouzade-Dominguez%26aufirst%3DM.-L.%26aulast%3DHuledal%26aufirst%3DG.%26aulast%3DKolly%26aufirst%3DC.%26aulast%3DLueoend%26aufirst%3DR.%2BM.%26aulast%3DMachauer%26aufirst%3DR.%26aulast%3DVeenstra%26aufirst%3DS.%2BJ.%26aulast%3DHurth%26aufirst%3DK.%26aulast%3DRueeger%26aufirst%3DH.%26aulast%3DTintelnot-Blomley%26aufirst%3DM.%26aulast%3DStaufenbiel%26aufirst%3DM.%26aulast%3DShimshek%26aufirst%3DD.%2BR.%26aulast%3DPerrot%26aufirst%3DL.%26aulast%3DFrieauff%26aufirst%3DW.%26aulast%3DDubost%26aufirst%3DV.%26aulast%3DSchiller%26aufirst%3DH.%26aulast%3DVogg%26aufirst%3DB.%26aulast%3DBeltz%26aufirst%3DK.%26aulast%3DAvrameas%26aufirst%3DA.%26aulast%3DKretz%26aufirst%3DS.%26aulast%3DPezous%26aufirst%3DN.%26aulast%3DRondeau%26aufirst%3DJ.%26aulast%3DBeckmann%26aufirst%3DN.%26aulast%3DHartmann%26aufirst%3DA.%26aulast%3DVormfelde%26aufirst%3DS.%26aulast%3DDavid%26aufirst%3DO.%2BJ.%26aulast%3DGalli%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DR.%26aulast%3DGraf%26aufirst%3DA.%26atitle%3DLopez%2520Lopez%252C%2520C.%2520The%2520BACE-1%2520inhibitor%2520CNP520%2520for%2520prevention%2520trials%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2018%26volume%3D10%26spage%3De9316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span> Alzforum. <a href="https://www.alzforum.org/therapeutics/umibecestat" class="extLink">https://www.alzforum.org/therapeutics/umibecestat</a> (accessed Aug 10, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Alzforum.+https%3A%2F%2Fwww.alzforum.org%2Ftherapeutics%2Fumibecestat+%28accessed+Aug+10%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hampel, H.</span>; <span class="NLM_string-name">Vassar, R.</span>; <span class="NLM_string-name">De Strooper, B.</span>; <span class="NLM_string-name">Hardy, J.</span>; <span class="NLM_string-name">Willem, M.</span>; <span class="NLM_string-name">Singh, N.</span>; <span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Yan, R.</span>; <span class="NLM_string-name">Vanmechelen, E.</span>; <span class="NLM_string-name">De Vos, A.</span>; <span class="NLM_string-name">Nistico, R.</span>; <span class="NLM_string-name">Corbo, M.</span>; <span class="NLM_string-name">Imbimbo, B. P.</span>; <span class="NLM_string-name">Streffer, J.</span>; <span class="NLM_string-name">Voytyuk, I.</span>; <span class="NLM_string-name">Timmers, M.</span>; <span class="NLM_string-name">Tahami Monfared, A. A.</span>, <span class="NLM_string-name">Irizarry, M.</span>; <span class="NLM_string-name">Albala, B.</span>; <span class="NLM_string-name">Koyama, A.</span>; <span class="NLM_string-name">Watanabe, N.</span>; <span class="NLM_string-name">Kimura, T.</span>; <span class="NLM_string-name">Yarenis, L.</span>; <span class="NLM_string-name">Lista, S.</span>; <span class="NLM_string-name">Kramer, L.</span>; <span class="NLM_string-name">Vergallo, A.</span></span> <span> </span><span class="NLM_article-title">The β-Secretase BACE1 in Alzheimer’s disease</span>.  <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2020</span><span class="refDoi"> DOI: 10.1016/j.biopsych.2020.02.001</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2Fj.biopsych.2020.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=32223911" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=H.+Hampel&author=R.+Vassar&author=B.+De+Strooper&author=J.+Hardy&author=M.+Willem&author=N.+Singh&author=J.+Zhou&author=R.+Yan&author=E.+Vanmechelen&author=A.+De+Vos&author=R.+Nistico&author=M.+Corbo&author=B.+P.+Imbimbo&author=J.+Streffer&author=I.+Voytyuk&author=M.+Timmers&author=A.+A.+Tahami+Monfared&author=M.+Irizarry&author=B.+Albala&author=A.+Koyama&author=N.+Watanabe&author=T.+Kimura&author=L.+Yarenis&author=S.+Lista&author=L.+Kramer&author=A.+Vergallo&title=The+%CE%B2-Secretase+BACE1+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.biopsych.2020.02.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2020.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2020.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DHampel%26aufirst%3DH.%26atitle%3DThe%2520%25CE%25B2-Secretase%2520BACE1%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBiol.%2520Psychiatry%26date%3D2020%26doi%3D10.1016%2Fj.biopsych.2020.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voytyuk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snellinx, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Loo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenthaler, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span> <span> </span><span class="NLM_article-title">BACE2 distribution in major brain cell types and identification of novel substrates</span>. <i>Life Sci. Alliance</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e201800026</span>, <span class="refDoi"> DOI: 10.26508/lsa.201800026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.26508%2Flsa.201800026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=30456346" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2018&pages=e201800026&author=I.+Voytyukauthor=S.+A.+Muellerauthor=J.+Herberauthor=A.+Snellinxauthor=D.+Moecharsauthor=G.+van+Looauthor=S.+F.+Lichtenthalerauthor=B.+De+Strooper&title=BACE2+distribution+in+major+brain+cell+types+and+identification+of+novel+substrates&doi=10.26508%2Flsa.201800026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.26508%2Flsa.201800026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.26508%252Flsa.201800026%26sid%3Dliteratum%253Aachs%26aulast%3DVoytyuk%26aufirst%3DI.%26aulast%3DMueller%26aufirst%3DS.%2BA.%26aulast%3DHerber%26aufirst%3DJ.%26aulast%3DSnellinx%26aufirst%3DA.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3Dvan%2BLoo%26aufirst%3DG.%26aulast%3DLichtenthaler%26aufirst%3DS.%2BF.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26atitle%3DBACE2%2520distribution%2520in%2520major%2520brain%2520cell%2520types%2520and%2520identification%2520of%2520novel%2520substrates%26jtitle%3DLife%2520Sci.%2520Alliance%26date%3D2018%26volume%3D1%26spage%3De201800026%26doi%3D10.26508%2Flsa.201800026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurose, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unemura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyajima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiroyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyabu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuyvetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghys, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iso, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.</span></span> <span> </span><span class="NLM_article-title">Rational design of novel 1,3-oxazine based β-secretase (BACE1) inhibitors: Incorporation of a double bond to reduce P-gp efflux leading to robust Aβ reduction in the brain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5122</span>– <span class="NLM_lpage">5137</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptVWhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5122-5137&author=K.+Fuchinoauthor=Y.+Mitsuokaauthor=M.+Masuiauthor=N.+Kuroseauthor=S.+Yoshidaauthor=K.+Komanoauthor=T.+Yamamotoauthor=M.+Ogawaauthor=C.+Unemuraauthor=M.+Hosonoauthor=H.+Itoauthor=G.+Sakaguchiauthor=S.+Andoauthor=S.+Ohnishiauthor=Y.+Kidoauthor=T.+Fukushimaauthor=H.+Miyajimaauthor=S.+Hiroyamaauthor=K.+Koyabuauthor=D.+Dhuyvetterauthor=H.+Borghysauthor=H.+J.M.+Gijsenauthor=Y.+Yamanoauthor=Y.+Isoauthor=K.+Kusakabe&title=Rational+design+of+novel+1%2C3-oxazine+based+%CE%B2-secretase+%28BACE1%29+inhibitors%3A+Incorporation+of+a+double+bond+to+reduce+P-gp+efflux+leading+to+robust+A%CE%B2+reduction+in+the+brain&doi=10.1021%2Facs.jmedchem.8b00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain</span></div><div class="casAuthors">Fuchino, Kouki; Mitsuoka, Yasunori; Masui, Moriyasu; Kurose, Noriyuki; Yoshida, Shuhei; Komano, Kazuo; Yamamoto, Takahiko; Ogawa, Masayoshi; Unemura, Chie; Hosono, Motoko; Ito, Hisanori; Sakaguchi, Gaku; Ando, Shigeru; Ohnishi, Shuichi; Kido, Yasuto; Fukushima, Tamio; Miyajima, Hirofumi; Hiroyama, Shuichi; Koyabu, Kiyotaka; Dhuyvetter, Deborah; Borghys, Herman; Gijsen, Harrie J. M.; Yamano, Yoshinori; Iso, Yasuyoshi; Kusakabe, Ken-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5122-5137</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Accumulation of Aβ peptides is a hallmark of Alzheimer's disease (AD) and is considered a causal factor in the pathogenesis of AD.  β-Secretase (BACE1) is a key enzyme responsible for producing Aβ peptides, and thus agents that inhibit BACE1 should be beneficial for disease-modifying treatment of AD.  Here we describe the discovery and optimization of novel oxazine-based BACE1 inhibitors by lowering amidine basicity with the incorporation of a double bond to improve brain penetration.  Starting from a 1,3-dihydrooxazine lead I identified by a hit-to-lead SAR following HTS, we adopted a pKa lowering strategy to reduce the P-gp efflux and the high hERG potential leading to the discovery of II that produced significant Aβ redn. with long duration in pharmacodynamic models and exhibited wide safety margins in cardiovascular safety models.  This compd. II improved the brain-to-plasma ratio relative to I by reducing P-gp recognition, which was demonstrated by a P-gp knockout mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGPZsGRa22ZLVg90H21EOLACvtfcHk0liLAc47CE_u0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptVWhsLo%253D&md5=ac366bddfe3492a0a47ce02918b5ea41</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00002%26sid%3Dliteratum%253Aachs%26aulast%3DFuchino%26aufirst%3DK.%26aulast%3DMitsuoka%26aufirst%3DY.%26aulast%3DMasui%26aufirst%3DM.%26aulast%3DKurose%26aufirst%3DN.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DKomano%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DUnemura%26aufirst%3DC.%26aulast%3DHosono%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DSakaguchi%26aufirst%3DG.%26aulast%3DAndo%26aufirst%3DS.%26aulast%3DOhnishi%26aufirst%3DS.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DMiyajima%26aufirst%3DH.%26aulast%3DHiroyama%26aufirst%3DS.%26aulast%3DKoyabu%26aufirst%3DK.%26aulast%3DDhuyvetter%26aufirst%3DD.%26aulast%3DBorghys%26aufirst%3DH.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.M.%26aulast%3DYamano%26aufirst%3DY.%26aulast%3DIso%26aufirst%3DY.%26aulast%3DKusakabe%26aufirst%3DK.%26atitle%3DRational%2520design%2520of%2520novel%25201%252C3-oxazine%2520based%2520%25CE%25B2-secretase%2520%2528BACE1%2529%2520inhibitors%253A%2520Incorporation%2520of%2520a%2520double%2520bond%2520to%2520reduce%2520P-gp%2520efflux%2520leading%2520to%2520robust%2520A%25CE%25B2%2520reduction%2520in%2520the%2520brain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5122%26epage%3D5137%26doi%3D10.1021%2Facs.jmedchem.8b00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sako, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unemura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuyvetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghys, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iso, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and centrally active 6-substituted 5-fluoro-1,3-dihydro-oxazine β-secretase (BACE1) inhibitors via active conformation stabilization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5525</span>– <span class="NLM_lpage">5546</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVarsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5525-5546&author=K.+Nakaharaauthor=K.+Fuchinoauthor=K.+Komanoauthor=N.+Asadaauthor=G.+Tadanoauthor=T.+Hasegawaauthor=T.+Yamamotoauthor=Y.+Sakoauthor=M.+Ogawaauthor=C.+Unemuraauthor=M.+Hosonoauthor=H.+Itoauthor=G.+Sakaguchiauthor=S.+Andoauthor=S.+Ohnishiauthor=Y.+Kidoauthor=T.+Fukushimaauthor=D.+Dhuyvetterauthor=H.+Borghysauthor=H.+J.+M.+Gijsenauthor=Y.+Yamanoauthor=Y.+Isoauthor=K.+Kusakabe&title=Discovery+of+potent+and+centrally+active+6-substituted+5-fluoro-1%2C3-dihydro-oxazine+%CE%B2-secretase+%28BACE1%29+inhibitors+via+active+conformation+stabilization&doi=10.1021%2Facs.jmedchem.8b00011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization</span></div><div class="casAuthors">Nakahara, Kenji; Fuchino, Kouki; Komano, Kazuo; Asada, Naoya; Tadano, Genta; Hasegawa, Tsuyoshi; Yamamoto, Takahiko; Sako, Yusuke; Ogawa, Masayoshi; Unemura, Chie; Hosono, Motoko; Ito, Hisanori; Sakaguchi, Gaku; Ando, Shigeru; Ohnishi, Shuichi; Kido, Yasuto; Fukushima, Tamio; Dhuyvetter, Deborah; Borghys, Herman; Gijsen, Harrie J. M.; Yamano, Yoshinori; Iso, Yasuyoshi; Kusakabe, Ken-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5525-5546</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">β-Secretase (BACE1) has an essential role in the prodn. of amyloid β peptides that accumulate in patients with Alzheimer's disease (AD).  Thus, inhibition of BACE1 is considered to be a disease-modifying approach for the treatment of AD.  The authors' hit-to-lead efforts led to a cellular potent 1,3-dihydro-oxazine I, which however inhibited hERG and showed high P-gp efflux.  The close analog of 5-fluoro-oxazine II reduced P-gp efflux; further introduction of electron withdrawing groups at the 6-position improved potency and also mitigated P-gp efflux and hERG inhibition.  Changing to a pyrazine followed by optimization of substituents on both the oxazine and the pyrazine culminated in III with robust Aβ redn. in vivo at low doses as well as reduced CYP2D6 inhibition.  On the basis of the X-ray anal. and the QM calcn. of given dihydro-oxazines, it was reasoned that the substituents at the 6-position as well as the 5-fluorine on the oxazine would stabilize a bioactive conformation to increase potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBTrC8rX3RE7Vg90H21EOLACvtfcHk0liLAc47CE_u0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVarsLs%253D&md5=e622beaca28e64ea0da30c87d0828086</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00011%26sid%3Dliteratum%253Aachs%26aulast%3DNakahara%26aufirst%3DK.%26aulast%3DFuchino%26aufirst%3DK.%26aulast%3DKomano%26aufirst%3DK.%26aulast%3DAsada%26aufirst%3DN.%26aulast%3DTadano%26aufirst%3DG.%26aulast%3DHasegawa%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DSako%26aufirst%3DY.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DUnemura%26aufirst%3DC.%26aulast%3DHosono%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DSakaguchi%26aufirst%3DG.%26aulast%3DAndo%26aufirst%3DS.%26aulast%3DOhnishi%26aufirst%3DS.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DDhuyvetter%26aufirst%3DD.%26aulast%3DBorghys%26aufirst%3DH.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26aulast%3DYamano%26aufirst%3DY.%26aulast%3DIso%26aufirst%3DY.%26aulast%3DKusakabe%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520centrally%2520active%25206-substituted%25205-fluoro-1%252C3-dihydro-oxazine%2520%25CE%25B2-secretase%2520%2528BACE1%2529%2520inhibitors%2520via%2520active%2520conformation%2520stabilization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5525%26epage%3D5546%26doi%3D10.1021%2Facs.jmedchem.8b00011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Woltering, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wostl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilpert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travagli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastrini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marconi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabellieri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Power, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narquizian, R.</span></span> <span> </span><span class="NLM_article-title">BACE1 inhibitors: A head group scan on a series of amides</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4239</span>– <span class="NLM_lpage">4243</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2Fj.bmcl.2013.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=23735744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFaktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4239-4243&author=T.+J.+Wolteringauthor=W.+Wostlauthor=H.+Hilpertauthor=M.+Rogers-Evansauthor=E.+Pinardauthor=A.+Maywegauthor=M.+Gobelauthor=D.+W.+Bannerauthor=J.+Benzauthor=M.+Travagliauthor=M.+Pollastriniauthor=G.+Marconiauthor=E.+Gabellieriauthor=W.+Gubaauthor=H.+Mauserauthor=M.+Andreiniauthor=H.+Jacobsenauthor=E.+Powerauthor=R.+Narquizian&title=BACE1+inhibitors%3A+A+head+group+scan+on+a+series+of+amides&doi=10.1016%2Fj.bmcl.2013.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 inhibitors: A head group scan on a series of amides</span></div><div class="casAuthors">Woltering, Thomas J.; Wostl, Wolfgang; Hilpert, Hans; Rogers-Evans, Mark; Pinard, Emmanuel; Mayweg, Alexander; Gobel, Martin; Banner, David W.; Benz, Jorg; Travagli, Massimiliano; Pollastrini, Martina; Marconi, Guido; Gabellieri, Emanuele; Guba, Wolfgang; Mauser, Harald; Andreini, Matteo; Jacobsen, Helmut; Power, Eoin; Narquizian, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4239-4243</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of amides bearing a variety of amidine head groups was investigated as BACE1 inhibitors with respect to inhibitory activity in a BACE1 enzyme as well as a cell-based assay.  Detn. of their basicity as well as their properties as substrates of P-glycoprotein revealed that a 2-amino-1,3-oxazine head group would be a suitable starting point for further development of brain penetrating compds. for potential Alzheimer's disease treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEF94wd3_rd7Vg90H21EOLACvtfcHk0liOOecy_V35CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFaktLk%253D&md5=3da315c76199617083b762ea111057fd</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DWoltering%26aufirst%3DT.%2BJ.%26aulast%3DWostl%26aufirst%3DW.%26aulast%3DHilpert%26aufirst%3DH.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DPinard%26aufirst%3DE.%26aulast%3DMayweg%26aufirst%3DA.%26aulast%3DGobel%26aufirst%3DM.%26aulast%3DBanner%26aufirst%3DD.%2BW.%26aulast%3DBenz%26aufirst%3DJ.%26aulast%3DTravagli%26aufirst%3DM.%26aulast%3DPollastrini%26aufirst%3DM.%26aulast%3DMarconi%26aufirst%3DG.%26aulast%3DGabellieri%26aufirst%3DE.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DMauser%26aufirst%3DH.%26aulast%3DAndreini%26aufirst%3DM.%26aulast%3DJacobsen%26aufirst%3DH.%26aulast%3DPower%26aufirst%3DE.%26aulast%3DNarquizian%26aufirst%3DR.%26atitle%3DBACE1%2520inhibitors%253A%2520A%2520head%2520group%2520scan%2520on%2520a%2520series%2520of%2520amides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4239%26epage%3D4243%26doi%3D10.1016%2Fj.bmcl.2013.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hilpert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltering, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wostl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humm, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krummenacher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozmen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergadano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochstrasser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David-Pierson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narquizian, R.</span></span> <span> </span><span class="NLM_article-title">β-Secretase (BACE1) inhibitors with high <i>in vivo</i> efficacy suitable for clinical evaluation in Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3980</span>– <span class="NLM_lpage">3995</span>, <span class="refDoi"> DOI: 10.1021/jm400225m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400225m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVymuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3980-3995&author=H.+Hilpertauthor=W.+Gubaauthor=T.+J.+Wolteringauthor=W.+Wostlauthor=E.+Pinardauthor=H.+Mauserauthor=A.+V.+Maywegauthor=M.+Rogers-Evansauthor=R.+Hummauthor=D.+Krummenacherauthor=T.+Muserauthor=C.+Schniderauthor=H.+Jacobsenauthor=L.+Ozmenauthor=A.+Bergadanoauthor=D.+W.+Bannerauthor=R.+Hochstrasserauthor=A.+Kuglstatterauthor=P.+David-Piersonauthor=H.+Fischerauthor=A.+Polaraauthor=R.+Narquizian&title=%CE%B2-Secretase+%28BACE1%29+inhibitors+with+high+in+vivo+efficacy+suitable+for+clinical+evaluation+in+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm400225m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer's Disease</span></div><div class="casAuthors">Hilpert, Hans; Guba, Wolfgang; Woltering, Thomas J.; Wostl, Wolfgang; Pinard, Emmanuel; Mauser, Harald; Mayweg, Alexander V.; Rogers-Evans, Mark; Humm, Roland; Krummenacher, Daniela; Muser, Thorsten; Schnider, Christian; Jacobsen, Helmut; Ozmen, Laurence; Bergadano, Alessandra; Banner, David W.; Hochstrasser, Remo; Kuglstatter, Andreas; David-Pierson, Pascale; Fischer, Holger; Polara, Alessandra; Narquizian, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3980-3995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacol. profile of this class of BACE1 inhibitors.  The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF Aβ40 and 42 in rats at oral doses as low as 1 mg/kg.  The effect was long lasting, showing a significant redn. of Aβ40 and 42 even after 24 h.  In contrast to 89, compd. 1b lacking the CF3 group was virtually inactive in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmoKRrAxxHErVg90H21EOLACvtfcHk0liOOecy_V35CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVymuro%253D&md5=e5d311d1c8fecfaed043d3a0bf16c168</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Fjm400225m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400225m%26sid%3Dliteratum%253Aachs%26aulast%3DHilpert%26aufirst%3DH.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DWoltering%26aufirst%3DT.%2BJ.%26aulast%3DWostl%26aufirst%3DW.%26aulast%3DPinard%26aufirst%3DE.%26aulast%3DMauser%26aufirst%3DH.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DHumm%26aufirst%3DR.%26aulast%3DKrummenacher%26aufirst%3DD.%26aulast%3DMuser%26aufirst%3DT.%26aulast%3DSchnider%26aufirst%3DC.%26aulast%3DJacobsen%26aufirst%3DH.%26aulast%3DOzmen%26aufirst%3DL.%26aulast%3DBergadano%26aufirst%3DA.%26aulast%3DBanner%26aufirst%3DD.%2BW.%26aulast%3DHochstrasser%26aufirst%3DR.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DDavid-Pierson%26aufirst%3DP.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DPolara%26aufirst%3DA.%26aulast%3DNarquizian%26aufirst%3DR.%26atitle%3D%25CE%25B2-Secretase%2520%2528BACE1%2529%2520inhibitors%2520with%2520high%2520in%2520vivo%2520efficacy%2520suitable%2520for%2520clinical%2520evaluation%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3980%26epage%3D3995%26doi%3D10.1021%2Fjm400225m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, N.</span>; <span class="NLM_string-name">Ueda, K.</span>; <span class="NLM_string-name">Itoh, N.</span>; <span class="NLM_string-name">Suzuki, S.</span>; <span class="NLM_string-name">Sakaguchi, G.</span>; <span class="NLM_string-name">Kato, A.</span>; <span class="NLM_string-name">Yukimasa, A.</span>; <span class="NLM_string-name">Hori, A.</span>; <span class="NLM_string-name">Koriyama, Y.</span>; <span class="NLM_string-name">Haraguchi, H.</span>; <span class="NLM_string-name">Yasui, K.</span>; <span class="NLM_string-name">Kanda, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation of 2-Aminodihydrothiazine Derivatives as β-Secretase Inhibitors</span>. <span class="NLM_patent">WO2007049532A1</span>, March 5, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=N.+Kobayashi&author=K.+Ueda&author=N.+Itoh&author=S.+Suzuki&author=G.+Sakaguchi&author=A.+Kato&author=A.+Yukimasa&author=A.+Hori&author=Y.+Koriyama&author=H.+Haraguchi&author=K.+Yasui&author=Y.+Kanda&title=Preparation+of+2-Aminodihydrothiazine+Derivatives+as+%CE%B2-Secretase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DN.%26atitle%3DPreparation%2520of%25202-Aminodihydrothiazine%2520Derivatives%2520as%2520%25CE%25B2-Secretase%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+Highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0liOOecy_V35CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520Highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosea, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callegari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianfrogna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E.C.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasman, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPerle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedza, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahematpura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raunig, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spracklin, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Deusen, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasgar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1124/dmd.104.001230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1124%2Fdmd.104.001230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=15502009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlentw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=165-174&author=A.+Doranauthor=R.+S.+Obachauthor=B.+J.+Smithauthor=N.+A.+Hoseaauthor=S.+Beckerauthor=E.+Callegariauthor=C.+Chenauthor=X.+Chenauthor=E.+Chooauthor=J.+Cianfrognaauthor=L.+M.+Coxauthor=J.+P.+Gibbsauthor=M.+A.+Gibbsauthor=H.+Hatchauthor=C.+E.C.A.+Hopauthor=I.+N.+Kasmanauthor=J.+LaPerleauthor=J.+Liuauthor=X.+Liuauthor=M.+Logmanauthor=D.+Maclinauthor=F.+M.+Nedzaauthor=F.+Nelsonauthor=E.+Olsonauthor=S.+Rahematpuraauthor=D.+Raunigauthor=S.+Rogersauthor=K.+Schmidtauthor=D.+K.+Spracklinauthor=M.+Szewcauthor=M.+Troutmanauthor=E.+Tsengauthor=M.+Tuauthor=J.+W.+Van+Deusenauthor=K.+Venkatakrishnanauthor=G.+Walensauthor=E.+Q.+Wangauthor=D.+Wongauthor=A.+S.+Yasgarauthor=C.+Zhang&title=The+impact+of+P-glycoprotein+on+the+disposition+of+drugs+targeted+for+indications+of+the+central+nervous+system%3A+Evaluation+using+the+MDR1A%2F1B+knockout+mouse+model&doi=10.1124%2Fdmd.104.001230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model</span></div><div class="casAuthors">Doran, Angela; Obach, R. Scott; Smith, Bill J.; Hosea, Natilie A.; Becker, Stacey; Callegari, Ernesto; Chen, Cuiping; Chen, Xi; Choo, Edna; Cianfrogna, Julie; Cox, Loretta M.; Gibbs, John P.; Gibbs, Megan A.; Hatch, Heather; Hop, Cornelis E. C. A.; Kasman, Ilana N.; LaPerle, Jennifer; Liu, JianHua; Liu, Xingrong; Logman, Michael; Maclin, Debra; Nedza, Frank M.; Nelson, Frederick; Olson, Emily; Rahematpura, Sandhya; Raunig, David; Rogers, Sabrinia; Schmidt, Kari; Spracklin, Douglas K.; Szewc, Mark; Troutman, Matthew; Tseng, Elaine; Tu, Meihua; Van Deusen, Jeffrey W.; Venkatakrishnan, Karthik; Walens, Gary; Wang, Ellen Q.; Wong, Diane; Yasgar, Adam S.; Zhang, Chenghong</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-174</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Thirty-two structurally diverse drugs used for the treatment of various conditions of the central nervous system (CNS), along with two active metabolites, and eight non-CNS drugs were measured in brain, plasma, and cerebrospinal fluid in the P-glycoprotein (P-gp) knockout mouse model after s.c. administration, and the data were compared with corresponding data obtained in wild-type mice.  Total brain-to-plasma (B/P) ratios for the CNS agents ranged from 0.060 to 24.  Of the 34 CNS-active agents, only 7 demonstrated B/P area under the plasma concn. curve ratios between P-gp knockout and wild-type mice that did not differ significantly from unity.  Most of the remaining drugs demonstrated 1.1- to 2.6-fold greater B/P ratios in P-gp knockout mice vs. wild-type mice.  Three, risperidone, its active metabolite 9-hydroxyrisperidone, and metoclopramide, showed marked differences in B/P ratios between knockout and wild-type mice (6.6- to 17-fold).  Differences in B/P ratios and cerebrospinal fluid/plasma ratios between wild-type and knockout animals were correlated.  Through the use of this model, it appears that most CNS-active agents demonstrate at least some P-gp-mediated transport that can affect brain concns.  However, the impact for the majority of agents is probably minor.  The example of risperidone illustrates that even good P-gp substrates can still be clin. useful CNS-active agents.  However, for such agents, unbound plasma concns. may need to be greater than values projected using receptor affinity data to achieve adequate receptor occupancy for effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCLikZvvYtAbVg90H21EOLACvtfcHk0liCOZZaAvRZlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlentw%253D%253D&md5=58acf489206dfeaaa96da4329e403710</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fdmd.104.001230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.104.001230%26sid%3Dliteratum%253Aachs%26aulast%3DDoran%26aufirst%3DA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DBecker%26aufirst%3DS.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChoo%26aufirst%3DE.%26aulast%3DCianfrogna%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DL.%2BM.%26aulast%3DGibbs%26aufirst%3DJ.%2BP.%26aulast%3DGibbs%26aufirst%3DM.%2BA.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DHop%26aufirst%3DC.%2BE.C.A.%26aulast%3DKasman%26aufirst%3DI.%2BN.%26aulast%3DLaPerle%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLogman%26aufirst%3DM.%26aulast%3DMaclin%26aufirst%3DD.%26aulast%3DNedza%26aufirst%3DF.%2BM.%26aulast%3DNelson%26aufirst%3DF.%26aulast%3DOlson%26aufirst%3DE.%26aulast%3DRahematpura%26aufirst%3DS.%26aulast%3DRaunig%26aufirst%3DD.%26aulast%3DRogers%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DSpracklin%26aufirst%3DD.%2BK.%26aulast%3DSzewc%26aufirst%3DM.%26aulast%3DTroutman%26aufirst%3DM.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DTu%26aufirst%3DM.%26aulast%3DVan%2BDeusen%26aufirst%3DJ.%2BW.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26aulast%3DWalens%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DE.%2BQ.%26aulast%3DWong%26aufirst%3DD.%26aulast%3DYasgar%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DC.%26atitle%3DThe%2520impact%2520of%2520P-glycoprotein%2520on%2520the%2520disposition%2520of%2520drugs%2520targeted%2520for%2520indications%2520of%2520the%2520central%2520nervous%2520system%253A%2520Evaluation%2520using%2520the%2520MDR1A%252F1B%2520knockout%2520mouse%2520model%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D165%26epage%3D174%26doi%3D10.1124%2Fdmd.104.001230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">CNS Drug design: balancing physicochemical properties for optimal brain exposure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2584</span>– <span class="NLM_lpage">2608</span>, <span class="refDoi"> DOI: 10.1021/jm501535r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501535r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2584-2608&author=Z.+Rankovic&title=CNS+Drug+design%3A+balancing+physicochemical+properties+for+optimal+brain+exposure&doi=10.1021%2Fjm501535r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure</span></div><div class="casAuthors">Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2584-2608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins.  Designing mols. that can overcome this protection system and achieve optimal concn. at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery.  Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochem. properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates.  This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most crit. physicochem. and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chem. strategies toward mols. with optimal brain exposure.  A summary of modern CNS pharmacokinetic concepts and methods is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8V0N1j49uuLVg90H21EOLACvtfcHk0liCOZZaAvRZlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP&md5=f01e3f2dc4e2eff7b0618124277a5cf8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm501535r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501535r%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DCNS%2520Drug%2520design%253A%2520balancing%2520physicochemical%2520properties%2520for%2520optimal%2520brain%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2584%26epage%3D2608%26doi%3D10.1021%2Fjm501535r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Didziapetris, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Japertas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdeef, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrauskas, A.</span></span> <span> </span><span class="NLM_article-title">Classification analysis of P-glycoprotein substrate specificity</span>. <i>J. Drug. Target.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1080/10611860310001648248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1080%2F10611860310001648248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=15203928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFOjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=391-406&author=R.+Didziapetrisauthor=P.+Japertasauthor=A.+Avdeefauthor=A.+Petrauskas&title=Classification+analysis+of+P-glycoprotein+substrate+specificity&doi=10.1080%2F10611860310001648248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Classification Analysis of P-Glycoprotein Substrate Specificity</span></div><div class="casAuthors">Didziapetris, Remigijus; Japertas, Pranas; Avdeef, Alex; Petrauskas, Alanas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">391-406</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1061-186X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Prediction of P-glycoprotein substrate specificity (SPGP) can be viewed as a constituent part of a compd.'s "pharmaceutical profiling" in drug design.  This task is difficult to achieve due to several factors that raised many contradictory opinions: (i) the disparity between the SPGP values obtained in different assays, (ii) the confusion between Pgp substrates and inhibitors, (iii) the confusion between lipophilicity and amphiphilicity of Pgp substrates, and (iv) the dilemma of describing class-specific relationships when Pgp has no binding sites of high ligand specificity.  In this work, the authors compiled SPGP data for 1000 compds.  All data were represented in a binary format, assigning SPGP = 1 for substrates and SPGP = 0 for nonsubstrates.  Each value was ranked according to the reliability of exptl. assay.  Two data sets were considered.  Set 1 included 220 compds. with SPGP from polarized transport across MDR1 transfected cell monolayers.  Set 2 included the entire list of 1000 compds., with SPGP values of generally lower reliability.  Both sets were analyzed using a stepwise classification structure-activity relationship (C-SAR) method, leading to derivation of simple rules for crude estn. of SPGP values.  The obtained rules are based on the following factors: (i) compd.'s size expressed through molar wt. or vol., (ii) H-accepting given by the Abraham's β (that can be crudely approximated by the sum of O and N atoms), and (iii) ionization given by the acid and base pKa values.  Very roughly, SPGP can be estd. by the "rule of fours".  Compds. with (N + O) ≥ 8, MW > 400 and acid pKa > 4 are likely to be Pgp substrates, whereas compds. with (N+O) ≤ 4, MW < 400 and base pKa < 8 are likely to be nonsubstrates.  The obtained results support the view that Pgp functioning can be compared to a complex "mini-pharmacokinetic" system with fuzzy specificity.  This system can be described by a probabilistic version of Abraham's solvation equation, suggesting a certain similarity between Pgp transport and chromatog. retention.  The chromatog. model does not work in the case of "marginal" compds. with properties close to the "global" physicochem. cut-offs.  In the latter case various class-specific rules must be considered.  These can be assocd. with the "amphiphilicity" and "biol. similarity" of compds.  The definition of class-specific effects entails construction of the knowledge base that can be very useful in ADME profiling of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsvKJmruZ7RLVg90H21EOLACvtfcHk0liCOZZaAvRZlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFOjs7k%253D&md5=5b7ea95eb2d9faded5645481c1330f03</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F10611860310001648248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10611860310001648248%26sid%3Dliteratum%253Aachs%26aulast%3DDidziapetris%26aufirst%3DR.%26aulast%3DJapertas%26aufirst%3DP.%26aulast%3DAvdeef%26aufirst%3DA.%26aulast%3DPetrauskas%26aufirst%3DA.%26atitle%3DClassification%2520analysis%2520of%2520P-glycoprotein%2520substrate%2520specificity%26jtitle%3DJ.%2520Drug.%2520Target.%26date%3D2003%26volume%3D11%26spage%3D391%26epage%3D406%26doi%3D10.1080%2F10611860310001648248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Oguma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.-I.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a 6-CF<sub>3</sub>-substituted 2-amino-dihydro-1,3-thiazine β-secretase inhibitor by <i>N</i>,<i>N</i>-diethylsulfur trifluoride-mediated chemoselective cyclization</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">4893</span>– <span class="NLM_lpage">4897</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.8b02179</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.8b02179" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFSrsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2019&pages=4893-4897&author=T.+Ogumaauthor=K.+Ananauthor=S.+Suzukiauthor=S.+Hisakawaauthor=A.+Takadaauthor=M.+Ogawaauthor=K.-I.+Kusakabe&title=Synthesis+of+a+6-CF3-substituted+2-amino-dihydro-1%2C3-thiazine+%CE%B2-secretase+inhibitor+by+N%2CN-diethylsulfur+trifluoride-mediated+chemoselective+cyclization&doi=10.1021%2Facs.joc.8b02179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a 6-CF3-Substituted 2-Amino-dihydro-1,3-thiazine β-Secretase Inhibitor by N,N-Diethylaminosulfur Trifluoride-Mediated Chemoselective Cyclization</span></div><div class="casAuthors">Oguma, Takuya; Anan, Kosuke; Suzuki, Shinji; Hisakawa, Shinya; Takada, Akihiro; Ogawa, Masayoshi; Kusakabe, Ken-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4893-4897</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of a 6-CF3-substituted 2-amino-dihydro-1,3-thiazine via N,N-diethylaminosulfur trifluoride (DAST)-mediated cyclization of N-hydroxypropyl thiourea I is described.  This reaction gave 6-CF3-1,3-thiazine II with high chem. yield and chemoselectivity, suppressing the common byproduct of oxazine.  This new protocol enabled access to 6-CF3-substituted 1,3-thiazine β-secretase inhibitor III.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB5R8g_SarTbVg90H21EOLACvtfcHk0lhqULkeHrWdOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFSrsbbO&md5=a84b7f683474108cbbccabc9c7fa7078</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.8b02179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.8b02179%26sid%3Dliteratum%253Aachs%26aulast%3DOguma%26aufirst%3DT.%26aulast%3DAnan%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DHisakawa%26aufirst%3DS.%26aulast%3DTakada%26aufirst%3DA.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DKusakabe%26aufirst%3DK.-I.%26atitle%3DSynthesis%2520of%2520a%25206-CF3-substituted%25202-amino-dihydro-1%252C3-thiazine%2520%25CE%25B2-secretase%2520inhibitor%2520by%2520N%252CN-diethylsulfur%2520trifluoride-mediated%2520chemoselective%2520cyclization%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2019%26volume%3D84%26spage%3D4893%26epage%3D4897%26doi%3D10.1021%2Facs.joc.8b02179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Anan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iso, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanegawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawachi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teisman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urmaliya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuyvetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghys, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bergh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verboven, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.</span></span> <span> </span><span class="NLM_article-title">Trifluoromethyl dihydrothiazine-based β-Secretase (BACE1) inhibitors with robust central β-amyloid reduction and minimal covalent binding burden</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1894</span>– <span class="NLM_lpage">1910</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201900478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1002%2Fcmdc.201900478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=31657130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFarur%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1894-1910&author=K.+Ananauthor=Y.+Isoauthor=T.+Ogumaauthor=K.+Nakaharaauthor=S.+Suzukiauthor=T.+Yamamotoauthor=E.+Matsuokaauthor=H.+Itoauthor=G.+Sakaguchiauthor=S.+Andoauthor=K.+Morimotoauthor=N.+Kanegawaauthor=Y.+Kidoauthor=T.+Kawachiauthor=T.+Fukushimaauthor=A.+Teismanauthor=V.+Urmaliyaauthor=D.+Dhuyvetterauthor=H.+Borghysauthor=N.+Austinauthor=A.+Van+Den+Berghauthor=P.+Verbovenauthor=F.+Bischoffauthor=H.+J.+M.+Gijsenauthor=Y.+Yamanoauthor=K.+Kusakabe&title=Trifluoromethyl+dihydrothiazine-based+%CE%B2-Secretase+%28BACE1%29+inhibitors+with+robust+central+%CE%B2-amyloid+reduction+and+minimal+covalent+binding+burden&doi=10.1002%2Fcmdc.201900478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden</span></div><div class="casAuthors">Anan, Kosuke; Iso, Yasuyoshi; Oguma, Takuya; Nakahara, Kenji; Suzuki, Shinji; Yamamoto, Takahiko; Matsuoka, Eriko; Ito, Hisanori; Sakaguchi, Gaku; Ando, Shigeru; Morimoto, Kenji; Kanegawa, Naoki; Kido, Yasuto; Kawachi, Tomoyuki; Fukushima, Tamio; Teisman, Ard; Urmaliya, Vijay; Dhuyvetter, Deborah; Borghys, Herman; Austin, Nigel; Van Den Bergh, An; Verboven, Peter; Bischoff, Francois; Gijsen, Harrie J. M.; Yamano, Yoshinori; Kusakabe, Kenichi</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1894-1910</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The β-site amyloid precursor protein cleaving enzyme 1 (BACE1, also known as β-secretase) is a promising target for the treatment of Alzheimer's disease.  A pKa lowering approach over the initial leads was adopted to mitigate hERG inhibition and P-gp efflux, leading to the design of 6-CF3 dihydrothiazine 8 (N-(3-((4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide).  Optimization of 8 led to the discovery of 15 (N-(3-((4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide) with an excellent balance of potency, hERG inhibition, P-gp efflux, and metabolic stability.  Oral administration of 8 elicited robust Aβ redn. in dog even at 0.16 mg/kg.  Reflecting the reduced hERG inhibitory activity, no QTc prolongation was obsd. at high doses.  The potential for reactive metabolite formation of 15 was realized in a nucleophile trapping assay using [14C]-KCN in human liver microsomes.  Utilizing covalent binding (CVB) in human hepatocytes and the max. projected human dosage, the daily CVB burden of 15 was calcd. to be at an acceptable value of below 1 mg/day.  However, hepatotoxicity was obsd. when 15 was subjected to a two-week tolerance study in dog, which prevented further evaluation of this compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppg1JHQpg4S7Vg90H21EOLACvtfcHk0lhqULkeHrWdOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFarur%252FM&md5=1fbb54003cfb52eceb1ab778705314d9</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900478%26sid%3Dliteratum%253Aachs%26aulast%3DAnan%26aufirst%3DK.%26aulast%3DIso%26aufirst%3DY.%26aulast%3DOguma%26aufirst%3DT.%26aulast%3DNakahara%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DMatsuoka%26aufirst%3DE.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DSakaguchi%26aufirst%3DG.%26aulast%3DAndo%26aufirst%3DS.%26aulast%3DMorimoto%26aufirst%3DK.%26aulast%3DKanegawa%26aufirst%3DN.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DKawachi%26aufirst%3DT.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DTeisman%26aufirst%3DA.%26aulast%3DUrmaliya%26aufirst%3DV.%26aulast%3DDhuyvetter%26aufirst%3DD.%26aulast%3DBorghys%26aufirst%3DH.%26aulast%3DAustin%26aufirst%3DN.%26aulast%3DVan%2BDen%2BBergh%26aufirst%3DA.%26aulast%3DVerboven%26aufirst%3DP.%26aulast%3DBischoff%26aufirst%3DF.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26aulast%3DYamano%26aufirst%3DY.%26aulast%3DKusakabe%26aufirst%3DK.%26atitle%3DTrifluoromethyl%2520dihydrothiazine-based%2520%25CE%25B2-Secretase%2520%2528BACE1%2529%2520inhibitors%2520with%2520robust%2520central%2520%25CE%25B2-amyloid%2520reduction%2520and%2520minimal%2520covalent%2520binding%2520burden%26jtitle%3DChemMedChem%26date%3D2019%26volume%3D14%26spage%3D1894%26epage%3D1910%26doi%3D10.1002%2Fcmdc.201900478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tadano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanegawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teisman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urmaliya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuyvetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghys, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bergh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iso, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.-i.</span></span> <span> </span><span class="NLM_article-title">Discovery of an extremely potent thiazine-based β-secretase (BACE1) inhibitor that minimized cardiovascular and liver toxicity at a low projected human dose</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9331</span>– <span class="NLM_lpage">9337</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01140</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01140" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVentrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9331-9337&author=G.+Tadanoauthor=K.+Komanoauthor=S.+Yoshidaauthor=S.+Suzukiauthor=K.+Nakaharaauthor=K.+Fuchinoauthor=K.+Fujimotoauthor=E.+Matsuokaauthor=T.+Yamamotoauthor=N.+Asadaauthor=H.+Itoauthor=G.+Sakaguchiauthor=N.+Kanegawaauthor=Y.+Kidoauthor=S.+Andoauthor=T.+Fukushimaauthor=A.+Teismanauthor=V.+Urmaliyaauthor=D.+Dhuyvetterauthor=H.+Borghysauthor=A.+Van+Den+Berghauthor=N.+Austinauthor=H.+J.+M.+Gijsenauthor=Y.+Yamanoauthor=Y.+Isoauthor=K.-i.+Kusakabe&title=Discovery+of+an+extremely+potent+thiazine-based+%CE%B2-secretase+%28BACE1%29+inhibitor+that+minimized+cardiovascular+and+liver+toxicity+at+a+low+projected+human+dose&doi=10.1021%2Facs.jmedchem.9b01140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25cR"><div class="casContent"><span class="casTitleNuber">25c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Extremely Potent Thiazine-Based β-Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose</span></div><div class="casAuthors">Tadano, Genta; Komano, Kazuo; Yoshida, Shuhei; Suzuki, Shinji; Nakahara, Kenji; Fuchino, Kouki; Fujimoto, Kazuki; Matsuoka, Eriko; Yamamoto, Takahiko; Asada, Naoya; Ito, Hisanori; Sakaguchi, Gaku; Kanegawa, Naoki; Kido, Yasuto; Ando, Shigeru; Fukushima, Tamio; Teisman, Ard; Urmaliya, Vijay; Dhuyvetter, Deborah; Borghys, Herman; Van Den Bergh, An; Austin, Nigel; Gijsen, Harrie J. M.; Yamano, Yoshinori; Iso, Yasuyoshi; Kusakabe, Ken-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9331-9337</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Genetic evidence points to deposition of amyloid-β (Aβ) as a causal factor for Alzheimer's disease.  Aβ generation is initiated when β-secretase (BACE1) cleaves the amyloid precursor protein.  Starting with an oxazine lead 1, we describe the discovery of a thiazine-based BACE1 inhibitor 5 with robust Aβ redn. in vivo at low concns., leading to a low projected human dose of 14 mg/day where 5 achieved sustained Aβ redn. of 80% at trough level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCgZp0A9J8rbVg90H21EOLACvtfcHk0liopMgN3RhqZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVentrnO&md5=8f6c618bad3fc4bcf7bfb97b48972fa3</span></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01140%26sid%3Dliteratum%253Aachs%26aulast%3DTadano%26aufirst%3DG.%26aulast%3DKomano%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DNakahara%26aufirst%3DK.%26aulast%3DFuchino%26aufirst%3DK.%26aulast%3DFujimoto%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DE.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DAsada%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DSakaguchi%26aufirst%3DG.%26aulast%3DKanegawa%26aufirst%3DN.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DAndo%26aufirst%3DS.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DTeisman%26aufirst%3DA.%26aulast%3DUrmaliya%26aufirst%3DV.%26aulast%3DDhuyvetter%26aufirst%3DD.%26aulast%3DBorghys%26aufirst%3DH.%26aulast%3DVan%2BDen%2BBergh%26aufirst%3DA.%26aulast%3DAustin%26aufirst%3DN.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26aulast%3DYamano%26aufirst%3DY.%26aulast%3DIso%26aufirst%3DY.%26aulast%3DKusakabe%26aufirst%3DK.-i.%26atitle%3DDiscovery%2520of%2520an%2520extremely%2520potent%2520thiazine-based%2520%25CE%25B2-secretase%2520%2528BACE1%2529%2520inhibitor%2520that%2520minimized%2520cardiovascular%2520and%2520liver%2520toxicity%2520at%2520a%2520low%2520projected%2520human%2520dose%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9331%26epage%3D9337%26doi%3D10.1021%2Facs.jmedchem.9b01140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1021/tx200168d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+A+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States&doi=10.1021%2Ftx200168d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0liopMgN3RhqZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520A%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410%26doi%3D10.1021%2Ftx200168d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swallow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgos, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span> <span> </span><span class="NLM_article-title">In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1616</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1021/tx300091x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx300091x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=1616-1632&author=R.+A.+Thompsonauthor=E.+M.+Isinauthor=Y.+Liauthor=L.+Weidolfauthor=K.+Pageauthor=I.+Wilsonauthor=S.+Swallowauthor=B.+Middletonauthor=S.+Stahlauthor=A.+J.+Fosterauthor=H.+Dolgosauthor=R.+Weaverauthor=J.+G.+Kenna&title=In+vitro+approach+to+assess+the+potential+for+risk+of+idiosyncratic+adverse+reactions+caused+by+candidate+drugs&doi=10.1021%2Ftx300091x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs</span></div><div class="casAuthors">Thompson, Richard A.; Isin, Emre M.; Li, Yan; Weidolf, Lars; Page, Ken; Wilson, Ian; Swallow, Steve; Middleton, Brian; Stahl, Simone; Foster, Alison J.; Dolgos, Hugues; Weaver, Richard; Kenna, J. Gerry</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1616-1632</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Idiosyncratic adverse drug reactions (IADRs) in humans can result in a broad range of clin. significant toxicities leading to attrition during drug development as well as postlicensing withdrawal or labeling.  IADRs arise from both drug and patient related mechanisms and risk factors.  Drug related risk factors, resulting from parent compd. or metabolites, may involve multiple contributory mechanisms including organelle toxicity, effects related to compd. disposition, and/or immune activation.  In the current study, we evaluate an in vitro approach, which explored both cellular effects and covalent binding (CVB) to assess IADR risks for drug candidates using 36 drugs which caused different patterns and severities of IADRs in humans.  The cellular effects were tested in an in vitro Panel of five assays which quantified (1) toxicity to THLE cells (SV40 T-antigen-immortalized human liver epithelial cells), which do not express P450s, (2) toxicity to a THLE cell line which selectively expresses P 450 3A4, (3) cytotoxicity in HepG2 cells in glucose and galactose media, which is indicative of mitochondrial injury, (4) inhibition of the human bile salt export pump, BSEP, and (5) inhibition of the rat multidrug resistance assocd. protein 2, Mrp2.  In addn., the CVB Burden was estd. by detg. the CVB of radiolabeled compd. to human hepatocytes and factoring in both the max. prescribed daily dose and the fraction of metab. leading to CVB.  Combining the aggregated results from the in vitro Panel assays with the CVB Burden data discriminated, with high specificity (78%) and sensitivity (100%), between 27 drugs, which had severe or marked IADR concern, and 9 drugs, which had low IADR concern, we propose that this integrated approach has the potential to enable selection of drug candidates with reduced propensity to cause IADRs in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFG8lfWXT4vLVg90H21EOLACvtfcHk0liopMgN3RhqZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslGqs70%253D&md5=e657aaf23d4efc5466bca68dee95bded</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1021%2Ftx300091x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx300091x%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DR.%2BA.%26aulast%3DIsin%26aufirst%3DE.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWeidolf%26aufirst%3DL.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DI.%26aulast%3DSwallow%26aufirst%3DS.%26aulast%3DMiddleton%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DS.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DDolgos%26aufirst%3DH.%26aulast%3DWeaver%26aufirst%3DR.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26atitle%3DIn%2520vitro%2520approach%2520to%2520assess%2520the%2520potential%2520for%2520risk%2520of%2520idiosyncratic%2520adverse%2520reactions%2520caused%2520by%2520candidate%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26spage%3D1616%26epage%3D1632%26doi%3D10.1021%2Ftx300091x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripp, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction Risks</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4896</span>– <span class="NLM_lpage">4933</span>, <span class="refDoi"> DOI: 10.1021/jm300065h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300065h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wlur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4896-4933&author=S.+T.+M.+Orrauthor=S.+L.+Rippauthor=T.+E.+Ballardauthor=J.+L.+Hendersonauthor=D.+O.+Scottauthor=R.+S.+Obachauthor=H.+Sunauthor=A.+S.+Kalgutkar&title=Mechanism-based+inactivation+%28MBI%29+of+cytochrome+P450+enzymes%3A+structure-activity+relationships+and+discovery+strategies+to+mitigate+drug-drug+interaction+Risks&doi=10.1021%2Fjm300065h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26cR"><div class="casContent"><span class="casTitleNuber">26c</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks</span></div><div class="casAuthors">Orr, Suvi T. M.; Ripp, Sharon L.; Ballard, T. Eric; Henderson, Jaclyn L.; Scott, Dennis O.; Obach, R. Scott; Sun, Hao; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4896-4933</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The importance of mitigating drug-drug interaction (DDI) risks, which arise from inhibition of major human cytochrome P 450 enzymes is a well-established component of the lead optimization process in drug discovery.  More recently, there has been much interest in clin. DDIs potentially arising via time- and concn.-dependent cytochrome P 450 inhibition, a phenomenon consistent with mechanism-based inactivation.  Inactivated P 450 is catalytically incompetent and must be replenished by newly synthesized protein.  Consequently, time-dependent inhibition of P450s presents a greater safety concern compared to reversible inhibition because of the increased propensity for pharmacokinetic interactions upon multiple dosing and the sustained duration of these interactions after discontinuation of the mechanism-based inactivator.  Mechanism-based or time-dependent P 450 inhibitors pose an addnl. risk of idiosyncratic drug toxicity since the mechanism of time-dependency often involves the formation of reactive metabolites, which can react with proteins other than the P 450 isoenzyme responsible for catalysis. in vitro time-dependent inhibition (TDI) of P 450 enzymes is now routinely assessed as part of lead optimization efforts in preclin. drug discovery.  However, identification of an in vitro TDI liability can raise several questions such as: What is the mechanism of TDI.  Does it involve the formation of reactive metabolites.  Is there a 1:1 correlation between P 450 TDI and RM formation (as measured from reactive metabolite trapping studies).  What is the likelihood that a P 450 time-dependent inhibitor will also cause toxicity.  What are the DDI risk mitigation options when dealing with P 450 inactivators in drug discovery - compd. progression or termination.  Several drugs exhibit in vitro TDI of P 450 enzymes, but only a fraction thereof causes clin. DDIs.  Hence, when do we initiate labor-intensive medicinal chem. efforts to design compds. devoid of P 450 TDI liability.  What are the best methods to precisely predict the likelihood of occurrence of clin. DDIs with drug candidates that inactivate P 450 enzymes.  What are (if any) the qualifying considerations for clin. progression of a P 450 time-dependent inactivator with projected clin. DDI risks.  In an effort to address these questions and hopefully provide answers to some of them, we embarked on the present venture wherein we highlight the current state-of-the-art knowledge in this field with a special emphasis on (a) available biochem. and mechanistic approaches in drug discovery to examine TDI of P 450 isoenzymes with new chem. entities, (b) structure-activity relationship studies with marketed drugs assocd. with DDIs via P 450 inactivation, (c) case studies of medicinal chem. tactics to abrogate P 450 inactivation liability, (d) strategies for progression of P 450 TDI-pos. drug candidates, and (e) the utility of in silico methodol., including the use of physiol.-based pharmacokinetic simulators, in drug discovery to predict the magnitude of clin. DDIs risks anticipated with new clin. candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDO60qqRvpS7Vg90H21EOLACvtfcHk0ljrF8Xb6PwGvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wlur8%253D&md5=aa4aa4f633b3b4f73b3d79917327b0de</span></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=10.1021%2Fjm300065h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300065h%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26aulast%3DBallard%26aufirst%3DT.%2BE.%26aulast%3DHenderson%26aufirst%3DJ.%2BL.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DMechanism-based%2520inactivation%2520%2528MBI%2529%2520of%2520cytochrome%2520P450%2520enzymes%253A%2520structure-activity%2520relationships%2520and%2520discovery%2520strategies%2520to%2520mitigate%2520drug-drug%2520interaction%2520Risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4896%26epage%3D4933%26doi%3D10.1021%2Fjm300065h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scheen, A. J.</span></span> <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.2165/00002018-200124120-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.2165%2F00002018-200124120-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=11735645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVyisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Scheen%2C+A.+J.+Drug+Saf.+2001%2C+24%2C+873%E2%80%93888%2C+10.2165%2F00002018-200124120-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26dR"><div class="casContent"><span class="casTitleNuber">26d</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity with thiazolidinediones: is it a class effect?</span></div><div class="casAuthors">Scheen, Andre J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">873-888</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Decreased insulin sensitivity plays a major role in various human diseases, particularly type 2 diabetes mellitus, and is assocd. with a higher risk of atherosclerosis and cardiovascular complications.  Thiazolidinediones, more commonly termed glitazones, are the first drugs to specifically target muscular insulin resistance.  They have proven efficacy for reducing plasma glucose levels in patients with type 2 diabetes mellitus treated with diet alone, sulfonylureas, metformin or insulin.  In addn., they are assocd. with some improvement of the cardiovascular risk profile.  However, troglitazone, the first compd. approved by the Food and Drug Administration in the US, proved to be hepatotoxic and was withdrawn from the market after the report of several dozen deaths or cases of severe hepatic failure requiring liver transplantation.  It remains unclear whether or not hepatotoxicity is a class effect or is related to unique properties of troglitazone.  Rosiglitazone and pioglitazone, two other glitazones, appear to have similar efficacy with regard to blood glucose control in patients with type 2 diabetes mellitus as compared with troglitazone.  In controlled clin. trials, the incidence of significant (≥3 × upper limit of normal) increases in liver enzyme levels (ALT in particular) was similar with rosiglitazone or pioglitazone as compared with placebo, whereas troglitazone was assocd. with a 3-fold greater incidence.  In contrast to the numerous case reports of acute liver failure in patients receiving troglitzone, only a few case reports of hepatotoxicity have been reported in patients treated with rosiglitazone until now, with a causal relationship remaining uncertain.  Furthermore, no single case of severe hepatotoxicity has been reported yet with pioglitazone.  It should be mentioned that troglitazone, unlike pioglitazone and rosiglitazone, induces the cytochrome P 450 isoform 3A4, which is partly responsible for its metab., and may be prone to drug interactions.  Importantly enough, obesity, insulin resistance and type 2 diabetes mellitus are assocd. with liver abnormalities, esp. non-alc. steatohepatitis, independent of any pharmacol. treatment.  This assocn. obviously complicates the selection of patients who are good candidates for a treatment with glitazones as well as the monitoring of liver tests after initiation of therapy with any thiazolidinedione compd.  While regular monitoring of liver enzymes is still recommended and more long term data are desirable, current evidence from clin. trials and postmarketing experience in the US supports the conclusion that rosiglitazone and pioglitazone do not share the hepatotoxic profile of troglitazone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTHR2dl31izbVg90H21EOLACvtfcHk0ljrF8Xb6PwGvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVyisrk%253D&md5=efa0b23e963c3c8f53a6b8cda8e404d2</span></div><a href="/servlet/linkout?suffix=cit26d&amp;dbid=16384&amp;doi=10.2165%2F00002018-200124120-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-200124120-00002%26sid%3Dliteratum%253Aachs%26aulast%3DScheen%26aufirst%3DA.%2BJ.%26jtitle%3DDrug%2520Saf.%26date%3D2001%26volume%3D24%26spage%3D873%26epage%3D888%26doi%3D10.2165%2F00002018-200124120-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fielden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamison, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. T.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueblood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshari, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightfoot-Dunn, R.</span></span> <span> </span><span class="NLM_article-title">Retinal toxicity induced by a novel β-secretase inhibitor in the Sprague-Dawley rat</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1177/0192623314553804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1177%2F0192623314553804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=25361751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCqu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=581-592&author=M.+R.+Fieldenauthor=J.+Wernerauthor=J.+A.+Jamisonauthor=A.+Coppiauthor=D.+Hickmanauthor=R.+T.+Dunnauthor=E.+Truebloodauthor=L.+Zhouauthor=C.+A.+Afshariauthor=R.+Lightfoot-Dunn&title=Retinal+toxicity+induced+by+a+novel+%CE%B2-secretase+inhibitor+in+the+Sprague-Dawley+rat&doi=10.1177%2F0192623314553804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal toxicity induced by a novel β-secretase inhibitor in the sprague-dawley rat</span></div><div class="casAuthors">Fielden, Mark R.; Werner, Jonathan; Jamison, Jeff A.; Coppi, Aldo; Hickman, Dean; Dunn, Robert T., II; Trueblood, Esther; Zhou, Lei; Afshari, Cynthia A.; Lightfoot-Dunn, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">581-592</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">β-Secretase 1 (BACE1) represents an attractive target for the treatment of Alzheimer's disease.  In the course of development of a novel small mol. BACE1 inhibitor (AMG-8718), retinal thinning was obsd. in a 1-mo toxicity study in the rat.  To further understand the lesion, an investigational study was conducted whereby rats were treated daily with AMG-8718 for 1 mo followed by a 2-mo treatment-free phase.  The earliest detectable change in the retina was an increase in autofluorescent granules in the retinal pigment epithelium (RPE) on day 5; however, there were no treatment-related light microscopic changes obsd. in the neuroretina and no changes obsd. by fundus autofluorescence or routine ophthalmoscopic examn. after 28 days of dosing.  Following 2 mo of recovery, there was significant retinal thinning attributed to loss of photoreceptor nuclei from the outer nuclear layer.  Electroretinog. changes were obsd. as early as day 14, before any microscopic evidence of photoreceptor loss.  BACE1 knockout rats were generated and found to have normal retinal morphol. indicating that the retinal toxicity induced by AMG-8718 was likely off-target.  These results suggest that AMG-8718 impairs phagolysosomal function in the rat RPE, which leads to photoreceptor dysfunction and ultimately loss of photoreceptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfyBfTezUdUrVg90H21EOLACvtfcHk0ljrF8Xb6PwGvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCqu7fP&md5=d6f4af801e795995739478385f5e36fd</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1177%2F0192623314553804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623314553804%26sid%3Dliteratum%253Aachs%26aulast%3DFielden%26aufirst%3DM.%2BR.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DJamison%26aufirst%3DJ.%2BA.%26aulast%3DCoppi%26aufirst%3DA.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DDunn%26aufirst%3DR.%2BT.%26aulast%3DTrueblood%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DAfshari%26aufirst%3DC.%2BA.%26aulast%3DLightfoot-Dunn%26aufirst%3DR.%26atitle%3DRetinal%2520toxicity%2520induced%2520by%2520a%2520novel%2520%25CE%25B2-secretase%2520inhibitor%2520in%2520the%2520Sprague-Dawley%2520rat%26jtitle%3DToxicol.%2520Pathol.%26date%3D2015%26volume%3D43%26spage%3D581%26epage%3D592%26doi%3D10.1177%2F0192623314553804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenthaler, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span> <span> </span><span class="NLM_article-title">BACE1 physiological functions may limit its use as therapeutic target for Alzheimer’s disease</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.tins.2016.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2Fj.tins.2016.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=26833257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2016&pages=158-169&author=S.+Baraoauthor=D.+Moecharsauthor=S.+F.+Lichtenthalerauthor=B.+De+Strooper&title=BACE1+physiological+functions+may+limit+its+use+as+therapeutic+target+for+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.tins.2016.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease</span></div><div class="casAuthors">Barao, Soraia; Moechars, Diederik; Lichtenthaler, Stefan F.; De Strooper, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">158-169</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The protease β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) is required for the prodn. of the amyloid-β (Aβ) peptide, which is central to the pathogenesis of Alzheimer's disease (AD).  Chronic inhibition of this protease may temper amyloid prodn. and cure or prevent AD.  However, while BACE1 inhibitors are being pushed forward as drug candidates, a remarkable gap in knowledge on the physiol. functions of BACE1 and its close homolog BACE2 becomes apparent.  Here we discuss the major discoveries of the past 3 years concerning BACE1 biol. and to what extent these could limit the use of BACE1 inhibitors in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtIpCCZlND1LVg90H21EOLACvtfcHk0lgW9igs10lGng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaksb4%253D&md5=2f85406ce8d4a917de49e26f0ae1ea87</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.tins.2016.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tins.2016.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DBarao%26aufirst%3DS.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DLichtenthaler%26aufirst%3DS.%2BF.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26atitle%3DBACE1%2520physiological%2520functions%2520may%2520limit%2520its%2520use%2520as%2520therapeutic%2520target%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DTrends%2520Neurosci.%26date%3D2016%26volume%3D39%26spage%3D158%26epage%3D169%26doi%3D10.1016%2Fj.tins.2016.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rochin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurbain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serneels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fort, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raposo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niel, G.</span></span> <span> </span><span class="NLM_article-title">BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">10658</span>– <span class="NLM_lpage">10663</span>, <span class="refDoi"> DOI: 10.1073/pnas.1220748110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1073%2Fpnas.1220748110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=23754390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejs7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=10658-10663&author=L.+Rochinauthor=I.+Hurbainauthor=L.+Serneelsauthor=C.+Fortauthor=B.+Wattauthor=P.+Leblancauthor=M.+S.+Marksauthor=B.+De+Strooperauthor=G.+Raposoauthor=G.+van+Niel&title=BACE2+processes+PMEL+to+form+the+melanosome+amyloid+matrix+in+pigment+cells&doi=10.1073%2Fpnas.1220748110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells</span></div><div class="casAuthors">Rochin, Leila; Hurbain, Ilse; Serneels, Lutgarde; Fort, Cecile; Watt, Brenda; Leblanc, Pascal; Marks, Michael S.; De Strooper, Bart; Raposo, Graca; van Niel, Guillaume</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">10658-10663,S10658/1-S10658/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Amyloids are often assocd. with pathol. processes such as in Alzheimer's disease (AD), but can also underlie physiol. processes such as pigmentation.  Formation of pathol. and functional amyloidogenic substrates can require precursor processing by proteases, as exemplified by the generation of Aβ peptide from amyloid precursor protein (APP) by beta-site APP cleaving enzyme (BACE)1 and γ-secretase.  Proteolytic processing of the pigment cell-specific Melanocyte Protein (PMEL) is also required to form functional amyloid fibrils during melanogenesis, but the enzymes involved are incompletely characterized.  Here we show that the BACE1 homolog BACE2 processes PMEL to generate functional amyloids.  BACE2 is highly expressed in pigment cells and Bace2-/- but not Bace1-/- mice display coat color defects, implying a specific role for BACE2 during melanogenesis.  By using biochem. and morphol. analyses, combined with RNA silencing, pharmacol. inhibition, and BACE2 overexpression in a human melanocytic cell line, we show that BACE2 cleaves the integral membrane form of PMEL within the juxtamembrane domain, releasing the PMEL luminal domain into endosomal precursors for the formation of amyloid fibrils and downstream melanosome morphogenesis.  These studies identify an amyloidogenic substrate of BACE2, reveal an important physiol. role for BACE2 in pigmentation, and highlight analogies in the generation of PMEL-derived functional amyloids and APP-derived pathol. amyloids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBEney5KFyLVg90H21EOLACvtfcHk0lgW9igs10lGng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejs7rK&md5=3deb3f80dca6a32748aa6fe2e50c2df1</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1220748110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1220748110%26sid%3Dliteratum%253Aachs%26aulast%3DRochin%26aufirst%3DL.%26aulast%3DHurbain%26aufirst%3DI.%26aulast%3DSerneels%26aufirst%3DL.%26aulast%3DFort%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DB.%26aulast%3DLeblanc%26aufirst%3DP.%26aulast%3DMarks%26aufirst%3DM.%2BS.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26aulast%3DRaposo%26aufirst%3DG.%26aulast%3Dvan%2BNiel%26aufirst%3DG.%26atitle%3DBACE2%2520processes%2520PMEL%2520to%2520form%2520the%2520melanosome%2520amyloid%2520matrix%2520in%2520pigment%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D10658%26epage%3D10663%26doi%3D10.1073%2Fpnas.1220748110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shimshek, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamurovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balavenkatraman, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morawiec, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreutzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schelle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jucker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertschi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzak, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, U.</span></span> <span> </span><span class="NLM_article-title">Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21917</span>, <span class="refDoi"> DOI: 10.1038/srep21917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1038%2Fsrep21917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=26912421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1eku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=21917&author=D.+R.+Shimshekauthor=L.+H.+Jacobsonauthor=C.+Kollyauthor=N.+Zamurovicauthor=K.+K.+Balavenkatramanauthor=L.+Morawiecauthor=R.+Kreutzerauthor=J.+Schelleauthor=M.+Juckerauthor=B.+Bertschiauthor=D.+Theilauthor=A.+Heierauthor=K.+Bigotauthor=K.+Beltzauthor=R.+Machauerauthor=I.+Brzakauthor=L.+Perrotauthor=U.+Neumann&title=Pharmacological+BACE1+and+BACE2+inhibition+induces+hair+depigmentation+by+inhibiting+PMEL17+processing+in+mice&doi=10.1038%2Fsrep21917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice</span></div><div class="casAuthors">Shimshek, Derya R.; Jacobson, Laura H.; Kolly, Carine; Zamurovic, Natasa; Balavenkatraman, Kamal Kumar; Morawiec, Laurent; Kreutzer, Robert; Schelle, Juliane; Jucker, Mathias; Bertschi, Barbara; Theil, Diethilde; Heier, Annabelle; Bigot, Karine; Beltz, Karen; Machauer, Rainer; Brzak, Irena; Perrot, Ludovic; Neumann, Ulf</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21917</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Melanocytes of the hair follicle produce melanin and are essential in detg. the differences in hair color.  Pigment cell-specific MELanocyte Protein (PMEL17) plays a crucial role in melanogenesis.  One of the crit. steps is the amyloid-like functional oligomerization of PMEL17.  Beta Site APP Cleaving Enzyme-2 (BACE2) and γ-secretase have been shown to be key players in generating the proteolytic fragments of PMEL17.  The β-secretase (BACE1) is responsible for the generation of amyloid-β (Aβ) fragments in the brain and is therefore proposed as a therapeutic target for Alzheimer's disease (AD).  Currently BACE1 inhibitors, most of which lack selectivity over BACE2, have demonstrated efficacious redn. of amyloid-β peptides in animals and the CSF of humans.  BACE2 knock-out mice have a deficiency in PMEL17 proteolytic processing leading to impaired melanin storage and hair depigmentation.  Here, we confirm BACE2-mediated inhibition of PMEL17 proteolytic processing in vitro in mouse and human melanocytes.  Furthermore, we show that wildtype as well as bace2+/- and bace2-/- mice treated with a potent dual BACE1/BACE2 inhibitor NB-360 display dose-dependent appearance of irreversibly depigmented hair.  Retinal pigmented epithelium showed no morphol. changes.  Our data demonstrates that BACE2 as well as addnl. BACE1 inhibition affects melanosome maturation and induces hair depigmentation in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtlQ-3Lxc4CLVg90H21EOLACvtfcHk0lgW9igs10lGng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1eku7Y%253D&md5=e3641d48cc7fcf08c4502b5899a49066</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1038%2Fsrep21917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep21917%26sid%3Dliteratum%253Aachs%26aulast%3DShimshek%26aufirst%3DD.%2BR.%26aulast%3DJacobson%26aufirst%3DL.%2BH.%26aulast%3DKolly%26aufirst%3DC.%26aulast%3DZamurovic%26aufirst%3DN.%26aulast%3DBalavenkatraman%26aufirst%3DK.%2BK.%26aulast%3DMorawiec%26aufirst%3DL.%26aulast%3DKreutzer%26aufirst%3DR.%26aulast%3DSchelle%26aufirst%3DJ.%26aulast%3DJucker%26aufirst%3DM.%26aulast%3DBertschi%26aufirst%3DB.%26aulast%3DTheil%26aufirst%3DD.%26aulast%3DHeier%26aufirst%3DA.%26aulast%3DBigot%26aufirst%3DK.%26aulast%3DBeltz%26aufirst%3DK.%26aulast%3DMachauer%26aufirst%3DR.%26aulast%3DBrzak%26aufirst%3DI.%26aulast%3DPerrot%26aufirst%3DL.%26aulast%3DNeumann%26aufirst%3DU.%26atitle%3DPharmacological%2520BACE1%2520and%2520BACE2%2520inhibition%2520induces%2520hair%2520depigmentation%2520by%2520inhibiting%2520PMEL17%2520processing%2520in%2520mice%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D21917%26doi%3D10.1038%2Fsrep21917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esterhazy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuetzer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rechsteiner, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebeli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilpert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matile, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prummer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieske, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marselli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr-Conte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebersold</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinas, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffel, M.</span></span> <span> </span><span class="NLM_article-title">Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2011.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2Fj.cmet.2011.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=21907142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFGltbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=365-377&author=D.+Esterhazyauthor=I.+Stuetzerauthor=H.+Wangauthor=M.+P.+Rechsteinerauthor=J.+Beauchampauthor=H.+Doebeliauthor=H.+Hilpertauthor=H.+Matileauthor=M.+Prummerauthor=A.+Schmidtauthor=N.+Lieskeauthor=B.+Boehmauthor=L.+Marselliauthor=D.+Boscoauthor=J.+Kerr-Conteauthor=+Aebersoldauthor=G.+A.+Spinasauthor=H.+Mochauthor=C.+Miglioriniauthor=M.+Stoffel&title=Bace2+is+a+%CE%B2+cell-enriched+protease+that+regulates+pancreatic+%CE%B2+cell+function+and+mass&doi=10.1016%2Fj.cmet.2011.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Bace2 Is a β Cell-Enriched Protease that Regulates Pancreatic β Cell Function and Mass</span></div><div class="casAuthors">Esterhazy, Daria; Stuetzer, Ina; Wang, Haiyan; Rechsteiner, Markus P.; Beauchamp, Jeremy; Doebeli, Heinz; Hilpert, Hans; Matile, Hugues; Prummer, Michael; Schmidt, Alexander; Lieske, Nora; Boehm, Bernhard; Marselli, Lorella; Bosco, Domenico; Kerr-Conte, Julie; Aebersold, Ruedi; Spinas, Giatgen Andreia; Moch, Holger; Migliorini, Cristiano; Stoffel, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-377</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Decreased β cell mass and function are hallmarks of type 2 diabetes.  Here we identified, through a siRNA screen, beta site amyloid precursor protein cleaving enzyme 2 (Bace2) as the sheddase of the proproliferative plasma membrane protein Tmem27 in murine and human β cells.  Mice with functionally inactive Bace2 and insulin-resistant mice treated with a newly identified Bace2 inhibitor both display augmented β cell mass and improved control of glucose homeostasis due to increased insulin levels.  These results implicate Bace2 in the control of β cell maintenance and provide a rational strategy to inhibit this protease for the expansion of functional pancreatic β cell mass.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNmw-BllVxx7Vg90H21EOLACvtfcHk0liDkLJZX27VDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFGltbbM&md5=489e20b2d997eb0cbaff195819e35d64</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2011.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2011.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DEsterhazy%26aufirst%3DD.%26aulast%3DStuetzer%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRechsteiner%26aufirst%3DM.%2BP.%26aulast%3DBeauchamp%26aufirst%3DJ.%26aulast%3DDoebeli%26aufirst%3DH.%26aulast%3DHilpert%26aufirst%3DH.%26aulast%3DMatile%26aufirst%3DH.%26aulast%3DPrummer%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DLieske%26aufirst%3DN.%26aulast%3DBoehm%26aufirst%3DB.%26aulast%3DMarselli%26aufirst%3DL.%26aulast%3DBosco%26aufirst%3DD.%26aulast%3DKerr-Conte%26aufirst%3DJ.%26aulast%3DAebersold%26aulast%3DSpinas%26aufirst%3DG.%2BA.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DMigliorini%26aufirst%3DC.%26aulast%3DStoffel%26aufirst%3DM.%26atitle%3DBace2%2520is%2520a%2520%25CE%25B2%2520cell-enriched%2520protease%2520that%2520regulates%2520pancreatic%2520%25CE%25B2%2520cell%2520function%2520and%2520mass%26jtitle%3DCell%2520Metab.%26date%3D2011%26volume%3D14%26spage%3D365%26epage%3D377%26doi%3D10.1016%2Fj.cmet.2011.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rulifson, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samayoa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baribault, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltzius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of human islet amyloid polypeptide as a BACE2 substrate</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0147254</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0147254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1371%2Fjournal.pone.0147254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=26840340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslOqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0147254&author=I.+C.+Rulifsonauthor=P.+Caoauthor=L.+Miaoauthor=D.+Kopeckyauthor=L.+Huangauthor=R.+D.+Whiteauthor=K.+Samayoaauthor=J.+Gardnerauthor=X.+Wuauthor=K.+Chenauthor=T.+Tsurudaauthor=O.+Homannauthor=H.+Baribaultauthor=H.+Yamaneauthor=T.+Carlsonauthor=J.+Wiltziusauthor=Y.+Li&title=Identification+of+human+islet+amyloid+polypeptide+as+a+BACE2+substrate&doi=10.1371%2Fjournal.pone.0147254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human islet amyloid polypeptide as a BACE2 substrate</span></div><div class="casAuthors">Rulifson, Ingrid C.; Cao, Ping; Miao, Li; Kopecky, David; Huang, Linda; White, Ryan D.; Samayoa, Kim; Gardner, Jonitha; Wu, Xiaosu; Chen, Kui; Tsuruda, Trace; Homann, Oliver; Baribault, Helene; Yamane, Harvey; Carlson, Tim; Wiltzius, Jed; Li, Yang</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0147254/1-e0147254/23</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Pancreatic amyloid formation by islet amyloid polypeptide (IAPP) is a hallmark pathol. feature of type 2 diabetes.  IAPP is stored in the secretory granules of pancreatic beta-cells and co-secreted with insulin to maintain glucose homeostasis.  IAPP is innocuous under homeostatic conditions but imbalances in prodn. or processing of IAPP may result in homodimer formation leading to the rapid prodn. of cytotoxic oligomers and amyloid fibrils.  The consequence is beta-cell dysfunction and the accumulation of proteinaceous plaques in and around pancreatic islets.  Beta-site APP-cleaving enzyme 2, BACE2, is an aspartyl protease commonly assocd. with BACE1, a related homolog responsible for amyloid processing in the brain and strongly implicated in Alzheimer's disease.  Herein, we identify two distinct sites of the mature human IAPP sequence that are susceptible to BACE2-mediated proteolytic activity.  The result of proteolysis is modulation of human IAPP fibrillation and human IAPP protein degrdn.  These results suggest a potential therapeutic role for BACE2 in type 2 diabetes-assocd. hyperamylinemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXxpM4hmm1pLVg90H21EOLACvtfcHk0liDkLJZX27VDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslOqtL4%253D&md5=ab081153a95c7462bd208bac8779bd1d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0147254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0147254%26sid%3Dliteratum%253Aachs%26aulast%3DRulifson%26aufirst%3DI.%2BC.%26aulast%3DCao%26aufirst%3DP.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DKopecky%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DSamayoa%26aufirst%3DK.%26aulast%3DGardner%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DTsuruda%26aufirst%3DT.%26aulast%3DHomann%26aufirst%3DO.%26aulast%3DBaribault%26aufirst%3DH.%26aulast%3DYamane%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DT.%26aulast%3DWiltzius%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520human%2520islet%2520amyloid%2520polypeptide%2520as%2520a%2520BACE2%2520substrate%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0147254%26doi%3D10.1371%2Fjournal.pone.0147254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alic, I.</span>; <span class="NLM_string-name">Goh, P. A.</span>; <span class="NLM_string-name">Murray, A.</span>; <span class="NLM_string-name">Portelius, E.</span>; <span class="NLM_string-name">Gkanatsiou, E.</span>; <span class="NLM_string-name">Gough, G.</span>; <span class="NLM_string-name">Mok, K. Y.</span>; <span class="NLM_string-name">Koschut, D.</span>; <span class="NLM_string-name">Brunmeir, R.</span>; <span class="NLM_string-name">Yeap, Y. J.</span>; <span class="NLM_string-name">O’Brien, N. L.</span>; <span class="NLM_string-name">Groet, J.</span>; <span class="NLM_string-name">Shao, X.</span>; <span class="NLM_string-name">Havlicek, S.</span>; <span class="NLM_string-name">Dunn, N. R.</span>; <span class="NLM_string-name">Kvartsberg, H.</span>; <span class="NLM_string-name">Brinkmalm, G.</span>; <span class="NLM_string-name">Hithersay, R.</span>; <span class="NLM_string-name">Startin, C.</span>; <span class="NLM_string-name">Hamburg, S.</span>; <span class="NLM_string-name">Phillips, M.</span>; <span class="NLM_string-name">Pervushin, K.</span>; <span class="NLM_string-name">Turmaine, M.</span>; <span class="NLM_string-name">Wallon, D.</span>; <span class="NLM_string-name">Rovelet-Lecrux, A.</span>; <span class="NLM_string-name">Soininen, H.</span>; <span class="NLM_string-name">Volpi, E.</span>; <span class="NLM_string-name">Martin, J. E.</span>; <span class="NLM_string-name">Foo, J. N.</span>; <span class="NLM_string-name">Becker, D. L.</span>; <span class="NLM_string-name">Rostagno, A.</span>; <span class="NLM_string-name">Ghiso, J.</span>; <span class="NLM_string-name">Krsnik, Z.</span>; <span class="NLM_string-name">Simic, G.</span>; <span class="NLM_string-name">Kostovic, I.</span>; <span class="NLM_string-name">Mitrecic, D.</span>; <span class="NLM_string-name">Francis, P. T.</span>; <span class="NLM_string-name">Blennow, K.</span>; <span class="NLM_string-name">Strydom, A.</span>; <span class="NLM_string-name">Hardy, J.</span>; <span class="NLM_string-name">Zetterberg, H.</span>; <span class="NLM_string-name">Nizetic, D.</span></span> <span> </span><span class="NLM_article-title">Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain</span>.  <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2020</span><span class="refDoi"> DOI: 10.1038/s41380-020-0806-5</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1038%2Fs41380-020-0806-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=32647257" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=I.+Alic&author=P.+A.+Goh&author=A.+Murray&author=E.+Portelius&author=E.+Gkanatsiou&author=G.+Gough&author=K.+Y.+Mok&author=D.+Koschut&author=R.+Brunmeir&author=Y.+J.+Yeap&author=N.+L.+O%E2%80%99Brien&author=J.+Groet&author=X.+Shao&author=S.+Havlicek&author=N.+R.+Dunn&author=H.+Kvartsberg&author=G.+Brinkmalm&author=R.+Hithersay&author=C.+Startin&author=S.+Hamburg&author=M.+Phillips&author=K.+Pervushin&author=M.+Turmaine&author=D.+Wallon&author=A.+Rovelet-Lecrux&author=H.+Soininen&author=E.+Volpi&author=J.+E.+Martin&author=J.+N.+Foo&author=D.+L.+Becker&author=A.+Rostagno&author=J.+Ghiso&author=Z.+Krsnik&author=G.+Simic&author=I.+Kostovic&author=D.+Mitrecic&author=P.+T.+Francis&author=K.+Blennow&author=A.+Strydom&author=J.+Hardy&author=H.+Zetterberg&author=D.+Nizetic&title=Patient-specific+Alzheimer-like+pathology+in+trisomy+21+cerebral+organoids+reveals+BACE2+as+a+gene+dose-sensitive+AD+suppressor+in+human+brain&doi=10.1038%2Fs41380-020-0806-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fs41380-020-0806-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41380-020-0806-5%26sid%3Dliteratum%253Aachs%26aulast%3DAlic%26aufirst%3DI.%26atitle%3DPatient-specific%2520Alzheimer-like%2520pathology%2520in%2520trisomy%252021%2520cerebral%2520organoids%2520reveals%2520BACE2%2520as%2520a%2520gene%2520dose-sensitive%2520AD%2520suppressor%2520in%2520human%2520brain%26jtitle%3DMol.%2520Psychiatry%26date%3D2020%26doi%3D10.1038%2Fs41380-020-0806-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kunishima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawachi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tani, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of 4-(4,6-dimethoxy-1,3,5-triazi-2-yl)-4-methylmorpholinium chloride</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">5327</span>– <span class="NLM_lpage">5330</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(99)00968-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2FS0040-4039%2899%2900968-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADyaK1MXksVynt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=5327-5330&author=M.+Kunishimaauthor=C.+Kawachiauthor=F.+Iwasakiauthor=K.+Teraoauthor=S.+Tani&title=Synthesis+and+characterization+of+4-%284%2C6-dimethoxy-1%2C3%2C5-triazi-2-yl%29-4-methylmorpholinium+chloride&doi=10.1016%2FS0040-4039%2899%2900968-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride</span></div><div class="casAuthors">Kunishima, Munetaka; Kawachi, Chiho; Iwasaki, Fumiaki; Terao, Keiji; Tani, Shohei</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">5327-5330</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) was quant. synthesized by the coupling of 2-chloro-4,6-dimethoxy-1,3,5-triazine and N-methylmorpholine in THF, and fully characterized.  Condensation of carboxylic acids and amines by DMTMM proceeded effectively in THF to give the corresponding amides in good yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5PCjoyBOjP7Vg90H21EOLACvtfcHk0lhk_38rvMY2-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVynt74%253D&md5=6bcb4ea20612a6f6cd57bc512e1f6374</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2899%2900968-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252899%252900968-5%26sid%3Dliteratum%253Aachs%26aulast%3DKunishima%26aufirst%3DM.%26aulast%3DKawachi%26aufirst%3DC.%26aulast%3DIwasaki%26aufirst%3DF.%26aulast%3DTerao%26aufirst%3DK.%26aulast%3DTani%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520characterization%2520of%25204-%25284%252C6-dimethoxy-1%252C3%252C5-triazi-2-yl%2529-4-methylmorpholinium%2520chloride%26jtitle%3DTetrahedron%2520Lett.%26date%3D1999%26volume%3D40%26spage%3D5327%26epage%3D5330%26doi%3D10.1016%2FS0040-4039%2899%2900968-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robak, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbage, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and applications of <i>tert</i>-butanesulfinamide</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">3600</span>– <span class="NLM_lpage">3740</span>, <span class="refDoi"> DOI: 10.1021/cr900382t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr900382t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltFChsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2010&pages=3600-3740&author=M.+T.+Robakauthor=M.+A.+Herbageauthor=J.+A.+Ellman&title=Synthesis+and+applications+of+tert-butanesulfinamide&doi=10.1021%2Fcr900382t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Applications of tert-Butanesulfinamide</span></div><div class="casAuthors">Robak, MaryAnn T.; Herbage, Melissa A.; Ellman, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3600-3740</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the past decade, an ever increasing collection of methods based upon the chiral amine reagent tert-butanesulfinamide (I) have become some of the most extensively used synthetic approaches for both the discovery and prodn. of drug candidates.  Either enantiomer of I is inexpensive to prep. on a large scale in enantiomerically pure form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLsVMjLa-pP7Vg90H21EOLACvtfcHk0lhk_38rvMY2-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltFChsbs%253D&md5=ad2c9e9a2b2044f47a00be408d0907d2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fcr900382t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900382t%26sid%3Dliteratum%253Aachs%26aulast%3DRobak%26aufirst%3DM.%2BT.%26aulast%3DHerbage%26aufirst%3DM.%2BA.%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520and%2520applications%2520of%2520tert-butanesulfinamide%26jtitle%3DChem.%2520Rev.%26date%3D2010%26volume%3D110%26spage%3D3600%26epage%3D3740%26doi%3D10.1021%2Fcr900382t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haveaux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekoker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidani, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosez, L.</span></span> <span> </span><span class="NLM_article-title">α-Chloro enamines, reactive intermediates for synthesis: 1-chloro-<i>N</i>,<i>N</i>,2-trimethylpropenylamine</span>. <i>Org. Synth.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1002/0471264180.os059.05</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1002%2F0471264180.os059.05" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADyaL3cXls1Omsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1980&pages=26-34&author=B.+Haveauxauthor=A.+Dekokerauthor=M.+Rensauthor=A.+R.+Sidaniauthor=J.+Toyeauthor=L.+Ghosez&title=%CE%B1-Chloro+enamines%2C+reactive+intermediates+for+synthesis%3A+1-chloro-N%2CN%2C2-trimethylpropenylamine&doi=10.1002%2F0471264180.os059.05"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">α-Chloro enamines, reactive intermediates for synthesis: 1-chloro-N,N,2-trimethylpropenylamine</span></div><div class="casAuthors">Haveaux, B.; Dekoker, A.; Rens, M.; Sidani, A. R.; Toye, J.; Ghosez, L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Syntheses</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26-34</span>CODEN:
                <span class="NLM_cas:coden">ORSYAT</span>;
        ISSN:<span class="NLM_cas:issn">0078-6209</span>.
    </div><div class="casAbstract">RR1C:CClNR2R3 [R = Me, Ph, H, R1 = H, R2 = Me, R3 = Ph; R = Me3C, Me, Ph, R1 = H, Me, R2 = R3 = Me; R = R1 = Me, R2R3 = (CH2)5; RR1 = (CH2)5, R2R3 = Et; R = Me, R1 = Cl, R2R3 = (CH2)4; R = R3 = Me, R1R2 = (CH2)4] were prepd. in 40-85% yields by treating RR1CHCONR2R3 with COCl2 to give RR1CHCCl:N+R2R3.Cl-, which was refluxed in CH2Cl2 in the presence of Et3N for 1 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGFmk9j628LVg90H21EOLACvtfcHk0lhk_38rvMY2-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXls1Omsbw%253D&md5=f2fc2d7e7e7a880884965bd3508f8b86</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2F0471264180.os059.05&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471264180.os059.05%26sid%3Dliteratum%253Aachs%26aulast%3DHaveaux%26aufirst%3DB.%26aulast%3DDekoker%26aufirst%3DA.%26aulast%3DRens%26aufirst%3DM.%26aulast%3DSidani%26aufirst%3DA.%2BR.%26aulast%3DToye%26aufirst%3DJ.%26aulast%3DGhosez%26aufirst%3DL.%26atitle%3D%25CE%25B1-Chloro%2520enamines%252C%2520reactive%2520intermediates%2520for%2520synthesis%253A%25201-chloro-N%252CN%252C2-trimethylpropenylamine%26jtitle%3DOrg.%2520Synth.%26date%3D1980%26volume%3D59%26spage%3D26%26epage%3D34%26doi%3D10.1002%2F0471264180.os059.05" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c','cit7d','cit7e','cit7f'],'ref8':['cit8a','cit8b','cit8c','cit8d'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b','cit12c','cit12d','cit12e'],'ref13':['cit13a','cit13b'],'ref14':['cit14a','cit14b'],'ref15':['cit15a','cit15b'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b'],'ref19':['cit19a','cit19b'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25a','cit25b','cit25c'],'ref26':['cit26a','cit26b','cit26c','cit26d'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29a','cit29b'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Anna Pasieka, Dawid Panek, Natalia Szałaj, Alba Espargaró, Anna Więckowska, Barbara Malawska, Raimon Sabaté, <span class="NLM_string-name hlFld-ContribAuthor">Marek Bajda</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Inhibitors of Amyloid-β and Tau Aggregation with Amyloid-β Disaggregating Properties: Extended In Cellulo, In Silico, and Kinetic Studies of Multifunctional Anti-Alzheimer’s Agents. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2021,</strong> <em>12 </em>
                                    (11)
                                     , 2057-2068. <a href="https://doi.org/10.1021/acschemneuro.1c00235" title="DOI URL">https://doi.org/10.1021/acschemneuro.1c00235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.1c00235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.1c00235%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DDual%252BInhibitors%252Bof%252BAmyloid-%2525CE%2525B2%252Band%252BTau%252BAggregation%252Bwith%252BAmyloid-%2525CE%2525B2%252BDisaggregating%252BProperties%25253A%252BExtended%252BIn%252BCellulo%25252C%252BIn%252BSilico%25252C%252Band%252BKinetic%252BStudies%252Bof%252BMultifunctional%252BAnti-Alzheimer%2525E2%252580%252599s%252BAgents%26aulast%3DPasieka%26aufirst%3DAnna%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D13042021%26date%3D14052021%26date%3D21052021%26volume%3D12%26issue%3D11%26spage%3D2057%26epage%3D2068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kazuki Fujimoto, Shuhei Yoshida, Genta Tadano, Naoya Asada, Kouki Fuchino, Shinji Suzuki, Eriko Matsuoka, Takahiko Yamamoto, Shiho Yamamoto, Shigeru Ando, Naoki Kanegawa, Yutaka Tonomura, Hisanori Ito, Diederik Moechars, Frederik J. R. Rombouts, Harrie J. M. Gijsen, <span class="NLM_string-name hlFld-ContribAuthor">Ken-ichi Kusakabe</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective β-Secretase (BACE1) Inhibitors over BACE2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 3075-3085. <a href="https://doi.org/10.1021/acs.jmedchem.0c01858" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01858</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01858%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BApproaches%252Bto%252BImproving%252BSelectivity%252Bthrough%252BUtilizing%252BExplicit%252BWater%252BMolecules%25253A%252BDiscovery%252Bof%252BSelective%252B%2525CE%2525B2-Secretase%252B%252528BACE1%252529%252BInhibitors%252Bover%252BBACE2%26aulast%3DFujimoto%26aufirst%3DKazuki%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D26102020%26date%3D15032021%26volume%3D64%26issue%3D6%26spage%3D3075%26epage%3D3085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Teeba  Athar</span>, <span class="hlFld-ContribAuthor ">K.  Al Balushi</span>, <span class="hlFld-ContribAuthor ">Shah Alam  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Molecular Biology Reports</span><span> <strong>2021,</strong> <em>16 </em><a href="https://doi.org/10.1007/s11033-021-06512-9" title="DOI URL">https://doi.org/10.1007/s11033-021-06512-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11033-021-06512-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11033-021-06512-9%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Biology%2520Reports%26atitle%3DRecent%252Badvances%252Bon%252Bdrug%252Bdevelopment%252Band%252Bemerging%252Btherapeutic%252Bagents%252Bfor%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DAthar%26aufirst%3DTeeba%26date%3D2021%26date%3D2021%26volume%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0013.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Representative BACE1 Inhibitors That Advanced into Clinical Trials</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Medicinal chemistry progression from hit to clinical candidate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structure of <b>1</b> bound to human BACE1 determined at 2.3 Å resolution (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7DCZ">7DCZ</a>). Key residues of Asp228, Asp32, Tyr71, Gly230, and Ala335 are shown in stick style. Compound <b>1</b> is shown by sticks with green carbons. Oxygen, nitrogen, fluorine, and sulfur atoms are colored red, blue, sky blue, and yellow, respectively. Hydrogen bonds are shown as dashed lines. The pocket surface colored gray is shown in B.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of compound <b>1</b> on CSF Aβ<sub>40</sub> levels after single oral administration in male Sprague–Dawley (Crl:CD(SD)) rats (<i>n</i> = 64, vehicle: 0.5% methyl cellulose (MC); <i>n</i> = 63, untreated control for Aβ measurement; <i>n</i> = 32, each dose). Compound <b>1</b> was administered orally, and Aβ<sub>40</sub> amounts in the CSF were measured using an ELISA system at the points of 0.5, 1, 2, 4, 6, 8, 10, and 24 h after administration. Aβ levels are represented as the percentage of untreated rats at each sampling point. Data shown were mean ± SEM for 7 to 8 rats in each time point of each group. *<i>p</i> < 0.05, **<i>p</i> < 0.01 versus vehicle group (Dunnett’s test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of compound <b>1</b> on CSF Aβ<sub>40</sub> levels after repeated oral administration in TOYO Beagle dogs (<i>n</i> = 3, vehicle; <i>n</i> = 3, each dose). Compound <b>1</b> was administered orally, and Aβ<sub>40</sub> amounts in the CSF were measured using an enzyme-linked immunosorbent assay (ELISA) system at the points of 12 and 24 h after administration at Day 1 (A) and Day 14 (B). Data shown are mean ± standard error of mean (SEM) levels expressed in percent from the predose level for 3 dogs in each group. **<i>p</i> < 0.01 versus vehicle group (Dunnett’s test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Aβ plaque quantification in the brain after repeated administration for 168 days in PS/APP mice (B6;SJL-TgN(APPSWE) × PS1<sup>I213T</sup> KI; <i>n</i> = 35, vehicle (0.5% MC); <i>n</i> = 15, untreated control for Aβ measurement; <i>n</i> = 35, each dose). Compound <b>1</b> was administered orally for 168 days, and the number of plaques and the plaque area in the cortex (A and B) and hippocampus (C and D) were measured by immunostaining using antiAβ antibody 24 to 32 h after the last administration. Untreated: control mice before administration (24 to 30 weeks old of PS/APP mice). Data shown are mean ± standard error (SE) for mice in each group. **<i>p</i> < 0.01 versus 0 mg/kg, once daily (vehicle) group (Dunnett’s test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>1</b> and Its Analogues <b>15</b>–<b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (<i>i</i>-Pr)<sub>2</sub>NH, <i>n</i>-BuLi, <i>t</i>-BuOAc, Ti(O<i>i</i>-Pr)<sub>3</sub>Cl, THF, −78 °C, 77%; (b) HCl, MeOH, dioxane, rt: (c) BH<sub>3</sub>, 0 °C to rt, then HCl, EtOAc, <i>i</i>-Pr<sub>2</sub>O, rt; (d) NaHCO<sub>3</sub>, Fmoc <i>N</i>-hydroxysuccinimide ester, THF/H<sub>2</sub>O; (e) IBX, DMSO, rt; (f) CH(OMe)<sub>3</sub>, Amberlite, MeOH, reflux, then piperidine, DMF, rt, 54% in 3 steps; (g) BzNCS, acetone 0 °C then H<sub>2</sub>SO<sub>4</sub>, 40 °C, 78%; (h) Fe, AcOH/H<sub>2</sub>O, 50 °C, 92%; (i) RCO<sub>2</sub>H, DMT-MM, MeOH, rt; or RCO<sub>2</sub>H, HCl, EDC·HCl, MeOH, 0 °C, 16–88%.</p></p></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Thiazine <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HCl, H<sub>2</sub>O, rt; (b) BzNCS, DCM, 0 °C to rt, 95% in 2 steps; (c) I<sub>2</sub>, DCM, rt; (d) pyrrolidine, THF, 60 °C, 80% in 2 steps; (e) hydrazine hydrate, EtOH, rt, 74%; (f) 5-cyanopicolinic acid, DMT-MM, MeOH, rt, 46%.</p></p></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/medium/jm0c01917_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Dihydrothiazine <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01917/20210218/images/large/jm0c01917_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01917&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LDA, <i>t</i>-BuOAc, Ti(O<i>i-</i>Pr)<sub>3</sub>Cl, THF, −78 °C; (b) HCl, dioxane, 60 °C; (c) BH<sub>3</sub>, THF, 45 °C, 75% in 3 steps; (d) BzNCS, DCM, 0 °C to rt; (e) Ghosez’s reagent, DCM, 0 °C to rt, 81% in 2 steps; (f) aq. H<sub>2</sub>SO<sub>4</sub>, 50 °C, 71%; (g) H<sub>2</sub>SO<sub>4</sub>, HNO<sub>3</sub>, 98%; (h) Fe, HCl, MeOH, 50 °C; (i) 5-cyanopicolinic acid, HCl, WSCD·HCl, MeOH, rt, 53% in 2 steps.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00841" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00841" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span>Alzheimer’s
Disease International.
World Alzheimer Report 2019. <a href="https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf" class="extLink">https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf</a> (accessed April 30, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Alzheimer%E2%80%99s%0ADisease+International.%0AWorld+Alzheimer+Report+2019.+https%3A%2F%2Fwww.alz.co.uk%2Fresearch%2FWorldAlzheimerReport2019.pdf+%28accessed+April+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span>Alzheimer’s Association.
2020 Alzheimer’s Disease Facts and Figures. <a href="https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf" class="extLink">https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf</a> (accessed April 30, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Alzheimer%E2%80%99s+Association.%0A2020+Alzheimer%E2%80%99s+Disease+Facts+and+Figures.+https%3A%2F%2Fwww.alz.org%2Fmedia%2FDocuments%2Falzheimers-facts-and-figures.pdf+%28accessed+April+30%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winblad, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amouyel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brayne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodaty, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cedazo-Minguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edvardsson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fratiglioni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisoni, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georges, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jönsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivipelto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangialasche, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rikkert, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakmar, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheltens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjernberg, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldemar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wimo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterberg, H.</span></span> <span> </span><span class="NLM_article-title">Defeating Alzheimer’s disease and other dementias: a priority for European science and society</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(16)00062-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2FS1474-4422%2816%2900062-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=26987701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A280%3ADC%252BC28fhsF2gsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=455-532&author=B.+Winbladauthor=P.+Amouyelauthor=S.+Andrieuauthor=C.+Ballardauthor=C.+Brayneauthor=H.+Brodatyauthor=A.+Cedazo-Minguezauthor=B.+Duboisauthor=D.+Edvardssonauthor=H.+Feldmanauthor=L.+Fratiglioniauthor=G.+B.+Frisoniauthor=S.+Gauthierauthor=J.+Georgesauthor=C.+Graffauthor=K.+Iqbalauthor=F.+Jessenauthor=G.+Johanssonauthor=L.+J%C3%B6nssonauthor=M.+Kivipeltoauthor=M.+Knappauthor=F.+Mangialascheauthor=R.+Melisauthor=A.+Nordbergauthor=M.+O.+Rikkertauthor=C.+Qiuauthor=T.+P.+Sakmarauthor=P.+Scheltensauthor=L.+S.+Schneiderauthor=R.+Sperlingauthor=L.+O.+Tjernbergauthor=G.+Waldemarauthor=A.+Wimoauthor=H.+Zetterberg&title=Defeating+Alzheimer%E2%80%99s+disease+and+other+dementias%3A+a+priority+for+European+science+and+society&doi=10.1016%2FS1474-4422%2816%2900062-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Defeating Alzheimer's disease and other dementias: a priority for European science and society</span></div><div class="casAuthors">Winblad Bengt; Amouyel Philippe; Andrieu Sandrine; Ballard Clive; Brayne Carol; Brodaty Henry; Cedazo-Minguez Angel; Johansson Gunilla; Jonsson Linus; Tjernberg Lars O; Wimo Anders; Dubois Bruno; Edvardsson David; Feldman Howard; Fratiglioni Laura; Mangialasche Francesca; Qiu Chengxuan; Frisoni Giovanni B; Gauthier Serge; Georges Jean; Graff Caroline; Iqbal Khalid; Jessen Frank; Kivipelto Miia; Knapp Martin; Melis Rene; Rikkert Marcel Olde; Nordberg Agneta; Sakmar Thomas P; Scheltens Philip; Schneider Lon S; Sperling Reisa; Waldemar Gunhild; Zetterberg Henrik</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-532</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQx4RT_lerTHq91pGlMMoT5fW6udTcc2eaxfJ-21JWDy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fhsF2gsQ%253D%253D&md5=c27e2804d324e1b44d4b5d8eb2a01dd8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2816%2900062-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252816%252900062-4%26sid%3Dliteratum%253Aachs%26aulast%3DWinblad%26aufirst%3DB.%26aulast%3DAmouyel%26aufirst%3DP.%26aulast%3DAndrieu%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DC.%26aulast%3DBrayne%26aufirst%3DC.%26aulast%3DBrodaty%26aufirst%3DH.%26aulast%3DCedazo-Minguez%26aufirst%3DA.%26aulast%3DDubois%26aufirst%3DB.%26aulast%3DEdvardsson%26aufirst%3DD.%26aulast%3DFeldman%26aufirst%3DH.%26aulast%3DFratiglioni%26aufirst%3DL.%26aulast%3DFrisoni%26aufirst%3DG.%2BB.%26aulast%3DGauthier%26aufirst%3DS.%26aulast%3DGeorges%26aufirst%3DJ.%26aulast%3DGraff%26aufirst%3DC.%26aulast%3DIqbal%26aufirst%3DK.%26aulast%3DJessen%26aufirst%3DF.%26aulast%3DJohansson%26aufirst%3DG.%26aulast%3DJ%25C3%25B6nsson%26aufirst%3DL.%26aulast%3DKivipelto%26aufirst%3DM.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DMangialasche%26aufirst%3DF.%26aulast%3DMelis%26aufirst%3DR.%26aulast%3DNordberg%26aufirst%3DA.%26aulast%3DRikkert%26aufirst%3DM.%2BO.%26aulast%3DQiu%26aufirst%3DC.%26aulast%3DSakmar%26aufirst%3DT.%2BP.%26aulast%3DScheltens%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DL.%2BS.%26aulast%3DSperling%26aufirst%3DR.%26aulast%3DTjernberg%26aufirst%3DL.%2BO.%26aulast%3DWaldemar%26aufirst%3DG.%26aulast%3DWimo%26aufirst%3DA.%26aulast%3DZetterberg%26aufirst%3DH.%26atitle%3DDefeating%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520other%2520dementias%253A%2520a%2520priority%2520for%2520European%2520science%2520and%2520society%26jtitle%3DLancet%2520Neurol.%26date%3D2016%26volume%3D15%26spage%3D455%26epage%3D532%26doi%3D10.1016%2FS1474-4422%2816%2900062-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benzinger, T. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazey, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santacruz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghetti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klunk, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDade, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossor, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span> <span> </span><span class="NLM_article-title">Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1202753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1056%2FNEJMoa1202753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=22784036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=795-804&author=R.+J.+Batemanauthor=C.+Xiongauthor=T.+L.+S.+Benzingerauthor=A.+M.+Faganauthor=A.+Goateauthor=N.+C.+Foxauthor=D.+S.+Marcusauthor=N.+J.+Cairnsauthor=X.+Xieauthor=T.+M.+Blazeyauthor=D.+M.+Holtzmanauthor=A.+Santacruzauthor=V.+Bucklesauthor=A.+Oliverauthor=K.+Moulderauthor=P.+S.+Aisenauthor=B.+Ghettiauthor=W.+E.+Klunkauthor=E.+McDadeauthor=R.+N.+Martinsauthor=C.+L.+Mastersauthor=R.+Mayeuxauthor=J.+M.+Ringmanauthor=M.+N.+Rossorauthor=P.+R.+Schofieldauthor=R.+A.+Sperlingauthor=S.+Sallowayauthor=J.+C.+Morris&title=Dominantly+Inherited+Alzheimer+Network.+Clinical+and+biomarker+changes+in+dominantly+inherited+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMoa1202753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and biomarker changes in dominantly inherited Alzheimer's disease</span></div><div class="casAuthors">Bateman, Randall J.; Xiong, Chengjie; Benzinger, Tammie L. S.; Fagan, Anne M.; Goate, Alison; Fox, Nick C.; Marcus, Daniel S.; Cairns, Nigel J.; Xie, Xianyun; Blazey, Tyler M.; Holtzman, David M.; Santacruz, Anna; Buckles, Virginia; Oliver, Angela; Moulder, Krista; Aisen, Paul S.; Ghetti, Bernardino; Klunk, William E.; McDade, Eric; Martins, Ralph N.; Masters, Colin L.; Mayeux, Richard; Ringman, John M.; Rossor, Martin N.; Schofield, Peter R.; Sperling, Reisa A.; Salloway, Stephen; Morris, John C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">795-804</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The order and magnitude of pathol. processes in Alzheimer's disease are not well understood, partly because the disease develops over many years.  Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to det. the sequence and magnitude of pathol. changes that culminate in symptomatic disease.  METHODS: In this prospective, longitudinal study, we analyzed data from 128 participants who underwent baseline clin. and cognitive assessments, brain imaging, and cerebrospinal fluid (CSF) and blood tests.  We used the participant's age at baseline assessment and the parent's age at the onset of symptoms of Alzheimer's disease to calc. the estd. years from expected symptom onset (age of the participant minus parent's age at symptom onset).  We conducted cross-sectional analyses of baseline data in relation to estd. years from expected symptom onset in order to det. the relative order and magnitude of pathophysiol. changes.  RESULTS: Concns. of amyloid-beta (Aβ)42 in the CSF appeared to decline 25 years before expected symptom onset.  Aβ deposition, as measured by positron-emission tomog. with the use of Pittsburgh compd. B, was detected 15 years before expected symptom onset.  Increased concns. of tau protein in the CSF and an increase in brain atrophy were detected 15 years before expected symptom onset.  Cerebral hypometabolism and impaired episodic memory were obsd. 10 years before expected symptom onset.  Global cognitive impairment, as measured by the Mini-Mental State Examn. and the Clin. Dementia Rating scale, was detected 5 years before expected symptom onset, and patients met diagnostic criteria for dementia at an av. of 3 years after expected symptom onset.  CONCLUSIONS: We found that autosomal dominant Alzheimer's disease was assocd. with a series of pathophysiol. changes over decades in CSF biochem. markers of Alzheimer's disease, brain amyloid deposition, and brain metab. as well as progressive cognitive impairment.  Our results require confirmation with the use of longitudinal data and may not apply to patients with sporadic Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptJNV9eDXBCLVg90H21EOLACvtfcHk0lgK0PzKLXfBjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktL7J&md5=c4f999ea3401af9651a2770724757bed</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1202753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1202753%26sid%3Dliteratum%253Aachs%26aulast%3DBateman%26aufirst%3DR.%2BJ.%26aulast%3DXiong%26aufirst%3DC.%26aulast%3DBenzinger%26aufirst%3DT.%2BL.%2BS.%26aulast%3DFagan%26aufirst%3DA.%2BM.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DFox%26aufirst%3DN.%2BC.%26aulast%3DMarcus%26aufirst%3DD.%2BS.%26aulast%3DCairns%26aufirst%3DN.%2BJ.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DBlazey%26aufirst%3DT.%2BM.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26aulast%3DSantacruz%26aufirst%3DA.%26aulast%3DBuckles%26aufirst%3DV.%26aulast%3DOliver%26aufirst%3DA.%26aulast%3DMoulder%26aufirst%3DK.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DGhetti%26aufirst%3DB.%26aulast%3DKlunk%26aufirst%3DW.%2BE.%26aulast%3DMcDade%26aufirst%3DE.%26aulast%3DMartins%26aufirst%3DR.%2BN.%26aulast%3DMasters%26aufirst%3DC.%2BL.%26aulast%3DMayeux%26aufirst%3DR.%26aulast%3DRingman%26aufirst%3DJ.%2BM.%26aulast%3DRossor%26aufirst%3DM.%2BN.%26aulast%3DSchofield%26aufirst%3DP.%2BR.%26aulast%3DSperling%26aufirst%3DR.%2BA.%26aulast%3DSalloway%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26atitle%3DDominantly%2520Inherited%2520Alzheimer%2520Network.%2520Clinical%2520and%2520biomarker%2520changes%2520in%2520dominantly%2520inherited%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D795%26epage%3D804%26doi%3D10.1056%2FNEJMoa1202753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span> <span> </span><span class="NLM_article-title">Targeting the β secretase BACE1 for Alzheimer’s disease therapy</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(13)70276-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2FS1474-4422%2813%2970276-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=24556009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1Cntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=319-329&author=R.+Yanauthor=R.+Vassar&title=Targeting+the+%CE%B2+secretase+BACE1+for+Alzheimer%E2%80%99s+disease+therapy&doi=10.1016%2FS1474-4422%2813%2970276-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the β secretase BACE1 for Alzheimer's disease therapy</span></div><div class="casAuthors">Yan, Riqiang; Vassar, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-329</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The β secretase, widely known as β-site amyloid precursor protein cleaving enzyme 1 (BACE1), initiates the prodn. of the toxic amyloid β (Aβ) that plays a crucial early part in Alzheimer's disease pathogenesis.  BACE1 is a prime therapeutic target for lowering cerebral Aβ concns. in Alzheimer's disease, and clin. development of BACE1 inhibitors is being intensely pursued.  Although BACE1 inhibitor drug development has proven challenging, several promising BACE1 inhibitors have recently entered human clin. trials.  The safety and efficacy of these drugs are being tested at present in healthy individuals and patients with Alzheimer's disease, and will soon be tested in individuals with presymptomatic Alzheimer's disease.  Although hopes are high that BACE1 inhibitors might be efficacious for the prevention or treatment of Alzheimer's disease, concerns have been raised about potential mechanism-based side-effects of these drugs.  The potential of therapeutic BACE1 inhibition might prove to be a watershed in the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8SsSfCAC6nbVg90H21EOLACvtfcHk0ljhOKc7ZBOCAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1Cntbo%253D&md5=11aeb06fee19cafc0b361e2c43900806</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2813%2970276-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252813%252970276-X%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26aulast%3DVassar%26aufirst%3DR.%26atitle%3DTargeting%2520the%2520%25CE%25B2%2520secretase%2520BACE1%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520therapy%26jtitle%3DLancet%2520Neurol.%26date%3D2014%26volume%3D13%26spage%3D319%26epage%3D329%26doi%3D10.1016%2FS1474-4422%2813%2970276-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snaedal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulem, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudbjartsson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhangale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttenlocher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsdottir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreassen, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jönsson, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palotie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, K.</span></span> <span> </span><span class="NLM_article-title">A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>488</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1038/nature11283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1038%2Fnature11283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=22801501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2012&pages=96-99&author=T.+Jonssonauthor=J.+K.+Atwalauthor=S.+Steinbergauthor=J.+Snaedalauthor=P.+V.+Jonssonauthor=S.+Bjornssonauthor=H.+Stefanssonauthor=P.+Sulemauthor=D.+Gudbjartssonauthor=J.+Maloneyauthor=K.+Hoyteauthor=A.+Gustafsonauthor=Y.+Liuauthor=Y.+Luauthor=T.+Bhangaleauthor=R.+R.+Grahamauthor=J.+Huttenlocherauthor=G.+Bjornsdottirauthor=O.+A.+Andreassenauthor=E.+G.+J%C3%B6nssonauthor=A.+Palotieauthor=T.+W.+Behrensauthor=O.+T.+Magnussonauthor=A.+Kongauthor=U.+Thorsteinsdottirauthor=R.+J.+Wattsauthor=K.+Stefansson&title=A+mutation+in+APP+protects+against+Alzheimer%E2%80%99s+disease+and+age-related+cognitive+decline&doi=10.1038%2Fnature11283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A mutation in APP protects against Alzheimer's disease and age-related cognitive decline</span></div><div class="casAuthors">Jonsson, Thorlakur; Atwal, Jasvinder K.; Steinberg, Stacy; Snaedal, Jon; Jonsson, Palmi V.; Bjornsson, Sigurbjorn; Stefansson, Hreinn; Sulem, Patrick; Gudbjartsson, Daniel; Maloney, Janice; Hoyte, Kwame; Gustafson, Amy; Liu, Yichin; Lu, Yanmei; Bhangale, Tushar; Graham, Robert R.; Huttenlocher, Johanna; Bjornsdottir, Gyda; Andreassen, Ole A.; Joensson, Erik G.; Palotie, Aarno; Behrens, Timothy W.; Magnusson, Olafur T.; Kong, Augustine; Thorsteinsdottir, Unnur; Watts, Ryan J.; Stefansson, Kari</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">488</span>
        (<span class="NLM_cas:issue">7409</span>),
    <span class="NLM_cas:pages">96-99</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The prevalence of dementia in the Western world in people over the age of 60 has been estd. to be greater than 5%, about two-thirds of which are due to Alzheimer's disease.  The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3).  Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1795 Icelanders.  We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease.  This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approx. 40% redn. in the formation of amyloidogenic peptides in vitro.  The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease.  Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4AFwQCLRQOLVg90H21EOLACvtfcHk0lhmSv4Jw2xhuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73M&md5=4db9cb2e3842d5a9d4af4ce102249b70</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature11283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11283%26sid%3Dliteratum%253Aachs%26aulast%3DJonsson%26aufirst%3DT.%26aulast%3DAtwal%26aufirst%3DJ.%2BK.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DSnaedal%26aufirst%3DJ.%26aulast%3DJonsson%26aufirst%3DP.%2BV.%26aulast%3DBjornsson%26aufirst%3DS.%26aulast%3DStefansson%26aufirst%3DH.%26aulast%3DSulem%26aufirst%3DP.%26aulast%3DGudbjartsson%26aufirst%3DD.%26aulast%3DMaloney%26aufirst%3DJ.%26aulast%3DHoyte%26aufirst%3DK.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DBhangale%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DR.%2BR.%26aulast%3DHuttenlocher%26aufirst%3DJ.%26aulast%3DBjornsdottir%26aufirst%3DG.%26aulast%3DAndreassen%26aufirst%3DO.%2BA.%26aulast%3DJ%25C3%25B6nsson%26aufirst%3DE.%2BG.%26aulast%3DPalotie%26aufirst%3DA.%26aulast%3DBehrens%26aufirst%3DT.%2BW.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DKong%26aufirst%3DA.%26aulast%3DThorsteinsdottir%26aufirst%3DU.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26aulast%3DStefansson%26aufirst%3DK.%26atitle%3DA%2520mutation%2520in%2520APP%2520protects%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520age-related%2520cognitive%2520decline%26jtitle%3DNature%26date%3D2012%26volume%3D488%26spage%3D96%26epage%3D99%26doi%3D10.1038%2Fnature11283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Oehlrich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prokopcova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span> <span> </span><span class="NLM_article-title">The evolution of amidine-based brain penetrant BACE1 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2033</span>– <span class="NLM_lpage">2045</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2Fj.bmcl.2014.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=24704031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvVSqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2033-2045&author=D.+Oehlrichauthor=H.+Prokopcovaauthor=H.+J.+M.+Gijsen&title=The+evolution+of+amidine-based+brain+penetrant+BACE1+inhibitors&doi=10.1016%2Fj.bmcl.2014.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of amidine-based brain penetrant BACE1 inhibitors</span></div><div class="casAuthors">Oehlrich, Daniel; Prokopcova, Hana; Gijsen, Harrie J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2033-2045</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Beta site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors hold great potential as disease modifying anti-Alzheimer's drugs.  This digest provides an overview of the amidine contg. class of BACE1 inhibitors, of which multiple examples are now progressing through clin. trials.  The various structural modifications highlight the struggle to combine potency with the optimal properties for a brain penetrant BACE1 inhibitor, and illustrate the crowded competitive landscape.  This overview concludes with a summary of potential issues including substrate and target selectivity and a synopsis of the status of the current and past clin. assets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-4h1WxzUvbbVg90H21EOLACvtfcHk0lhmSv4Jw2xhuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvVSqsrY%253D&md5=a929f7f1be0c7d2ff1a10fc5853de06b</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DOehlrich%26aufirst%3DD.%26aulast%3DProkopcova%26aufirst%3DH.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26atitle%3DThe%2520evolution%2520of%2520amidine-based%2520brain%2520penetrant%2520BACE1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2033%26epage%3D2045%26doi%3D10.1016%2Fj.bmcl.2014.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span>; <span class="NLM_string-name">Gijsen, H. J. M.</span></span> <span> </span><span class="NLM_article-title">Targeting β-secretase (BACE) for the Treatment of Alzheimer’s Disease</span>. In  <i>Comprehensive Medicinal Chemistry III</i>, <span class="NLM_edition">3</span>rd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Chackalamannil, S.</span>, <span class="NLM_string-name">Rotella, D. P.</span>, <span class="NLM_string-name">Ward, S. E.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Oxford</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">7</span>, pp  <span class="NLM_fpage">326</span>– <span class="NLM_lpage">383</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2FB978-0-12-409547-2.13809-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=326-383&author=A.+Hall&author=H.+J.+M.+Gijsenauthor=S.+Chackalamannil&author=D.+P.+Rotella&author=S.+E.+Ward&title=Comprehensive+Medicinal+Chemistry+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-409547-2.13809-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-409547-2.13809-0%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DA.%26atitle%3DTargeting%2520%25CE%25B2-secretase%2520%2528BACE%2529%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26btitle%3DComprehensive%2520Medicinal%2520Chemistry%2520III%26aulast%3DChackalamannil%26aufirst%3DS.%26pub%3DElsevier%26date%3D2017%26volume%3D7%26spage%3D326%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rombouts, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span> <span> </span><span class="NLM_article-title">New evolutions in the BACE1 inhibitor field from 2014 to 2018</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">777</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2Fj.bmcl.2018.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=30709653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=761-777&author=C.-C.+Hsiaoauthor=F.+Romboutsauthor=H.+J.+M.+Gijsen&title=New+evolutions+in+the+BACE1+inhibitor+field+from+2014+to+2018&doi=10.1016%2Fj.bmcl.2018.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">New evolutions in the BACE1 inhibitor field from 2014 to 2018</span></div><div class="casAuthors">Hsiao, Chien-Chi; Rombouts, Frederik; Gijsen, Harrie J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">761-777</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors offer the potential of disease-modifying treatment for Alzheimer's disease (AD).  Since 2014, major breakthroughs have appeared in the field of BACE1 inhibitors.  This review provides an overview of amidine-based BACE1 inhibitors between 2014 and 2018.  Herein are summarized (i) the structure-activity relationship, (ii) the physiol. results and (iii) the potential risks from a lack of selectivity.  This review also summarizes clin. scope, results and outlook of the compds. that have been or are currently under development in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3OfI_B-BJ-LVg90H21EOLACvtfcHk0lhmSv4Jw2xhuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCmu7s%253D&md5=049eda6ce97b31a04b5b579afd3e11e5</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DHsiao%26aufirst%3DC.-C.%26aulast%3DRombouts%26aufirst%3DF.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26atitle%3DNew%2520evolutions%2520in%2520the%2520BACE1%2520inhibitor%2520field%2520from%25202014%2520to%25202018%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D761%26epage%3D777%26doi%3D10.1016%2Fj.bmcl.2018.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osswald, H. L.</span></span> <span> </span><span class="NLM_article-title">BACE1 (β-secretase) inhibitors for the treatment of Alzheimer’s disease</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">6765</span>– <span class="NLM_lpage">6813</span>, <span class="refDoi"> DOI: 10.1039/C3CS60460H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1039%2FC3CS60460H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=24691405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2mt7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=6765-6813&author=A.+K.+Ghoshauthor=H.+L.+Osswald&title=BACE1+%28%CE%B2-secretase%29+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1039%2FC3CS60460H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7dR"><div class="casContent"><span class="casTitleNuber">7d</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Ghosh, Arun K.; Osswald, Heather L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6765-6813</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">BACE1 (β-secretase, memapsin 2, Asp2) has emerged as a promising target for the treatment of Alzheimer's disease.  BACE1 is an aspartic protease which functions in the first step of the pathway leading to the prodn. and deposition of amyloid-β peptide (Aβ).  Its gene deletion showed only mild phenotypes.  BACE1 inhibition has direct implications in the Alzheimer's disease pathol. without largely affecting viability.  However, inhibiting BACE1 selectively in vivo has presented many challenges to medicinal chemists.  Since its identification in 2000, inhibitors covering many different structural classes have been designed and developed.  These inhibitors can be largely classified as either peptidomimetic or non-peptidic inhibitors.  Progress in these fields resulted in inhibitors that contain many targeted drug-like characteristics.  In this review, we describe structure-based design strategies and evolution of a wide range of BACE1 inhibitors including compds. that have been shown to reduce brain Aβ, rescue the cognitive decline in transgenic AD mice and inhibitor drug candidates that are currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri59_pgGAbxLVg90H21EOLACvtfcHk0lgfIbyytjX_8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2mt7nJ&md5=dab445bf7efb6fdc0c80e032d3bb0071</span></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1039%2FC3CS60460H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC3CS60460H%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DOsswald%26aufirst%3DH.%2BL.%26atitle%3DBACE1%2520%2528%25CE%25B2-secretase%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2014%26volume%3D43%26spage%3D6765%26epage%3D6813%26doi%3D10.1039%2FC3CS60460H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeever, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillard, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. B.</span></span> <span> </span><span class="NLM_article-title">Structure based design of β-site APP cleaving enzyme 1 (BACE) inhibitors for the treatment of Alzheimer’s disease. disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4156</span>– <span class="NLM_lpage">4180</span>, <span class="refDoi"> DOI: 10.1021/jm301659n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301659n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKgtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4156-4180&author=J.+Yuanauthor=S.+Venkatramanauthor=Y.+Zhengauthor=B.+M.+McKeeverauthor=L.+W.+Dillardauthor=S.+B.+Singh&title=Structure+based+design+of+%CE%B2-site+APP+cleaving+enzyme+1+%28BACE%29+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease.+disease&doi=10.1021%2Fjm301659n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7eR"><div class="casContent"><span class="casTitleNuber">7e</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of β-Site APP Cleaving Enzyme 1 (BACE1) Inhibitors for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Yuan, Jing; Venkatraman, Shankar; Zheng, Yajun; McKeever, Brian M.; Dillard, Lawrence W.; Singh, Suresh B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4156-4180</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The amyloid hypothesis asserts that excess prodn. or reduced clearance of the amyloid-β (Aβ) peptides in the brain initiates a sequence of events that ultimately lead to Alzheimer's disease dementia.  The Aβ hypothesis has identified BACE1 as a therapeutic target to treat Alzheimer's and led to medicinal chem. efforts to design its inhibitors both in the pharmaceutical industry and in academia.  This review summarizes two distinct categories of inhibitors designed based on conformational states of "closed" and "open" forms of the enzyme.  In each category the inhibitors are classified based on the core catalytic interaction group or the aspartyl binding motif (ABM).  This review covers the description of inhibitors in each ABM class with X-ray crystal structures of key compds., their binding modes, related structure-activity data highlighting potency advances, and addnl. properties such as selectivity profile, P-gp efflux, pharmacokinetic, and pharmacodynamic data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRLs7KN_eIzbVg90H21EOLACvtfcHk0lgfIbyytjX_8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKgtr0%253D&md5=b703f57572b737b47658d86f5b730087</span></div><a href="/servlet/linkout?suffix=cit7e&amp;dbid=16384&amp;doi=10.1021%2Fjm301659n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301659n%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DMcKeever%26aufirst%3DB.%2BM.%26aulast%3DDillard%26aufirst%3DL.%2BW.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DStructure%2520based%2520design%2520of%2520%25CE%25B2-site%2520APP%2520cleaving%2520enzyme%25201%2520%2528BACE%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease.%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4156%26epage%3D4180%26doi%3D10.1021%2Fjm301659n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rombouts, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span> <span> </span><span class="NLM_article-title">Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1080/13543776.2021.1832463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1080%2F13543776.2021.1832463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=33006491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FmsVyltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2021&pages=25-52&author=F.+Romboutsauthor=K.-I.+Kusakabeauthor=C.-C.+Hsiaoauthor=H.+J.+M.+Gijsen&title=Small-molecule+BACE1+inhibitors%3A+a+patent+literature+review+%282011+to+2020%29&doi=10.1080%2F13543776.2021.1832463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7fR"><div class="casContent"><span class="casTitleNuber">7f</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)</span></div><div class="casAuthors">Rombouts Frederik; Hsiao Chien-Chi; Gijsen Harrie J M; Kusakabe Ken-Ichi</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on therapeutic patents</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Inhibition of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) has been extensively pursued as potential disease-modifying treatment for Alzheimer's disease (AD).  Clinical failures with BACE inhibitors have progressively raised the bar forever cleaner candidates with reduced cardiovascular liability, toxicity risk, and increased selectivity over cathepsin D (CatD) and BACE2.  AREAS COVERED:  This review provides an overview of patented BACE1 inhibitors between 2011 and 2020 per pharmaceutical company or research group and highlights the progress that was made in dialing out toxicity liabilities.  EXPERT OPINION:  Despite an increasingly crowded IP situation, significant progress was made using highly complex chemistry in avoiding toxicity liabilities, with BACE1/BACE2 selectivity being the most remarkable achievement.  However, clinical trial data suggest on-target toxicity is likely a contributing factor, which implies the only potential future of BACE1 inhibitors lies in careful titration of highly selective compounds in early populations where the amyloid burden is still minimal as prophylactic therapy, or as an affordable oral maintenance therapy following amyloid-clearing therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRr9NKN_f1WVVm8bhe6roZYfW6udTcc2ea3E3qrZUj6LLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FmsVyltg%253D%253D&md5=e7bc2b32c79cebbb2ab82259fa139b73</span></div><a href="/servlet/linkout?suffix=cit7f&amp;dbid=16384&amp;doi=10.1080%2F13543776.2021.1832463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2021.1832463%26sid%3Dliteratum%253Aachs%26aulast%3DRombouts%26aufirst%3DF.%26aulast%3DKusakabe%26aufirst%3DK.-I.%26aulast%3DHsiao%26aufirst%3DC.-C.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26atitle%3DSmall-molecule%2520BACE1%2520inhibitors%253A%2520a%2520patent%2520literature%2520review%2520%25282011%2520to%25202020%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2021%26volume%3D31%26spage%3D25%26epage%3D52%26doi%3D10.1080%2F13543776.2021.1832463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Timmers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Broeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramael, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slemmon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Waepenaert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieltjes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelborghs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercken, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Nueten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tritsmans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streffer, J. R.</span></span> <span> </span><span class="NLM_article-title">Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor</span>. <i>Alzheimers Dement (N Y)</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">212</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=201-212&author=M.+Timmersauthor=B.+Van+Broeckauthor=S.+Ramaelauthor=J.+Slemmonauthor=K.+De+Waepenaertauthor=A.+Russuauthor=J.+Bogertauthor=H.+Stieltjesauthor=L.+M.+Shawauthor=S.+Engelborghsauthor=D.+Moecharsauthor=M.+Merckenauthor=E.+Liuauthor=V.+Sinhaauthor=J.+Kempauthor=L.+Van+Nuetenauthor=L.+Tritsmansauthor=J.+R.+Streffer&title=Profiling+the+dynamics+of+CSF+and+plasma+A%CE%B2+reduction+after+treatment+with+JNJ-54861911%2C+a+potent+oral+BACE+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTimmers%26aufirst%3DM.%26aulast%3DVan%2BBroeck%26aufirst%3DB.%26aulast%3DRamael%26aufirst%3DS.%26aulast%3DSlemmon%26aufirst%3DJ.%26aulast%3DDe%2BWaepenaert%26aufirst%3DK.%26aulast%3DRussu%26aufirst%3DA.%26aulast%3DBogert%26aufirst%3DJ.%26aulast%3DStieltjes%26aufirst%3DH.%26aulast%3DShaw%26aufirst%3DL.%2BM.%26aulast%3DEngelborghs%26aufirst%3DS.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DMercken%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DSinha%26aufirst%3DV.%26aulast%3DKemp%26aufirst%3DJ.%26aulast%3DVan%2BNueten%26aufirst%3DL.%26aulast%3DTritsmans%26aufirst%3DL.%26aulast%3DStreffer%26aufirst%3DJ.%2BR.%26atitle%3DProfiling%2520the%2520dynamics%2520of%2520CSF%2520and%2520plasma%2520A%25CE%25B2%2520reduction%2520after%2520treatment%2520with%2520JNJ-54861911%252C%2520a%2520potent%2520oral%2520BACE%2520inhibitor%26jtitle%3DAlzheimers%2520Dement%2520%2528N%2520Y%2529%26date%3D2016%26volume%3D2%26spage%3D201%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Timmers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streffer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominaga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiraishi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatikola, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smekens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borjesson-Hanson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreasen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matias-Guiu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baquero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesseur, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tritsmans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Nueten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelborghs, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study</span>. <i>Alzheimer’s Res. Ther</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">85/1</span>– <span class="NLM_lpage">85/18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1186%2Fs13195-018-0415-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=85%2F1-85%2F18&author=M.+Timmersauthor=J.+R.+Strefferauthor=A.+Russuauthor=Y.+Tominagaauthor=H.+Shimizuauthor=A.+Shiraishiauthor=K.+Tatikolaauthor=P.+Smekensauthor=A.+Borjesson-Hansonauthor=N.+Andreasenauthor=J.+Matias-Guiuauthor=M.+Baqueroauthor=M.+Boadaauthor=I.+Tesseurauthor=L.+Tritsmansauthor=L.+Van+Nuetenauthor=S.+Engelborghs&title=Pharmacodynamics+of+atabecestat+%28JNJ-54861911%29%2C+an+oral+BACE1+inhibitor+in+patients+with+early+Alzheimer%E2%80%99s+disease%3A+randomized%2C+double-blind%2C+placebo-controlled+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1186%2Fs13195-018-0415-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13195-018-0415-6%26sid%3Dliteratum%253Aachs%26aulast%3DTimmers%26aufirst%3DM.%26aulast%3DStreffer%26aufirst%3DJ.%2BR.%26aulast%3DRussu%26aufirst%3DA.%26aulast%3DTominaga%26aufirst%3DY.%26aulast%3DShimizu%26aufirst%3DH.%26aulast%3DShiraishi%26aufirst%3DA.%26aulast%3DTatikola%26aufirst%3DK.%26aulast%3DSmekens%26aufirst%3DP.%26aulast%3DBorjesson-Hanson%26aufirst%3DA.%26aulast%3DAndreasen%26aufirst%3DN.%26aulast%3DMatias-Guiu%26aufirst%3DJ.%26aulast%3DBaquero%26aufirst%3DM.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DTesseur%26aufirst%3DI.%26aulast%3DTritsmans%26aufirst%3DL.%26aulast%3DVan%2BNueten%26aufirst%3DL.%26aulast%3DEngelborghs%26aufirst%3DS.%26atitle%3DPharmacodynamics%2520of%2520atabecestat%2520%2528JNJ-54861911%2529%252C%2520an%2520oral%2520BACE1%2520inhibitor%2520in%2520patients%2520with%2520early%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther%26date%3D2018%26volume%3D10%26spage%3D85%252F1%26epage%3D85%252F18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, G.</span></span> <span> </span><span class="NLM_article-title">Preliminary results of a trial of atabecestat in preclinical Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1485</span>, <span class="refDoi"> DOI: 10.1056/NEJMc1813435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1056%2FNEJMc1813435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=30970197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FjvFGqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=1483-1485&author=D.+Henleyauthor=N.+Raghavanauthor=R.+Sperlingauthor=P.+Aisenauthor=R.+Ramanauthor=G.+Romano&title=Preliminary+results+of+a+trial+of+atabecestat+in+preclinical+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMc1813435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease</span></div><div class="casAuthors">Henley David; Raghavan Nandini; Sperling Reisa; Aisen Paul; Raman Rema; Romano Gary</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1483-1485</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfD9bI0ZsheHELvajU9pjPfW6udTcc2ebjMkviHkMNtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FjvFGqtg%253D%253D&md5=42b37561fb1b3bd8102b7ba3ba64d588</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1813435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1813435%26sid%3Dliteratum%253Aachs%26aulast%3DHenley%26aufirst%3DD.%26aulast%3DRaghavan%26aufirst%3DN.%26aulast%3DSperling%26aufirst%3DR.%26aulast%3DAisen%26aufirst%3DP.%26aulast%3DRaman%26aufirst%3DR.%26aulast%3DRomano%26aufirst%3DG.%26atitle%3DPreliminary%2520results%2520of%2520a%2520trial%2520of%2520atabecestat%2520in%2520preclinical%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D1483%26epage%3D1485%26doi%3D10.1056%2FNEJMc1813435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streffer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brashear, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesseur, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tritsmans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Nueten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelborghs, S.</span></span> <span> </span><span class="NLM_article-title">Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study</span>. <i>Alzheimer's Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">58</span>, <span class="refDoi"> DOI: 10.1186/s13195-020-00614-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1186%2Fs13195-020-00614-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptlKgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=58&author=G.+Novakauthor=J.+R.+Strefferauthor=M.+Timmersauthor=D.+Henleyauthor=H.+R.+Brashearauthor=J.+Bogertauthor=A.+Russuauthor=L.+Janssensauthor=I.+Tesseurauthor=L.+Tritsmansauthor=L.+Van+Nuetenauthor=S.+Engelborghs&title=Long-term+safety+and+tolerability+of+atabecestat+%28JNJ-54861911%29%2C+an+oral+BACE1+inhibitor%2C+in+early+Alzheimer%E2%80%99s+disease+spectrum+patients%3A+a+randomized%2C+double-blind%2C+placebo-controlled+study+and+a+two-period+extension+study&doi=10.1186%2Fs13195-020-00614-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8dR"><div class="casContent"><span class="casTitleNuber">8d</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study</span></div><div class="casAuthors">Novak, Gerald; Streffer, Johannes Rolf; Timmers, Maarten; Henley, David; Brashear, H. Robert; Bogert, Jennifer; Russu, Alberto; Janssens, Luc; Tesseur, Ina; Tritsmans, Luc; Van Nueten, Luc; Engelborghs, Sebastiaan</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's Research & Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58</span>CODEN:
                <span class="NLM_cas:coden">ARTLCD</span>;
        ISSN:<span class="NLM_cas:issn">1758-9193</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Long-term safety and effect of atabecestat on cognitive performance in participants with pre-dementia AD in two phase 2 studies were assessed.  In placebo-controlled double-blind parent ALZ2002 study, participants aged 50 to 85 years were randomized to placebo or atabecestat 10 or 50 mg once daily for 6 mo.  Participants entered ALZ2004, 12-mo treatment extension with placebo or atabecestat 10 or 25 mg, followed by open-label phase.  Safety, changes in CSF biomarker levels, brain vol., and effects on cognitive performance were assessed.  Results: Of 114 participants randomized in ALZ2002, 99 completed, 90 entered ALZ2004 double-blind phase and 77 progressed to open-label phase.  CSF Aβ fragments and sAPPβ were reduced dose-proportionately.  Decreases in whole brain and hippocampal vols. were greater in participants with mild cognitive impairment due to AD than in preclin. AD, but were not affected by treatment.  In ALZ2004, change from baseline in RBANS trended toward worse scores for atabecestat vs. placebo.  Elevated liver enzyme adverse events reported in 12 participants on atabecestat resulted in dosage modification and increased frequency of safety monitoring.  Treatment discontinuation normalized ALT or AST in all except one with pretreatment elevation, which remained mildly elevated.  No case met ALT/AST > 3x ULN and total bilirubin > 2x ULN.  Conclusion: Atabecestat was assocd. with trend toward declines in cognition, and elevation of liver enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2u7CJgya_lLVg90H21EOLACvtfcHk0liyrcnk-JBBHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptlKgsr8%253D&md5=5e091a6f701db4bf4464d0e2b8eebba3</span></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=10.1186%2Fs13195-020-00614-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13195-020-00614-5%26sid%3Dliteratum%253Aachs%26aulast%3DNovak%26aufirst%3DG.%26aulast%3DStreffer%26aufirst%3DJ.%2BR.%26aulast%3DTimmers%26aufirst%3DM.%26aulast%3DHenley%26aufirst%3DD.%26aulast%3DBrashear%26aufirst%3DH.%2BR.%26aulast%3DBogert%26aufirst%3DJ.%26aulast%3DRussu%26aufirst%3DA.%26aulast%3DJanssens%26aufirst%3DL.%26aulast%3DTesseur%26aufirst%3DI.%26aulast%3DTritsmans%26aufirst%3DL.%26aulast%3DVan%2BNueten%26aufirst%3DL.%26aulast%3DEngelborghs%26aufirst%3DS.%26atitle%3DLong-term%2520safety%2520and%2520tolerability%2520of%2520atabecestat%2520%2528JNJ-54861911%2529%252C%2520an%2520oral%2520BACE1%2520inhibitor%252C%2520in%2520early%2520Alzheimer%25E2%2580%2599s%2520disease%2520spectrum%2520patients%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%2520and%2520a%2520two-period%2520extension%2520study%26jtitle%3DAlzheimer%2527s%2520Res.%2520Ther.%26date%3D2020%26volume%3D12%26spage%3D58%26doi%3D10.1186%2Fs13195-020-00614-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martenyi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBell, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calligaro, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span> <span> </span><span class="NLM_article-title">Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">16507</span>– <span class="NLM_lpage">16516</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.3647-11.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1523%2FJNEUROSCI.3647-11.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=22090477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFaksL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=16507-16516&author=P.+C.+Mayauthor=R.+A.+Deanauthor=S.+L.+Loweauthor=F.+Martenyiauthor=S.+M.+Sheehanauthor=L.+N.+Boggsauthor=S.+A.+Monkauthor=B.+M.+Mathesauthor=D.+J.+Mergottauthor=B.+M.+Watsonauthor=S.+L.+Stoutauthor=D.+E.+Timmauthor=E.+S.+LaBellauthor=C.+R.+Gonzalesauthor=M.+Nakanoauthor=S.+S.+Jheeauthor=M.+Yenauthor=L.+Ereshefskyauthor=T.+D.+Lindstromauthor=D.+O.+Calligaroauthor=P.+J.+Cockeauthor=D.+G.+Hallauthor=S.+Friedrichauthor=M.+Citronauthor=J.+E.+Audia&title=Robust+central+reduction+of+amyloid-%CE%B2+in+humans+with+an+orally+available%2C+non-peptidic+%CE%B2-secretase+inhibitor&doi=10.1523%2FJNEUROSCI.3647-11.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor</span></div><div class="casAuthors">May, Patrick C.; Dean, Robert A.; Lowe, Stephen L.; Martenyi, Ferenc; Sheehan, Scott M.; Boggs, Leonard N.; Monk, Scott A.; Mathes, Brian M.; Mergott, Dustin J.; Watson, Brian M.; Stout, Stephanie L.; Timm, David E.; LaBell, Elizabeth Smith; Gonzales, Celedon R.; Nakano, Masako; Jhee, Stanford S.; Yen, Mark; Ereshefsky, Larry; Lindstrom, Terry D.; Calligaro, David O.; Cocke, Patrick J.; Hall, D. Greg; Friedrich, Stuart; Citron, Martin; Audia, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">16507-16516</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">According to the amyloid cascade hypothesis, cerebral deposition of amyloid-β peptide (Aβ) is crit. for Alzheimer's disease (AD) pathogenesis.  Aβ generation is initiated when β-secretase (BACE1) cleaves the amyloid precursor protein.  For more than a decade, BACE1 has been a prime target for designing drugs to prevent or treat AD.  However, development of such agents has turned out to be extremely challenging, with major hurdles in cell penetration, oral bioavailability/metabolic clearance, and brain access.  Using a fragment-based chem. strategy, we have generated LY2811376 [(S)-4-(2,4-difluoro-5-pyrimidin-5-yl-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]thiazin-2-ylamine], the first orally available non-peptidic BACE1 inhibitor that produces profound Aβ-lowering effects in animals.  The biomarker changes obtained in preclin. animal models translate into man at doses of LY2811376 that were safe and well tolerated in healthy volunteers.  Prominent and long-lasting Aβ redns. in lumbar CSF were measured after oral dosing of 30 or 90 mg of LY2811376.  This represents the first translation of BACE1-driven biomarker changes in CNS from preclin. animal models to man.  Because of toxicol. findings identified in longer-term preclin. studies, this compd. is no longer progressing in clin. development.  However, BACE1 remains a viable target because the adverse effects reported here were recapitulated in LY2811376-treated BACE1 KO mice and thus are unrelated to BACE1 inhibition.  The magnitude and duration of central Aβ redn. obtainable with BACE1 inhibition positions this protease as a tractable small-mol. target through which to test the amyloid hypothesis in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqns_TvT2bZrVg90H21EOLACvtfcHk0lhwwmNLijth0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFaksL7F&md5=8f21f91ebd77e5fcf8b58b51c73a1a6b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3647-11.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3647-11.2011%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DP.%2BC.%26aulast%3DDean%26aufirst%3DR.%2BA.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DMartenyi%26aufirst%3DF.%26aulast%3DSheehan%26aufirst%3DS.%2BM.%26aulast%3DBoggs%26aufirst%3DL.%2BN.%26aulast%3DMonk%26aufirst%3DS.%2BA.%26aulast%3DMathes%26aufirst%3DB.%2BM.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26aulast%3DWatson%26aufirst%3DB.%2BM.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DTimm%26aufirst%3DD.%2BE.%26aulast%3DLaBell%26aufirst%3DE.%2BS.%26aulast%3DGonzales%26aufirst%3DC.%2BR.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DJhee%26aufirst%3DS.%2BS.%26aulast%3DYen%26aufirst%3DM.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DLindstrom%26aufirst%3DT.%2BD.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DCocke%26aufirst%3DP.%2BJ.%26aulast%3DHall%26aufirst%3DD.%2BG.%26aulast%3DFriedrich%26aufirst%3DS.%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26atitle%3DRobust%2520central%2520reduction%2520of%2520amyloid-%25CE%25B2%2520in%2520humans%2520with%2520an%2520orally%2520available%252C%2520non-peptidic%2520%25CE%25B2-secretase%2520inhibitor%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26spage%3D16507%26epage%3D16516%26doi%3D10.1523%2FJNEUROSCI.3647-11.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">May, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borders, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brier, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calligaro, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevorkyan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komjathy, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martenyi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaught, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winneroski, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D. J.</span></span> <span> </span><span class="NLM_article-title">The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1210</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4129-14.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1523%2FJNEUROSCI.4129-14.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=25609634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Oit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1199-1210&author=P.+C.+Mayauthor=B.+A.+Willisauthor=S.+L.+Loweauthor=R.+A.+Deanauthor=S.+A.+Monkauthor=P.+J.+Cockeauthor=J.+E.+Audiaauthor=L.+N.+Boggsauthor=A.+R.+Bordersauthor=R.+A.+Brierauthor=D.+O.+Calligaroauthor=T.+A.+Dayauthor=L.+Ereshefskyauthor=J.+A.+Ericksonauthor=H.+Gevorkyanauthor=C.+R.+Gonzalesauthor=D.+E.+Jamesauthor=S.+S.+Jheeauthor=S.+F.+Komjathyauthor=L.+Liauthor=T.+D.+Lindstromauthor=B.+M.+Mathesauthor=F.+Martenyiauthor=S.+M.+Sheehanauthor=S.+L.+Stoutauthor=D.+E.+Timmauthor=G.+M.+Vaughtauthor=B.+M.+Watsonauthor=L.+L.+Winneroskiauthor=Z.+Yangauthor=D.+J.+Mergott&title=The+potent+BACE1+inhibitor+LY2886721+elicits+robust+central+A%CE%B2+pharmacodynamic+responses+in+mice%2C+dogs%2C+and+humans&doi=10.1523%2FJNEUROSCI.4129-14.2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans</span></div><div class="casAuthors">May, Patrick C.; Willis, Brian A.; Lowe, Stephen L.; Dean, Robert A.; Monk, Scott A.; Cocke, Patrick J.; Audia, James E.; Boggs, Leonard N.; Borders, Anthony R.; Brier, Richard A.; Calligaro, David O.; Day, Theresa A.; Ereshefsky, Larry; Erickso, Jon A.; Gevorkyan, Hykop; Gonzales, Celedon R.; James, Douglas E.; Jhee, Stanford S.; Komjathy, Steven F.; Li, Linglin; Lindstrom, Terry D.; Mathe, Brian M.; Martenyi, Ferenc; Sheehan, Scott M.; Stout, Stephanie L.; Timm, David E.; Vaught, Grant M.; Watson, Brian M.; Winneroski, Leonard L.; Yang, Zhixiang; Mergott, Dustin J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1199-1210, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD).  Therefore, the development of potent and selective inhibitors of BACE1 has been a focus of many drug discovery efforts in academia and industry.  Herein, we report the nonclin. and early clin. development of LY2886721, a BACE1 active site inhibitor that reached phase 2 clin. trials in AD.  LY2886721 has high selectivity against key off-target proteases, which efficiently translates in vitro activity into robust in vivo amyloid β lowering in nonclin. animal models.  Similar potent and persistent amyloid β lowering was obsd. in plasma and lumbar CSF when single and multiple doses of LY2886721 were administered to healthy human subjects.  Collectively, these data add support for BACE1 inhibition as an effective means of amyloid lowering and as an attractive target for potential disease modification therapy in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDDFLhcsiUDLVg90H21EOLACvtfcHk0lhgg9_FvMuyUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Oit78%253D&md5=7e16cc00767a8af4da7dd17b6e40e8f5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4129-14.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4129-14.2015%26sid%3Dliteratum%253Aachs%26aulast%3DMay%26aufirst%3DP.%2BC.%26aulast%3DWillis%26aufirst%3DB.%2BA.%26aulast%3DLowe%26aufirst%3DS.%2BL.%26aulast%3DDean%26aufirst%3DR.%2BA.%26aulast%3DMonk%26aufirst%3DS.%2BA.%26aulast%3DCocke%26aufirst%3DP.%2BJ.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DBoggs%26aufirst%3DL.%2BN.%26aulast%3DBorders%26aufirst%3DA.%2BR.%26aulast%3DBrier%26aufirst%3DR.%2BA.%26aulast%3DCalligaro%26aufirst%3DD.%2BO.%26aulast%3DDay%26aufirst%3DT.%2BA.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DErickson%26aufirst%3DJ.%2BA.%26aulast%3DGevorkyan%26aufirst%3DH.%26aulast%3DGonzales%26aufirst%3DC.%2BR.%26aulast%3DJames%26aufirst%3DD.%2BE.%26aulast%3DJhee%26aufirst%3DS.%2BS.%26aulast%3DKomjathy%26aufirst%3DS.%2BF.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLindstrom%26aufirst%3DT.%2BD.%26aulast%3DMathes%26aufirst%3DB.%2BM.%26aulast%3DMartenyi%26aufirst%3DF.%26aulast%3DSheehan%26aufirst%3DS.%2BM.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DTimm%26aufirst%3DD.%2BE.%26aulast%3DVaught%26aufirst%3DG.%2BM.%26aulast%3DWatson%26aufirst%3DB.%2BM.%26aulast%3DWinneroski%26aufirst%3DL.%2BL.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMergott%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520potent%2520BACE1%2520inhibitor%2520LY2886721%2520elicits%2520robust%2520central%2520A%25CE%25B2%2520pharmacodynamic%2520responses%2520in%2520mice%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DJ.%2520Neurosci.%26date%3D2015%26volume%3D35%26spage%3D1199%26epage%3D1210%26doi%3D10.1523%2FJNEUROSCI.4129-14.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mergott, D.</span>; <span class="NLM_string-name">Audia, J.</span>; <span class="NLM_string-name">Barberis, M.</span>; <span class="NLM_string-name">Beck, J.</span>; <span class="NLM_string-name">Boggs, L.</span>; <span class="NLM_string-name">Boyer, R.</span>; <span class="NLM_string-name">Brier, R.</span>; <span class="NLM_string-name">Borders, A.</span>; <span class="NLM_string-name">Daugherty, L.</span>; <span class="NLM_string-name">Dean, R.</span>; <span class="NLM_string-name">Ereshefsky, L.</span>; <span class="NLM_string-name">Erickson, J.</span>; <span class="NLM_string-name">Garcia-Losada, P.</span>; <span class="NLM_string-name">Gevorkyan, H.</span>; <span class="NLM_string-name">Green, S.</span>; <span class="NLM_string-name">Hembre, E.</span>; <span class="NLM_string-name">Irizarry, M.</span>; <span class="NLM_string-name">James, D.</span>; <span class="NLM_string-name">Jhee, S.</span>; <span class="NLM_string-name">Lin, Q.</span>; <span class="NLM_string-name">Lopez, J.</span>; <span class="NLM_string-name">Lo, A.</span>; <span class="NLM_string-name">Lowe, S.</span>; <span class="NLM_string-name">Mathes, B.</span>; <span class="NLM_string-name">May, P.</span>; <span class="NLM_string-name">McKinzie, D.</span>; <span class="NLM_string-name">Monk, S.</span>; <span class="NLM_string-name">Nakano, M.</span>; <span class="NLM_string-name">Porter, W.</span>; <span class="NLM_string-name">Shi, Y.</span>; <span class="NLM_string-name">Stout, S.</span>; <span class="NLM_string-name">Timm, D.</span>; <span class="NLM_string-name">Watson, B.</span>; <span class="NLM_string-name">Willis, B.</span>; <span class="NLM_string-name">Winneroski, L.</span>; <span class="NLM_string-name">Yang, Z.</span>; <span class="NLM_string-name">Zimmer, J.</span></span> <span> </span><span class="NLM_article-title">Discovery, Structure Disclosure, and Early Clinical Development of LY3202626, a Low-Dose, CNS-penetrant BACE Inhibitor</span>.  <i>Abstracts of Papers</i>; <span class="NLM_publisher-name">256th ACS National Meeting & Exposition</span>, <span class="NLM_publisher-loc">Boston, MA, United States</span>, August 19–23, <span class="NLM_year">2018</span>.  <span class="NLM_fpage">MEDI-330</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=MEDI-330&author=D.+Mergott&author=J.+Audia&author=M.+Barberis&author=J.+Beck&author=L.+Boggs&author=R.+Boyer&author=R.+Brier&author=A.+Borders&author=L.+Daugherty&author=R.+Dean&author=L.+Ereshefsky&author=J.+Erickson&author=P.+Garcia-Losada&author=H.+Gevorkyan&author=S.+Green&author=E.+Hembre&author=M.+Irizarry&author=D.+James&author=S.+Jhee&author=Q.+Lin&author=J.+Lopez&author=A.+Lo&author=S.+Lowe&author=B.+Mathes&author=P.+May&author=D.+McKinzie&author=S.+Monk&author=M.+Nakano&author=W.+Porter&author=Y.+Shi&author=S.+Stout&author=D.+Timm&author=B.+Watson&author=B.+Willis&author=L.+Winneroski&author=Z.+Yang&author=J.+Zimmer&title=Discovery%2C+Structure+Disclosure%2C+and+Early+Clinical+Development+of+LY3202626%2C+a+Low-Dose%2C+CNS-penetrant+BACE+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMergott%26aufirst%3DD.%26atitle%3DDiscovery%252C%2520Structure%2520Disclosure%252C%2520and%2520Early%2520Clinical%2520Development%2520of%2520LY3202626%252C%2520a%2520Low-Dose%252C%2520CNS-penetrant%2520BACE%2520Inhibitor%26jtitle%3DAbstracts%2520of%2520Papers%26pub%3D256th%2520ACS%2520National%2520Meeting%2520%2526%2520Exposition%26date%3D2018%26spage%3DMEDI-330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunskill, A. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iserloh, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazakevich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meredith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misiaszek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossiter, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-8931)–A β-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10435</span>– <span class="NLM_lpage">10450</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00307</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00307" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKnsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10435-10450&author=J.+D.+Scottauthor=S.+W.+Liauthor=A.+P.+J.+Brunskillauthor=X.+Chenauthor=K.+Coxauthor=J.+N.+Cummingauthor=M.+Formanauthor=E.+J.+Gilbertauthor=R.+A.+Hodgsonauthor=L.+A.+Hydeauthor=Q.+Jiangauthor=U.+Iserlohauthor=I.+Kazakevichauthor=R.+Kuvelkarauthor=H.+Meiauthor=J.+Meredithauthor=J.+Misiaszekauthor=P.+Orthauthor=L.+M.+Rossiterauthor=M.+Slaterauthor=J.+Stoneauthor=C.+O.+Stricklandauthor=J.+H.+Voigtauthor=G.+Wangauthor=H.+Wangauthor=Y.+Wuauthor=W.+J.+Greenleeauthor=E.+M.+Parkerauthor=M.+E.+Kennedyauthor=A.+W.+Stamford&title=Discovery+of+the+3-imino-1%2C2%2C4-thiadiazinane+1%2C1-dioxide+derivative+verubecestat+%28MK-8931%29%E2%80%93A+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+1+inhibitor+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.6b00307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Scott, Jack D.; Li, Sarah W.; Brunskill, Andrew P. J.; Chen, Xia; Cox, Kathleen; Cumming, Jared N.; Forman, Mark; Gilbert, Eric J.; Hodgson, Robert A.; Hyde, Lynn A.; Jiang, Qin; Iserloh, Ulrich; Kazakevich, Irina; Kuvelkar, Reshma; Mei, Hong; Meredith, John; Misiaszek, Jeffrey; Orth, Peter; Rossiter, Lana M.; Slater, Meagan; Stone, Julie; Strickland, Corey O.; Voigt, Johannes H.; Wang, Ganfeng; Wang, Hongwu; Wu, Yusheng; Greenlee, William J.; Parker, Eric M.; Kennedy, Matthew E.; Stamford, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10435-10450</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Verubecestat (MK-8931), a diaryl amide substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide deriv., is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clin. evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease.  Although not selective over the closely related aspartyl protease BACE2, verubecesat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain Aβ levels in rats and nonhuman primates, and CSF Aβ levels in humans.  In this annotation, the authors describe the discovery of verubecesat, including design, validation, and selected SAR around the novel iminothiadiazinane dioxide core, as well as aspects of its preclin. and Phase 1 clin. characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpN5wdoirs8rVg90H21EOLACvtfcHk0lhgg9_FvMuyUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKnsLnI&md5=517155e2d4f186261b1451ff4556a621</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00307%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DBrunskill%26aufirst%3DA.%2BP.%2BJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DForman%26aufirst%3DM.%26aulast%3DGilbert%26aufirst%3DE.%2BJ.%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DIserloh%26aufirst%3DU.%26aulast%3DKazakevich%26aufirst%3DI.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DMeredith%26aufirst%3DJ.%26aulast%3DMisiaszek%26aufirst%3DJ.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DRossiter%26aufirst%3DL.%2BM.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DStone%26aufirst%3DJ.%26aulast%3DStrickland%26aufirst%3DC.%2BO.%26aulast%3DVoigt%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26atitle%3DDiscovery%2520of%2520the%25203-imino-1%252C2%252C4-thiadiazinane%25201%252C1-dioxide%2520derivative%2520verubecestat%2520%2528MK-8931%2529%25E2%2580%2593A%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10435%26epage%3D10450%26doi%3D10.1021%2Facs.jmedchem.6b00307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dockendorf, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleijn, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palcza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troyer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, M. S.</span></span> <span> </span><span class="NLM_article-title">The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra150</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aad9704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1126%2Fscitranslmed.aad9704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=27807285" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra150&author=M.+E.+Kennedyauthor=X.+Chenauthor=R.+A.+Hodgsonauthor=L.+A.+Hydeauthor=R.+Kuvelkarauthor=E.+M.+Parkerauthor=A.+W.+Stamfordauthor=J.+N.+Cummingauthor=W.+Liauthor=J.+D.+Scottauthor=K.+Coxauthor=M.+F.+Dockendorfauthor=H.+J.+Kleijnauthor=H.+Meiauthor=J.+A.+Stoneauthor=M.+Eganauthor=L.+Ereshefskyauthor=S.+Jheeauthor=B.+A.+Mattsonauthor=J.+Palczaauthor=M.+Tanenauthor=M.+D.+Troyerauthor=J.+L.+Tsengauthor=M.+S.+Forman&title=The+BACE1+inhibitor+verubecestat+%28MK-8931%29+reduces+CNS+%CE%B2-amyloid+in+animal+models+and+in+Alzheimer%E2%80%99s+disease+patients&doi=10.1126%2Fscitranslmed.aad9704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aad9704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aad9704%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DDockendorf%26aufirst%3DM.%2BF.%26aulast%3DKleijn%26aufirst%3DH.%2BJ.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DStone%26aufirst%3DJ.%2BA.%26aulast%3DEgan%26aufirst%3DM.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DJhee%26aufirst%3DS.%26aulast%3DMattson%26aufirst%3DB.%2BA.%26aulast%3DPalcza%26aufirst%3DJ.%26aulast%3DTanen%26aufirst%3DM.%26aulast%3DTroyer%26aufirst%3DM.%2BD.%26aulast%3DTseng%26aufirst%3DJ.%2BL.%26aulast%3DForman%26aufirst%3DM.%2BS.%26atitle%3DThe%2520BACE1%2520inhibitor%2520verubecestat%2520%2528MK-8931%2529%2520reduces%2520CNS%2520%25CE%25B2-amyloid%2520in%2520animal%2520models%2520and%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520patients%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra150%26doi%3D10.1126%2Fscitranslmed.aad9704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span>; <span class="NLM_string-name">Scott, J. D.</span>; <span class="NLM_string-name">Strickland, C. O.</span></span> <span> </span><span class="NLM_article-title">Verubecestat</span>. In  <i>Comprehensive Medicinal Chemistry III</i>, <span class="NLM_edition">3</span>rd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Chackalamannil, S.</span>, <span class="NLM_string-name">Rotella, D. P.</span>, <span class="NLM_string-name">Ward, S. E.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Oxford</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">8</span>, pp  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">251</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=204-251&author=J.+N.+Cumming&author=J.+D.+Scott&author=C.+O.+Stricklandauthor=S.+Chackalamannil&author=D.+P.+Rotella&author=S.+E.+Ward&title=Comprehensive+Medicinal+Chemistry+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26atitle%3DVerubecestat%26btitle%3DComprehensive%2520Medicinal%2520Chemistry%2520III%26aulast%3DChackalamannil%26aufirst%3DS.%26pub%3DElsevier%26date%3D2017%26volume%3D8%26spage%3D204%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kost, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozley, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, D.</span></span> <span> </span><span class="NLM_article-title">Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">1691</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1706441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1056%2FNEJMoa1706441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=29719179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFyqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1691-1703&author=M.+F.+Eganauthor=J.+Kostauthor=P.+N.+Tariotauthor=P.+S.+Aisenauthor=J.+L.+Cummingsauthor=B.+Vellasauthor=C.+Surauthor=Y.+Mukaiauthor=T.+Vossauthor=C.+Furtekauthor=E.+Mahoneyauthor=L.+H.+Mozleyauthor=R.+Vandenbergheauthor=Y.+Moauthor=D.+Michelson&title=Randomized+trial+of+verubecestat+for+mild-to-moderate+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMoa1706441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease</span></div><div class="casAuthors">Egan, Michael F.; Kost, James; Tariot, Pierre N.; Aisen, Paul S.; Cummings, Jeffrey L.; Vellas, Bruno; Sur, Cyrille; Mukai, Yuki; Voss, Tiffini; Furtek, Christine; Mahoney, Erin; Mozley, Lyn Harper; Vandenberghe, Rik; Mo, Yi; Michelson, David</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1691-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Alzheimer's disease is characterized by the deposition of amyloid-beta (Aβ) plaques in the brain.  Aβ is produced from the sequential cleavage of amyloid precursor protein by β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) followed by γ-secretase.  Verubecestat is an oral BACE-1 inhibitor that reduces the Aβ level in the cerebrospinal fluid of patients with Alzheimer's disease.  Methods: We conducted a randomized, double-blind, placebo-controlled, 78-wk trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had a clin. diagnosis of mild-to-moderate Alzheimer's disease.  The coprimary outcomes were the change from baseline to week 78 in the score on the cognitive subscale of the Alzheimer's disease Assessment Scale (ADAS-cog; scores range from 0 to 70, with higher scores indicating worse dementia) and in the score on the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory scale (ADCS-ADL; scores range from 0 to 78, with lower scores indicating worse function).  Results: A total of 1958 patients underwent randomization; 653 were randomly assigned to receive verubecestat at a dose of 12 mg per day (the 12-mg group), 652 to receive verubecestat at a dose of 40 mg per day (the 40-mg group), and 653 to receive matching placebo.  The trial was terminated early for futility 50 mo after onset, which was within 5 mo before its scheduled completion, and after enrollment of the planned 1958 patients was complete.  The estd. mean change from baseline to week 78 in the ADAS-cog score was 7.9 in the 12-mg group, 8.0 in the 40-mg group, and 7.7 in the placebo group (P = 0.63 for the comparison between the 12-mg group and the placebo group and P = 0.46 for the comparison between the 40-mg group and the placebo group).  The estd. mean change from baseline to week 78 in the ADCS-ADL score was -8.4 in the 12-mg group, -8.2 in the 40-mg group, and -8.9 in the placebo group (P = 0.49 for the comparison between the 12-mg group and the placebo group and P = 0.32 for the comparison between the 40-mg group and the placebo group).  Adverse events, including rash, falls and injuries, sleep disturbance, suicidal ideation, wt. loss, and hair-color change, were more common in the verubecestat groups than in the placebo group. conclusions Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was assocd. with treatment-related adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroW5Tf-VIj2LVg90H21EOLACvtfcHk0ljhfMBthXxJEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFyqsbs%253D&md5=e6ecfbd2981616b343468ae8bed1db2d</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706441%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DKost%26aufirst%3DJ.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DCummings%26aufirst%3DJ.%2BL.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DMukai%26aufirst%3DY.%26aulast%3DVoss%26aufirst%3DT.%26aulast%3DFurtek%26aufirst%3DC.%26aulast%3DMahoney%26aufirst%3DE.%26aulast%3DMozley%26aufirst%3DL.%2BH.%26aulast%3DVandenberghe%26aufirst%3DR.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DMichelson%26aufirst%3DD.%26atitle%3DRandomized%2520trial%2520of%2520verubecestat%2520for%2520mild-to-moderate%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D1691%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1706441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kost, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dyck, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozley, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, D.</span></span> <span> </span><span class="NLM_article-title">Randomized trial of verubecestat for prodromal Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">1408</span>– <span class="NLM_lpage">1420</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1812840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1056%2FNEJMoa1812840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=30970186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotFehtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=1408-1420&author=M.+F.+Eganauthor=J.+Kostauthor=T.+Vossauthor=Y.+Mukaiauthor=P.+S.+Aisenauthor=J.+L.+Cummingsauthor=P.+N.+Tariotauthor=B.+Vellasauthor=C.+H.+van+Dyckauthor=M.+Boadaauthor=Y.+Zhangauthor=W.+Liauthor=C.+Furtekauthor=E.+Mahoneyauthor=L.+H.+Mozleyauthor=Y.+Moauthor=C.+Surauthor=D.+Michelson&title=Randomized+trial+of+verubecestat+for+prodromal+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMoa1812840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12eR"><div class="casContent"><span class="casTitleNuber">12e</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of verubecestat for prodromal Alzheimer's disease</span></div><div class="casAuthors">Egan, Michael F.; Kost, James; Voss, Tiffini; Mukai, Yuki; Aisen, Paul S.; Cummings, Jeffrey L.; Tariot, Pierre N.; Vellas, Bruno; van Dyck, Christopher H.; Boada, Merce; Zhang, Ying; Li, Wen; Furtek, Christine; Mahoney, Erin; Mozley, Lyn Harper; Mo, Yi; Sur, Cyrille; Michelson, David</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1408-1420</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia.  Verubecestat is an orally administered β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor that blocks prodn. of amyloid-beta (Aβ).  The drug did not prevent clin. progression in a trial involving patients with mild-to-moderate dementia due to Alzheimer's disease. methods We conducted a randomized, double-blind, placebo-controlled, 104-wk trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had memory impairment and elevated brain amyloid levels but whose condition did not meet the case definition of dementia.  The primary outcome was the change from baseline to week 104 in the score on the Clin. Dementia Rating Scale-Sum of Boxes (CDR-SB; scores range from 0 to 18, with higher scores indicating worse cognition and daily function).  Secondary outcomes included other assessments of cognition and daily function. results The trial was terminated for futility after 1454 patients had been enrolled; 485 had been assigned to receive verubecestat at a dose of 12 mg per day (the 12-mg group), 484 to receive verubecestat at a dose of 40 mg per day (the 40-mg group), and 485 to receive placebo.  A total of 234 patients, 231 patients, and 239 patients per group, resp., completed 104 wk of the trial regimen.  The estd. mean change from baseline to week 104 in the CDR-SB score was 1.65 in the 12-mg group, 2.02 in the 40-mg group, and 1.58 in the placebo group (P = 0.67 for the comparison between the 12-mg group and the placebo group and P = 0.01 for the comparison between the 40-mg group and the placebo group), suggesting a worse outcome in the higher-dose group than in the placebo group.  The estd. rate of progression to dementia due to Alzheimer's disease was 24.5, 25.5, and 19.3 events per 100 patient-years in the 12-mg group, the 40-mg group, and the placebo group, resp. (hazard ratio for 40 mg vs. placebo, 1.38; 97.51% confidence interval, 1.07 to 1.79, not adjusted for multiple comparisons), favoring placebo.  Adverse events were more common in the verubecestat groups than in the placebo group. conclusions Verubecestat did not improve clin. ratings of dementia among patients with prodromal Alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who received placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2_0d9EBVvSrVg90H21EOLACvtfcHk0ljZMZ-k8By-pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotFehtrY%253D&md5=4f46fb485bfbd366eca939d40a7ee873</span></div><a href="/servlet/linkout?suffix=cit12e&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1812840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1812840%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DKost%26aufirst%3DJ.%26aulast%3DVoss%26aufirst%3DT.%26aulast%3DMukai%26aufirst%3DY.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DCummings%26aufirst%3DJ.%2BL.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3Dvan%2BDyck%26aufirst%3DC.%2BH.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DFurtek%26aufirst%3DC.%26aulast%3DMahoney%26aufirst%3DE.%26aulast%3DMozley%26aufirst%3DL.%2BH.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DMichelson%26aufirst%3DD.%26atitle%3DRandomized%2520trial%2520of%2520verubecestat%2520for%2520prodromal%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D1408%26epage%3D1420%26doi%3D10.1056%2FNEJMoa1812840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Eketjall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspersson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogstedt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeppsson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falting, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeberlein, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugler, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebers, G.</span></span> <span> </span><span class="NLM_article-title">AZD3293: A novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.3233/JAD-150834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.3233%2FJAD-150834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=26890753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A280%3ADC%252BC28jhvFWqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2016&pages=1109-1123&author=S.+Eketjallauthor=J.+Jansonauthor=K.+Kasperssonauthor=A.+Bogstedtauthor=F.+Jeppssonauthor=J.+Faltingauthor=S.+B.+Haeberleinauthor=A.+R.+Kuglerauthor=R.+C.+Alexanderauthor=G.+Cebers&title=AZD3293%3A+A+novel%2C+orally+active+BACE1+inhibitor+with+high+potency+and+permeability+and+markedly+slow+off-rate+kinetics&doi=10.3233%2FJAD-150834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics</span></div><div class="casAuthors">Eketjall Susanna; Janson Juliette; Bogstedt Anna; Eketjall Susanna; Janson Juliette; Bogstedt Anna; Kaspersson Karin; Jeppsson Fredrik; Falting Johanna; Jeppsson Fredrik; Haeberlein Samantha Budd; Kugler Alan R; Alexander Robert C; Cebers Gvido</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease : JAD</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1109-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A growing body of pathological, biomarker, genetic, and mechanistic data suggests that amyloid accumulation, as a result of changes in production, processing, and/or clearance of brain amyloid-β peptide (Aβ) concentrations, plays a key role in the pathogenesis of Alzheimer's disease (AD).  Beta-secretase 1 (BACE1) mediates the first step in the processing of amyloid-β protein precursor (AβPP) to Aβ peptides, with the soluble N terminal fragment of AβPP (sAβPPβ) as a direct product, and BACE1 inhibition is an attractive target for therapeutic intervention to reduce the production of Aβ.  Here, we report the in vitro and in vivo pharmacological profile of AZD3293, a potent, highly permeable, orally active, blood-brain barrier (BBB) penetrating, BACE1 inhibitor with unique slow off-rate kinetics.  The in vitro potency of AZD3293 was demonstrated in several cellular models, including primary cortical neurons.  In vivo in mice, guinea pigs, and dogs, AZD3293 displayed significant dose- and time-dependent reductions in plasma, cerebrospinal fluid, and brain concentrations of Aβ40, Aβ42, and sAβPPβ.  The in vitro potency of AZD3293 in mouse and guinea pig primary cortical neuronal cells was correlated to the in vivo potency expressed as free AZD3293 concentrations in mouse and guinea pig brains.  In mice and dogs, the slow off-rate from BACE1 may have translated into a prolongation of the observed effect beyond the turnover rate of Aβ.  The preclinical data strongly support the clinical development of AZD3293, and patients with AD are currently being recruited into a combined Phase 2/3 study to test the disease-modifying properties of AZD3293.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8YDBirvcLa6qcneEtCi92fW6udTcc2eZpA7Ih4PSn2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jhvFWqtA%253D%253D&md5=afb144f0247c7dd1ecf2ccd8bebcafa4</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.3233%2FJAD-150834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-150834%26sid%3Dliteratum%253Aachs%26aulast%3DEketjall%26aufirst%3DS.%26aulast%3DJanson%26aufirst%3DJ.%26aulast%3DKaspersson%26aufirst%3DK.%26aulast%3DBogstedt%26aufirst%3DA.%26aulast%3DJeppsson%26aufirst%3DF.%26aulast%3DFalting%26aufirst%3DJ.%26aulast%3DHaeberlein%26aufirst%3DS.%2BB.%26aulast%3DKugler%26aufirst%3DA.%2BR.%26aulast%3DAlexander%26aufirst%3DR.%2BC.%26aulast%3DCebers%26aufirst%3DG.%26atitle%3DAZD3293%253A%2520A%2520novel%252C%2520orally%2520active%2520BACE1%2520inhibitor%2520with%2520high%2520potency%2520and%2520permeability%2520and%2520markedly%2520slow%2520off-rate%2520kinetics%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2016%26volume%3D50%26spage%3D1109%26epage%3D1123%26doi%3D10.3233%2FJAD-150834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selzler, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bragg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krull, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shcherbinin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shering, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacSweeney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, J. R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials</span>. <i>JAMA Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1001/jamaneurol.2019.3988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1001%2Fjamaneurol.2019.3988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=31764959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A280%3ADC%252BB3MfivFehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2020&pages=199-209&author=A.+M.+Wesselsauthor=P.+N.+Tariotauthor=J.+A.+Zimmerauthor=K.+J.+Selzlerauthor=S.+M.+Braggauthor=S.+W.+Andersenauthor=J.+Landryauthor=J.+H.+Krullauthor=A.+M.+Downingauthor=B.+A.+Willisauthor=S.+Shcherbininauthor=J.+Mullenauthor=P.+Barkerauthor=J.+Schumiauthor=C.+Sheringauthor=B.+R.+Matthewsauthor=R.+A.+Sternauthor=B.+Vellasauthor=S.+Cohenauthor=E.+MacSweeneyauthor=M.+Boadaauthor=J.+R.+Sims&title=Efficacy+and+safety+of+lanabecestat+for+treatment+of+early+and+mild+Alzheimer+disease%3A+The+AMARANTH+and+DAYBREAK-ALZ+randomized+clinical+trials&doi=10.1001%2Fjamaneurol.2019.3988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials</span></div><div class="casAuthors">Wessels Alette M; Zimmer Jennifer A; Selzler Katherine J; Bragg Sonja M; Andersen Scott W; Landry John; Krull James H; Downing AnnCatherine M; Willis Brian A; Shcherbinin Sergey; Matthews Brandy R; Sims John R; Tariot Pierre N; Mullen Jamie; Barker Peter; Schumi Jennifer; Shering Craig; Mullen Jamie; Stern Robert A; Vellas Bruno; Cohen Sharon; MacSweeney Emer; Boada Merce; Boada Merce</div><div class="citationInfo"><span class="NLM_cas:title">JAMA neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-209</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Alzheimer disease (AD) is a neurodegenerative disorder characterized by cognitive deterioration and impaired activities of daily living.  Current treatments provide only minor symptomatic improvements with limited benefit duration.  Lanabecestat, a brain-permeable inhibitor of human beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1/β-secretase), was developed to modify the clinical course of AD by slowing disease progression.  Objective:  To assess whether lanabecestat slows the progression of AD compared with placebo in patients with early AD (mild cognitive impairment) and mild AD dementia.  Design, Setting, and Participants:  AMARANTH (first patient visit on September 30, 2014; last patient visit on October 4, 2018) and DAYBREAK-ALZ (first patient visit on July 1, 2016; last patient visit on September 28, 2018) were randomized, placebo-controlled, phase 2/3 and phase 3 clinical trials lasting 104 weeks and 78 weeks, respectively.  AMARANTH and DAYBREAK-ALZ were multicenter, global, double-blind studies conducted at 257 and 251 centers, respectively, located in 15 and 18 countries or territories, respectively.  A population-based sample of men and women aged 55 to 85 years who met National Institute on Aging-Alzheimer's Association criteria for early AD or mild AD dementia was screened using cognitive assessments, and the presence of amyloid was confirmed.  Patients were excluded for unstable medical conditions or medication use, significant cerebrovascular pathologic findings, or a history of vitiligo and/or current evidence of postinflammatory hypopigmentation.  AMARANTH screened 6871 patients; 2218 (32.3%) were randomized, and 539 patients completed the study.  DAYBREAK-ALZ screened 5706 patients; 1722 (30.2%) were randomized, and 76 patients completed the study.  Interventions:  Patients were randomized (1:1:1) to once-daily oral doses of lanabecestat (20 mg), lanabecestat (50 mg), or placebo.  Main Outcomes and Measures:  The primary outcome measure was change from baseline on the 13-item Alzheimer Disease Assessment Scale-cognitive subscale.  Secondary outcomes included Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory, Clinical Dementia Rating, Functional Activities Questionnaire, Mini-Mental State Examination, and Neuropsychiatric Inventory.  Efficacy analyses were conducted on the intent-to-treat population.  Results:  Among 2218 AMARANTH patients, the mean (SD) age was 71.3 (7.1) years, and 1177 of 2218 (53.1%) were women.  Among 1722 DAYBREAK-ALZ patients, the mean (SD) age was 72.3 (7.0) years, and 1023 of 1722 (59.4%) were women.  Both studies were terminated early after futility analysis.  There were no consistent, reproducible dose-related findings on primary or secondary efficacy measures.  Psychiatric adverse events, weight loss, and hair color changes were reported in a higher percentage of patients receiving lanabecestat than placebo.  Conclusions and Relevance:  Treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline.  Trial Registration:  ClinicalTrials.gov identifiers: NCT02245737 and NCT02783573.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWiVGh1IBjdC86Js-BCLiifW6udTcc2eaSMl38BSsenbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfivFehug%253D%253D&md5=af37918a3575efef243bd58895bcdb78</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1001%2Fjamaneurol.2019.3988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaneurol.2019.3988%26sid%3Dliteratum%253Aachs%26aulast%3DWessels%26aufirst%3DA.%2BM.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DZimmer%26aufirst%3DJ.%2BA.%26aulast%3DSelzler%26aufirst%3DK.%2BJ.%26aulast%3DBragg%26aufirst%3DS.%2BM.%26aulast%3DAndersen%26aufirst%3DS.%2BW.%26aulast%3DLandry%26aufirst%3DJ.%26aulast%3DKrull%26aufirst%3DJ.%2BH.%26aulast%3DDowning%26aufirst%3DA.%2BM.%26aulast%3DWillis%26aufirst%3DB.%2BA.%26aulast%3DShcherbinin%26aufirst%3DS.%26aulast%3DMullen%26aufirst%3DJ.%26aulast%3DBarker%26aufirst%3DP.%26aulast%3DSchumi%26aufirst%3DJ.%26aulast%3DShering%26aufirst%3DC.%26aulast%3DMatthews%26aufirst%3DB.%2BR.%26aulast%3DStern%26aufirst%3DR.%2BA.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DMacSweeney%26aufirst%3DE.%26aulast%3DBoada%26aufirst%3DM.%26aulast%3DSims%26aufirst%3DJ.%2BR.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520lanabecestat%2520for%2520treatment%2520of%2520early%2520and%2520mild%2520Alzheimer%2520disease%253A%2520The%2520AMARANTH%2520and%2520DAYBREAK-ALZ%2520randomized%2520clinical%2520trials%26jtitle%3DJAMA%2520Neurol.%26date%3D2020%26volume%3D77%26spage%3D199%26epage%3D209%26doi%3D10.1001%2Fjamaneurol.2019.3988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> Alzforum. <a href="https://www.alzforum.org/therapeutics/elenbecestat" class="extLink">https://www.alzforum.org/therapeutics/elenbecestat</a> (accessed August 10, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Alzforum.+https%3A%2F%2Fwww.alzforum.org%2Ftherapeutics%2Felenbecestat+%28accessed+August+10%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span>; <span class="NLM_string-name">Motoki, T.</span>; <span class="NLM_string-name">Kaneko, T.</span>; <span class="NLM_string-name">Takaishi, M.</span>; <span class="NLM_string-name">Ishida, T.</span>; <span class="NLM_string-name">Takeda, K.</span>; <span class="NLM_string-name">Kita, Y.</span>; <span class="NLM_string-name">Yamamoto, N.</span>; <span class="NLM_string-name">Khan, A.</span>; <span class="NLM_string-name">Dimopoulos, P.</span></span> Preparation of Condensed Aminodihydrothiazine Derivatives as Inhibitors of β-Site APP-cleaving Enzyme 1 (BACE1). <span class="NLM_patent">WO 2009091016 A1</span>, July 23, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Suzuki%2C+Y.%3B+Motoki%2C+T.%3B+Kaneko%2C+T.%3B+Takaishi%2C+M.%3B+Ishida%2C+T.%3B+Takeda%2C+K.%3B+Kita%2C+Y.%3B+Yamamoto%2C+N.%3B+Khan%2C+A.%3B+Dimopoulos%2C+P.+Preparation+of+Condensed+Aminodihydrothiazine+Derivatives+as+Inhibitors+of+%CE%B2-Site+APP-cleaving+Enzyme+1+%28BACE1%29.+WO+2009091016+A1%2C+July+23%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DY.%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ufer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouzade-Dominguez, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huledal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lueoend, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueeger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tintelnot-Blomley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staufenbiel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimshek, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieauff, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubost, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avrameas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezous, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vormfelde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, A.</span></span> <span> </span><span class="NLM_article-title">Lopez Lopez, C. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer’s disease</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e9316</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.15252%2Femmm.201809316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=30224383" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=e9316&author=U.+Neumannauthor=M.+Uferauthor=L.+H.+Jacobsonauthor=M.-L.+Rouzade-Dominguezauthor=G.+Huledalauthor=C.+Kollyauthor=R.+M.+Lueoendauthor=R.+Machauerauthor=S.+J.+Veenstraauthor=K.+Hurthauthor=H.+Rueegerauthor=M.+Tintelnot-Blomleyauthor=M.+Staufenbielauthor=D.+R.+Shimshekauthor=L.+Perrotauthor=W.+Frieauffauthor=V.+Dubostauthor=H.+Schillerauthor=B.+Voggauthor=K.+Beltzauthor=A.+Avrameasauthor=S.+Kretzauthor=N.+Pezousauthor=J.+Rondeauauthor=N.+Beckmannauthor=A.+Hartmannauthor=S.+Vormfeldeauthor=O.+J.+Davidauthor=B.+Galliauthor=R.+Ramosauthor=A.+Graf&title=Lopez+Lopez%2C+C.+The+BACE-1+inhibitor+CNP520+for+prevention+trials+in+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.15252%2Femmm.201809316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201809316%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DU.%26aulast%3DUfer%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DL.%2BH.%26aulast%3DRouzade-Dominguez%26aufirst%3DM.-L.%26aulast%3DHuledal%26aufirst%3DG.%26aulast%3DKolly%26aufirst%3DC.%26aulast%3DLueoend%26aufirst%3DR.%2BM.%26aulast%3DMachauer%26aufirst%3DR.%26aulast%3DVeenstra%26aufirst%3DS.%2BJ.%26aulast%3DHurth%26aufirst%3DK.%26aulast%3DRueeger%26aufirst%3DH.%26aulast%3DTintelnot-Blomley%26aufirst%3DM.%26aulast%3DStaufenbiel%26aufirst%3DM.%26aulast%3DShimshek%26aufirst%3DD.%2BR.%26aulast%3DPerrot%26aufirst%3DL.%26aulast%3DFrieauff%26aufirst%3DW.%26aulast%3DDubost%26aufirst%3DV.%26aulast%3DSchiller%26aufirst%3DH.%26aulast%3DVogg%26aufirst%3DB.%26aulast%3DBeltz%26aufirst%3DK.%26aulast%3DAvrameas%26aufirst%3DA.%26aulast%3DKretz%26aufirst%3DS.%26aulast%3DPezous%26aufirst%3DN.%26aulast%3DRondeau%26aufirst%3DJ.%26aulast%3DBeckmann%26aufirst%3DN.%26aulast%3DHartmann%26aufirst%3DA.%26aulast%3DVormfelde%26aufirst%3DS.%26aulast%3DDavid%26aufirst%3DO.%2BJ.%26aulast%3DGalli%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DR.%26aulast%3DGraf%26aufirst%3DA.%26atitle%3DLopez%2520Lopez%252C%2520C.%2520The%2520BACE-1%2520inhibitor%2520CNP520%2520for%2520prevention%2520trials%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2018%26volume%3D10%26spage%3De9316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span> Alzforum. <a href="https://www.alzforum.org/therapeutics/umibecestat" class="extLink">https://www.alzforum.org/therapeutics/umibecestat</a> (accessed Aug 10, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Alzforum.+https%3A%2F%2Fwww.alzforum.org%2Ftherapeutics%2Fumibecestat+%28accessed+Aug+10%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hampel, H.</span>; <span class="NLM_string-name">Vassar, R.</span>; <span class="NLM_string-name">De Strooper, B.</span>; <span class="NLM_string-name">Hardy, J.</span>; <span class="NLM_string-name">Willem, M.</span>; <span class="NLM_string-name">Singh, N.</span>; <span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Yan, R.</span>; <span class="NLM_string-name">Vanmechelen, E.</span>; <span class="NLM_string-name">De Vos, A.</span>; <span class="NLM_string-name">Nistico, R.</span>; <span class="NLM_string-name">Corbo, M.</span>; <span class="NLM_string-name">Imbimbo, B. P.</span>; <span class="NLM_string-name">Streffer, J.</span>; <span class="NLM_string-name">Voytyuk, I.</span>; <span class="NLM_string-name">Timmers, M.</span>; <span class="NLM_string-name">Tahami Monfared, A. A.</span>, <span class="NLM_string-name">Irizarry, M.</span>; <span class="NLM_string-name">Albala, B.</span>; <span class="NLM_string-name">Koyama, A.</span>; <span class="NLM_string-name">Watanabe, N.</span>; <span class="NLM_string-name">Kimura, T.</span>; <span class="NLM_string-name">Yarenis, L.</span>; <span class="NLM_string-name">Lista, S.</span>; <span class="NLM_string-name">Kramer, L.</span>; <span class="NLM_string-name">Vergallo, A.</span></span> <span> </span><span class="NLM_article-title">The β-Secretase BACE1 in Alzheimer’s disease</span>.  <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2020</span><span class="refDoi"> DOI: 10.1016/j.biopsych.2020.02.001</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2Fj.biopsych.2020.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=32223911" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=H.+Hampel&author=R.+Vassar&author=B.+De+Strooper&author=J.+Hardy&author=M.+Willem&author=N.+Singh&author=J.+Zhou&author=R.+Yan&author=E.+Vanmechelen&author=A.+De+Vos&author=R.+Nistico&author=M.+Corbo&author=B.+P.+Imbimbo&author=J.+Streffer&author=I.+Voytyuk&author=M.+Timmers&author=A.+A.+Tahami+Monfared&author=M.+Irizarry&author=B.+Albala&author=A.+Koyama&author=N.+Watanabe&author=T.+Kimura&author=L.+Yarenis&author=S.+Lista&author=L.+Kramer&author=A.+Vergallo&title=The+%CE%B2-Secretase+BACE1+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.biopsych.2020.02.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2020.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2020.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DHampel%26aufirst%3DH.%26atitle%3DThe%2520%25CE%25B2-Secretase%2520BACE1%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBiol.%2520Psychiatry%26date%3D2020%26doi%3D10.1016%2Fj.biopsych.2020.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voytyuk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snellinx, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Loo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenthaler, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span> <span> </span><span class="NLM_article-title">BACE2 distribution in major brain cell types and identification of novel substrates</span>. <i>Life Sci. Alliance</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e201800026</span>, <span class="refDoi"> DOI: 10.26508/lsa.201800026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.26508%2Flsa.201800026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=30456346" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2018&pages=e201800026&author=I.+Voytyukauthor=S.+A.+Muellerauthor=J.+Herberauthor=A.+Snellinxauthor=D.+Moecharsauthor=G.+van+Looauthor=S.+F.+Lichtenthalerauthor=B.+De+Strooper&title=BACE2+distribution+in+major+brain+cell+types+and+identification+of+novel+substrates&doi=10.26508%2Flsa.201800026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.26508%2Flsa.201800026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.26508%252Flsa.201800026%26sid%3Dliteratum%253Aachs%26aulast%3DVoytyuk%26aufirst%3DI.%26aulast%3DMueller%26aufirst%3DS.%2BA.%26aulast%3DHerber%26aufirst%3DJ.%26aulast%3DSnellinx%26aufirst%3DA.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3Dvan%2BLoo%26aufirst%3DG.%26aulast%3DLichtenthaler%26aufirst%3DS.%2BF.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26atitle%3DBACE2%2520distribution%2520in%2520major%2520brain%2520cell%2520types%2520and%2520identification%2520of%2520novel%2520substrates%26jtitle%3DLife%2520Sci.%2520Alliance%26date%3D2018%26volume%3D1%26spage%3De201800026%26doi%3D10.26508%2Flsa.201800026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurose, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unemura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyajima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiroyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyabu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuyvetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghys, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iso, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.</span></span> <span> </span><span class="NLM_article-title">Rational design of novel 1,3-oxazine based β-secretase (BACE1) inhibitors: Incorporation of a double bond to reduce P-gp efflux leading to robust Aβ reduction in the brain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5122</span>– <span class="NLM_lpage">5137</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptVWhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5122-5137&author=K.+Fuchinoauthor=Y.+Mitsuokaauthor=M.+Masuiauthor=N.+Kuroseauthor=S.+Yoshidaauthor=K.+Komanoauthor=T.+Yamamotoauthor=M.+Ogawaauthor=C.+Unemuraauthor=M.+Hosonoauthor=H.+Itoauthor=G.+Sakaguchiauthor=S.+Andoauthor=S.+Ohnishiauthor=Y.+Kidoauthor=T.+Fukushimaauthor=H.+Miyajimaauthor=S.+Hiroyamaauthor=K.+Koyabuauthor=D.+Dhuyvetterauthor=H.+Borghysauthor=H.+J.M.+Gijsenauthor=Y.+Yamanoauthor=Y.+Isoauthor=K.+Kusakabe&title=Rational+design+of+novel+1%2C3-oxazine+based+%CE%B2-secretase+%28BACE1%29+inhibitors%3A+Incorporation+of+a+double+bond+to+reduce+P-gp+efflux+leading+to+robust+A%CE%B2+reduction+in+the+brain&doi=10.1021%2Facs.jmedchem.8b00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain</span></div><div class="casAuthors">Fuchino, Kouki; Mitsuoka, Yasunori; Masui, Moriyasu; Kurose, Noriyuki; Yoshida, Shuhei; Komano, Kazuo; Yamamoto, Takahiko; Ogawa, Masayoshi; Unemura, Chie; Hosono, Motoko; Ito, Hisanori; Sakaguchi, Gaku; Ando, Shigeru; Ohnishi, Shuichi; Kido, Yasuto; Fukushima, Tamio; Miyajima, Hirofumi; Hiroyama, Shuichi; Koyabu, Kiyotaka; Dhuyvetter, Deborah; Borghys, Herman; Gijsen, Harrie J. M.; Yamano, Yoshinori; Iso, Yasuyoshi; Kusakabe, Ken-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5122-5137</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Accumulation of Aβ peptides is a hallmark of Alzheimer's disease (AD) and is considered a causal factor in the pathogenesis of AD.  β-Secretase (BACE1) is a key enzyme responsible for producing Aβ peptides, and thus agents that inhibit BACE1 should be beneficial for disease-modifying treatment of AD.  Here we describe the discovery and optimization of novel oxazine-based BACE1 inhibitors by lowering amidine basicity with the incorporation of a double bond to improve brain penetration.  Starting from a 1,3-dihydrooxazine lead I identified by a hit-to-lead SAR following HTS, we adopted a pKa lowering strategy to reduce the P-gp efflux and the high hERG potential leading to the discovery of II that produced significant Aβ redn. with long duration in pharmacodynamic models and exhibited wide safety margins in cardiovascular safety models.  This compd. II improved the brain-to-plasma ratio relative to I by reducing P-gp recognition, which was demonstrated by a P-gp knockout mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGPZsGRa22ZLVg90H21EOLACvtfcHk0ljtxnOxYJZuxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptVWhsLo%253D&md5=ac366bddfe3492a0a47ce02918b5ea41</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00002%26sid%3Dliteratum%253Aachs%26aulast%3DFuchino%26aufirst%3DK.%26aulast%3DMitsuoka%26aufirst%3DY.%26aulast%3DMasui%26aufirst%3DM.%26aulast%3DKurose%26aufirst%3DN.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DKomano%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DUnemura%26aufirst%3DC.%26aulast%3DHosono%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DSakaguchi%26aufirst%3DG.%26aulast%3DAndo%26aufirst%3DS.%26aulast%3DOhnishi%26aufirst%3DS.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DMiyajima%26aufirst%3DH.%26aulast%3DHiroyama%26aufirst%3DS.%26aulast%3DKoyabu%26aufirst%3DK.%26aulast%3DDhuyvetter%26aufirst%3DD.%26aulast%3DBorghys%26aufirst%3DH.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.M.%26aulast%3DYamano%26aufirst%3DY.%26aulast%3DIso%26aufirst%3DY.%26aulast%3DKusakabe%26aufirst%3DK.%26atitle%3DRational%2520design%2520of%2520novel%25201%252C3-oxazine%2520based%2520%25CE%25B2-secretase%2520%2528BACE1%2529%2520inhibitors%253A%2520Incorporation%2520of%2520a%2520double%2520bond%2520to%2520reduce%2520P-gp%2520efflux%2520leading%2520to%2520robust%2520A%25CE%25B2%2520reduction%2520in%2520the%2520brain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5122%26epage%3D5137%26doi%3D10.1021%2Facs.jmedchem.8b00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sako, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unemura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuyvetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghys, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iso, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and centrally active 6-substituted 5-fluoro-1,3-dihydro-oxazine β-secretase (BACE1) inhibitors via active conformation stabilization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5525</span>– <span class="NLM_lpage">5546</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVarsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5525-5546&author=K.+Nakaharaauthor=K.+Fuchinoauthor=K.+Komanoauthor=N.+Asadaauthor=G.+Tadanoauthor=T.+Hasegawaauthor=T.+Yamamotoauthor=Y.+Sakoauthor=M.+Ogawaauthor=C.+Unemuraauthor=M.+Hosonoauthor=H.+Itoauthor=G.+Sakaguchiauthor=S.+Andoauthor=S.+Ohnishiauthor=Y.+Kidoauthor=T.+Fukushimaauthor=D.+Dhuyvetterauthor=H.+Borghysauthor=H.+J.+M.+Gijsenauthor=Y.+Yamanoauthor=Y.+Isoauthor=K.+Kusakabe&title=Discovery+of+potent+and+centrally+active+6-substituted+5-fluoro-1%2C3-dihydro-oxazine+%CE%B2-secretase+%28BACE1%29+inhibitors+via+active+conformation+stabilization&doi=10.1021%2Facs.jmedchem.8b00011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization</span></div><div class="casAuthors">Nakahara, Kenji; Fuchino, Kouki; Komano, Kazuo; Asada, Naoya; Tadano, Genta; Hasegawa, Tsuyoshi; Yamamoto, Takahiko; Sako, Yusuke; Ogawa, Masayoshi; Unemura, Chie; Hosono, Motoko; Ito, Hisanori; Sakaguchi, Gaku; Ando, Shigeru; Ohnishi, Shuichi; Kido, Yasuto; Fukushima, Tamio; Dhuyvetter, Deborah; Borghys, Herman; Gijsen, Harrie J. M.; Yamano, Yoshinori; Iso, Yasuyoshi; Kusakabe, Ken-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5525-5546</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">β-Secretase (BACE1) has an essential role in the prodn. of amyloid β peptides that accumulate in patients with Alzheimer's disease (AD).  Thus, inhibition of BACE1 is considered to be a disease-modifying approach for the treatment of AD.  The authors' hit-to-lead efforts led to a cellular potent 1,3-dihydro-oxazine I, which however inhibited hERG and showed high P-gp efflux.  The close analog of 5-fluoro-oxazine II reduced P-gp efflux; further introduction of electron withdrawing groups at the 6-position improved potency and also mitigated P-gp efflux and hERG inhibition.  Changing to a pyrazine followed by optimization of substituents on both the oxazine and the pyrazine culminated in III with robust Aβ redn. in vivo at low doses as well as reduced CYP2D6 inhibition.  On the basis of the X-ray anal. and the QM calcn. of given dihydro-oxazines, it was reasoned that the substituents at the 6-position as well as the 5-fluorine on the oxazine would stabilize a bioactive conformation to increase potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBTrC8rX3RE7Vg90H21EOLACvtfcHk0ljtxnOxYJZuxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVarsLs%253D&md5=e622beaca28e64ea0da30c87d0828086</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00011%26sid%3Dliteratum%253Aachs%26aulast%3DNakahara%26aufirst%3DK.%26aulast%3DFuchino%26aufirst%3DK.%26aulast%3DKomano%26aufirst%3DK.%26aulast%3DAsada%26aufirst%3DN.%26aulast%3DTadano%26aufirst%3DG.%26aulast%3DHasegawa%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DSako%26aufirst%3DY.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DUnemura%26aufirst%3DC.%26aulast%3DHosono%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DSakaguchi%26aufirst%3DG.%26aulast%3DAndo%26aufirst%3DS.%26aulast%3DOhnishi%26aufirst%3DS.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DDhuyvetter%26aufirst%3DD.%26aulast%3DBorghys%26aufirst%3DH.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26aulast%3DYamano%26aufirst%3DY.%26aulast%3DIso%26aufirst%3DY.%26aulast%3DKusakabe%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520centrally%2520active%25206-substituted%25205-fluoro-1%252C3-dihydro-oxazine%2520%25CE%25B2-secretase%2520%2528BACE1%2529%2520inhibitors%2520via%2520active%2520conformation%2520stabilization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5525%26epage%3D5546%26doi%3D10.1021%2Facs.jmedchem.8b00011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Woltering, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wostl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilpert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travagli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollastrini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marconi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabellieri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Power, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narquizian, R.</span></span> <span> </span><span class="NLM_article-title">BACE1 inhibitors: A head group scan on a series of amides</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4239</span>– <span class="NLM_lpage">4243</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2Fj.bmcl.2013.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=23735744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFaktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4239-4243&author=T.+J.+Wolteringauthor=W.+Wostlauthor=H.+Hilpertauthor=M.+Rogers-Evansauthor=E.+Pinardauthor=A.+Maywegauthor=M.+Gobelauthor=D.+W.+Bannerauthor=J.+Benzauthor=M.+Travagliauthor=M.+Pollastriniauthor=G.+Marconiauthor=E.+Gabellieriauthor=W.+Gubaauthor=H.+Mauserauthor=M.+Andreiniauthor=H.+Jacobsenauthor=E.+Powerauthor=R.+Narquizian&title=BACE1+inhibitors%3A+A+head+group+scan+on+a+series+of+amides&doi=10.1016%2Fj.bmcl.2013.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 inhibitors: A head group scan on a series of amides</span></div><div class="casAuthors">Woltering, Thomas J.; Wostl, Wolfgang; Hilpert, Hans; Rogers-Evans, Mark; Pinard, Emmanuel; Mayweg, Alexander; Gobel, Martin; Banner, David W.; Benz, Jorg; Travagli, Massimiliano; Pollastrini, Martina; Marconi, Guido; Gabellieri, Emanuele; Guba, Wolfgang; Mauser, Harald; Andreini, Matteo; Jacobsen, Helmut; Power, Eoin; Narquizian, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4239-4243</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of amides bearing a variety of amidine head groups was investigated as BACE1 inhibitors with respect to inhibitory activity in a BACE1 enzyme as well as a cell-based assay.  Detn. of their basicity as well as their properties as substrates of P-glycoprotein revealed that a 2-amino-1,3-oxazine head group would be a suitable starting point for further development of brain penetrating compds. for potential Alzheimer's disease treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEF94wd3_rd7Vg90H21EOLACvtfcHk0liwvpk_LVvjgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFaktLk%253D&md5=3da315c76199617083b762ea111057fd</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DWoltering%26aufirst%3DT.%2BJ.%26aulast%3DWostl%26aufirst%3DW.%26aulast%3DHilpert%26aufirst%3DH.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DPinard%26aufirst%3DE.%26aulast%3DMayweg%26aufirst%3DA.%26aulast%3DGobel%26aufirst%3DM.%26aulast%3DBanner%26aufirst%3DD.%2BW.%26aulast%3DBenz%26aufirst%3DJ.%26aulast%3DTravagli%26aufirst%3DM.%26aulast%3DPollastrini%26aufirst%3DM.%26aulast%3DMarconi%26aufirst%3DG.%26aulast%3DGabellieri%26aufirst%3DE.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DMauser%26aufirst%3DH.%26aulast%3DAndreini%26aufirst%3DM.%26aulast%3DJacobsen%26aufirst%3DH.%26aulast%3DPower%26aufirst%3DE.%26aulast%3DNarquizian%26aufirst%3DR.%26atitle%3DBACE1%2520inhibitors%253A%2520A%2520head%2520group%2520scan%2520on%2520a%2520series%2520of%2520amides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4239%26epage%3D4243%26doi%3D10.1016%2Fj.bmcl.2013.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hilpert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltering, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wostl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humm, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krummenacher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozmen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergadano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochstrasser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David-Pierson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narquizian, R.</span></span> <span> </span><span class="NLM_article-title">β-Secretase (BACE1) inhibitors with high <i>in vivo</i> efficacy suitable for clinical evaluation in Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3980</span>– <span class="NLM_lpage">3995</span>, <span class="refDoi"> DOI: 10.1021/jm400225m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400225m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVymuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3980-3995&author=H.+Hilpertauthor=W.+Gubaauthor=T.+J.+Wolteringauthor=W.+Wostlauthor=E.+Pinardauthor=H.+Mauserauthor=A.+V.+Maywegauthor=M.+Rogers-Evansauthor=R.+Hummauthor=D.+Krummenacherauthor=T.+Muserauthor=C.+Schniderauthor=H.+Jacobsenauthor=L.+Ozmenauthor=A.+Bergadanoauthor=D.+W.+Bannerauthor=R.+Hochstrasserauthor=A.+Kuglstatterauthor=P.+David-Piersonauthor=H.+Fischerauthor=A.+Polaraauthor=R.+Narquizian&title=%CE%B2-Secretase+%28BACE1%29+inhibitors+with+high+in+vivo+efficacy+suitable+for+clinical+evaluation+in+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm400225m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer's Disease</span></div><div class="casAuthors">Hilpert, Hans; Guba, Wolfgang; Woltering, Thomas J.; Wostl, Wolfgang; Pinard, Emmanuel; Mauser, Harald; Mayweg, Alexander V.; Rogers-Evans, Mark; Humm, Roland; Krummenacher, Daniela; Muser, Thorsten; Schnider, Christian; Jacobsen, Helmut; Ozmen, Laurence; Bergadano, Alessandra; Banner, David W.; Hochstrasser, Remo; Kuglstatter, Andreas; David-Pierson, Pascale; Fischer, Holger; Polara, Alessandra; Narquizian, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3980-3995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacol. profile of this class of BACE1 inhibitors.  The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF Aβ40 and 42 in rats at oral doses as low as 1 mg/kg.  The effect was long lasting, showing a significant redn. of Aβ40 and 42 even after 24 h.  In contrast to 89, compd. 1b lacking the CF3 group was virtually inactive in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmoKRrAxxHErVg90H21EOLACvtfcHk0liwvpk_LVvjgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVymuro%253D&md5=e5d311d1c8fecfaed043d3a0bf16c168</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Fjm400225m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400225m%26sid%3Dliteratum%253Aachs%26aulast%3DHilpert%26aufirst%3DH.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DWoltering%26aufirst%3DT.%2BJ.%26aulast%3DWostl%26aufirst%3DW.%26aulast%3DPinard%26aufirst%3DE.%26aulast%3DMauser%26aufirst%3DH.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DHumm%26aufirst%3DR.%26aulast%3DKrummenacher%26aufirst%3DD.%26aulast%3DMuser%26aufirst%3DT.%26aulast%3DSchnider%26aufirst%3DC.%26aulast%3DJacobsen%26aufirst%3DH.%26aulast%3DOzmen%26aufirst%3DL.%26aulast%3DBergadano%26aufirst%3DA.%26aulast%3DBanner%26aufirst%3DD.%2BW.%26aulast%3DHochstrasser%26aufirst%3DR.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DDavid-Pierson%26aufirst%3DP.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DPolara%26aufirst%3DA.%26aulast%3DNarquizian%26aufirst%3DR.%26atitle%3D%25CE%25B2-Secretase%2520%2528BACE1%2529%2520inhibitors%2520with%2520high%2520in%2520vivo%2520efficacy%2520suitable%2520for%2520clinical%2520evaluation%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3980%26epage%3D3995%26doi%3D10.1021%2Fjm400225m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, N.</span>; <span class="NLM_string-name">Ueda, K.</span>; <span class="NLM_string-name">Itoh, N.</span>; <span class="NLM_string-name">Suzuki, S.</span>; <span class="NLM_string-name">Sakaguchi, G.</span>; <span class="NLM_string-name">Kato, A.</span>; <span class="NLM_string-name">Yukimasa, A.</span>; <span class="NLM_string-name">Hori, A.</span>; <span class="NLM_string-name">Koriyama, Y.</span>; <span class="NLM_string-name">Haraguchi, H.</span>; <span class="NLM_string-name">Yasui, K.</span>; <span class="NLM_string-name">Kanda, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation of 2-Aminodihydrothiazine Derivatives as β-Secretase Inhibitors</span>. <span class="NLM_patent">WO2007049532A1</span>, March 5, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=N.+Kobayashi&author=K.+Ueda&author=N.+Itoh&author=S.+Suzuki&author=G.+Sakaguchi&author=A.+Kato&author=A.+Yukimasa&author=A.+Hori&author=Y.+Koriyama&author=H.+Haraguchi&author=K.+Yasui&author=Y.+Kanda&title=Preparation+of+2-Aminodihydrothiazine+Derivatives+as+%CE%B2-Secretase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DN.%26atitle%3DPreparation%2520of%25202-Aminodihydrothiazine%2520Derivatives%2520as%2520%25CE%25B2-Secretase%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+Highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0liwvpk_LVvjgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520Highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosea, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callegari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianfrogna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E.C.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasman, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPerle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedza, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahematpura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raunig, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spracklin, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Deusen, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasgar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1124/dmd.104.001230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1124%2Fdmd.104.001230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=15502009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlentw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=165-174&author=A.+Doranauthor=R.+S.+Obachauthor=B.+J.+Smithauthor=N.+A.+Hoseaauthor=S.+Beckerauthor=E.+Callegariauthor=C.+Chenauthor=X.+Chenauthor=E.+Chooauthor=J.+Cianfrognaauthor=L.+M.+Coxauthor=J.+P.+Gibbsauthor=M.+A.+Gibbsauthor=H.+Hatchauthor=C.+E.C.A.+Hopauthor=I.+N.+Kasmanauthor=J.+LaPerleauthor=J.+Liuauthor=X.+Liuauthor=M.+Logmanauthor=D.+Maclinauthor=F.+M.+Nedzaauthor=F.+Nelsonauthor=E.+Olsonauthor=S.+Rahematpuraauthor=D.+Raunigauthor=S.+Rogersauthor=K.+Schmidtauthor=D.+K.+Spracklinauthor=M.+Szewcauthor=M.+Troutmanauthor=E.+Tsengauthor=M.+Tuauthor=J.+W.+Van+Deusenauthor=K.+Venkatakrishnanauthor=G.+Walensauthor=E.+Q.+Wangauthor=D.+Wongauthor=A.+S.+Yasgarauthor=C.+Zhang&title=The+impact+of+P-glycoprotein+on+the+disposition+of+drugs+targeted+for+indications+of+the+central+nervous+system%3A+Evaluation+using+the+MDR1A%2F1B+knockout+mouse+model&doi=10.1124%2Fdmd.104.001230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model</span></div><div class="casAuthors">Doran, Angela; Obach, R. Scott; Smith, Bill J.; Hosea, Natilie A.; Becker, Stacey; Callegari, Ernesto; Chen, Cuiping; Chen, Xi; Choo, Edna; Cianfrogna, Julie; Cox, Loretta M.; Gibbs, John P.; Gibbs, Megan A.; Hatch, Heather; Hop, Cornelis E. C. A.; Kasman, Ilana N.; LaPerle, Jennifer; Liu, JianHua; Liu, Xingrong; Logman, Michael; Maclin, Debra; Nedza, Frank M.; Nelson, Frederick; Olson, Emily; Rahematpura, Sandhya; Raunig, David; Rogers, Sabrinia; Schmidt, Kari; Spracklin, Douglas K.; Szewc, Mark; Troutman, Matthew; Tseng, Elaine; Tu, Meihua; Van Deusen, Jeffrey W.; Venkatakrishnan, Karthik; Walens, Gary; Wang, Ellen Q.; Wong, Diane; Yasgar, Adam S.; Zhang, Chenghong</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-174</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Thirty-two structurally diverse drugs used for the treatment of various conditions of the central nervous system (CNS), along with two active metabolites, and eight non-CNS drugs were measured in brain, plasma, and cerebrospinal fluid in the P-glycoprotein (P-gp) knockout mouse model after s.c. administration, and the data were compared with corresponding data obtained in wild-type mice.  Total brain-to-plasma (B/P) ratios for the CNS agents ranged from 0.060 to 24.  Of the 34 CNS-active agents, only 7 demonstrated B/P area under the plasma concn. curve ratios between P-gp knockout and wild-type mice that did not differ significantly from unity.  Most of the remaining drugs demonstrated 1.1- to 2.6-fold greater B/P ratios in P-gp knockout mice vs. wild-type mice.  Three, risperidone, its active metabolite 9-hydroxyrisperidone, and metoclopramide, showed marked differences in B/P ratios between knockout and wild-type mice (6.6- to 17-fold).  Differences in B/P ratios and cerebrospinal fluid/plasma ratios between wild-type and knockout animals were correlated.  Through the use of this model, it appears that most CNS-active agents demonstrate at least some P-gp-mediated transport that can affect brain concns.  However, the impact for the majority of agents is probably minor.  The example of risperidone illustrates that even good P-gp substrates can still be clin. useful CNS-active agents.  However, for such agents, unbound plasma concns. may need to be greater than values projected using receptor affinity data to achieve adequate receptor occupancy for effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCLikZvvYtAbVg90H21EOLACvtfcHk0ljiXURnTURvvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlentw%253D%253D&md5=58acf489206dfeaaa96da4329e403710</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fdmd.104.001230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.104.001230%26sid%3Dliteratum%253Aachs%26aulast%3DDoran%26aufirst%3DA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DBecker%26aufirst%3DS.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChoo%26aufirst%3DE.%26aulast%3DCianfrogna%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DL.%2BM.%26aulast%3DGibbs%26aufirst%3DJ.%2BP.%26aulast%3DGibbs%26aufirst%3DM.%2BA.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DHop%26aufirst%3DC.%2BE.C.A.%26aulast%3DKasman%26aufirst%3DI.%2BN.%26aulast%3DLaPerle%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLogman%26aufirst%3DM.%26aulast%3DMaclin%26aufirst%3DD.%26aulast%3DNedza%26aufirst%3DF.%2BM.%26aulast%3DNelson%26aufirst%3DF.%26aulast%3DOlson%26aufirst%3DE.%26aulast%3DRahematpura%26aufirst%3DS.%26aulast%3DRaunig%26aufirst%3DD.%26aulast%3DRogers%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DSpracklin%26aufirst%3DD.%2BK.%26aulast%3DSzewc%26aufirst%3DM.%26aulast%3DTroutman%26aufirst%3DM.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DTu%26aufirst%3DM.%26aulast%3DVan%2BDeusen%26aufirst%3DJ.%2BW.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26aulast%3DWalens%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DE.%2BQ.%26aulast%3DWong%26aufirst%3DD.%26aulast%3DYasgar%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DC.%26atitle%3DThe%2520impact%2520of%2520P-glycoprotein%2520on%2520the%2520disposition%2520of%2520drugs%2520targeted%2520for%2520indications%2520of%2520the%2520central%2520nervous%2520system%253A%2520Evaluation%2520using%2520the%2520MDR1A%252F1B%2520knockout%2520mouse%2520model%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D165%26epage%3D174%26doi%3D10.1124%2Fdmd.104.001230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">CNS Drug design: balancing physicochemical properties for optimal brain exposure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2584</span>– <span class="NLM_lpage">2608</span>, <span class="refDoi"> DOI: 10.1021/jm501535r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501535r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2584-2608&author=Z.+Rankovic&title=CNS+Drug+design%3A+balancing+physicochemical+properties+for+optimal+brain+exposure&doi=10.1021%2Fjm501535r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure</span></div><div class="casAuthors">Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2584-2608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins.  Designing mols. that can overcome this protection system and achieve optimal concn. at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery.  Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochem. properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates.  This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most crit. physicochem. and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chem. strategies toward mols. with optimal brain exposure.  A summary of modern CNS pharmacokinetic concepts and methods is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8V0N1j49uuLVg90H21EOLACvtfcHk0ljiXURnTURvvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP&md5=f01e3f2dc4e2eff7b0618124277a5cf8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm501535r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501535r%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DCNS%2520Drug%2520design%253A%2520balancing%2520physicochemical%2520properties%2520for%2520optimal%2520brain%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2584%26epage%3D2608%26doi%3D10.1021%2Fjm501535r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Didziapetris, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Japertas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdeef, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrauskas, A.</span></span> <span> </span><span class="NLM_article-title">Classification analysis of P-glycoprotein substrate specificity</span>. <i>J. Drug. Target.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1080/10611860310001648248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1080%2F10611860310001648248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=15203928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFOjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=391-406&author=R.+Didziapetrisauthor=P.+Japertasauthor=A.+Avdeefauthor=A.+Petrauskas&title=Classification+analysis+of+P-glycoprotein+substrate+specificity&doi=10.1080%2F10611860310001648248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Classification Analysis of P-Glycoprotein Substrate Specificity</span></div><div class="casAuthors">Didziapetris, Remigijus; Japertas, Pranas; Avdeef, Alex; Petrauskas, Alanas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">391-406</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1061-186X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Prediction of P-glycoprotein substrate specificity (SPGP) can be viewed as a constituent part of a compd.'s "pharmaceutical profiling" in drug design.  This task is difficult to achieve due to several factors that raised many contradictory opinions: (i) the disparity between the SPGP values obtained in different assays, (ii) the confusion between Pgp substrates and inhibitors, (iii) the confusion between lipophilicity and amphiphilicity of Pgp substrates, and (iv) the dilemma of describing class-specific relationships when Pgp has no binding sites of high ligand specificity.  In this work, the authors compiled SPGP data for 1000 compds.  All data were represented in a binary format, assigning SPGP = 1 for substrates and SPGP = 0 for nonsubstrates.  Each value was ranked according to the reliability of exptl. assay.  Two data sets were considered.  Set 1 included 220 compds. with SPGP from polarized transport across MDR1 transfected cell monolayers.  Set 2 included the entire list of 1000 compds., with SPGP values of generally lower reliability.  Both sets were analyzed using a stepwise classification structure-activity relationship (C-SAR) method, leading to derivation of simple rules for crude estn. of SPGP values.  The obtained rules are based on the following factors: (i) compd.'s size expressed through molar wt. or vol., (ii) H-accepting given by the Abraham's β (that can be crudely approximated by the sum of O and N atoms), and (iii) ionization given by the acid and base pKa values.  Very roughly, SPGP can be estd. by the "rule of fours".  Compds. with (N + O) ≥ 8, MW > 400 and acid pKa > 4 are likely to be Pgp substrates, whereas compds. with (N+O) ≤ 4, MW < 400 and base pKa < 8 are likely to be nonsubstrates.  The obtained results support the view that Pgp functioning can be compared to a complex "mini-pharmacokinetic" system with fuzzy specificity.  This system can be described by a probabilistic version of Abraham's solvation equation, suggesting a certain similarity between Pgp transport and chromatog. retention.  The chromatog. model does not work in the case of "marginal" compds. with properties close to the "global" physicochem. cut-offs.  In the latter case various class-specific rules must be considered.  These can be assocd. with the "amphiphilicity" and "biol. similarity" of compds.  The definition of class-specific effects entails construction of the knowledge base that can be very useful in ADME profiling of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsvKJmruZ7RLVg90H21EOLACvtfcHk0lhv94LOkEVAag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFOjs7k%253D&md5=5b7ea95eb2d9faded5645481c1330f03</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F10611860310001648248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10611860310001648248%26sid%3Dliteratum%253Aachs%26aulast%3DDidziapetris%26aufirst%3DR.%26aulast%3DJapertas%26aufirst%3DP.%26aulast%3DAvdeef%26aufirst%3DA.%26aulast%3DPetrauskas%26aufirst%3DA.%26atitle%3DClassification%2520analysis%2520of%2520P-glycoprotein%2520substrate%2520specificity%26jtitle%3DJ.%2520Drug.%2520Target.%26date%3D2003%26volume%3D11%26spage%3D391%26epage%3D406%26doi%3D10.1080%2F10611860310001648248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Oguma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.-I.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a 6-CF<sub>3</sub>-substituted 2-amino-dihydro-1,3-thiazine β-secretase inhibitor by <i>N</i>,<i>N</i>-diethylsulfur trifluoride-mediated chemoselective cyclization</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">4893</span>– <span class="NLM_lpage">4897</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.8b02179</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.8b02179" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFSrsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2019&pages=4893-4897&author=T.+Ogumaauthor=K.+Ananauthor=S.+Suzukiauthor=S.+Hisakawaauthor=A.+Takadaauthor=M.+Ogawaauthor=K.-I.+Kusakabe&title=Synthesis+of+a+6-CF3-substituted+2-amino-dihydro-1%2C3-thiazine+%CE%B2-secretase+inhibitor+by+N%2CN-diethylsulfur+trifluoride-mediated+chemoselective+cyclization&doi=10.1021%2Facs.joc.8b02179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a 6-CF3-Substituted 2-Amino-dihydro-1,3-thiazine β-Secretase Inhibitor by N,N-Diethylaminosulfur Trifluoride-Mediated Chemoselective Cyclization</span></div><div class="casAuthors">Oguma, Takuya; Anan, Kosuke; Suzuki, Shinji; Hisakawa, Shinya; Takada, Akihiro; Ogawa, Masayoshi; Kusakabe, Ken-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4893-4897</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of a 6-CF3-substituted 2-amino-dihydro-1,3-thiazine via N,N-diethylaminosulfur trifluoride (DAST)-mediated cyclization of N-hydroxypropyl thiourea I is described.  This reaction gave 6-CF3-1,3-thiazine II with high chem. yield and chemoselectivity, suppressing the common byproduct of oxazine.  This new protocol enabled access to 6-CF3-substituted 1,3-thiazine β-secretase inhibitor III.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB5R8g_SarTbVg90H21EOLACvtfcHk0lhv94LOkEVAag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFSrsbbO&md5=a84b7f683474108cbbccabc9c7fa7078</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.8b02179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.8b02179%26sid%3Dliteratum%253Aachs%26aulast%3DOguma%26aufirst%3DT.%26aulast%3DAnan%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DHisakawa%26aufirst%3DS.%26aulast%3DTakada%26aufirst%3DA.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DKusakabe%26aufirst%3DK.-I.%26atitle%3DSynthesis%2520of%2520a%25206-CF3-substituted%25202-amino-dihydro-1%252C3-thiazine%2520%25CE%25B2-secretase%2520inhibitor%2520by%2520N%252CN-diethylsulfur%2520trifluoride-mediated%2520chemoselective%2520cyclization%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2019%26volume%3D84%26spage%3D4893%26epage%3D4897%26doi%3D10.1021%2Facs.joc.8b02179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Anan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iso, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanegawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawachi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teisman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urmaliya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuyvetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghys, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bergh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verboven, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.</span></span> <span> </span><span class="NLM_article-title">Trifluoromethyl dihydrothiazine-based β-Secretase (BACE1) inhibitors with robust central β-amyloid reduction and minimal covalent binding burden</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1894</span>– <span class="NLM_lpage">1910</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201900478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1002%2Fcmdc.201900478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=31657130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFarur%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1894-1910&author=K.+Ananauthor=Y.+Isoauthor=T.+Ogumaauthor=K.+Nakaharaauthor=S.+Suzukiauthor=T.+Yamamotoauthor=E.+Matsuokaauthor=H.+Itoauthor=G.+Sakaguchiauthor=S.+Andoauthor=K.+Morimotoauthor=N.+Kanegawaauthor=Y.+Kidoauthor=T.+Kawachiauthor=T.+Fukushimaauthor=A.+Teismanauthor=V.+Urmaliyaauthor=D.+Dhuyvetterauthor=H.+Borghysauthor=N.+Austinauthor=A.+Van+Den+Berghauthor=P.+Verbovenauthor=F.+Bischoffauthor=H.+J.+M.+Gijsenauthor=Y.+Yamanoauthor=K.+Kusakabe&title=Trifluoromethyl+dihydrothiazine-based+%CE%B2-Secretase+%28BACE1%29+inhibitors+with+robust+central+%CE%B2-amyloid+reduction+and+minimal+covalent+binding+burden&doi=10.1002%2Fcmdc.201900478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden</span></div><div class="casAuthors">Anan, Kosuke; Iso, Yasuyoshi; Oguma, Takuya; Nakahara, Kenji; Suzuki, Shinji; Yamamoto, Takahiko; Matsuoka, Eriko; Ito, Hisanori; Sakaguchi, Gaku; Ando, Shigeru; Morimoto, Kenji; Kanegawa, Naoki; Kido, Yasuto; Kawachi, Tomoyuki; Fukushima, Tamio; Teisman, Ard; Urmaliya, Vijay; Dhuyvetter, Deborah; Borghys, Herman; Austin, Nigel; Van Den Bergh, An; Verboven, Peter; Bischoff, Francois; Gijsen, Harrie J. M.; Yamano, Yoshinori; Kusakabe, Kenichi</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1894-1910</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The β-site amyloid precursor protein cleaving enzyme 1 (BACE1, also known as β-secretase) is a promising target for the treatment of Alzheimer's disease.  A pKa lowering approach over the initial leads was adopted to mitigate hERG inhibition and P-gp efflux, leading to the design of 6-CF3 dihydrothiazine 8 (N-(3-((4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide).  Optimization of 8 led to the discovery of 15 (N-(3-((4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide) with an excellent balance of potency, hERG inhibition, P-gp efflux, and metabolic stability.  Oral administration of 8 elicited robust Aβ redn. in dog even at 0.16 mg/kg.  Reflecting the reduced hERG inhibitory activity, no QTc prolongation was obsd. at high doses.  The potential for reactive metabolite formation of 15 was realized in a nucleophile trapping assay using [14C]-KCN in human liver microsomes.  Utilizing covalent binding (CVB) in human hepatocytes and the max. projected human dosage, the daily CVB burden of 15 was calcd. to be at an acceptable value of below 1 mg/day.  However, hepatotoxicity was obsd. when 15 was subjected to a two-week tolerance study in dog, which prevented further evaluation of this compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppg1JHQpg4S7Vg90H21EOLACvtfcHk0lhv94LOkEVAag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFarur%252FM&md5=1fbb54003cfb52eceb1ab778705314d9</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900478%26sid%3Dliteratum%253Aachs%26aulast%3DAnan%26aufirst%3DK.%26aulast%3DIso%26aufirst%3DY.%26aulast%3DOguma%26aufirst%3DT.%26aulast%3DNakahara%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DMatsuoka%26aufirst%3DE.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DSakaguchi%26aufirst%3DG.%26aulast%3DAndo%26aufirst%3DS.%26aulast%3DMorimoto%26aufirst%3DK.%26aulast%3DKanegawa%26aufirst%3DN.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DKawachi%26aufirst%3DT.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DTeisman%26aufirst%3DA.%26aulast%3DUrmaliya%26aufirst%3DV.%26aulast%3DDhuyvetter%26aufirst%3DD.%26aulast%3DBorghys%26aufirst%3DH.%26aulast%3DAustin%26aufirst%3DN.%26aulast%3DVan%2BDen%2BBergh%26aufirst%3DA.%26aulast%3DVerboven%26aufirst%3DP.%26aulast%3DBischoff%26aufirst%3DF.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26aulast%3DYamano%26aufirst%3DY.%26aulast%3DKusakabe%26aufirst%3DK.%26atitle%3DTrifluoromethyl%2520dihydrothiazine-based%2520%25CE%25B2-Secretase%2520%2528BACE1%2529%2520inhibitors%2520with%2520robust%2520central%2520%25CE%25B2-amyloid%2520reduction%2520and%2520minimal%2520covalent%2520binding%2520burden%26jtitle%3DChemMedChem%26date%3D2019%26volume%3D14%26spage%3D1894%26epage%3D1910%26doi%3D10.1002%2Fcmdc.201900478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tadano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanegawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teisman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urmaliya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuyvetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghys, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bergh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iso, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.-i.</span></span> <span> </span><span class="NLM_article-title">Discovery of an extremely potent thiazine-based β-secretase (BACE1) inhibitor that minimized cardiovascular and liver toxicity at a low projected human dose</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9331</span>– <span class="NLM_lpage">9337</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01140</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01140" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVentrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9331-9337&author=G.+Tadanoauthor=K.+Komanoauthor=S.+Yoshidaauthor=S.+Suzukiauthor=K.+Nakaharaauthor=K.+Fuchinoauthor=K.+Fujimotoauthor=E.+Matsuokaauthor=T.+Yamamotoauthor=N.+Asadaauthor=H.+Itoauthor=G.+Sakaguchiauthor=N.+Kanegawaauthor=Y.+Kidoauthor=S.+Andoauthor=T.+Fukushimaauthor=A.+Teismanauthor=V.+Urmaliyaauthor=D.+Dhuyvetterauthor=H.+Borghysauthor=A.+Van+Den+Berghauthor=N.+Austinauthor=H.+J.+M.+Gijsenauthor=Y.+Yamanoauthor=Y.+Isoauthor=K.-i.+Kusakabe&title=Discovery+of+an+extremely+potent+thiazine-based+%CE%B2-secretase+%28BACE1%29+inhibitor+that+minimized+cardiovascular+and+liver+toxicity+at+a+low+projected+human+dose&doi=10.1021%2Facs.jmedchem.9b01140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25cR"><div class="casContent"><span class="casTitleNuber">25c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Extremely Potent Thiazine-Based β-Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose</span></div><div class="casAuthors">Tadano, Genta; Komano, Kazuo; Yoshida, Shuhei; Suzuki, Shinji; Nakahara, Kenji; Fuchino, Kouki; Fujimoto, Kazuki; Matsuoka, Eriko; Yamamoto, Takahiko; Asada, Naoya; Ito, Hisanori; Sakaguchi, Gaku; Kanegawa, Naoki; Kido, Yasuto; Ando, Shigeru; Fukushima, Tamio; Teisman, Ard; Urmaliya, Vijay; Dhuyvetter, Deborah; Borghys, Herman; Van Den Bergh, An; Austin, Nigel; Gijsen, Harrie J. M.; Yamano, Yoshinori; Iso, Yasuyoshi; Kusakabe, Ken-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9331-9337</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Genetic evidence points to deposition of amyloid-β (Aβ) as a causal factor for Alzheimer's disease.  Aβ generation is initiated when β-secretase (BACE1) cleaves the amyloid precursor protein.  Starting with an oxazine lead 1, we describe the discovery of a thiazine-based BACE1 inhibitor 5 with robust Aβ redn. in vivo at low concns., leading to a low projected human dose of 14 mg/day where 5 achieved sustained Aβ redn. of 80% at trough level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCgZp0A9J8rbVg90H21EOLACvtfcHk0lhhyGpaz-Ttdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVentrnO&md5=8f6c618bad3fc4bcf7bfb97b48972fa3</span></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01140%26sid%3Dliteratum%253Aachs%26aulast%3DTadano%26aufirst%3DG.%26aulast%3DKomano%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DNakahara%26aufirst%3DK.%26aulast%3DFuchino%26aufirst%3DK.%26aulast%3DFujimoto%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DE.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DAsada%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DSakaguchi%26aufirst%3DG.%26aulast%3DKanegawa%26aufirst%3DN.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DAndo%26aufirst%3DS.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DTeisman%26aufirst%3DA.%26aulast%3DUrmaliya%26aufirst%3DV.%26aulast%3DDhuyvetter%26aufirst%3DD.%26aulast%3DBorghys%26aufirst%3DH.%26aulast%3DVan%2BDen%2BBergh%26aufirst%3DA.%26aulast%3DAustin%26aufirst%3DN.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26aulast%3DYamano%26aufirst%3DY.%26aulast%3DIso%26aufirst%3DY.%26aulast%3DKusakabe%26aufirst%3DK.-i.%26atitle%3DDiscovery%2520of%2520an%2520extremely%2520potent%2520thiazine-based%2520%25CE%25B2-secretase%2520%2528BACE1%2529%2520inhibitor%2520that%2520minimized%2520cardiovascular%2520and%2520liver%2520toxicity%2520at%2520a%2520low%2520projected%2520human%2520dose%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9331%26epage%3D9337%26doi%3D10.1021%2Facs.jmedchem.9b01140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1021/tx200168d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+A+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States&doi=10.1021%2Ftx200168d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0lhhyGpaz-Ttdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520A%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410%26doi%3D10.1021%2Ftx200168d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swallow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgos, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span> <span> </span><span class="NLM_article-title">In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1616</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1021/tx300091x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx300091x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=1616-1632&author=R.+A.+Thompsonauthor=E.+M.+Isinauthor=Y.+Liauthor=L.+Weidolfauthor=K.+Pageauthor=I.+Wilsonauthor=S.+Swallowauthor=B.+Middletonauthor=S.+Stahlauthor=A.+J.+Fosterauthor=H.+Dolgosauthor=R.+Weaverauthor=J.+G.+Kenna&title=In+vitro+approach+to+assess+the+potential+for+risk+of+idiosyncratic+adverse+reactions+caused+by+candidate+drugs&doi=10.1021%2Ftx300091x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs</span></div><div class="casAuthors">Thompson, Richard A.; Isin, Emre M.; Li, Yan; Weidolf, Lars; Page, Ken; Wilson, Ian; Swallow, Steve; Middleton, Brian; Stahl, Simone; Foster, Alison J.; Dolgos, Hugues; Weaver, Richard; Kenna, J. Gerry</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1616-1632</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Idiosyncratic adverse drug reactions (IADRs) in humans can result in a broad range of clin. significant toxicities leading to attrition during drug development as well as postlicensing withdrawal or labeling.  IADRs arise from both drug and patient related mechanisms and risk factors.  Drug related risk factors, resulting from parent compd. or metabolites, may involve multiple contributory mechanisms including organelle toxicity, effects related to compd. disposition, and/or immune activation.  In the current study, we evaluate an in vitro approach, which explored both cellular effects and covalent binding (CVB) to assess IADR risks for drug candidates using 36 drugs which caused different patterns and severities of IADRs in humans.  The cellular effects were tested in an in vitro Panel of five assays which quantified (1) toxicity to THLE cells (SV40 T-antigen-immortalized human liver epithelial cells), which do not express P450s, (2) toxicity to a THLE cell line which selectively expresses P 450 3A4, (3) cytotoxicity in HepG2 cells in glucose and galactose media, which is indicative of mitochondrial injury, (4) inhibition of the human bile salt export pump, BSEP, and (5) inhibition of the rat multidrug resistance assocd. protein 2, Mrp2.  In addn., the CVB Burden was estd. by detg. the CVB of radiolabeled compd. to human hepatocytes and factoring in both the max. prescribed daily dose and the fraction of metab. leading to CVB.  Combining the aggregated results from the in vitro Panel assays with the CVB Burden data discriminated, with high specificity (78%) and sensitivity (100%), between 27 drugs, which had severe or marked IADR concern, and 9 drugs, which had low IADR concern, we propose that this integrated approach has the potential to enable selection of drug candidates with reduced propensity to cause IADRs in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFG8lfWXT4vLVg90H21EOLACvtfcHk0lhhyGpaz-Ttdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslGqs70%253D&md5=e657aaf23d4efc5466bca68dee95bded</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1021%2Ftx300091x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx300091x%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DR.%2BA.%26aulast%3DIsin%26aufirst%3DE.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWeidolf%26aufirst%3DL.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DI.%26aulast%3DSwallow%26aufirst%3DS.%26aulast%3DMiddleton%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DS.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DDolgos%26aufirst%3DH.%26aulast%3DWeaver%26aufirst%3DR.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26atitle%3DIn%2520vitro%2520approach%2520to%2520assess%2520the%2520potential%2520for%2520risk%2520of%2520idiosyncratic%2520adverse%2520reactions%2520caused%2520by%2520candidate%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26spage%3D1616%26epage%3D1632%26doi%3D10.1021%2Ftx300091x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripp, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction Risks</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4896</span>– <span class="NLM_lpage">4933</span>, <span class="refDoi"> DOI: 10.1021/jm300065h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300065h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wlur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4896-4933&author=S.+T.+M.+Orrauthor=S.+L.+Rippauthor=T.+E.+Ballardauthor=J.+L.+Hendersonauthor=D.+O.+Scottauthor=R.+S.+Obachauthor=H.+Sunauthor=A.+S.+Kalgutkar&title=Mechanism-based+inactivation+%28MBI%29+of+cytochrome+P450+enzymes%3A+structure-activity+relationships+and+discovery+strategies+to+mitigate+drug-drug+interaction+Risks&doi=10.1021%2Fjm300065h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26cR"><div class="casContent"><span class="casTitleNuber">26c</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks</span></div><div class="casAuthors">Orr, Suvi T. M.; Ripp, Sharon L.; Ballard, T. Eric; Henderson, Jaclyn L.; Scott, Dennis O.; Obach, R. Scott; Sun, Hao; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4896-4933</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The importance of mitigating drug-drug interaction (DDI) risks, which arise from inhibition of major human cytochrome P 450 enzymes is a well-established component of the lead optimization process in drug discovery.  More recently, there has been much interest in clin. DDIs potentially arising via time- and concn.-dependent cytochrome P 450 inhibition, a phenomenon consistent with mechanism-based inactivation.  Inactivated P 450 is catalytically incompetent and must be replenished by newly synthesized protein.  Consequently, time-dependent inhibition of P450s presents a greater safety concern compared to reversible inhibition because of the increased propensity for pharmacokinetic interactions upon multiple dosing and the sustained duration of these interactions after discontinuation of the mechanism-based inactivator.  Mechanism-based or time-dependent P 450 inhibitors pose an addnl. risk of idiosyncratic drug toxicity since the mechanism of time-dependency often involves the formation of reactive metabolites, which can react with proteins other than the P 450 isoenzyme responsible for catalysis. in vitro time-dependent inhibition (TDI) of P 450 enzymes is now routinely assessed as part of lead optimization efforts in preclin. drug discovery.  However, identification of an in vitro TDI liability can raise several questions such as: What is the mechanism of TDI.  Does it involve the formation of reactive metabolites.  Is there a 1:1 correlation between P 450 TDI and RM formation (as measured from reactive metabolite trapping studies).  What is the likelihood that a P 450 time-dependent inhibitor will also cause toxicity.  What are the DDI risk mitigation options when dealing with P 450 inactivators in drug discovery - compd. progression or termination.  Several drugs exhibit in vitro TDI of P 450 enzymes, but only a fraction thereof causes clin. DDIs.  Hence, when do we initiate labor-intensive medicinal chem. efforts to design compds. devoid of P 450 TDI liability.  What are the best methods to precisely predict the likelihood of occurrence of clin. DDIs with drug candidates that inactivate P 450 enzymes.  What are (if any) the qualifying considerations for clin. progression of a P 450 time-dependent inactivator with projected clin. DDI risks.  In an effort to address these questions and hopefully provide answers to some of them, we embarked on the present venture wherein we highlight the current state-of-the-art knowledge in this field with a special emphasis on (a) available biochem. and mechanistic approaches in drug discovery to examine TDI of P 450 isoenzymes with new chem. entities, (b) structure-activity relationship studies with marketed drugs assocd. with DDIs via P 450 inactivation, (c) case studies of medicinal chem. tactics to abrogate P 450 inactivation liability, (d) strategies for progression of P 450 TDI-pos. drug candidates, and (e) the utility of in silico methodol., including the use of physiol.-based pharmacokinetic simulators, in drug discovery to predict the magnitude of clin. DDIs risks anticipated with new clin. candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDO60qqRvpS7Vg90H21EOLACvtfcHk0lj5BcBOESPR-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wlur8%253D&md5=aa4aa4f633b3b4f73b3d79917327b0de</span></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=10.1021%2Fjm300065h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300065h%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26aulast%3DBallard%26aufirst%3DT.%2BE.%26aulast%3DHenderson%26aufirst%3DJ.%2BL.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DMechanism-based%2520inactivation%2520%2528MBI%2529%2520of%2520cytochrome%2520P450%2520enzymes%253A%2520structure-activity%2520relationships%2520and%2520discovery%2520strategies%2520to%2520mitigate%2520drug-drug%2520interaction%2520Risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4896%26epage%3D4933%26doi%3D10.1021%2Fjm300065h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scheen, A. J.</span></span> <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.2165/00002018-200124120-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.2165%2F00002018-200124120-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=11735645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVyisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Scheen%2C+A.+J.+Drug+Saf.+2001%2C+24%2C+873%E2%80%93888%2C+10.2165%2F00002018-200124120-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26dR"><div class="casContent"><span class="casTitleNuber">26d</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity with thiazolidinediones: is it a class effect?</span></div><div class="casAuthors">Scheen, Andre J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">873-888</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Decreased insulin sensitivity plays a major role in various human diseases, particularly type 2 diabetes mellitus, and is assocd. with a higher risk of atherosclerosis and cardiovascular complications.  Thiazolidinediones, more commonly termed glitazones, are the first drugs to specifically target muscular insulin resistance.  They have proven efficacy for reducing plasma glucose levels in patients with type 2 diabetes mellitus treated with diet alone, sulfonylureas, metformin or insulin.  In addn., they are assocd. with some improvement of the cardiovascular risk profile.  However, troglitazone, the first compd. approved by the Food and Drug Administration in the US, proved to be hepatotoxic and was withdrawn from the market after the report of several dozen deaths or cases of severe hepatic failure requiring liver transplantation.  It remains unclear whether or not hepatotoxicity is a class effect or is related to unique properties of troglitazone.  Rosiglitazone and pioglitazone, two other glitazones, appear to have similar efficacy with regard to blood glucose control in patients with type 2 diabetes mellitus as compared with troglitazone.  In controlled clin. trials, the incidence of significant (≥3 × upper limit of normal) increases in liver enzyme levels (ALT in particular) was similar with rosiglitazone or pioglitazone as compared with placebo, whereas troglitazone was assocd. with a 3-fold greater incidence.  In contrast to the numerous case reports of acute liver failure in patients receiving troglitzone, only a few case reports of hepatotoxicity have been reported in patients treated with rosiglitazone until now, with a causal relationship remaining uncertain.  Furthermore, no single case of severe hepatotoxicity has been reported yet with pioglitazone.  It should be mentioned that troglitazone, unlike pioglitazone and rosiglitazone, induces the cytochrome P 450 isoform 3A4, which is partly responsible for its metab., and may be prone to drug interactions.  Importantly enough, obesity, insulin resistance and type 2 diabetes mellitus are assocd. with liver abnormalities, esp. non-alc. steatohepatitis, independent of any pharmacol. treatment.  This assocn. obviously complicates the selection of patients who are good candidates for a treatment with glitazones as well as the monitoring of liver tests after initiation of therapy with any thiazolidinedione compd.  While regular monitoring of liver enzymes is still recommended and more long term data are desirable, current evidence from clin. trials and postmarketing experience in the US supports the conclusion that rosiglitazone and pioglitazone do not share the hepatotoxic profile of troglitazone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTHR2dl31izbVg90H21EOLACvtfcHk0lj5BcBOESPR-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVyisrk%253D&md5=efa0b23e963c3c8f53a6b8cda8e404d2</span></div><a href="/servlet/linkout?suffix=cit26d&amp;dbid=16384&amp;doi=10.2165%2F00002018-200124120-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-200124120-00002%26sid%3Dliteratum%253Aachs%26aulast%3DScheen%26aufirst%3DA.%2BJ.%26jtitle%3DDrug%2520Saf.%26date%3D2001%26volume%3D24%26spage%3D873%26epage%3D888%26doi%3D10.2165%2F00002018-200124120-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fielden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamison, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. T.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueblood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshari, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightfoot-Dunn, R.</span></span> <span> </span><span class="NLM_article-title">Retinal toxicity induced by a novel β-secretase inhibitor in the Sprague-Dawley rat</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1177/0192623314553804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1177%2F0192623314553804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=25361751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCqu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=581-592&author=M.+R.+Fieldenauthor=J.+Wernerauthor=J.+A.+Jamisonauthor=A.+Coppiauthor=D.+Hickmanauthor=R.+T.+Dunnauthor=E.+Truebloodauthor=L.+Zhouauthor=C.+A.+Afshariauthor=R.+Lightfoot-Dunn&title=Retinal+toxicity+induced+by+a+novel+%CE%B2-secretase+inhibitor+in+the+Sprague-Dawley+rat&doi=10.1177%2F0192623314553804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal toxicity induced by a novel β-secretase inhibitor in the sprague-dawley rat</span></div><div class="casAuthors">Fielden, Mark R.; Werner, Jonathan; Jamison, Jeff A.; Coppi, Aldo; Hickman, Dean; Dunn, Robert T., II; Trueblood, Esther; Zhou, Lei; Afshari, Cynthia A.; Lightfoot-Dunn, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">581-592</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">β-Secretase 1 (BACE1) represents an attractive target for the treatment of Alzheimer's disease.  In the course of development of a novel small mol. BACE1 inhibitor (AMG-8718), retinal thinning was obsd. in a 1-mo toxicity study in the rat.  To further understand the lesion, an investigational study was conducted whereby rats were treated daily with AMG-8718 for 1 mo followed by a 2-mo treatment-free phase.  The earliest detectable change in the retina was an increase in autofluorescent granules in the retinal pigment epithelium (RPE) on day 5; however, there were no treatment-related light microscopic changes obsd. in the neuroretina and no changes obsd. by fundus autofluorescence or routine ophthalmoscopic examn. after 28 days of dosing.  Following 2 mo of recovery, there was significant retinal thinning attributed to loss of photoreceptor nuclei from the outer nuclear layer.  Electroretinog. changes were obsd. as early as day 14, before any microscopic evidence of photoreceptor loss.  BACE1 knockout rats were generated and found to have normal retinal morphol. indicating that the retinal toxicity induced by AMG-8718 was likely off-target.  These results suggest that AMG-8718 impairs phagolysosomal function in the rat RPE, which leads to photoreceptor dysfunction and ultimately loss of photoreceptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfyBfTezUdUrVg90H21EOLACvtfcHk0lj5BcBOESPR-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCqu7fP&md5=d6f4af801e795995739478385f5e36fd</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1177%2F0192623314553804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623314553804%26sid%3Dliteratum%253Aachs%26aulast%3DFielden%26aufirst%3DM.%2BR.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DJamison%26aufirst%3DJ.%2BA.%26aulast%3DCoppi%26aufirst%3DA.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DDunn%26aufirst%3DR.%2BT.%26aulast%3DTrueblood%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DAfshari%26aufirst%3DC.%2BA.%26aulast%3DLightfoot-Dunn%26aufirst%3DR.%26atitle%3DRetinal%2520toxicity%2520induced%2520by%2520a%2520novel%2520%25CE%25B2-secretase%2520inhibitor%2520in%2520the%2520Sprague-Dawley%2520rat%26jtitle%3DToxicol.%2520Pathol.%26date%3D2015%26volume%3D43%26spage%3D581%26epage%3D592%26doi%3D10.1177%2F0192623314553804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenthaler, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span> <span> </span><span class="NLM_article-title">BACE1 physiological functions may limit its use as therapeutic target for Alzheimer’s disease</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.tins.2016.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2Fj.tins.2016.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=26833257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2016&pages=158-169&author=S.+Baraoauthor=D.+Moecharsauthor=S.+F.+Lichtenthalerauthor=B.+De+Strooper&title=BACE1+physiological+functions+may+limit+its+use+as+therapeutic+target+for+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.tins.2016.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease</span></div><div class="casAuthors">Barao, Soraia; Moechars, Diederik; Lichtenthaler, Stefan F.; De Strooper, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">158-169</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The protease β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) is required for the prodn. of the amyloid-β (Aβ) peptide, which is central to the pathogenesis of Alzheimer's disease (AD).  Chronic inhibition of this protease may temper amyloid prodn. and cure or prevent AD.  However, while BACE1 inhibitors are being pushed forward as drug candidates, a remarkable gap in knowledge on the physiol. functions of BACE1 and its close homolog BACE2 becomes apparent.  Here we discuss the major discoveries of the past 3 years concerning BACE1 biol. and to what extent these could limit the use of BACE1 inhibitors in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtIpCCZlND1LVg90H21EOLACvtfcHk0li-w6ndE5RhEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaksb4%253D&md5=2f85406ce8d4a917de49e26f0ae1ea87</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.tins.2016.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tins.2016.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DBarao%26aufirst%3DS.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DLichtenthaler%26aufirst%3DS.%2BF.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26atitle%3DBACE1%2520physiological%2520functions%2520may%2520limit%2520its%2520use%2520as%2520therapeutic%2520target%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DTrends%2520Neurosci.%26date%3D2016%26volume%3D39%26spage%3D158%26epage%3D169%26doi%3D10.1016%2Fj.tins.2016.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rochin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurbain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serneels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fort, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raposo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niel, G.</span></span> <span> </span><span class="NLM_article-title">BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">10658</span>– <span class="NLM_lpage">10663</span>, <span class="refDoi"> DOI: 10.1073/pnas.1220748110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1073%2Fpnas.1220748110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=23754390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejs7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=10658-10663&author=L.+Rochinauthor=I.+Hurbainauthor=L.+Serneelsauthor=C.+Fortauthor=B.+Wattauthor=P.+Leblancauthor=M.+S.+Marksauthor=B.+De+Strooperauthor=G.+Raposoauthor=G.+van+Niel&title=BACE2+processes+PMEL+to+form+the+melanosome+amyloid+matrix+in+pigment+cells&doi=10.1073%2Fpnas.1220748110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells</span></div><div class="casAuthors">Rochin, Leila; Hurbain, Ilse; Serneels, Lutgarde; Fort, Cecile; Watt, Brenda; Leblanc, Pascal; Marks, Michael S.; De Strooper, Bart; Raposo, Graca; van Niel, Guillaume</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">10658-10663,S10658/1-S10658/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Amyloids are often assocd. with pathol. processes such as in Alzheimer's disease (AD), but can also underlie physiol. processes such as pigmentation.  Formation of pathol. and functional amyloidogenic substrates can require precursor processing by proteases, as exemplified by the generation of Aβ peptide from amyloid precursor protein (APP) by beta-site APP cleaving enzyme (BACE)1 and γ-secretase.  Proteolytic processing of the pigment cell-specific Melanocyte Protein (PMEL) is also required to form functional amyloid fibrils during melanogenesis, but the enzymes involved are incompletely characterized.  Here we show that the BACE1 homolog BACE2 processes PMEL to generate functional amyloids.  BACE2 is highly expressed in pigment cells and Bace2-/- but not Bace1-/- mice display coat color defects, implying a specific role for BACE2 during melanogenesis.  By using biochem. and morphol. analyses, combined with RNA silencing, pharmacol. inhibition, and BACE2 overexpression in a human melanocytic cell line, we show that BACE2 cleaves the integral membrane form of PMEL within the juxtamembrane domain, releasing the PMEL luminal domain into endosomal precursors for the formation of amyloid fibrils and downstream melanosome morphogenesis.  These studies identify an amyloidogenic substrate of BACE2, reveal an important physiol. role for BACE2 in pigmentation, and highlight analogies in the generation of PMEL-derived functional amyloids and APP-derived pathol. amyloids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBEney5KFyLVg90H21EOLACvtfcHk0li-w6ndE5RhEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejs7rK&md5=3deb3f80dca6a32748aa6fe2e50c2df1</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1220748110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1220748110%26sid%3Dliteratum%253Aachs%26aulast%3DRochin%26aufirst%3DL.%26aulast%3DHurbain%26aufirst%3DI.%26aulast%3DSerneels%26aufirst%3DL.%26aulast%3DFort%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DB.%26aulast%3DLeblanc%26aufirst%3DP.%26aulast%3DMarks%26aufirst%3DM.%2BS.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26aulast%3DRaposo%26aufirst%3DG.%26aulast%3Dvan%2BNiel%26aufirst%3DG.%26atitle%3DBACE2%2520processes%2520PMEL%2520to%2520form%2520the%2520melanosome%2520amyloid%2520matrix%2520in%2520pigment%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D10658%26epage%3D10663%26doi%3D10.1073%2Fpnas.1220748110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shimshek, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamurovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balavenkatraman, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morawiec, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreutzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schelle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jucker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertschi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzak, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, U.</span></span> <span> </span><span class="NLM_article-title">Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21917</span>, <span class="refDoi"> DOI: 10.1038/srep21917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1038%2Fsrep21917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=26912421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1eku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=21917&author=D.+R.+Shimshekauthor=L.+H.+Jacobsonauthor=C.+Kollyauthor=N.+Zamurovicauthor=K.+K.+Balavenkatramanauthor=L.+Morawiecauthor=R.+Kreutzerauthor=J.+Schelleauthor=M.+Juckerauthor=B.+Bertschiauthor=D.+Theilauthor=A.+Heierauthor=K.+Bigotauthor=K.+Beltzauthor=R.+Machauerauthor=I.+Brzakauthor=L.+Perrotauthor=U.+Neumann&title=Pharmacological+BACE1+and+BACE2+inhibition+induces+hair+depigmentation+by+inhibiting+PMEL17+processing+in+mice&doi=10.1038%2Fsrep21917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice</span></div><div class="casAuthors">Shimshek, Derya R.; Jacobson, Laura H.; Kolly, Carine; Zamurovic, Natasa; Balavenkatraman, Kamal Kumar; Morawiec, Laurent; Kreutzer, Robert; Schelle, Juliane; Jucker, Mathias; Bertschi, Barbara; Theil, Diethilde; Heier, Annabelle; Bigot, Karine; Beltz, Karen; Machauer, Rainer; Brzak, Irena; Perrot, Ludovic; Neumann, Ulf</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21917</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Melanocytes of the hair follicle produce melanin and are essential in detg. the differences in hair color.  Pigment cell-specific MELanocyte Protein (PMEL17) plays a crucial role in melanogenesis.  One of the crit. steps is the amyloid-like functional oligomerization of PMEL17.  Beta Site APP Cleaving Enzyme-2 (BACE2) and γ-secretase have been shown to be key players in generating the proteolytic fragments of PMEL17.  The β-secretase (BACE1) is responsible for the generation of amyloid-β (Aβ) fragments in the brain and is therefore proposed as a therapeutic target for Alzheimer's disease (AD).  Currently BACE1 inhibitors, most of which lack selectivity over BACE2, have demonstrated efficacious redn. of amyloid-β peptides in animals and the CSF of humans.  BACE2 knock-out mice have a deficiency in PMEL17 proteolytic processing leading to impaired melanin storage and hair depigmentation.  Here, we confirm BACE2-mediated inhibition of PMEL17 proteolytic processing in vitro in mouse and human melanocytes.  Furthermore, we show that wildtype as well as bace2+/- and bace2-/- mice treated with a potent dual BACE1/BACE2 inhibitor NB-360 display dose-dependent appearance of irreversibly depigmented hair.  Retinal pigmented epithelium showed no morphol. changes.  Our data demonstrates that BACE2 as well as addnl. BACE1 inhibition affects melanosome maturation and induces hair depigmentation in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtlQ-3Lxc4CLVg90H21EOLACvtfcHk0li-w6ndE5RhEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1eku7Y%253D&md5=e3641d48cc7fcf08c4502b5899a49066</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1038%2Fsrep21917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep21917%26sid%3Dliteratum%253Aachs%26aulast%3DShimshek%26aufirst%3DD.%2BR.%26aulast%3DJacobson%26aufirst%3DL.%2BH.%26aulast%3DKolly%26aufirst%3DC.%26aulast%3DZamurovic%26aufirst%3DN.%26aulast%3DBalavenkatraman%26aufirst%3DK.%2BK.%26aulast%3DMorawiec%26aufirst%3DL.%26aulast%3DKreutzer%26aufirst%3DR.%26aulast%3DSchelle%26aufirst%3DJ.%26aulast%3DJucker%26aufirst%3DM.%26aulast%3DBertschi%26aufirst%3DB.%26aulast%3DTheil%26aufirst%3DD.%26aulast%3DHeier%26aufirst%3DA.%26aulast%3DBigot%26aufirst%3DK.%26aulast%3DBeltz%26aufirst%3DK.%26aulast%3DMachauer%26aufirst%3DR.%26aulast%3DBrzak%26aufirst%3DI.%26aulast%3DPerrot%26aufirst%3DL.%26aulast%3DNeumann%26aufirst%3DU.%26atitle%3DPharmacological%2520BACE1%2520and%2520BACE2%2520inhibition%2520induces%2520hair%2520depigmentation%2520by%2520inhibiting%2520PMEL17%2520processing%2520in%2520mice%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D21917%26doi%3D10.1038%2Fsrep21917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esterhazy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuetzer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rechsteiner, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebeli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilpert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matile, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prummer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieske, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marselli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr-Conte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebersold</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinas, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffel, M.</span></span> <span> </span><span class="NLM_article-title">Bace2 is a β cell-enriched protease that regulates pancreatic β cell function and mass</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2011.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2Fj.cmet.2011.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=21907142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFGltbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=365-377&author=D.+Esterhazyauthor=I.+Stuetzerauthor=H.+Wangauthor=M.+P.+Rechsteinerauthor=J.+Beauchampauthor=H.+Doebeliauthor=H.+Hilpertauthor=H.+Matileauthor=M.+Prummerauthor=A.+Schmidtauthor=N.+Lieskeauthor=B.+Boehmauthor=L.+Marselliauthor=D.+Boscoauthor=J.+Kerr-Conteauthor=+Aebersoldauthor=G.+A.+Spinasauthor=H.+Mochauthor=C.+Miglioriniauthor=M.+Stoffel&title=Bace2+is+a+%CE%B2+cell-enriched+protease+that+regulates+pancreatic+%CE%B2+cell+function+and+mass&doi=10.1016%2Fj.cmet.2011.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Bace2 Is a β Cell-Enriched Protease that Regulates Pancreatic β Cell Function and Mass</span></div><div class="casAuthors">Esterhazy, Daria; Stuetzer, Ina; Wang, Haiyan; Rechsteiner, Markus P.; Beauchamp, Jeremy; Doebeli, Heinz; Hilpert, Hans; Matile, Hugues; Prummer, Michael; Schmidt, Alexander; Lieske, Nora; Boehm, Bernhard; Marselli, Lorella; Bosco, Domenico; Kerr-Conte, Julie; Aebersold, Ruedi; Spinas, Giatgen Andreia; Moch, Holger; Migliorini, Cristiano; Stoffel, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-377</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Decreased β cell mass and function are hallmarks of type 2 diabetes.  Here we identified, through a siRNA screen, beta site amyloid precursor protein cleaving enzyme 2 (Bace2) as the sheddase of the proproliferative plasma membrane protein Tmem27 in murine and human β cells.  Mice with functionally inactive Bace2 and insulin-resistant mice treated with a newly identified Bace2 inhibitor both display augmented β cell mass and improved control of glucose homeostasis due to increased insulin levels.  These results implicate Bace2 in the control of β cell maintenance and provide a rational strategy to inhibit this protease for the expansion of functional pancreatic β cell mass.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNmw-BllVxx7Vg90H21EOLACvtfcHk0lhpew-te2dxCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFGltbbM&md5=489e20b2d997eb0cbaff195819e35d64</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2011.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2011.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DEsterhazy%26aufirst%3DD.%26aulast%3DStuetzer%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRechsteiner%26aufirst%3DM.%2BP.%26aulast%3DBeauchamp%26aufirst%3DJ.%26aulast%3DDoebeli%26aufirst%3DH.%26aulast%3DHilpert%26aufirst%3DH.%26aulast%3DMatile%26aufirst%3DH.%26aulast%3DPrummer%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DLieske%26aufirst%3DN.%26aulast%3DBoehm%26aufirst%3DB.%26aulast%3DMarselli%26aufirst%3DL.%26aulast%3DBosco%26aufirst%3DD.%26aulast%3DKerr-Conte%26aufirst%3DJ.%26aulast%3DAebersold%26aulast%3DSpinas%26aufirst%3DG.%2BA.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DMigliorini%26aufirst%3DC.%26aulast%3DStoffel%26aufirst%3DM.%26atitle%3DBace2%2520is%2520a%2520%25CE%25B2%2520cell-enriched%2520protease%2520that%2520regulates%2520pancreatic%2520%25CE%25B2%2520cell%2520function%2520and%2520mass%26jtitle%3DCell%2520Metab.%26date%3D2011%26volume%3D14%26spage%3D365%26epage%3D377%26doi%3D10.1016%2Fj.cmet.2011.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rulifson, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samayoa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baribault, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltzius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of human islet amyloid polypeptide as a BACE2 substrate</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0147254</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0147254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1371%2Fjournal.pone.0147254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=26840340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslOqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0147254&author=I.+C.+Rulifsonauthor=P.+Caoauthor=L.+Miaoauthor=D.+Kopeckyauthor=L.+Huangauthor=R.+D.+Whiteauthor=K.+Samayoaauthor=J.+Gardnerauthor=X.+Wuauthor=K.+Chenauthor=T.+Tsurudaauthor=O.+Homannauthor=H.+Baribaultauthor=H.+Yamaneauthor=T.+Carlsonauthor=J.+Wiltziusauthor=Y.+Li&title=Identification+of+human+islet+amyloid+polypeptide+as+a+BACE2+substrate&doi=10.1371%2Fjournal.pone.0147254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human islet amyloid polypeptide as a BACE2 substrate</span></div><div class="casAuthors">Rulifson, Ingrid C.; Cao, Ping; Miao, Li; Kopecky, David; Huang, Linda; White, Ryan D.; Samayoa, Kim; Gardner, Jonitha; Wu, Xiaosu; Chen, Kui; Tsuruda, Trace; Homann, Oliver; Baribault, Helene; Yamane, Harvey; Carlson, Tim; Wiltzius, Jed; Li, Yang</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0147254/1-e0147254/23</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Pancreatic amyloid formation by islet amyloid polypeptide (IAPP) is a hallmark pathol. feature of type 2 diabetes.  IAPP is stored in the secretory granules of pancreatic beta-cells and co-secreted with insulin to maintain glucose homeostasis.  IAPP is innocuous under homeostatic conditions but imbalances in prodn. or processing of IAPP may result in homodimer formation leading to the rapid prodn. of cytotoxic oligomers and amyloid fibrils.  The consequence is beta-cell dysfunction and the accumulation of proteinaceous plaques in and around pancreatic islets.  Beta-site APP-cleaving enzyme 2, BACE2, is an aspartyl protease commonly assocd. with BACE1, a related homolog responsible for amyloid processing in the brain and strongly implicated in Alzheimer's disease.  Herein, we identify two distinct sites of the mature human IAPP sequence that are susceptible to BACE2-mediated proteolytic activity.  The result of proteolysis is modulation of human IAPP fibrillation and human IAPP protein degrdn.  These results suggest a potential therapeutic role for BACE2 in type 2 diabetes-assocd. hyperamylinemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXxpM4hmm1pLVg90H21EOLACvtfcHk0lhpew-te2dxCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslOqtL4%253D&md5=ab081153a95c7462bd208bac8779bd1d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0147254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0147254%26sid%3Dliteratum%253Aachs%26aulast%3DRulifson%26aufirst%3DI.%2BC.%26aulast%3DCao%26aufirst%3DP.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DKopecky%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DSamayoa%26aufirst%3DK.%26aulast%3DGardner%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DTsuruda%26aufirst%3DT.%26aulast%3DHomann%26aufirst%3DO.%26aulast%3DBaribault%26aufirst%3DH.%26aulast%3DYamane%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DT.%26aulast%3DWiltzius%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520human%2520islet%2520amyloid%2520polypeptide%2520as%2520a%2520BACE2%2520substrate%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0147254%26doi%3D10.1371%2Fjournal.pone.0147254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alic, I.</span>; <span class="NLM_string-name">Goh, P. A.</span>; <span class="NLM_string-name">Murray, A.</span>; <span class="NLM_string-name">Portelius, E.</span>; <span class="NLM_string-name">Gkanatsiou, E.</span>; <span class="NLM_string-name">Gough, G.</span>; <span class="NLM_string-name">Mok, K. Y.</span>; <span class="NLM_string-name">Koschut, D.</span>; <span class="NLM_string-name">Brunmeir, R.</span>; <span class="NLM_string-name">Yeap, Y. J.</span>; <span class="NLM_string-name">O’Brien, N. L.</span>; <span class="NLM_string-name">Groet, J.</span>; <span class="NLM_string-name">Shao, X.</span>; <span class="NLM_string-name">Havlicek, S.</span>; <span class="NLM_string-name">Dunn, N. R.</span>; <span class="NLM_string-name">Kvartsberg, H.</span>; <span class="NLM_string-name">Brinkmalm, G.</span>; <span class="NLM_string-name">Hithersay, R.</span>; <span class="NLM_string-name">Startin, C.</span>; <span class="NLM_string-name">Hamburg, S.</span>; <span class="NLM_string-name">Phillips, M.</span>; <span class="NLM_string-name">Pervushin, K.</span>; <span class="NLM_string-name">Turmaine, M.</span>; <span class="NLM_string-name">Wallon, D.</span>; <span class="NLM_string-name">Rovelet-Lecrux, A.</span>; <span class="NLM_string-name">Soininen, H.</span>; <span class="NLM_string-name">Volpi, E.</span>; <span class="NLM_string-name">Martin, J. E.</span>; <span class="NLM_string-name">Foo, J. N.</span>; <span class="NLM_string-name">Becker, D. L.</span>; <span class="NLM_string-name">Rostagno, A.</span>; <span class="NLM_string-name">Ghiso, J.</span>; <span class="NLM_string-name">Krsnik, Z.</span>; <span class="NLM_string-name">Simic, G.</span>; <span class="NLM_string-name">Kostovic, I.</span>; <span class="NLM_string-name">Mitrecic, D.</span>; <span class="NLM_string-name">Francis, P. T.</span>; <span class="NLM_string-name">Blennow, K.</span>; <span class="NLM_string-name">Strydom, A.</span>; <span class="NLM_string-name">Hardy, J.</span>; <span class="NLM_string-name">Zetterberg, H.</span>; <span class="NLM_string-name">Nizetic, D.</span></span> <span> </span><span class="NLM_article-title">Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain</span>.  <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2020</span><span class="refDoi"> DOI: 10.1038/s41380-020-0806-5</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1038%2Fs41380-020-0806-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=32647257" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=I.+Alic&author=P.+A.+Goh&author=A.+Murray&author=E.+Portelius&author=E.+Gkanatsiou&author=G.+Gough&author=K.+Y.+Mok&author=D.+Koschut&author=R.+Brunmeir&author=Y.+J.+Yeap&author=N.+L.+O%E2%80%99Brien&author=J.+Groet&author=X.+Shao&author=S.+Havlicek&author=N.+R.+Dunn&author=H.+Kvartsberg&author=G.+Brinkmalm&author=R.+Hithersay&author=C.+Startin&author=S.+Hamburg&author=M.+Phillips&author=K.+Pervushin&author=M.+Turmaine&author=D.+Wallon&author=A.+Rovelet-Lecrux&author=H.+Soininen&author=E.+Volpi&author=J.+E.+Martin&author=J.+N.+Foo&author=D.+L.+Becker&author=A.+Rostagno&author=J.+Ghiso&author=Z.+Krsnik&author=G.+Simic&author=I.+Kostovic&author=D.+Mitrecic&author=P.+T.+Francis&author=K.+Blennow&author=A.+Strydom&author=J.+Hardy&author=H.+Zetterberg&author=D.+Nizetic&title=Patient-specific+Alzheimer-like+pathology+in+trisomy+21+cerebral+organoids+reveals+BACE2+as+a+gene+dose-sensitive+AD+suppressor+in+human+brain&doi=10.1038%2Fs41380-020-0806-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fs41380-020-0806-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41380-020-0806-5%26sid%3Dliteratum%253Aachs%26aulast%3DAlic%26aufirst%3DI.%26atitle%3DPatient-specific%2520Alzheimer-like%2520pathology%2520in%2520trisomy%252021%2520cerebral%2520organoids%2520reveals%2520BACE2%2520as%2520a%2520gene%2520dose-sensitive%2520AD%2520suppressor%2520in%2520human%2520brain%26jtitle%3DMol.%2520Psychiatry%26date%3D2020%26doi%3D10.1038%2Fs41380-020-0806-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kunishima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawachi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tani, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of 4-(4,6-dimethoxy-1,3,5-triazi-2-yl)-4-methylmorpholinium chloride</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">5327</span>– <span class="NLM_lpage">5330</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(99)00968-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1016%2FS0040-4039%2899%2900968-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADyaK1MXksVynt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=5327-5330&author=M.+Kunishimaauthor=C.+Kawachiauthor=F.+Iwasakiauthor=K.+Teraoauthor=S.+Tani&title=Synthesis+and+characterization+of+4-%284%2C6-dimethoxy-1%2C3%2C5-triazi-2-yl%29-4-methylmorpholinium+chloride&doi=10.1016%2FS0040-4039%2899%2900968-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride</span></div><div class="casAuthors">Kunishima, Munetaka; Kawachi, Chiho; Iwasaki, Fumiaki; Terao, Keiji; Tani, Shohei</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">5327-5330</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) was quant. synthesized by the coupling of 2-chloro-4,6-dimethoxy-1,3,5-triazine and N-methylmorpholine in THF, and fully characterized.  Condensation of carboxylic acids and amines by DMTMM proceeded effectively in THF to give the corresponding amides in good yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5PCjoyBOjP7Vg90H21EOLACvtfcHk0lhrPY6yptBOeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVynt74%253D&md5=6bcb4ea20612a6f6cd57bc512e1f6374</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2899%2900968-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252899%252900968-5%26sid%3Dliteratum%253Aachs%26aulast%3DKunishima%26aufirst%3DM.%26aulast%3DKawachi%26aufirst%3DC.%26aulast%3DIwasaki%26aufirst%3DF.%26aulast%3DTerao%26aufirst%3DK.%26aulast%3DTani%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520characterization%2520of%25204-%25284%252C6-dimethoxy-1%252C3%252C5-triazi-2-yl%2529-4-methylmorpholinium%2520chloride%26jtitle%3DTetrahedron%2520Lett.%26date%3D1999%26volume%3D40%26spage%3D5327%26epage%3D5330%26doi%3D10.1016%2FS0040-4039%2899%2900968-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robak, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbage, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and applications of <i>tert</i>-butanesulfinamide</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">3600</span>– <span class="NLM_lpage">3740</span>, <span class="refDoi"> DOI: 10.1021/cr900382t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr900382t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltFChsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2010&pages=3600-3740&author=M.+T.+Robakauthor=M.+A.+Herbageauthor=J.+A.+Ellman&title=Synthesis+and+applications+of+tert-butanesulfinamide&doi=10.1021%2Fcr900382t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Applications of tert-Butanesulfinamide</span></div><div class="casAuthors">Robak, MaryAnn T.; Herbage, Melissa A.; Ellman, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3600-3740</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the past decade, an ever increasing collection of methods based upon the chiral amine reagent tert-butanesulfinamide (I) have become some of the most extensively used synthetic approaches for both the discovery and prodn. of drug candidates.  Either enantiomer of I is inexpensive to prep. on a large scale in enantiomerically pure form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLsVMjLa-pP7Vg90H21EOLACvtfcHk0lhrPY6yptBOeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltFChsbs%253D&md5=ad2c9e9a2b2044f47a00be408d0907d2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fcr900382t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr900382t%26sid%3Dliteratum%253Aachs%26aulast%3DRobak%26aufirst%3DM.%2BT.%26aulast%3DHerbage%26aufirst%3DM.%2BA.%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520and%2520applications%2520of%2520tert-butanesulfinamide%26jtitle%3DChem.%2520Rev.%26date%3D2010%26volume%3D110%26spage%3D3600%26epage%3D3740%26doi%3D10.1021%2Fcr900382t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haveaux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekoker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidani, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosez, L.</span></span> <span> </span><span class="NLM_article-title">α-Chloro enamines, reactive intermediates for synthesis: 1-chloro-<i>N</i>,<i>N</i>,2-trimethylpropenylamine</span>. <i>Org. Synth.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1002/0471264180.os059.05</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=10.1002%2F0471264180.os059.05" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;key=1%3ACAS%3A528%3ADyaL3cXls1Omsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1980&pages=26-34&author=B.+Haveauxauthor=A.+Dekokerauthor=M.+Rensauthor=A.+R.+Sidaniauthor=J.+Toyeauthor=L.+Ghosez&title=%CE%B1-Chloro+enamines%2C+reactive+intermediates+for+synthesis%3A+1-chloro-N%2CN%2C2-trimethylpropenylamine&doi=10.1002%2F0471264180.os059.05"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">α-Chloro enamines, reactive intermediates for synthesis: 1-chloro-N,N,2-trimethylpropenylamine</span></div><div class="casAuthors">Haveaux, B.; Dekoker, A.; Rens, M.; Sidani, A. R.; Toye, J.; Ghosez, L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Syntheses</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26-34</span>CODEN:
                <span class="NLM_cas:coden">ORSYAT</span>;
        ISSN:<span class="NLM_cas:issn">0078-6209</span>.
    </div><div class="casAbstract">RR1C:CClNR2R3 [R = Me, Ph, H, R1 = H, R2 = Me, R3 = Ph; R = Me3C, Me, Ph, R1 = H, Me, R2 = R3 = Me; R = R1 = Me, R2R3 = (CH2)5; RR1 = (CH2)5, R2R3 = Et; R = Me, R1 = Cl, R2R3 = (CH2)4; R = R3 = Me, R1R2 = (CH2)4] were prepd. in 40-85% yields by treating RR1CHCONR2R3 with COCl2 to give RR1CHCCl:N+R2R3.Cl-, which was refluxed in CH2Cl2 in the presence of Et3N for 1 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGFmk9j628LVg90H21EOLACvtfcHk0lhrPY6yptBOeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXls1Omsbw%253D&md5=f2fc2d7e7e7a880884965bd3508f8b86</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2F0471264180.os059.05&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471264180.os059.05%26sid%3Dliteratum%253Aachs%26aulast%3DHaveaux%26aufirst%3DB.%26aulast%3DDekoker%26aufirst%3DA.%26aulast%3DRens%26aufirst%3DM.%26aulast%3DSidani%26aufirst%3DA.%2BR.%26aulast%3DToye%26aufirst%3DJ.%26aulast%3DGhosez%26aufirst%3DL.%26atitle%3D%25CE%25B1-Chloro%2520enamines%252C%2520reactive%2520intermediates%2520for%2520synthesis%253A%25201-chloro-N%252CN%252C2-trimethylpropenylamine%26jtitle%3DOrg.%2520Synth.%26date%3D1980%26volume%3D59%26spage%3D26%26epage%3D34%26doi%3D10.1002%2F0471264180.os059.05" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7DCZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7DCZ','PDB','7DCZ'); return false;">PDB: 7DCZ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i51"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01917">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_67271"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01917?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01917</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental procedures for PK/PD study; measurement of Aβ plaque formation in PS/APP mice; determination of CVB values in human liver microsomes; synthesis of [<sup>14</sup>C]-<b>15</b>, <sup>1</sup>H, and <sup>13</sup>C NMR spectra for compound <b>1</b>; HPLC traces for compounds <b>1</b>, <b>13</b>, <b>14</b>, <b>15</b>, <b>16</b>, <b>17</b>, and <b>18</b>; and crystallographic data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01917/suppl_file/jm0c01917_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES strings, BACE1 IC<sub>50</sub>, and cellular Aβ<sub>40</sub> IC<sub>50</sub> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01917/suppl_file/jm0c01917_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01917/suppl_file/jm0c01917_si_001.pdf">jm0c01917_si_001.pdf (528.22 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01917/suppl_file/jm0c01917_si_002.csv">jm0c01917_si_002.csv (0.91 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB accession code for the X-ray structure of <b>1</b> bound to human BACE1 is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7DCZ">7DCZ</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01917&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01917%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-4%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01917" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679913208be91991","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
